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This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary. 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the hazardous substance described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a hazardous substance’s toxicologic properties.  Other pertinent 
literature is also presented, but is described in less detail than the key studies.  The profile is not intended 
to be an exhaustive document; however, more comprehensive sources of specialty information are 
referenced. 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a public health statement that describes, in nontechnical language, a substance’s relevant 
toxicological properties.  Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance’s health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA. 
Each profile includes the following: 
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects; 
(B) A determination of whether adequate information on the health effects of each substance 
is available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and 
(C) Where appropriate, identification of toxicologic testing needed to identify the types or 
levels of exposure that may present significant risk of adverse health effects in humans. 
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.   
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel 
and was made available for public review.  Final responsibility for the contents and views expressed in 
this toxicological profile resides with ATSDR. 
























The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization 
Act (SARA) of 1986  (Public law 99-499) which amended the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980  (CERCLA or Superfund).  This public law directed ATSDR to 
prepare toxicological profiles for hazardous substances most commonly found at facilities on the 
CERCLA National Priorities List and that pose the most significant potential threat to human health, as 
determined by ATSDR and the EPA.  The availability of the revised priority list of 275  hazardous 
substances was announced in the Federal Register on November 17, 1997 (62  FR 61332).  For prior 
versions of the list of substances, see Federal Register notices dated April 29, 1996 (61 FR 18744); April 
17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 
1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February
28, 1994 (59 FR 9486).  Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR 





























       




QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 

Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 

Section 3.7 Children’s Susceptibility 

Section 6.6 Exposures of Children 

Other Sections of Interest: 
Section 3.8 Biomarkers of Exposure and Effect 
Section 3.11 Methods for Reducing Toxic Effects 
ATSDR Information Center  
Phone: 1-888-42-ATSDR or (404) 498-0110 Fax: (770) 488-4178 
E-mail: atsdric@cdc.gov Internet: http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 




























Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, 
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226­
1998 • Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347­
4976 • FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact: ACOEM, 55 West Seegers Road, Arlington Heights, 
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
1. 	 Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
2.	 Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
3. 	 Data Needs Review.  The Research Implementation Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance. 











































A peer review panel was assembled for 1,2-, 1,3-, and 1,4-dichlorobenzenes.  The panel consisted of the 
following members:
1. 	 Dr. Olen Brown, Emeritus Research Professor, University of Missouri, 527 North Cedar Lake 
Drive West, Columbia, Missouri; 
2. 	 Dr. Robert Michaels, President, RAM TRAC Corporation, 3100 Rosendale Road, Schenectady, 
New York; and 
3.	 Dr. Clint Skinner, President, Skinner Associates, 3985 Shooting Star Road, Creston, California. 
These experts collectively have knowledge of dichlorobenzenes’ physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.   
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
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1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about dichlorobenzenes (DCBs) and the effects of 
exposure to them.   
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites are then placed on the National Priorities List (NPL) and are targeted for 
long-term federal clean-up activities.  1,2-, 1,3-, and 1,4-Dichlorobenzene have been identified in 
at least 281, 175, and 330, respectively, of the 1,662 current or former NPL sites.  Although the 
total number of NPL sites evaluated for these substances is not known, the possibility exists that 
the number of sites at which dichlorobenzenes are found may increase in the future as more sites 
are evaluated. This information is important because these sites may be sources of exposure and 
exposure to these substances may harm you. 
When a substance is released either from a large area, such as an industrial plant, or from a 
container, such as a drum or bottle, it enters the environment. Such a release does not always 
lead to exposure. You can be exposed to a substance only when you come in contact with it.  
You may be exposed by breathing, eating, or drinking the substance, or by skin contact. 
If you are exposed to dichlorobenzenes, many factors will determine whether you will be 
harmed.  These factors include the dose (how much), the duration (how long), and how you 
come in contact with them.  You must also consider any other chemicals you are exposed to and 
your age, sex, diet, family traits, lifestyle, and state of health. 
1.1 WHAT ARE DICHLOROBENZENES? 
Each of the three types of DCBs (i.e., 1,2-DCB, 1,3-DCB, and 1,4-DCB) contains two chlorine 
atoms connected to one benzene molecule.  1,2-DCB is a colorless to pale yellow liquid used to 
make herbicides.  1,3-DCB is a colorless liquid used to make herbicides, insecticides, medicine, 
















1. PUBLIC HEALTH STATEMENT 
smells like mothballs and it is one of two chemicals commonly used to make mothballs.  
1,4-DCB also is used to make deodorant blocks used in garbage cans and restrooms, and to help 
control odors in animal-holding facilities.  1,4-DCB has been used as an insecticide on fruit and 
as an agent to control mold and mildew growth on tobacco seeds, leather, and some fabrics.  
Recently, using 1,4-DCB to make resins has become very important. 
When a package of 1,4-DCB is opened, it ‘sublimates’, that is, it slowly changes from a solid 
into a vapor, and enters the atmosphere.  The vapor acts as a deodorizer and insect killer.  Most 
of the 1,2-, 1,3-, and 1,4-DCB released into the environment is present as a vapor.  DCBs can 
burn, but they do not burn easily. Most people begin to smell 1,4-DCB when it is in the air at a 
concentration of 0.18 parts per million (ppm) and 0.011 ppm in water. 
DCBs do not occur naturally; chemical companies produce them to make products for home use 
and other chemicals such as herbicides and plastics.  More information about the properties and 
uses of 1,2-, 1,3-, and 1,4-DCB is provided in Chapters 4 and 5. 
1.2 	 WHAT HAPPENS TO DICHLOROBENZENES WHEN THEY ENTER THE 
ENVIRONMENT? 
Most of the 1,4-DCB enters the environment when it is used in mothballs and in toilet-deodorizer 
blocks. Some 1,4-DCB is released to the air by factories that make or use it, and only a little is 
released to soil and water. Very little 1,4-DCB enters the environment from hazardous waste 
sites. Some 1,2- and 1,3-DCBs are released into the environment when used to make herbicides 
and when people use products that contain these chemicals.  Companies that make 1,4-DCB also 
make unwanted amounts of 1,2-DCB during the process.  1,2-DCB is released to the 
environment when companies dispose of these unwanted supplies. 
Because DCBs do not dissolve easily in water, the small amounts that enter water quickly 
evaporate into the air. If they are released to groundwater, they may be transported through the 





















1. PUBLIC HEALTH STATEMENT 
not easily broken down by soil organisms.  Evidence suggests that plants and fish absorb DCBs.  
1,4-DCB has been detected at concentrations of up to 470 parts per billion (ppb) in fish. 
More information about DCBs in the environment is provided in Chapters 5 and 6. 
1.3 HOW MIGHT I BE EXPOSED TO DICHLOROBENZENES? 
Humans are exposed to 1,4-DCB mainly by breathing vapors from 1,4-DCB products used in the 
home, such as mothballs and toilet-deodorizer blocks.  Reported levels of 1,4-DCB in some
homes and public restrooms have ranged from 0.291 to 272 parts of 1,4-DCB per billion parts 
(ppb) of air. 1,2- and 1,3-DCB are not found frequently in the air of homes and buildings 
because, unlike 1,4-DCB, these chemicals are not used in household products.  Outdoor levels of 
1,4-DCB range from 0.01 to 1 ppb and are much lower than levels in homes and buildings.  
Levels in the air around hazardous waste sites are low and range from 0.01 to 4.2 ppb.  Outdoor 
air levels generally range from 0.01 to 0.1 ppb for 1,2-DCB and from 0.001 to 0.1 ppb for 
1,3-DCB. 
DCBs have been found in samples of drinking water from surface water sources.  1,4-DCB was 
found in 13% of surface water samples collected during a national survey.  These samples 
contained about 0.008–154 ppb of 1,4-DCB. DCBs also have been found in drinking water from
wells but at low concentrations. DCBs are found only infrequently in soil, but they have been 
detected in soil around hazardous waste sites in the United States. 
DCBs have been detected in beef, pork, chicken, eggs, baked goods, soft drinks, butter, peanut 
butter, fruits, vegetables, and fish. However, the levels of DCBs in foods are generally low. 
The average daily adult intake of 1,4-DCB is about 35 micrograms (µg), which comes mainly 
from breathing 1,4-DCB vapors released from products in homes and businesses.  The average 





















1. PUBLIC HEALTH STATEMENT 
Individuals can be occupationally exposed to DCBs in workplace air at much higher levels than 
the general public is exposed. Levels measured in the air of factories that make or process 
1,4-DCB products have ranged from 5.6 to 748 ppm of air.  In addition, people who live or work 
near industrial facilities or hazardous waste sites that have high levels of DCBs may have greater 
exposure to these compounds due to emissions from the facilities and waste sites.  People who 
work or live in buildings where air fresheners, toilet block deodorants, or moth balls containing 
1,4-DCB are used also are expected to have a higher exposure to this compound, which could 
occur from skin contact as well as by breathing. 
More information on how you could be exposed to DCBs is given in Chapter 6. 
1.4 HOW CAN DICHLOROBENZENES ENTER AND LEAVE MY BODY? 
The main way DCBs enter your body is through the lungs when you breathe in DCB vapors 
released in the workplace or in the home from use of products that contain it.  When you breathe 
in these chemicals for a few hours, it is likely that some of the DCBs that have entered your body 
will get into your bloodstream. 
DCBs also can get into your body if you drink water or eat certain foods that contain them, such 
as meat, chicken, eggs, or fish.  Most of the DCBs that enter your body from food and water will 
get into your bloodstream.  It is not likely that DCBs will enter your body through the skin if you 
touch products that contain them. 
1,4-DCB used in the home could be accidentally swallowed, especially by young children.  This 
possibility exists because household products that contain 1,4-DCB, particularly some kinds of 
mothballs and deodorant blocks, might be freely available in closets or bathrooms. 
Most of the DCB that enters your body (perhaps more than 95%) leaves through the urine in less 
than a week. Small amounts (perhaps 1–2%) leave your body in the feces and in the air you 

















1. PUBLIC HEALTH STATEMENT 
Most of the DCBs that enter your body are changed into other chemicals, mainly 
dichlorophenols. It is not known if these breakdown products are more or less harmful than the 
DCBs themselves. 
More information about how DCBs enter and leave the body is found in Chapter 3. 
1.5 HOW CAN DICHLOROBENZENES AFFECT MY HEALTH? 
Scientists use many tests to protect the public from harmful effects of toxic chemicals and to find 
ways for treating persons who have been harmed. 
One way to learn whether a chemical will harm people is to determine how the body absorbs, 
uses, and releases the chemical.  For some chemicals, animal testing may be necessary.  Animal 
testing may also help identify health effects such as cancer or birth defects.  Without laboratory 
animals, scientists would lose a basic method for getting information needed to make wise 
decisions that protect public health.  Scientists have the responsibility to treat research animals 
with care and compassion.  Scientists must comply with strict animal care guidelines because 
laws today protect the welfare of research animals. 
Most of the information on health effects of DCBs is from studies of 1,2- and 1,4-DCB.  Very 
little is known about the health effects of 1,3-DCB, especially in humans, but they are likely to 
be similar to those of the other DCBs. 
Inhaling the vapor or dusts of 1,2-DCB and 1,4-DCB at very high concentrations could be very 
irritating to your eyes and nose and cause burning and tearing of the eyes, coughing, difficult 
breathing, and an upset stomach.  These concentrations could occur in workplaces, but are much 
higher than you would be exposed to in the home.  1,4-DCB is the only DCB that is commonly 
used in household products (mainly mothballs and toilet-deodorizer blocks).  Scientists have no 
clear evidence that the moderate use of common household products containing 1,4 DCB will 
cause any problems to your health.  A recent study reports limited evidence suggesting that 


















1. PUBLIC HEALTH STATEMENT 
health problems, such as dizziness, headaches, and liver problems, from very high levels of 
1,4-DCB in the home.  However, these people used very high amounts of 1,4-DCB products and 
continued to use the products for months or even years, even though they felt ill.  People who ate 
1,4-DCB products regularly for long periods (months to years) because of its sweet taste 
developed skin blotches and problems with red blood cells, such as anemia (iron-poor blood).  
Little information is available about the effects of skin contact with DCBs.  1,4-DCB might 
cause a burning feeling in your skin if you hold mothballs or toilet-deodorizer blocks against 
your skin for a long time. 
Breathing or eating any of the DCBs caused harmful effects in the liver of laboratory animals.  
Animal studies also found that 1,2-DCB and 1,4-DCB caused effects in the kidneys and blood, 
and that 1,3-DCB caused thyroid and pituitary effects.  There is no clear evidence that 1,2-DCB 
and 1,4-DCB impair reproduction or fetal development in animals at levels below those that also 
cause serious health effects in the mother, although there is an indication that 1,4-DCB can affect 
development of the nervous system after birth.   
Lifetime exposure to 1,4-DCB by breathing or eating induced liver cancer in mice.  1,2-DCB 
was not carcinogenic in laboratory animals, and 1,3-DCB has not been tested for its potential to 
cause cancer.  The animal studies suggest that 1,4-DCB could play a role in the development of 
cancer in humans, but we do not definitely know this.  The U.S. Department of Health and 
Human Services (DHHS) has determined that 1,4-DCB might be a human carcinogen.  The 
International Agency for Research on Cancer (IARC) determined that 1,4-DCB is possibly 
carcinogenic to humans.  Both IARC and the EPA concluded that 1,2-DCB and 1,3-DCB are not 
classifiable as to human carcinogenicity.   
More information about how DCBs can affect your health is given in Chapter 3. 
1.6 HOW CAN DICHLOROBENZENES AFFECT CHILDREN? 
This section discusses potential health effects in humans from exposures during the period from


















1. PUBLIC HEALTH STATEMENT 
Children are exposed to DCBs in many of the same ways adults are.  It is possible that mothballs 
and toilet bowl deodorant blocks containing 1,4-DCB could be played with or accidentally 
swallowed, especially by young children.  Because children tend to be curious about unknown 
powders and liquids, and because these products might be easily accessible in cabinets, closets, 
or bathrooms, children could be at a higher risk of exposure to 1,4-DCB than adults. 
Children who are exposed to DCBs are likely to exhibit the same effects as adults, although this 
is not known for certain.  Thus, all health problems of DCBs observed in adults are of potential 
concern in children. 
Children can also be exposed to DCBs prenatally, because all three isomers have been detected 
in placenta samples, as well as through breast feeding.  There is no reliable evidence suggesting 
that DCBs cause birth defects, although animal data raise concern for effects of 1,4-DCB on 
postnatal development of the nervous system.  
1.7 	 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO DICHLORO­
BENZENES? 
If your doctor finds that you have been exposed to substantial amounts of DCBs, ask whether 
your children might also have been exposed.  Your doctor might need to ask your state health 
department to investigate. 
You and your children could be exposed to 1,4-DCB in your home if you use consumer products 
that contain 1,4-DCB, such as some toilet bowl cleaners and mothballs.  Exposure of children to 
1,4-DCB can be minimized by discouraging them from playing with, swallowing, or having skin 
contact with treated products.  These items should be stored out of reach of young children and 
kept in their original containers to prevent accidental poisonings.  Keep your Poison Control 



















1. PUBLIC HEALTH STATEMENT 
1.8 	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
EXPOSED TO DICHLOROBENZENES? 
Several tests can be used to show if you have been exposed to DCBs.  The most commonly used 
tests measure their dichlorophenol breakdown products in urine and blood.  These tests require 
special equipment that is not routinely available in a doctor's office, but they can be performed in 
a special laboratory. 
The presence of the dichlorophenol breakdown products in the urine indicates a person has been 
exposed to DCBs within the previous day or two.  For example, detection of 2,5-dichlorophenol 
in urine is commonly used to determine worker exposure to 1,4-DCB in industrial settings.  
Another test measures levels of DCBs in your blood, but this is used less often.  Neither of these 
tests can be used to show how high the level of DCB exposure was or to predict whether harmful 
health effects will follow.
More information about how 1,4-DCB can be measured in exposed people is presented in 
Chapters 3 and 7. 
1.9 	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law. The EPA, the Occupational Safety and Health 
Administration (OSHA), and the Food and Drug Administration (FDA) are some federal 
agencies that develop regulations for toxic substances.  Recommendations provide valuable 
guidelines to protect public health, but cannot be enforced by law.  The Agency for Toxic 
Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety 
and Health (NIOSH) are two federal organizations that develop recommendations for toxic 
substances. 
Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a 


















1. PUBLIC HEALTH STATEMENT 
on levels that affect animals; they are then adjusted to levels that will help protect humans.  
Sometimes these not-to-exceed levels differ among federal organizations because they used 
different exposure times (an 8-hour workday or a 24-hour day), different animal studies, or other 
factors. 
Recommendations and regulations are also updated periodically as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for dichlorobenzenes include the following: 
The federal government has taken a number of steps to protect people from excessive exposure 
to DCBs. EPA has listed 1,2-, 1,3-, and 1,4-DCB as hazardous wastes and subjects them to 
hazardous waste regulations.  EPA has set maximum levels of 600 micrograms (µg) of 1,2-DCB 
and 75 µg of 1,4-DCB per liter of drinking water. 1,4-DCB is a pesticide registered with EPA, 
and its manufacturers must provide certain kinds of information to EPA for it to be registered for 
use as a pesticide. OSHA has set maximum levels of 50 ppm for 1,2-DCB and 75 ppm for 
1,4-DCB in workplace air for an 8-hour day, 40-hour workweek. 
More information about federal and state regulations regarding DCBs is presented in Chapter 8. 
1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below. 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses that result from exposure to 
hazardous substances. 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You 






















1. PUBLIC HEALTH STATEMENT 
and technical assistance number at 1-888-42ATSDR (1-888-422-8737), by e-mail at 
atsdric@cdc.gov, or by writing to: 
Agency for Toxic Substances and Disease Registry 
  Division of Toxicology and Environmental Medicine 
1600 Clifton Road NE 
  Mailstop F-32 
  Atlanta, GA 30333 
  Fax: 1-770-488-4178 
Organizations for-profit may request copies of final Toxicological Profiles from the following: 
National Technical Information Service (NTIS) 

5285 Port Royal Road 

  Springfield, VA 22161 

Phone: 1-800-553-6847 or 1-703-605-6000 



























2. RELEVANCE TO PUBLIC HEALTH 

2.1 	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO DICHLOROBENZENES IN 
THE UNITED STATES  
Dichlorobenzenes (DCBs) are chlorinated aromatic compounds that have three isomeric forms.  1,2-DCB 
is a colorless to pale yellow liquid used primarily as a precursor for 3,4-dichloroaniline herbicides.  
1,3-DCB is a colorless liquid used in the production of various herbicides, insecticides, pharmaceuticals, 
and dyes.  1,4-DCB, the most commercially important dichlorobenzene isomer, is a volatile colorless to 
white crystalline material with a mothball-like, penetrating odor.  It is used as a deodorant for restrooms, 
for moth control, and in the production of polyphenylene sulfide (PPS) resin. 
DCBs are not known to occur naturally in the environment.  The primary sources of 1,4-DCB of 
industrial or commercial origin in the environment are releases from space deodorants and moth 
repellants into the atmosphere.  1,4-DCB might also be released into water through waste water streams 
and landfill leachate and to soil through sewage sludge application, disposal of industrial waste, and 
atmospheric deposition.  1,2- and 1,3-DCBs are expected to be released to the environment during their 
use in herbicide production or during the use of other products containing these isomers.  1,2-DCB is 
produced in large quantities as a by-product during the production of 1,4-DCB and can be released into 
the environment during the disposal of unused supplies. 
1,2-, 1,3-, and 1,4-DCB have similar physical and chemical properties, and consequently are expected to 
have similar environmental fates.  DCBs will exist predominantly in the vapor-phase in the atmosphere.  
They are degraded in the atmosphere by reaction with hydroxyl radicals, with atmospheric lifetimes 
(theoretically calculated) of about 1 month.  The detection of these chemicals in rainwater suggests that 
atmospheric removal via washout is possible.  Depending on soil type, DCBs are expected to be
moderately mobile in soil and to volatilize from surface water and soil surfaces to the atmosphere.  
Volatilization, sorption, biodegradation, and bioaccumulation are likely to be competing processes, with 
the dominant fate being determined by local environmental conditions.  
DCB concentrations in soil, water, and food are generally low in comparison to concentrations in air, 
indicating that exposure of the general population to DCBs is predominantly by inhalation.  Individuals 























2. RELEVANCE TO PUBLIC HEALTH 
1,4-isomer in deodorant and moth repellent products.  Measured DCB concentrations in ambient outdoor 
air generally range from 0.01 to 0.1 ppb for 1,2-DCB, from 0.001 to 0.1 ppb for 1,3-DCB, and from
0.01 to 1 ppb for 1,4-DCB.  The average daily adult intakes of 1,2-, 1,3-, and 1,4-DCB from ambient air 
have been estimated to be about 1.8, 0.8, and 35 µg/day, respectively.  The heavy use of products 
containing 1,4-DCB in homes and other buildings has resulted in higher concentrations of this substance 
in indoor air compared to concentrations in outdoor air.  Measured 1,4-DCB concentrations in indoor air 
generally range from 0.1 ppb to 100 ppb.  Indoor inhalation exposure to 1,2- or 1,3-DCB is not expected 
to be important since these substances are not used in household and consumer products to the extent of 
1,4-DCB. 1,2- and 1,4-DCB have been detected in adipose tissue at concentrations ranging from <0.1 to 
38 ppb and from 0.2 to 500 ppb, respectively.  1,4-DCB has been detected in blood samples at 
concentrations ranging from below 0.04 to 45 ppb, while measured 1,2-DCB concentrations in blood are 
below 3 ppb.
Children can be exposed to DCBs prenatally, as indicated by the detection of all three isomers in placenta 
samples, as well as through breast feeding.  1,2-DCB concentrations measured in whole human milk 
range from 3 to 29 ppb.  1,3- and 1,4-DCB were detected together in whole human milk with mean and 
maximum concentrations of 6 and 75 ppb, respectively.  These isomers were detected in milkfat samples 
at a mean concentration of 161 ppb and a maximum concentration of 4,180 ppb.  1,2-, 1,3-, and 1,4-DCB 
measured separately in whole human milk samples had concentrations of 9, <5, and 25 ppb, respectively, 
while the milk fat of these samples contained 230 ppb of 1,2-DCB and 640 ppb of 1,4-DCB.  Children 
and adults are perhaps at equal risk for exposure to 1,4-DCB since there is no evidence to indicate that 
children are likely to be exposed to lower amounts of 1,4-DCB from everyday living.  While actual 
exposure reports are limited to a small number of case reports, available evidence suggests that children 
may be exposed to 1,4-DCB if they eat or play with moth balls or toilet deodorizers. 
2.2 SUMMARY OF HEALTH EFFECTS  
1,2-Dichlorobenzene. 1,2-DCB is quickly and extensively absorbed through both the gastrointestinal 
tract and the respiratory tract; studies measuring the absorption of 1,2-DCB following dermal exposure 
are not available. Following absorption, 1,2-DCB is distributed throughout the body, but tends to be 
found in greatest levels in the fat, kidney, and liver.  1,2-DCB is initially metabolized by cytochrome 
P-450 enzymes, specifically P4502E1, to an active epoxide followed by hydrolysis to 2,3-dichlorophenol 
or 3,4-dichlorophenol.  The dichlorophenols may be further oxidized or, more often, be conjugated to 





















2. RELEVANCE TO PUBLIC HEALTH 
unconjugated metabolites reported in the available studies.  Metabolism is believed to occur mainly in the 
liver, but may occur at lower levels in other tissues, such as the kidney or lung. Elimination of 1,2-DCB 
from the body is rapid, with the majority of a single dose being removed within the first 75 hours 
postexposure; elimination occurs primarily in the urine as metabolites. 
Information on health effects of 1,2-DCB in humans is essentially limited to observations of respiratory
tract and eye irritation in workers chronically exposed to the vapor.  The potential for inhaled 1,2-DCB to 
cause respiratory tract effects is also shown by the induction of nasal olfactory lesions in an acute-
duration study in mice.  This effect occurred at concentrations similar to or below the lowest exposure 
levels that caused systemic effects in rats, mice, and guinea pigs in other acute and intermediate-duration 
inhalation studies. No intermediate-duration studies examined the nasal cavity, indicating that a critical 
effect for longer-term inhalation exposures cannot be identified.  The liver is the primary systemic target 
of toxicity in animals exposed to 1,2-DCB.  Acute-, intermediate,- and chronic-duration inhalation and 
oral studies clearly identify the liver as a sensitive target of oral exposure, inducing increases in liver 
weight at low levels of exposure and histological changes such as cloudy swelling and centrilobular 
degeneration and necrosis at higher levels in rats and mice. 
Data on the possible effects of 1,2-DCB on reproductive or developmental end points in humans are not 
available. Studies by both the oral and inhalation routes of exposure failed to find effects of 1,2-DCB on 
histology of reproductive organs or indices of reproduction in rats and mice.  Similarly, limited available 
data suggest that inhalation and oral exposure to 1,2-DCB do not significantly affect prenatal 
development in rats or rabbits.   
Data on the possible carcinogenic effects of 1,2-DCB in humans are not available.  Exposure to 1,2-DCB 
by the oral route has not been shown to cause an increase in tumor formation following lifetime exposure 
in rats or mice.  The potential carcinogenic effects of 1,2-DCB by other routes of exposure have not been 
evaluated. EPA determined that 1,2-DCB is not classifiable as to human carcinogenicity and categorized 
it in cancer weight-of-evidence Group D. The International Agency for Research on Cancer (IARC) 
similarly determined that 1,2-DCB is not classifiable as to carcinogenicity to humans (Group 3).   
A more detailed discussion of the hepatic and respiratory effects associated with 1,2-DCB exposure 
follows. The reader is referred to Section 2.2, Discussion of Health Effects by Route of Exposure, for 






















2. RELEVANCE TO PUBLIC HEALTH 
Hepatic Effects. Data on the hepatic effects of 1,2-DCB in exposed humans are not available for any
exposure route.  The liver is the primary target in animals orally exposed to 1,2-DCB, generally resulting 
in centrilobular damage in acute- and subchronic-duration studies.  A single exposure to 1,500 mg/kg in 
rats caused lethal central necrosis. In rats exposed to 455 mg/kg/day for 15 days, severe liver damage, 
characterized by intense necrosis and fatty changes and porphyria, were reported.  Similarly, rats exposed 
to 300 mg/kg/day for 10 days showed hepatic necrosis of slight severity and increased serum alanine 
aminotransferase (ALT).  However, an acute (14-day) study by the National Toxicology Program  showed 
no hepatic effects in male or female rats given doses as high as 500 or 1,000 mg/kg/day for 
14 consecutive days.  The inconsistency between these findings might be due to a small number of 
animals in the14-day study and a low incidence and severity of lesions in the 10-day study.  Centrilobular 
liver effects similar to those reported in the acute studies were found in several intermediate-duration 
studies in rats and mice, occurring in rats exposed to 188 mg/kg/day for 138 doses, rats exposed to 
400 mg/kg/day for 90 days, rats exposed to 250 mg/kg/day or greater for 13 weeks, and mice exposed to 
250 mg/kg/day for 13 weeks.  A chronic study in rats and mice found no nonneoplastic liver effects in 
either sex of either species, even at exposures up to 120 mg/kg/day, suggesting that the nonneoplastic 
hepatic effects of 1,2-DCB may have a threshold, which might fall between 120 and 188 mg/kg/day. 
Respiratory Tract Effects.    Periodic industrial hygiene surveys and medical examinations were 
conducted in a plant where an unreported number of men were exposed to 1,2-DCB at an average level of 
15 ppm (range, 1–44 ppm) for an unreported duration; no nasal or eye irritation was attributable to 
exposure. Additionally, the study author noted that the researchers detected 1,2-DCB odor at a 
concentration of 50 ppm without eye or nasal irritation during repeated vapor inhalation experiments on 
animals.  An earlier source reported that occupational exposure to 100 ppm of 1,2-DCB caused irritation 
of the eyes and respiratory passages of exposed humans.  Data on the effects of 1,2-DCB on the 
respiratory tract in humans following oral or dermal exposure are not available. 
In male mice exposed to 1,2-DCB in mean concentrations of 0, 64, or 163 ppm for 6 hours/day, 
5 days/week for 4, 9, or 14 days, histopathologic lesions were observed in the olfactory epithelium of the 
nasal cavity at ≥64 ppm.  The olfactory epithelial lesions were graded as very severe following the 4-day
exposure and moderate after the 14 day exposure, indicating to the study authors that repair may occur 
despite continued exposure.  The more severe cases were characterized by a complete loss of olfactory
epithelium, which left only partially denuded basement membrane.  No histological alterations were 

























2. RELEVANCE TO PUBLIC HEALTH 
respiratory tract tissues were reported in intermediate- or chronic-duration inhalation studies in animals; 
however, in most cases, evaluation of nasal tissues was not conducted. 
1,3-Dichlorobenzene.  Data on the absorption of 1,3-DCB in humans and animals are not available for 
any route of exposure; however, absorption of the compound can be inferred from studies that have 
detected 1,3-DCB or metabolites in the breast milk, blood, and fat of humans and in the bile and urine of 
exposed animals. Distribution is believed to be similar to the other DCB isomers, but data demonstrating 
this are not currently available.  Similar to the other DCB isomers, 1,3-DCB is initially metabolized by
cytochrome P 450 enzymes, followed by extensive conjugation, primarily to glutathione.  1,3-DCB is 
eliminated mainly in the urine, similar to the other DCB isomers. 
Studies on the toxic effects of 1,3-DCB in humans are not available.  No studies evaluating the toxicity of 
1,3-DCB following dermal or inhalation exposure in animals were located.  Information on the oral 
toxicity of 1,3-DCB in animals is available from one 90-day systemic toxicity study and one 
developmental toxicity study.  The intermediate-duration study found effects in the thyroid, pituitary, and 
liver of rats, with thyroid lesions occurring at dose levels lower than those inducing pituitary and liver 
effects. The information on the developmental toxicity study of 1,3-DCB is from a gavage study reported 
without details as an abstract, which reported no treatment-related effects on prenatal development in rats.  
Reproductive function and carcinogenicity have not been evaluated in humans or animals exposed to 
1,3-DCB. EPA determined that 1,3-DCB is not classifiable as to human carcinogenicity and categorized 
it in cancer weight-of-evidence Group D. IARC similarly determined that 1,3-DCB is not classifiable as 
to carcinogenicity to humans (Group 3).
A more detailed discussion of the endocrine and hepatic effects associated with 1,3-DCB exposure 
follows. The reader is referred to Section 2.2, Discussion of Health Effects by Route of Exposure, for 
additional information on these and other health effects. 
Endocrine Effects.    In a 90-day study in rats given 0, 9, 37, 147, or 588 mg/kg/day, the most sensitive 
reported effects were on the pituitary and thyroid glands.  Histologically, depletion of colloid density in
the thyroid, characterized by decreased follicular size with scant colloid and follicles lined by cells that 
were cuboidal to columnar, was increased in a dose-related manner in males exposed to ≥9 mg/kg/day,
and in females exposed to ≥37 mg/kg/day.  The pituitary glands of males exposed to 1,3-DCB showed 
cytoplasmic vacuolization of the pars distalis in all exposed groups, but the incidence was statistically
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≥9 mg/kg/day and females at ≥37 mg/kg/day, and serum calcium in both sexes at ≥37 mg/kg/day were 
also believed by the authors to be related to effects on endocrine end points, possibly reflecting a 
disruption of hormonal feedback mechanisms, or target organ effects on the pituitary, hypothalamus, 
and/or other endocrine organs. 
Hepatic Effects.    In male and female rats exposed by gavage to up to 735 mg/kg/day for 10 days, 
hepatic effects included significantly increased relative liver weight in males at ≥147 mg/kg/day and 
females at ≥368 mg/kg/day, and altered histopathology at ≥368 mg/kg/day in both sexes.  The main 
hepatic histological change was dose-related centrolobular hepatocellular degeneration, characterized by
varying degrees of cytoplasmic vacuolization and swelling with intact membranes.  Other hepatic 
alterations included hepatocellular necrosis that was sporadically noted in animals exposed to 
≥147 mg/kg/day; this change was usually minimal to mild, and tended to increase in incidence and 
severity in males in a dose-related manner.  In a 90-day study of 1,3-DCB toxicity, rats of both sexes were 
exposed by gavage to up to 588 mg/kg/day.  Relative liver weights were increased in both sexes at 
≥147 mg/kg/day.  Dose-related increases in histological lesions, including inflammation, hepatocellular 
alterations, and hepatocellular necrosis were reported at doses of ≥147 mg/kg/day.  Other statistically
significant liver-associated effects included significantly increased serum aspartate aminotransferase 
(AST) levels (90–100% higher than controls) in males at ≥9 mg/kg/day and females at ≥37 mg/kg/day, 
but whether these changes were due to an effect on the liver or an endocrine effect is not clear.  Serum
lactate dehydrogenase (LDH) levels were also reduced in males at ≥9 mg/kg/day, but the biological 
significance of a decrease in liver enzymes is unclear.
1,4-Dichlorobenzene. Following inhalation or oral exposure, absorption of 1,4-DCB is rapid and 
complete.  Data on the absorption of 1,4-DCB following dermal exposure are not available; however, 
absorption is believed to be very low, based on a very high (>6 g/kg) dermal LD50 for 1,4-DCB in rats, 
and on a lack of systemic effects in humans who held solid 1,4-DCB in their hands.  Similar to the other 
dichlorobenzene isomers, 1,4-DCB is distributed throughout the body, but tends to be found in greatest 
levels in fat, liver, and kidney.  Metabolism of 1,4-DCB is similar to that of 1,2-DCB, with an initial 
oxidation to an epoxide, followed by hydrolysis to 2,5-dichlorophenol.  Extensive phase II metabolism
occurs subsequently, with eliminated metabolites found mainly as the sulfate, glucuronide, or mercapturic 




















2. RELEVANCE TO PUBLIC HEALTH 
Information on the health effects of 1,4-DCB in humans is available from limited observations in exposed 
workers and case reports.  Workers who were chronically exposed to 1,4-DCB vapor experienced 
irritation of the nose and eyes and case reports of people who inhaled or ingested 1,4-DCB suggest that 
the liver, nervous system, and hematopoietic system are systemic targets in humans.  The available 
limited information on these systemic effects in humans is consistent with findings in animals exposed to 
1,4-DCB. 
The acute, intermediate,- and chronic-duration toxicity of 1,4-DCB in animals has been evaluated in a 
number of studies, predominantly in rats and mice.  The respiratory tract is a target of inhaled 1,4-DCB as 
shown by histopathological changes in the lungs of acutely exposed rats and guinea pigs and nasal 
olfactory epithelium of chronically exposed rats and mice.  Liver and kidney effects are the best studied 
and most consistently observed effects of inhalation and oral exposure.  There is a general pattern in 
which increased liver weight and hepatocellular hypertrophy are predominant effects at exposure levels 
below those inducing more serious histopathological changes in the liver (e.g., congestion, fatty 
degeneration, focal necrosis) and clinical signs of toxicity in the respiratory tract (e.g., nose and eye 
irritation following inhalation exposure) and nervous system (e.g., tremors and salivation).  Exposure of 
male rats to 1,4-DCB, but not female rats or either sex of other species, causes development of renal 
lesions that have been shown to be the result of interaction with the protein α2µ-globulin, a mechanism
specific to male rats and not relevant to humans.  There are a few reports of effects on the hematologic 
system, adrenal gland, and thyroid, but these occurred at inhalation or oral exposure levels similar to or 
higher than those causing liver and kidney effects.  Chronic inhalation exposure to 1,4-DCB induced 
nasal olfactory epithelial lesions in rats at concentrations below those causing liver effects. 
Data on the effects of 1,4-DCB on reproductive end points in humans are not available.  Oral or inhalation
exposure to 1,4-DCB has not been demonstrated to produce treatment-related adverse changes in 
reproductive tissue histology or on reproductive end points in animals.  Two-generation inhalation and 
oral studies in rats found that 1,4-DCB did not affect reproductive performance but induced postnatal 
toxicity in F1 and F2 offspring, including reductions in survival on day 4, body weight gain, and 
neurobehavioral performance at doses similar to or lower than those inducing liver effects in 
intermediate-duration systemic toxicity studies.  No teratogenic effects were induced in rats by inhalation 
or oral exposure to 1,4-DCB, although indications of fetotoxicity (e.g., extra ribs) occurred at levels that 




















2. RELEVANCE TO PUBLIC HEALTH 
1,4-DCB is carcinogenic in animals following chronic inhalation and oral exposure.  Inhalation and oral 
lifetime studies found liver tumors in male and female mice but not in rats of either sex.  Chronic oral 
exposure also induced renal tubular cell adenocarcinomas in male rats, but these appear to be associated 
with male rat-specific α2µ-globulin nephropathy and not relevant to carcinogenicity in humans.  IARC 
determined that 1,4-DCB is possibly carcinogenic to humans (Group 2B).  The Department of Health and 
Human Services (DHHS) concluded that 1,4-DCB is reasonably anticipated to be a human carcinogen. 
A more detailed discussion of the hepatic, respiratory, developmental, and carcinogenic effects associated 
with 1,4-DCB exposure follows. The reader is referred to Section 2.2, Discussion of Health Effects by
Route of Exposure, for additional information on these effects and other health effects. 
Hepatic Effects.    In two human fatalities believed to be caused by 1,4-DCB inhalation, the subjects 
died of massive hepatic necrosis; the exposure concentrations are not known.  A 3 year-old child who had 
been playing with crystals containing 1,4-DCB for 4–5 days was jaundiced with pale mucous membranes, 
indicative of liver damage. 
Many animal studies by both the oral and inhalation routes have confirmed the liver as a sensitive target 
for 1,4-DCB toxicity.  Inhaled exposure concentrations of 158–211 ppm, at exposure durations from
2 weeks to 7 months, resulted in increased liver weights, cloudy swelling of the liver, and, at higher 
exposure levels, centrilobular hypercellular hypertrophy and necrosis.  Exposure to 270 ppm for 13 weeks 
caused increased liver weight in rats and mice and hepatocellular hypertrophy and increased serum
enzymes in mice.  Exposure to 538 ppm for 10 weeks, and throughout mating and gestation for females, 
resulted in hepatocellular hypertrophy and increased liver weights in both the parental (F0) generation and 
the F1 generation offspring.  In chronic inhalation studies in rats and mice, no effects were seen in either 
sex of either species at 75 ppm, but at 300 ppm, histological changes in the lung were seen in male mice, 
but not in female mice or in either sex of rats.  Acute oral studies have demonstrated hepatic effects 
(increased liver weight) at concentrations as low as 300 mg/kg in rats, with higher concentrations 
resulting in increased liver cell proliferation and vacuolated and/or basophilic cytoplasm of centrilobular 
cells. Similar hepatic effects occurred in mice orally exposed to 300 mg/kg/day for 1 week.  In rats 
exposed to 1,4-DCB for 13 weeks, increased relative liver weight was seen at ≥75 mg/kg/day, with 
centrilobular hypertrophy present at 300 mg/kg/day (Lake et al. 1997), and necrosis reported at 
1,200 mg/kg/day (NTP 1987); oral studies in mice have reported similar effects (NTP 1987). A study of 
1,4-DCB in male and female Beagle dogs found that oral exposure to 50 or 75 mg/kg/day caused 
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deposition, and hepatic portal inflammation after 6–12 months.  In the only chronic-duration (2-year) oral 
study of 1,4-DCB toxicity, no effects were seen in either sex of rats exposed to up to 300 mg/kg/day, 
while both sexes of mice showed significant, dose-related increases in hepatocellular degeneration, 
starting at 300 mg/kg/day.
Respiratory Tract Effects.    A case of pulmonary granulomatosis was reported to have occurred in a 
53-year-old woman who for 12–15 years had been inhaling 1,4-DCB crystals that were scattered on a 
weekly basis on the carpets and furniture of her home.  A lung biopsy revealed the presence of 1,4-DCB 
crystals with the surrounding lung parenchyma being distorted by fibrosis, thickening of the alveolar 
walls, and marked infiltrates of lymphocytes and mononuclear phagocytes.  These effects are most likely
related to the physical interaction of 1,4-DCB crystals (or any crystals when inhaled) with lung tissue, 
rather than to chemical toxicity.  A health survey of 58 men occupationally exposed to 1,4-DCB for 
8 hours/day, 5 days/week for 8 months to 25 years (average, 4.75 years) found the odor to be faint at 15– 
30 ppm and strong at 30–60 ppm, with painful irritation of the nose and eyes usually occurring at 
concentrations ranging from 80 to 160 ppm.  At levels >160 ppm, the air was considered not breathable 
for unacclimated persons. 
An evaluation of 953 adult participants in the Third National Health and Nutrition Examination Survey of 
the general U.S. population found statistically significant inverse associations between blood levels of 
1,4-DCB and two measures of pulmonary function.  When compared with subjects in the lowest decile of 
1,4-DCB blood concentration (0.10 ppb), subjects in the highest decile (>4.40 ppb) had decrements of 
-153 mL in forced expiratory volume in 1 second (FEV1) and -346 mL/second in maximum mid-
expiratory flow rate (MMEFR).  There were no significant associations with forced vital capacity (FVC) 
or peak expiratory flow rate (PEFR).  Although it is unclear whether the observed decrements in FEV1 
and MMEFR are biologically meaningful, and other studies investigating effects of 1,4-DCB on lung
function are not available, the findings suggest that exposure to 1,4-DCB may possibly contribute to 
decreases in lung function. 
Pulmonary effects (interstitial edema, congestion, and alveolar hemorrhage) were observed in rats and 
guinea pigs following intermittent exposure to 175 ppm of 1,4-DCB for 16 days.  The experimental 
design and report of this study have a number of deficiencies, such that the observations provide only
qualitative evidence of exposure-related acute respiratory effects.  Support for the respiratory tract as a 
target for inhaled 1,4-DCB in animals is provided by the induction of nasal lesions in rats and mice 























2. RELEVANCE TO PUBLIC HEALTH 
histological changes of the nasal olfactory epithelium occurred in female rats exposed to 75 or 300 ppm, 
and male rats and female mice exposed to 300 ppm.  In rats treated with 1,200 or 1,500 mg/kg/day or 
greater by gavage for 13 weeks, epithelial necrosis of the nasal turbinates was reported; similar effects 
were not seen in mice exposed by gavage to up to 1,800 mg/kg/day, or in rats or mice exposed by gavage 
for 2 years to up to 600 mg/kg/day. 
Developmental Effects.    A 21-year-old woman who had eaten 1–2 blocks of 1,4-DCB toilet 
freshener per week for the first 38 weeks of pregnancy gave birth to an apparently normal child.  In a 
2-generation study of the effects of inhaled 1,4-DCB on reproduction and development, the number of 
pups that died during the perinatal period was increased, and the body weights at postnatal day 0 and 
28 were significantly decreased, in animals exposed to 538 ppm; exposures to 66 or 211 ppm had no 
effect on developmental end points.  In rabbits exposed to 300 ppm, but not those exposed to 800 ppm, 
there was a significant increase in the number of resorptions and the percentages of resorbed 
implantations per litter; the fact that the effect did not occur in the rabbits exposed to the higher exposure 
level suggests that it was not treatment-related.  A 2-generation oral study in rats found toxicity in the 
offspring at doses ≥90 mg/kg/day; effects included reduced birth weight in F1 pups, increased mortality
on postnatal day 4 in F1 and F2 pups, clinical manifestations of dry and scaly skin (until approximately
postnatal day 7) in F1 and F2 pups, and reduced neurobehavioral performance (draw-up reflex evaluated at 
weaning) in F2 pups.  No exposure-related changes occurred at 30 mg/kg/day.  Other evaluations of 
developmental effects of 1,4-DCB following oral exposure have been negative. 
Cancer.    Data on the carcinogenic effects of 1,4-DCB in humans are not available.  1,4-DCB has been 
shown to be carcinogenic in chronic animal studies by both the inhalation and oral routes.  Following 
lifetime inhalation exposure, a dose-related increase in hepatocellular adenomas and carcinomas was 
observed in mice of both sexes, whereas incidences of liver or other tumors were not increased in rats.  
Following lifetime oral exposure, hepatic tumors (hepatocellular adenomas and carcinomas and 
histiocytic sarcomas) were increased in mice of both sexes, but not in either sex of rats.  The oral bioassay
also found that the male rats exposed to 1,4-DCB developed renal tubular cell adenocarcinomas, but these 
are believed to be the result of interaction with α2µ-globulin, a renal protein not present in humans.  Data 
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2.3 MINIMAL RISK LEVELS (MRLs) 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for 
dichlorobenzenes.  An MRL is defined as an estimate of daily human exposure to a substance that is 
likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of 
exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of 
effect or the most sensitive health effect(s) for a specific duration within a given route of exposure.  
MRLs are based on noncancerous health effects only and do not consider carcinogenic effects.  MRLs can 
be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes.  
Appropriate methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1994k), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
Inhalation MRLs 
1,2-Dichlorobenzene 
Acute-Duration Exposure.    No MRL was derived for acute-duration inhalation exposure to 
1,2-DCB due to insufficient data. No information was located regarding the acute inhalation toxicity of 
1,2-DCB in humans. The nasal cavity was a target of acute inhalation in animals as shown by a study in 
which male mice were exposed to 64 or 163 ppm of 1,2-DCB for 6 hours/day, 5 days/week for 4, 9, or 
14 days (Zissu 1995).  Histological examinations of the upper and lower respiratory tracts found that 
nasal olfactory epithelial lesions occurred at both levels of exposure.  The nasal lesions were graded as 
very severe following the 4 day exposure and moderate after the 14 day exposure, suggesting to the study 
authors that some tissue repair might have occurred despite continued exposure.  The more severe cases 
were characterized by a complete loss of olfactory epithelium, which left only the partially denuded 
basement membrane.  No histological alterations were observed in the respiratory epithelium of the nasal 
























2. RELEVANCE TO PUBLIC HEALTH 
Acute systemic effects of inhaled 1,2-DCB include histopathology in the liver (marked centrilobular 
necrosis) and kidneys (cloudy swelling of tubular epithelium) of rats exposed to 977 ppm for 1 hour 
(Hollingsworth et al. 1958), but not to 539 ppm for 3 or 6.5 hours (Hollingsworth et al. 1958) or 322 ppm
for 6 hours/day for 10 days (DuPont 1982).  Maternal body weight gain was decreased in rats and rabbits 
that were exposed to 100, 200, or 400 ppm of 1,2-DCB for 6 hours/day on days 6–15 (rats) or 6– 
18 (rabbits) of gestation (Hayes et al. 1985).  No prenatal developmental toxicity was observed in the 
rabbits, although skeletal variations (delayed ossification of cervical vertebral centra) occurred in fetuses 
of rats at 400 ppm, indicating that developmental effects occurred in rats at concentrations that also 
caused maternal toxicity. Based on these findings, a lowest-observed-adverse-effect level (LOAEL) of 
100 ppm for systemic toxicity and 400 ppm for developmental toxicity are identified. 
The nasal histopathology findings in mice show that the upper respiratory tract is a sensitive target for 
acute inhalation exposure to 1,2-DCB, as serious olfactory lesions occurred at exposure concentrations 
below those that caused systemic or developmental effects in rats and rabbits.  The 64 ppm LOAEL for 
severe nasal olfactory lesions precludes derivation of an acute inhalation MRL for 1,2-DCB because:  
(1) a no-observed-adverse-effect level (NOAEL) for nasal lesions was not determined, (2) no other 
animal studies tested exposure levels below 100 ppm or evaluated the nasal cavity, and (3) it is not 
ATSDR’s practice to derive MRLs based on serious LOAELs. 
Intermediate-Duration Exposure.    No intermediate-duration inhalation MRL was derived for 
1,2-DCB due to insufficient data.  Information on the toxicity of intermediate-duration inhalation 
exposures to 1,2-DCB is limited to the findings of a multispecies intermediate study (Hollingsworth et al. 
1958) and a 2-generation reproduction study in rats (Bio/dynamics 1989).  In the intermediate study, rats 
and guinea pigs were exposed to 49 or 93 ppm for 7 hours/day, 5 days/week for 6–7 months 
(Hollingsworth et al. 1958).  Mice were similarly exposed to 49 ppm only, and rabbits and monkeys were 
similarly exposed to 93 ppm only, although the rabbit and monkey data are compromised by small 
numbers of animals (two rabbits/sex and two female monkeys).  No compound-related histopathological 
or other changes occurred in any of the animals exposed to 49 ppm.  The only remarkable findings at 
93 ppm were statistically significant decreases in final body weight (8.9% less than controls) in male rats 
and absolute spleen weight (20% less than controls) in male guinea pigs, indicating that the NOAEL and 
LOAEL for systemic effects are 49 and 93 ppm, respectively.  In the reproductive toxicity study, male 
and female rats were exposed to 50, 150, or 394 ppm of 1,2-DCB for 6 hours/day, 7 days/week for 
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related renal changes were found in adult males of both generations at all levels of exposure, but these 
effects are specific to male rats and are not relevant to humans.  Decreased body weight gain, increased 
absolute and relative liver weights, and centrilobular hepatocyte hypertrophy occurred in adult rats of 
both sexes and generations at ≥150 ppm, indicating that the NOAEL and LOAEL for systemic effects are 
50 and 150 ppm.  There were no effects on reproduction in either generation, indicating that the NOAEL 
for reproductive toxicity is 394 ppm.  As discussed in the acute inhalation MRL section, a NOAEL of 
200 ppm and a LOAEL of 400 ppm were found for developmental toxicity (skeletal variations) in rats 
(Hayes et al. 1985). 
As discussed above, NOAELs of 49–50 ppm and LOAELs of 93–150 ppm are identified for systemic 
effects in intermediate-duration inhalation studies of 1,2-DCB in rats and guinea pigs (Bio/dynamics 
1989; Hollingsworth et al. 1958).  Neither of these studies evaluated possible effects in the nasal cavity, a 
known sensitive target of 1,2-DCB based on acute data.  As indicated in the acute inhalation MRL 
section, 64 ppm was a serious LOAEL for nasal olfactory lesions in rats intermittently exposed to 
1,2-DCB for 4–14 days (Zissu 1995).  Derivation of an intermediate-duration MRL for 1,2-DCB is 
precluded because the 64 ppm serious LOAEL for acute exposure is lower than the available 
intermediate-duration LOAELs for systemic and developmental effects. 
Chronic-Duration Exposure.    No MRL was derived for chronic-duration inhalation exposure to 
1,2-DCB due to insufficient data. The available information consists of two limited human reports.  
Workers who were exposed to concentrations of 1,2-DCB ranging from 1 to 44 ppm (average 15 ppm) for 
unreported durations did not experience eye or nasal irritation, or show any changes in standard blood and 
urine indices, as determined by periodic occupational health examinations (Hollingsworth et al. 1958).  
1,2-DCB also did not cause eye or nasal irritation in workers exposed to approximately 50 ppm
(researchers exposed during the conduct of inhalation studies in animals), although the odor was 
perceptible at this level (Hollingsworth et al. 1958). Occupational exposure to higher concentrations of 
100 ppm 1,2-DCB was reported to be irritating to the eyes and respiratory passages (Elkins 1950).  The 
lack of adequate exposure-response data and any additional information in these reports, as well as a lack 
of chronic toxicity data in animals, precludes derivation of a chronic inhalation MRL. 
1,3-Dichlorobenzene
No MRLs were derived for inhalation exposure to 1,3-DCB due to a lack of acute-, intermediate-, and 






















2. RELEVANCE TO PUBLIC HEALTH 
1,4-Dichlorobenzene 
Acute-Duration Exposure.     




A limited amount of information is available on the toxicity of inhaled 1,4-DCB in humans.  Case reports 
of people who inhaled 1,4-DCB provide indications that the liver and nervous system are systemic targets 
of inhalation toxicity in humans, but are limited by lack of adequate quantitative exposure information 
and/or verification that 1,4-DCB was the only factor associated with the effects (Cotter 1953; Miyai et al. 
1988; Reygagne et al. 1992). 
Observations in workers who were occupationally exposed to 1,4-DCB for 8 hours/day, 5 days/week for 
an average of 4.75 years (range from 8 months to 25 years) provide information relevant to acute 
inhalation exposures.  The odor was found to be faint at 15–30 ppm and strong at 30–60 ppm.  Painful 
irritation of the eyes and nose was usually experienced at 50–80 ppm, although the irritation threshold 
was higher (80–160 ppm) in workers acclimated to exposure.  Concentrations above 160 ppm caused 
severe irritation and were considered intolerable to people not adapted to it.  The odor and irritation 
effects are considered to be good acute warning properties that are expected prevent excessive exposures, 
although the industrial experience indicates that it is possible for people to become sufficiently acclimated 
to tolerate high concentrations of the vapor (Hollingsworth et al. 1956).  Periodic occupational health 
examinations showed no cataracts or any other lens changes in the eyes, or effects on clinical indices (red 
blood cell count, total and differential white blood cell counts, hemoglobin, hematocrit, mean corpuscular 
volume, blood urea nitrogen, sedimentation rate, or urinalysis) attributable to exposure. 
Information on effects of acute-duration inhalation exposure to 1,4-DCB in animals is available from
short-term systemic toxicity studies in rats and guinea pigs (Hollingsworth et al. 1956), a male 
reproduction study rats (Anderson and Hodge 1976), and developmental toxicity studies in rats and 
rabbits (Hayes et al. 1985; Hodge et al. 1977).  In the systemic toxicity study, five rats of each sex and 
five guinea pigs of each sex were exposed to 173 ppm of 1,4-DCB for 7 hours/day, 5 days/week for 
16 days (Hollingsworth et al. 1956).  Mild histological effects of interstitial edema, congestion, and 
alveolar hemorrhage were observed in the lungs of male rats and female guinea pigs.  The experimental 























2. RELEVANCE TO PUBLIC HEALTH 
only qualitative evidence of exposure-related respiratory effects.  In the reproduction study (a dominant 
lethal test), a NOAEL of 450 ppm was identified for reproductive performance in male mice that were 
exposed for 6 hours/day for 5 days prior to weekly mating with unexposed females for 8 weeks 
(Anderson and Hodge 1976).  No maternal or developmental toxicity occurred in rats that were exposed 
to 75–500 ppm for 6 hours/day on days 6–15 of gestation (Hodge et al. 1977), indicating that the highest 
NOAEL for reproductive effects in rats is 500 ppm.  A developmental study in which rabbits were 
exposed to 100–800 ppm for 6 hours/day on gestation days 6–18 found evidence of fetotoxicity (a minor 
variation of the circulatory system) only at 800 ppm, which was also maternally toxic as shown by body
weight loss early in gestation (Hayes et al. 1985), indicating that 800 ppm is a LOAEL for maternal and 
developmental effects in rabbits. 
The lung is the target of concern for inhaled 1,4-DCB in rats and guinea pigs acutely exposed to 173 ppm
(Hollingsworth et al. 1956) because the only effects observed in the acute reproductive and 
developmental studies were indications of maternal and fetotoxicity in rabbits at a much higher levels of 
800 ppm (Hayes et al. 1985).  Support for the respiratory tract as a sensitive target for 1,4-DCB vapor in 
animals is provided by the induction of nasal lesions in rats intermittently exposed to levels as low as 
75 ppm for 104 weeks in the study used to derive the chronic inhalation MRL for 1,4-DCB (Aiso et al. 
2005b; Japan Bioassay Research Center 1995).  Additionally, the animal data are consistent with the 
human experience indicating that occupational exposure to 1,4-DCB causes painful nose and eye irritation 
in the range of 50–160 ppm (Hollingsworth et al. 1956).  The current Threshold Limit Value-Time
Weighted Average (TLV-TWA) for 1,4-DCB of 10 ppm, which is intended to minimize the potential for 
eye irritation in exposed workers (ACGIH 2001), is largely based on the human findings of 
Hollingsworth et al. (1956). 
As discussed above, eye and nose irritation are critical effects of acute and longer-term inhalation 
exposures to 1,4-DCB in humans.  Because odor detection is a warning property expected to prevent 
irritation caused by 1,4 DCB (Hollingsworth et al. 1956), the highest level at which an odor was detected 
that was simultaneously without irritant effects, 30 ppm, was designated a minimal LOAEL for irritation 
for the purposes of derivation of the MRL; the 15 ppm level was therefore designated a NOAEL for 
irritant effects. Using the NOAEL of 15 ppm for eye and nose irritation in humans, and applying a total 
uncertainty factor of 10 (for individual variability), an MRL of 2 ppm was derived for acute inhalation 
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Intermediate-Duration Exposure. 
•	 An MRL of 0.2 ppm has been derived for intermediate-duration (15–364 days) inhalation 
exposure to 1,4-DCB. 
A limited amount of information is available on the intermediate-duration toxicity of inhaled 1,4-DCB in 
humans.  Case reports of people who inhaled 1,4-DCB over periods of months provide indications that 
the liver and nervous system are systemic targets of inhalation toxicity in humans, but are limited by lack 
of adequate quantitative exposure information and/or verification that 1,4-DCB was the only factor 
associated with the effects (Cotter 1953; Miyai et al. 1988; Reygagne et al. 1992). 
Information on effects of intermediate-duration inhalation exposure to 1,4-DCB in animals is available 
from 4–7-month toxicity studies in rats, mice, guinea pigs, rabbits, and monkeys (Hollingsworth et al. 
1956), a 13-week toxicity study in rats and mice (Aiso et al. 2005a), and a 2-generation reproductive/ 
developmental toxicity study in rats (Tyl and Neeper-Bradley 1989).  These studies show that hepatic 
effects increase in severity with increasing level of exposure, ranging from increased liver weight at low 
levels to degenerative and necrotic changes at higher concentrations, and identify the liver as the most 
sensitive target of intermediate-duration inhalation of 1,4-DCB.  The lowest reliable hepatic effect levels 
are identified in the 13-week and 2-generation studies, as discussed below. 
In the 13-week study, groups of 10 male and 10 female F344 rats and 10 male and 10 female BDF1 mice 
were chamber-exposed to 1,4-DCB vapor (>99.9% pure) at concentrations of 0, 25, 55, 120, 270, or 
600 ppm for 6 hours/day, 5 days/week for 13 weeks (Aiso et al. 2005a).  End points evaluated during the 
study included clinical signs (daily) and body weight and food consumption (weekly).  End points 
evaluated at the end of the 13-week exposure period included hematology (red blood cells [RBC], 
hemoglobin [Hb], Hematocrit [Hct], mean corpuscular volume [MCV], mean corpuscular hemogloblin 
[MCH]), blood biochemistry (total protein, albumin, total cholesterol, triglyceride, phospholipid, AST, 
ALT, alkaline phosphatase, blood urea nitrogen [BUN], creatine), organ weights, and histopathology.  
The histological examinations were comprehensive and included the nasal cavity, in accordance with 
OECD test guidelines for a 90-day inhalation study (Aiso 2005; OECD 1981).  
There were no exposure-related effects on survival, clinical signs, or body weight gain in the rats (Aiso et 
al. 2005a). Hematological changes suggestive of microcytic anemia occurred in male rats, including
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and MCV and MCH at 600 ppm.  Serum biochemical changes included significant increases in total 
protein in both sexes at 600 ppm, albumin in females at ≥270 ppm and males at 600 ppm, and total 
cholesterol and phospholipid in males at ≥270 ppm and females at 600 ppm, and significant decreases in 
triglycerides in males at 600 ppm, AST in both sexes at 600 ppm, and ALT and AP in males at ≥270 ppm.  
The biological significance of decreases in serum levels of liver enzymes is unclear.  Organ weight 
changes included >10% increases in absolute and relative weights of liver in males at ≥270 ppm and 
females at 600 ppm, kidneys in males at ≥270 ppm, and spleen in males at 600 ppm.  Histological effects 
included significantly increased incidences of centrilobular hepatocellular hypertrophy in the liver in male
rats at 600 ppm and kidney lesions indicative of α2µ-globulin nephropathy in male rats at ≥270 ppm.  
There were no histopathological changes in hematopoietic tissues, suggesting that the anemia in the male 
rats was secondary to α2µ-globulin nephropathy-related effects on erythropoietin synthesis in the renal 
tubules. 
There were no exposure-related effects on survival, clinical signs, or body weight gain in the mice (Aiso 
et al. 2005a).  Organ weight changes in the mice included >10% increases in liver weight in males at 
≥270 ppm (relative) and 600 ppm (absolute) and females at 600 ppm (absolute and relative); relative liver 
weights were 9.7, 9.7, 10.1, 23.9, and 62.6% higher than controls in the low- to high-dose males.  There 
were no significant hematological changes in either sex.  Serum ALT levels were significantly increased 
in males at ≥270 ppm (18.2, 9.1, 18.2, 54.5 and 164% higher than controls in the low- to high-dose 
groups). Other serum biochemical changes included significant increases in ALT in females at 600 ppm,
AST in males at 600 ppm, and total cholesterol and total protein in both sexes at 600 ppm.  Histological 
examinations showed significantly increased incidences of centrilobular hepatocellular hypertrophy in 
male mice at ≥270 ppm and female mice at 600 ppm; incidences in the control to high dose males were
0/10, 0/10, 0/10, 0/10, 10/10, and 10/10.  Affected hepatocytes were characterized by cell enlargement, 
varying nuclear size and shape, and coarse chromatin and inclusion bodies in the nucleus; the severity of 
these lesions was rated as slight at 270 ppm (males) and moderate at 600 ppm (both sexes).  The moderate 
hepatocellular hypertrophy in the 600 ppm male mice was accompanied by single cell necrosis (1/10) and 
focal liver necrosis (2/10). 
The lowest effect level in the 13-week study (Aiso et al. 2005a) study is 270 ppm based on the kidney and 
hematological effects in male rats and liver effects in rats and mice.  The kidney and hematological 
effects are consistent with α2µ-globulin nephropathy, which is specific to male rats and not relevant to 
humans.  The mice were more sensitive to the liver effects of 1,4-DCB than the rats because the only
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increased serum ALT occurred in addition to increased liver weight in the 270 ppm mice.  Additionally,
at the next highest tested level of 600 ppm, the mice had nuclear changes and evidence of necrosis in the 
hypertrophic hepatocytes, and increased serum AST as well as ALT, whereas none of these indicators of 
hepatocellular damage occurred in the rats.  Based on increased relative liver weight (>10%) in both 
species and histological and serum enzyme changes in the mice, this study identified a NOAEL of 
120 ppm and a LOAEL of 270 ppm for hepatic effects. 
In the two-generation study, groups of 28 Sprague-Dawley rats of each sex were exposed to actual mean 
1,4-DCB concentrations of 0, 66, 211, and 538 ppm (Tyl and Neeper-Bradley 1989).  Additional groups 
of 10 females were similarly exposed for 10 weeks in a satellite study.  The animals in the main study
were paired within groups for a 3 week mating period to produce the F1 generation.  Main study males 
that did not successfully mate in the first 10 days of the mating period were paired with the satellite 
females for 10 days.  Main study females that did not successfully mate during the first 10 days of the 
mating period were paired with proven males for the remaining 11 days of the mating period. Exposures 
of the main study F0 females were continued throughout the mating period and the first 19 days of
gestation, discontinued from gestation day 20 through postnatal day 4, and then resumed until sacrifice at 
weaning on postnatal day 28.  Exposures of the satellite F0 females were continued through mating until
sacrifice on gestation day 15.  Exposures of the F0 males continued until sacrificed at the end of the study
and satellite mating periods. Groups of 28 F1 weanlings/sex and satellite groups of 10 F1 female 
weanlings were exposed for 11 weeks and mated as described above to produce the F2 generation.  
Additionally, 20 F1 weanlings/sex from the control and high exposure groups served as recovery animals 
that were observed without exposure for 5 weeks prior to sacrifice.  Complete necropsies were performed 
on all F0 and F1 adult (parental) animals, F1 recovery animals, F1 weanlings not used in the rest of the 
study, and F2 weanlings, and histology was evaluated in the F0 and F1 parental animals.  Histological 
examinations were conducted on the liver and kidneys in all groups and on selected other tissues 
(pituitary, vagina, uterus, ovaries, testes, epididymides, seminal vesicles, prostate, and tissues with gross 
lesions) in the control and high-exposure groups.  The kidney evaluation included examination for the 
presence of α2µ-globulin droplets.  Additional end points evaluated in the parental generations included 
clinical observations, mortality, body weight, and food consumption.  Mating and fertility indices were 
determined for F0 and F1 males and females, and gestational, live birth, postnatal survival (4, 7, 14, 21, 
and 28 days), and lactation indices were determined for the F1 and F2 litters. 
No effects on reproductive parameters in either generation were reported, although systemic toxicity
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nephropathy was found in F0 and F1 adult males at ≥66 ppm.  Manifestations of this male rat-specific 
renal syndrome included α2µ-globulin accumulation and increased kidney weights at ≥66 ppm, and other 
characteristic histological changes at 538 ppm.  Body weights and weight gains were significantly 
reduced in F0 and F1 adult males and F1 adult females during the pre-breed exposure periods at 538 ppm.  
Absolute liver weights were increased in F0 males by 6, 16, and 38% in the 66, 211, and 538 ppm groups, 
respectively; the differences were statistically significantly different from control in the 211 and 538 ppm
groups. In F0 females, absolute liver weights were increased by 9 and 31% at 211 and 538 ppm, 
respectively, but statistical significance was achieved only at 538 ppm.  Similar changes were seen in 
relative liver weights of the F0 generation, with respective increases of 5, 14, and 52% in the 66, 211, and 
538 ppm males and 4, 9, and 31% in the 66, 211, and 538 ppm females; all groups of treated males, and 
the 211 and 538 ppm female groups, were statistically significantly different from controls.  Relative liver 
weights were also significantly increased in F1 adult males at ≥211 ppm and in F1 adult females at 
538 ppm.  Hepatocellular hypertrophy was observed in the livers of F0 and F1 males and females at 
538 ppm; no hepatic histological changes were induced at the lower exposure concentrations.  Other 
effects also occurred in the F0 and F1 males and females at 538 ppm, indicating that there was a consistent 
pattern of adult toxicity at the high exposure level, including reduced food consumption and increased 
incidences of clinical signs (e.g., tremors, unkempt appearance, urine stains, salivation, and nasal and 
ocular discharges); these effects only sporadically occurred at 211 ppm.  Other effects at 538 ppm
included reduced gestational and lactational body weight gain, and postnatal toxicity, as evidenced by
increased number of stillborn pups, reduced pup body weight, and reduced postnatal survival in F1 and/or 
F2 litters. This study identified:  (1) a NOAEL of 66 ppm and LOAEL of 211 ppm for increased (>10% 
above controls) relative liver weight in adult rats, and (2) a serious LOAEL of 538 ppm for systemic 
toxicity (central nervous system and other clinical signs) in adult rats and developmental toxicity
(increased stillbirths and perinatal mortality) in their offspring (Tyl and Neeper-Bradley 1989).  The 
identification of increased liver weight as a critical effect of 1,4-DCB toxicity is supported by findings of 
increased liver weight and serum liver enzyme levels and histopathologic liver lesions following repeated 
oral exposure (Naylor and Stout 1996). 
Benchmark dose (BMD) analysis of the male rat serum ALT data (Aiso et al. 2005a) was conducted using 
all appropriate continuous-variable models in the EPA Benchmark Dose Software (Version 1.3.2) and a 
benchmark response (BMR) of 1 standard deviation change from the control mean.  None of the models 
provided an adequate fit to the variance, precluding the use of this data set for selecting a point of 
departure for deriving an MRL.  Available continuous-variable models were also fit to the Tyl and 













   




   










2. RELEVANCE TO PUBLIC HEALTH 
The 2-degree polynomial model was the best fitting model, predicting a benchmark concentration 
(BMC1sd) and BMCL1sd (lower 95% confidence limit on the BMC1sd) of 120 and 92 ppm, respectively.  A 
summary of the predicted BMCs and BMCL for both end points, as well as details of the BMD modeling, 
are presented in Appendix A.   
Using the BMCL1sd of 92 ppm for increased liver weight in male rats and EPA (1994k) inhalation 
reference concentration (RfC) methodology to determine the MRL, the BMCL1sd of 92 ppm was duration-
adjusted for intermittent exposure, as follows: 
BMCL1sd ADJ	 = (BMCL1sd) (hours/24 hours) (days/7 days) 
= (92 ppm) (6 hours/24 hours) (7 days/7 days) 
=  23  ppm  
1,4-DCB exhibited the effects outside of the respiratory tract and consequently is treated as a 
category 3 gas for purposes of calculating the MRL.  The human equivalent concentration (HEC) for 
extrarespiratory effects produced by a category 3 gas is calculated by multiplying the duration-adjusted 
BMCL1sd (BMCL1sd ADJ, see below) by the ratio of blood:gas partition coefficients (Hb/g) in animals and 
humans (EPA 1994k).  Hb/g values were not available for 1,4-DCB in rats and humans.  Using a default 
value of 1 for the ratio of partition coefficients, the BMCL1sd HEC becomes 23 ppm: 
BMCL1sd HEC	 = (BMCL1sd ADJ) x [(Hb/g)RAT / (Hb/g)HUMAN],

= 23 ppm x [1] = 23 ppm
 
The BMCL1sd HEC was divided by a total uncertainty factor of 100 to derive the MRL.  This uncertainty
factor is comprised of component factors of 10 for interspecies extrapolation, and 10 for human 
variability.  Although the rat exposure concentration was adjusted to a HEC, an uncertainty factor of 
10 was still applied, because HEC calculation was based on an assumption of equivalent blood-gas 
partition coefficients, and not on actual data.  Dividing the 23 ppm BMCL1sd HEC for increased liver weight 
in male rats by an uncertainty factor of 100 (10 for interspecies extrapolation and 10 for human 
variability) yields an MRL of 0.2 ppm for intermediate-duration inhalation exposure to 1,4-DCB. 
Chronic-Duration Exposure. 























2. RELEVANCE TO PUBLIC HEALTH 
A limited amount of information is available on the long-term toxicity of inhaled 1,4-DCB in humans.  
Periodic occupational health examinations of workers who were exposed to 1,4-DCB for an average of 
4.75 years (range, 8 months to 25 years) showed no changes in standard blood and urine indices 
(Hollingsworth et al. 1956).  The odor was found to be faint at 15–30 ppm and strong at 30–60 ppm.  
Painful irritation of the eyes and nose was usually experienced at 50–80 ppm, although the irritation 
threshold was higher (80–160 ppm) in workers acclimated to exposure.  Concentrations above 160 ppm
caused severe irritation and were considered intolerable to people not adapted to it.  Occasional 
examination of the eyes showed no cataracts or any other lens changes.  The odor and irritation properties 
are considered to be fairly good warning properties that should prevent excessive exposures, although the 
industrial experience indicates that it is possible for people to become sufficiently acclimated to tolerate 
high concentrations of the vapor (Hollingsworth et al. 1956).  The data from this study are inadequate for 
chronic MRL derivation due to poor characterization of long-term exposure levels, insufficient 
investigation of systemic health end points, and reporting and other study deficiencies.  Although the 
available occupational data are insufficient for chronic MRL derivation, the nose and eye irritation 
findings in humans are consistent with nasal effects observed in chronically exposed animals, as 
discussed below. 
Information on the chronic inhalation toxicity of 1,4-DCB in animals is available from two studies in rats 
and mice (Aiso et al. 2005b; Japan Bioassay Research Center 1995; Riley et al. 1980a, 1980b).  In the 
Riley et al. (1980a, 1980b) studies, rats of both sexes and female mice were exposed to 75 or 500 ppm of 
1,4-DCB for 5 hours/day, 5 days/week for up to 76 weeks (rats) or 57 weeks (mice), followed by
32 weeks (rats) or 18–19 weeks (mice) without exposure.  There were no exposure-related 
histopathological changes in the nasal cavity or other tissues in either species.  Liver and kidney weights 
were increased in rats of both sexes at 500 ppm, but the toxicological significance is questionable due to 
the negative histopathology findings and the lack of related clinical chemistry effects.  Evaluation of the 
mouse data is limited by reporting insufficiencies in the available summary of the study.
In the other chronic study (Aiso et al. 2005b; Japan Bioassay Research Center 1995), groups of 50 male 
and female F344/DuCrj rats and 50 male and female Crj:BDF1 mice were exposed to 1,4-DCB in target 
concentrations of 0, 20, 75, or 300 ppm for 6 hours/day, 5 days/week for 104 weeks.  Study end points 
included clinical signs and mortality, body weight (weekly for the first 13 weeks, and subsequently every
4 weeks), and hematology, blood biochemistry, and urinalysis indices (evaluated at end of study).  
Selected organ weight measurements (liver, kidneys, heart, lungs, spleen, adrenal, brain, testis, and ovary)


















2. RELEVANCE TO PUBLIC HEALTH 
the study or at time of unscheduled death.  No interim pathology examinations were performed.  As 
summarized below, this study identifies a NOAEL of 20 ppm and a LOAEL of 75 ppm for dose-related 
eosinophilic changes in the olfactory epithelium in female rats. 
For the rats, the actual mean chamber concentrations were 0, 19.8, 74.8, or 298.4 ppm over the duration 
of the study (Aiso et al. 2005b; Japan Bioassay Research Center 1995).  The number of rats surviving to 
scheduled termination was significantly (p<0.05) reduced at 300 ppm in males.  Survival in the male rats 
was noticeably lower than controls beginning at approximately study week 80, and overall survival at 0, 
20, 75, and 300 ppm was 66% (33/50), 68% (34/50), 58% (29/50), and 36% (18/50), respectively. There 
were no exposure-related decreases in survival in the female rats, or effects on growth or food 
consumption in either sex.  Changes in various hematological and blood biochemical indices (mean cell 
volume, total cholesterol, phospholipids, blood urea nitrogen, creatinine, and calcium in males; total 
protein, total bilirubin, blood urea nitrogen, and potassium in females) occurred at 300 ppm, but a lack of 
numerical data and statistical analysis precludes interpretations of significance for these end points.  
Absolute and relative liver weights in both sexes and kidney weights in males were significantly 
increased at 300 ppm.  Additional findings included histopathological changes in the kidneys and nasal 
epithelia. The kidney lesions occurred only in male rats at 300 ppm and included significantly increased 
incidences of mineralization of the renal papilla and in hyperplasia of the urothelium.  The nasal lesions 
mainly included increased incidences of eosinophilic changes (globules) in the olfactory epithelium
(moderate or greater severity) in males at 300 ppm and females at ≥75 ppm.  Incidences of this lesion at 0, 
20, 75, and 300 ppm were 1/50, 2/50, 2/50, and 7/50 in males, and 28/50, 29/50, 39/50, and 47/50 in 
females.  The increases were statistically significant (p≤0.05, Fisher's Exact Test performed by ATSDR) 
at ≥75 ppm in females and 300 ppm in males, and there was a trend of increasing response with 
increasing dose in both sexes (Cochran-Armitage test, performed by ATSDR).  Other nasal lesions that 
were significantly increased at 300 ppm were eosinophilic globules in the respiratory epithelium (11/50, 
10/50, 14/50, 38/50) and respiratory metaplasia in the nasal gland (5/50, 4/50, 4/50, 33/50) in females at 
300 ppm.  Kidney lesions were increased only in male rats at 300 ppm and included significantly 
increased incidences of mineralization of the renal papilla (0/50, 1/50, 0/50, 41/50) and in hyperplasia of 
the urothelium (7/50, 8/50, 13/50, 32/50).   
For the mice, the actual mean chamber concentrations were 0, 19.9, 74.8, or 298.3 ppm over the duration 
of the study. Survival was significantly reduced in male mice at 300 ppm (due to an increase in liver 
tumor deaths), but comparable to controls in the females.  Terminal body weight was significantly


















2. RELEVANCE TO PUBLIC HEALTH 
hematological and blood biochemical indices (total cholesterol, serum glutamic oxaloacetic transaminase 
[SGOT], serum glutamic pyruvic transaminase [SGPT], lactic dehydrogenase [LDH], and alkaline 
phosphatase [AP] in both sexes; platelet numbers, total protein, albumin, total cholesterol, blood urea 
nitrogen, and calcium in females) occurred at 300 ppm (Japan Bioassay Research Center 1995), but a lack 
of reported numerical data and results of statistical analysis precludes interpretation of these end points.  
Absolute and relative liver and kidney weights in both sexes were significantly increased at 300 ppm.  
Additional findings included histopathological changes in the nasal cavity, liver, and testes.  The nasal 
lesions included significantly increased incidences of respiratory metaplasia in the nasal gland (moderate 
severity) in males at 75 ppm (9/49, 12/49, 18/50, 11/49) and olfactory epithelium (slight severity) in 
males at 75 ppm (23/49, 30/49, 37/50, 22/49) and females at 300 ppm (7/50, 6/50, 2/49, 20/50); the 
effects in the males were not dose-related (i.e., incidences were increased at 75 ppm but not at 300 ppm).  
The incidence of centrilobular hepatocellular hypertrophy was significantly increased in male mice at 
300 ppm (0/49, 0/49, 0/50, 34/49).  Incidences of liver tumors were also increased at 300 ppm; these 
included hepatocellular carcinoma in males (12/49, 17/49, 16/50, 38/49) and females (2/50, 4/50, 2/49, 
41/50), hepatocellular adenoma in females (2/50, 10/50, 6/49, 20/50), hepatoblastoma in males (0/49, 
2/49, 0/50, 8/49) and females (0/50, 0/50, 0/49, 6/50), and histiocytic sarcoma in males (0/49, 3/49, 1/50, 
6/49).  Testicular mineralization was significantly increased in males at ≥75 ppm (27/49, 35/49, 42/50,
41/49) (Japan Bioassay Research Center 1995).  The testicular mineralization was not considered to be a 
toxicologically significant effect (Aiso 2006) because (1) no signs of testicular toxicity were observed in 
mice exposed for 13 weeks (Aiso et al. 2005a), and (2) it was confined to the testicular capsules and 
testicular blood vessels and not observed in the testicular parenchyma, indicating that it is a finding 
commonly observed in aged mice independent of exposure to 1,4-DCB (Aiso 2006).   
The results of this study indicate that moderate or severe eosinophilic changes in the nasal olfactory
epithelium in female rats is the most sensitive toxic effect in the most sensitive species and sex.  The 
NOAEL and LOAEL for these nasal lesions are 19.8 and 74.8 ppm, respectively.  To derive a point of 
departure for MRL derivation, BMD analysis was conducted using the incidences of the nasal lesions 
(moderate or greater severity) in the female rats.  Data for other end points were not modeled because the 
effects occurred at higher concentrations (nasal lesions and hepatocellular hypertrophy in mice, kidney 
lesions in rats) or were not toxicologically significant (testicular mineralization in mice).  All 
dichotomous models in the Benchmark Dose Software (version 1.3.2) were fit to the female rat nasal 
lesion incidence data.  All models provided adequate fits to the data, and the quantal linear model 
provided the best fit to the data.  Using a BMR level of 10% extra risk above the control incidence, the 



















   
        
       
 
    












2. RELEVANCE TO PUBLIC HEALTH 
confidence limit (BMCL10) of 9.51 ppm. A summary of the predicted BMCs and BMCLs, as well as 
details of the BMD modeling, are presented in Appendix A.   
Using the BMCL10 value of 9.51 ppm for increased incidences of nasal lesions in female rats and EPA 
(1994k) inhalation RfC methodology to determine the MRL, the BMCL10 was duration-adjusted for 
intermittent exposure, as follows: 
BMCL10 ADJ = (BMCL10) (hours/24 hours) (days/7 days) 
= (9.51 ppm) (6 hours/24 hours) (5 days/7 days) 
= 1.70 ppm
For the nasal olfactory epithelium changes in female rats, 1,4-DCB was treated as a category 1 gas with 
effects in the extrathoracic region for purposes of calculating the HEC.  Using EPA (1988, 1994b) 
reference values, the regional gas deposition ratio was calculated as follows (EPA 1994a): 
RGDRET = [(VE/SAET)A/(VE/SAET)H] 
=  (0.24 m3/day/15cm2)/(20 m3/day/200cm2) 
= 0.16 
 where: RGDRET = regional gas deposition ratio in the extrathoracic region 
VE = minute volume in rats (VE)A or humans (VE)H 
  SAET = extrathoracic surface area in rats (SAET)A or humans (SAET)H 
The HEC was calculated by multiplying the rat BMCL10 ADJ by the RGDRET to yield a BMCL10 HEC of 
0.27 ppm, as follows: 
BMCL10 HEC = BMCL10 ADJ x RGDRET
 = 1.70 ppm x 0.16 
= 0.27 ppm
The BMCL10 HEC of 0.27 ppm for nasal effects in rats was divided by a total uncertainty factor of 30 to 
calculate the MRL.  This uncertainty factor is comprised of component factors of 3 for interspecies 
extrapolation and 10 for human variability.  A 3-fold uncertainty factor was used instead of a default 
10-fold factor to extrapolate from rats to humans, because the dosimetry adjustment (i.e., calculation of 
the human equivalent exposure for time and concentration [NOAELHEC]) addresses one of the two areas 
of uncertainty encompassed in an interspecies extrapolation factor.  The dosimetric adjustment addresses 
the pharmacokinetic component of the extrapolation factor, but the pharmaco-dynamic area of uncertainty
remains as a partial factor for interspecies uncertainty.  Dividing the 0.27 ppm NOAEL10 HEC by the 































•	 An MRL of 0.7 mg/kg/day has been derived for acute-duration (≤14 days) oral exposure to 
1,2-DCB. 
Information on effects of acute oral exposure to sublethal doses of 1,2-DCB consists of findings in three 
systemic toxicity studies in rats and mice and one developmental toxicity study in rats (NTP 1985; 
Rimington and Ziegler 1963; Robinson et al. 1991; Ruddick et al. 1983).  These studies administered the 
compound by gavage and collectively identify the liver as the most sensitive target.  Severe liver damage, 
characterized by intense necrosis and fatty changes as well as porphyria, occurred in rats administered 
455 mg/kg/day for 15 consecutive days (Rimington and Ziegler 1963).  Rats that were exposed to 
300 mg/kg/day for 10 consecutive days had hepatic effects that included necrosis and increased serum
ALT (Robinson et al. 1991).  Hepatocellular degeneration and necrosis occurred in mice that were 
exposed to 250 or 500 mg/kg/day for 14 consecutive days (NTP 1985).  The 15-day rat and 14-day mouse 
studies are limited by small numbers of animals (3–5 per dose) and lack of a NOAEL due a single dose 
level (Rimington and Ziegler 1963) or lack of histopathology evaluations at doses lower than the LOAEL 
(NTP 1985). The 10-day study (Robinson et al. 1991) is the most appropriate basis for MRL derivation 
because it is well designed, included four dose levels, and provides dose-response data for several hepatic 
end points.  
In the Robinson et al. (1991) study, groups of 10 male and 10 female Sprague-Dawley rats were treated 
with 1,2-DCB in corn oil by gavage at doses of 0, 37.5, 75, 150, or 300 mg/kg/day for 10 consecutive 
days.  The doses were selected on the basis of a reported rat oral LD50 of 500 mg/kg.  End points 
evaluated during the study included clinical signs, body weight, and food and water consumption.  
Evaluations at the end of the exposure period included hematology (five indices), serum chemistry 
(nine indices including aspartate AST, ALT, LDH, cholesterol, blood urea nitrogen, and creatinine), and 
selected organ weights (brain, liver, spleen, lungs, thymus, kidneys, adrenal glands, heart, and testes or 
ovaries). Histological examinations were performed on various tissues including liver, kidneys, urinary
























2. RELEVANCE TO PUBLIC HEALTH 
(brain, sciatic nerve), immunological (spleen, thymus, lymph nodes), gastrointestinal (duodenum, ileum, 
jejunum, salivary gland, colon, cecum, rectum), endocrine (adrenal glands, pancreas), and reproductive 
(testes, seminal vesicles, prostate, ovaries) in the high-dose and control groups.  Target organs identified 
in the high-dose group were also histologically evaluated at the lower dose levels. 
No clinical signs or effects on survival were observed (Robinson et al. 1991). Body weight gain was 
significantly reduced in the male rats at 300 mg/kg/day (final body weights were 10.9% lower than 
controls), but not in females, and there were no exposure-related changes in food consumption in either 
sex. Statistically significant changes in organ weights predominantly occurred at 300 mg/kg/day,
including significantly decreased absolute spleen weight in both sexes and decreased absolute heart, 
kidney, thymus, and testes weights in males.  Liver weight (absolute and relative) was significantly 
increased in females at ≥150 mg/kg/day and males at 300 mg/kg/day; compared to controls in the low- to 
high-dose females, absolute liver weights were 1.8, 9.0, 20.5, and 29.0% increased and relative liver 
weights were 6.8, 7.6, 21.7, and 34.5% increased.  Clinical chemistry findings included significantly 
increased serum ALT in both sexes at 300 mg/kg/day and serum phosphorus in females at 
≥150 mg/kg/day.  Serum cholesterol was significantly increased in females at ≥37.5 mg/kg/day, but the 
toxicological significance is unclear because the values were similar at all dose levels and showed no 
dose-response. Histopathological findings were limited to the liver and included necrosis that was slight 
in severity and significantly (p=0.04) increased in males at 300 mg/kg/day (4/10 compared to 0/10 in
controls); incidences in the other dose groups were not reported, although the study authors indicated that 
target organs in the high-dose groups were histologically evaluated at the lower dose levels.  Incidences 
of other hepatic lesions were not significantly increased, but included inflammation (characterized by 
lymphocyte and macrophage infiltrates) and degeneration of hepatocytes (characterized by varying 
degrees of fibrillar or vacuolated cytoplasm and swelling with intact cell membranes).  This study
identified a NOAEL of 75 mg/kg/day and a LOAEL of 150 mg/kg/day for increased liver weight (>10%) 
in female rats, as well as a LOAEL of 300 mg/kg/day for liver necrosis in male rats.   
To derive a point of departure for MRL derivation, BMD dose analysis was conducted using the rat 
absolute liver weight data. The liver lesion data were not subjected to BMD analysis because incidences 
of liver necrosis were only reported for control and high-dose rats.  Serum liver enzyme (ALT, AST, 
LDH) data were not subjected to BMD analysis because a statistically significant increase was noted only
for serum ALT in the high-dose group of male rats and the magnitude of the increase (50% higher than 
the control serum ALT level) is not considered to be adverse.  All continuous variable models in the EPA 
























2. RELEVANCE TO PUBLIC HEALTH 
rats. One standard deviation increase from the control mean value was selected as the BMR in the 
absence of a biological rationale for using an alternative BMR.  A summary of the predicted BMDs and 
BMDLs, as well as details of the BMD modeling, are presented in Appendix A.  The linear model was 
determined to the best-fitting model for the liver weight data in male rats (provided a BMD1sd of 
249.04 mg/kg/day and a BMDL1sd of 158.55 mg/kg/day) and female rats (provided a BMD1sd of 
84.67 mg/kg/day and a BMDL1sd of 67.73 mg/kg/day).  Among the best-fitting model results, the lowest 
BMDL1sd of 67.73 mg/kg/day was selected as the point of departure for deriving the MRL.  The BMDL1sd 
of 67.73 mg/kg/day was divided by an uncertainty factor of 100 (10 for extrapolation from animals to 
humans and 10 for human variability) to derive an MRL of 0.7 mg/kg/day for acute-duration oral 
exposure to 1,2-DCB. 
Intermediate-Duration Exposure. 
•	 An MRL of 0.6 mg/kg/day has been derived for intermediate-duration (15–364 days) oral 
exposure to 1,2-DCB. 
Information on effects of intermediate-duration oral exposure to 1,2-DCB is available from three 
intermediate studies in rats and mice identifying the liver as the most sensitive target of toxicity
(Hollingsworth et al. 1958; NTP 1985; Robinson et al. 1991).  Incidences of degenerative liver lesions 
were significantly increased in rats exposed to 250–500 mg/kg/day for ≥13 weeks (Hollingsworth et al. 
1958; NTP 1985; Robinson et al. 1991) and mice exposed to 250 mg/kg/day for 13 weeks (NTP 1985). 
Necrotic lesions occurred in several rats at 125 mg/kg/day (1/10 males, 3/10 females), but the increase 
was not statistically significant (NTP 1985).  Other hepatic findings in rats exposed to lower doses (125– 
188 mg/kg/day for ≥13 weeks) included increases in relative liver weight and serum levels of ALT, 
cholesterol, serum protein, and decreases in serum triglycerides.  Increased serum ALT is an inconsistent 
finding because it was induced in rats exposed to ≥100 mg/kg/day for 90 days (Robinson et al. 1991), but 
not in rats exposed to ≥125 mg/kg/day for 13 weeks (NTP 1985). Additionally, the increase in serum
ALT was not dose-related and serum levels of other liver-associated enzymes were not increased in either 
the Robinson et al. (1991) study (AST, LDH, and AP) or the NTP (1985) study (AP and GGTP).  The 
lowest LOAEL is 125 mg/kg/day, which is a minimal LOAEL for increased liver weight in rats in the 
NTP (1985) study. 
In the NTP (1985) study, groups of 10 male and 10 female F344 rats and 10 male and 10 female 
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5 days/week for 13 weeks.  Histology examinations of the liver were limited to the control and three 
highest dose groups.  Degenerative lesions were significantly (p≤0.05) increased in both species at 
≥250 mg/kg/day.  Changes in the rats included necrosis of individual hepatocytes at ≥250 mg/kg/day and 
centrilobular degeneration at 500 mg/kg/day; total incidences of these lesions at 0, 125, 250, and 
500 mg/kg/day were 0/10, 1/10, 4/9, and 8/10 in males, and 0/10, 3/10, 5/10, and 7/8 in females.  Relative 
liver weights were significantly increased at 125, 250, and 500 mg/kg/day in the males (8, 17, and 45% 
higher than controls) and females (8, 15, and 30%); increased relative liver weights were not seen at 
lower doses in either sex. There were no increases in serum levels of liver enzymes [ALT, AP, or GGPT]
at any dose in either sex.  Serum cholesterol was significantly increased in males at ≥30 mg/kg/day (50.0, 
17.6, 26.5, 70.6, and 109% higher than controls in the low to high dose groups; not significant at 
60 mg/kg/day) and females at ≥125 mg/kg/day (12.2, 12.2, 32.6, 26.5, and 51.0%).  Although increases in 
serum cholesterol were observed at doses as low as 30 mg/kg/day, the toxicological significance is 
unclear because there was no clear dose-response unless the increase at 30 mg/kg/day is considered to be 
outlying.  Urinary concentrations of uroporphyrin and coproporphyrin were 3–5 times higher than 
controls in the 500 mg/kg/day males and females, but this increase was not considered indicative of 
porphyria because total porphyrin concentration in the liver was not altered at any dose level and no 
pigmentation indicative of porphyria was observed by ultraviolet light at necropsy.  The 60 and 
125 mg/kg/day doses are the NOAEL and LOAEL, respectively, for hepatic effects in rats based on the 
increases in liver weight in both sexes.   
In the mice, no compound-related histopathological changes were observed in either sex at 0 and 
125 mg/kg/day or in females at 250 mg/kg/day.  Lesions that were significantly increased included 
necrosis of individual hepatocytes, hepatocellular degeneration and/or pigment deposition in 4/10 males 
at 250 mg/kg/day, and centrilobular necrosis, necrosis of individual hepatocytes, and/or hepatocellular 
degeneration in 9/10 males and 9/10 females at 500 mg/kg/day.  Relative liver weights were significantly
increased at 500 mg/kg/day in both sexes, but there were no exposure-related changes in serum levels of 
ALT, AP, or GGPT in either sex at any dose (no other clinical chemistry indices were examined in the 
mice). Based on the liver lesion data, the NOAEL and LOAEL in mice are 125 and 250 mg/kg/day, 
respectively.
To derive a point of departure for MRL derivation, BMD analysis was conducted using liver lesion and 
liver weight data from the NTP (1985) study.  Dichotomous models available in the EPA Benchmark 
Dose Software (Version 1.3.2) were fit to data for incidences of liver lesions (single cell necrosis, 


























2. RELEVANCE TO PUBLIC HEALTH 
mice. Because there were no apparent differences in sensitivity to 1,2-DCB among the male and female 
rats, the liver lesion data were combined to increase the statistical power for BMD analysis.  For each data 
set, BMDs and their lower 95% confidence limits (BMDLs) were calculated using a BMR of 10% extra 
risk. All available models provided adequate fit to liver lesion data for male and female rats combined.  
The best-fitting model was the quantal quadratic model, which provided a BMD10 of 108.71 mg/kg/day
and a BMDL10 of 92.08 mg/kg/day.  The log-probit model was determined to be the best-fitting model for 
the male mouse incidence data and provided a BMD10 of 176.05 mg/kg/day and BMDL10 of 
114.58 mg/kg/day.  Continuous variable models in the EPA Benchmark Dose Software were fit to the 
relative liver weight data for male and female rats using a BMR of 1 standard deviation from the control 
mean. Adequate fits were not obtained for the male rat liver weight data, but the linear model was the 
best-fitting model for the female data, resulting in a BMD1sd of 108.15 mg/kg/day and a BMDL1sd of
89.27 mg/kg/day.  A summary of the predicted BMDs and BMDLs for both end points, as well as details 
of the BMD modeling, are presented in Appendix A. 
The BMDL1sd of 89.27 mg/kg/day from the best-fitting modeling results of the female rat relative liver 
weight data is lower than the BMDL10 of 92.08 mg/kg/day from the best-fitting modeling results of liver 
lesion incidences in the male and female rats combined and the BMDL10 of 114.58 mg/kg/day from the 
best-fitting model results of liver lesion incidences in the male mice.  Therefore, the BMDL1sd of 
89.27 mg/kg/day for increased relative liver weight in the female rats was selected as the point of 
departure for the MRL. The BMDL1sd of 89.27 mg/kg/day was adjusted for intermittent experimental 
exposure (5 days/7 days) to give a duration-adjusted BMDL1sd of 63.76 mg/kg/day, and divided by an 
uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability) to derive an 
intermediate-duration oral MRL of 0.6 mg/kg/day for 1,2-DCB.   
Chronic-Duration Exposure. 
•	 An MRL of 0.3 mg/kg/day has been derived for chronic-duration (≥365 days) oral exposure to 
1,2-DCB. 
One chronic oral toxicity study of 1,2-DCB is available.  In this study groups of F344/N rats 
(50/sex/group) and B6C3F1 mice (50/sex/group) were administered 1,2-DCB in corn oil by gavage in 
doses of 0, 60, or 120 mg/kg/day for 5 days/week for 103 weeks (NTP 1985).  Evaluations included 
clinical signs, body weight, and necropsy and histology on all animals.  Organ weight and clinical 






















2. RELEVANCE TO PUBLIC HEALTH 
significantly increased incidence of renal tubular regeneration in the male mice.  This lesion showed a 
dose-related trend, and was statistically significantly elevated in high-dose animals, but not in low-dose 
animals.  The NOAEL for the lesion was therefore 60 mg/kg/day, and the LOAEL was 120 mg/kg/day. 
To derive a point of departure for MRL derivation, BMD analysis was conducted using the kidney lesion 
incidence data. All dichotomous models in the Benchmark Dose Software (version 1.3.2) were fit to the 
male mouse incidence data for renal tubule regeneration.  A 10% extra risk above the control incidence 
was selected as the BMR in the absence of a biological rationale for using an alternative BMR.  A 
summary of the predicted BMDs and BMDLs, as well as details of the BMD modeling, are presented in 
Appendix A.  The logistic model was the best-fitting model, resulting in a BMD10 of 62.96 mg/kg/day and 
a BMDL10 of 43.04 mg/kg/day.  The BMDL10 43.04 mg/kg/day was adjusted for intermittent 
experimental exposure (5 days/7 days) to give a duration-adjusted BMDL10 of 30.74 mg/kg/day, and 
divided by an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human 
variability) to derive a chronic-duration oral MRL of 0.3 mg/kg/day for 1,2-DCB. 
1,3-Dichlorobenzene 
Acute-Duration Exposure. 
•	 An MRL of 0.4 mg/kg/day has been derived for acute-duration (≤14 days) oral exposure to 
1,3-DCB. 
The acute oral database for 1,3-DCB consists of one short-term toxicity study in which groups of 10 male
and 10 female Sprague Dawley rats were administered gavage doses of 0, 37, 147, 368, or 735 mg/kg/day 
in corn oil for 10 consecutive days (McCauley et al. 1995).  End points evaluated during the study
included clinical signs, survival, body weight, and food and water consumption.  At the end of the study, 
blood was collected for hematology and serum chemistry analyses (erythrocytes, leukocytes, hemoglobin, 
hematocrit, mean corpuscular volume, glucose, BUN, creatinine, AP, AST, ALT, cholesterol, LDH, and 
calcium levels), and selected organs were weighed (brain, liver, spleen, lungs with lower half of trachea, 
thymus, kidneys, adrenal glands, heart, and gonads). Gross pathology was evaluated in all animals, and 
comprehensive histological examinations were performed in the high dose and control groups; histology 
in the lower dose groups was limited to the liver.  Inflammatory and degenerative lesions were graded on 























2. RELEVANCE TO PUBLIC HEALTH 
No compound-related deaths or overt clinical signs were observed (McCauley et al. 1995).  Body weight 
was significantly reduced in both sexes at 735 mg/kg/day (20 and 13% lower than controls in males and 
females, respectively).  Food consumption was significantly decreased at 735 mg/kg/day in males (12%, 
normalized by body weight), and water consumption was significantly increased (8–13%) in females at 
≥735 mg/kg/day.  The hematological evaluation showed 8% decreased MCV in females at 
735 mg/kg/day.  The clinical chemistry analyses showed statistically significant changes in several 
indices, but serum cholesterol was the only end point that had values that exceeded the reference range.  
Serum cholesterol was significantly increased in females at 368 and 735 mg/kg/day (94 and 63% higher 
than controls, respectively), as well as in males at 368 and 735 mg/kg/day (79 and 84% higher than 
controls, respectively).  Relative liver weight was significantly increased in males at ≥147 mg/kg/day and 
females at ≥368 mg/kg/day; increases in the males were 9.1, 31.3, 50.63, and 32.5% higher than controls 
in the low- to high-dose groups.  Other significant changes in relative organ weight included decreased 
spleen weight in females at ≥368 mg/kg/day and males at 735 mg/kg/day, decreased thymus weight in 
both sexes at 735 mg/kg/day, and decreased testes weight in males at 735 mg/kg/day.  Absolute organ 
weights were not reported.  Histological changes primarily occurred in the liver, particularly centrilobular 
hepatocellular degeneration at ≥368 mg/kg/day.  This lesion was characterized by varying degrees of 
cytoplasmic vacuolization and swelling with intact membranes, and occurred in the 368 and 
735 mg/kg/day groups in 2/10 and 9/10 males, respectively, and 6/10 and 10/10 females, respectively; 
incidences in the other groups were not reported but are presumed to be 0/10.  Other hepatic alterations 
included hepatocellular necrosis that was sporadically noted in the 147, 368, and 735 mg/kg/day groups.  
This change was usually minimal to mild, and was reported to increase in incidence and severity in the 
males in a dose-related manner; however, incidences were not reported.  The only other reported 
histological change was atrophy of the thymus, characterized by loss of normal differentiation between 
medulla and cortex. The thymic atrophy was observed in 2/10 males (both marked in severity) and 
2/9 females (both mild in severity) at 735 mg/kg/day; this change was not observed in controls, and the 
other dosed groups were not examined.  The 147 mg/kg/day dose is the LOAEL (minimal) for liver 
effects based on the >10% increase in relative liver weight in male rats.  The NOAEL for increased liver 
weight is 37 mg/kg/day. 
To derive a point of departure for MRL derivation, BMD analysis was conducted using liver effects data 
from the McCauley et al. (1995) study.  The liver effects data modeled included incidences of 
hepatocellular degeneration, absolute liver weights and mean serum cholesterol levels.  All dichotomous 
variable models available in the EPA Benchmark Dose Software (Version 1.3.2) were fit to the incidence 
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continuous variable models in the BMD software were fit to the mean absolute liver weight data and 
mean serum cholesterol level data in male and female rats using a BMR of 1 standard deviation increase 
above the control mean.  A summary of the predicted BMDs and BMDLs for all end points, as well as 
details of the BMD modeling, are presented in Appendix A.  The best-fitting models resulted in a 
BMDL10 of 207.86 mg/kg/day for hepatocellular degeneration in male rats (log-probit model), a 
BMDL10 of 159.37 mg/kg/day for hepatocellular degeneration in female rats (log-probit model), and a 
BMDL1sd of 36.32 mg/kg/day for absolute liver weight changes in female rats (2-degree polynomial 
model).  The lowest BMDL1sd of 36.32 mg/kg/day was selected as the most conservative point of 
departure for deriving an MRL.  The BMDL1sd of 36.32 mg/kg/day was divided by an uncertainty factor 
of 100 (10 for animal to human extrapolation and 10 for human variability) to derive an acute-duration 
oral MRL of 0.4 mg/kg/day for 1,3-DCB.   
Intermediate-Duration Exposure. 
•	 An MRL of 0.02 mg/kg/day has been derived for intermediate-duration (15–364 days) oral 
exposure to 1,3-DCB. 
The database for intermediate-duration oral exposure to 1,3-DCB consists of one intermediate toxicity
study in which groups of 10 male and 10 female Sprague Dawley rats were administered gavage doses of 
0, 9, 37, 147, or 588 mg/kg/day in corn oil for 90 consecutive days (McCauley et al. 1995).  End points 
evaluated during the study included clinical signs and mortality, body weight, and food and water 
consumption.  At end of the exposure period, blood was collected for hematology and serum chemistry
analyses (erythrocytes, leukocytes, hemoglobin, hematocrit, mean corpuscular volume, glucose, BUN, 
creatinine, AP, AST, ALT, cholesterol, LDH, and calcium levels), selected organs were weighed (brain, 
liver, spleen, lungs with lower half of trachea, thymus, kidneys, adrenal glands, heart, and gonads), and 
gross pathology was assessed.  Histological examinations were performed on all tissues that were 
examined grossly in all high-dose rats and in one-half of control rats, as well as in the liver, thyroid, and 
pituitary glands from all animals in the 9, 37, and 147 mg/kg/day dose groups.  Inflammatory and 
degenerative lesions were graded on a relative scale from one to four depending on the severity (minimal, 
mild, moderate, or marked).   
No compound-related deaths or overt clinical signs were observed (McCauley et al. 1995).  Body weight 
was reduced in both sexes at 588 mg/kg/day (24 and 10% lower than controls in males and females, 
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despite increased food and water consumption in the same groups.  Other effects included increased 
relative kidney weight in males at ≥147 mg/kg/day and females at 588 mg/kg/day, but there were no renal 
histopathological changes in any of the exposed animals.  Hematological alterations consisted of 
significant increases in leukocyte levels in males at 147 mg/kg/day and females at 588 mg/kg/day, and in
erythrocyte levels in males at 588 mg/kg/day.  As discussed below, histopathology and serum chemistry
findings indicated that the thyroid, pituitary, and liver were the most sensitive targets of toxicity. 
Thyroid effects included significantly (p≤0.05) increased incidences of reduced colloidal density in 
follicles that exceeded normal variability in male rats at ≥9 mg/kg/day and female rats at ≥37 mg/kg/day
(control to high dose group incidences of 2/10, 8/10, 10/10, 8/9, and 8/8 in males, and 1/10, 5/10, 8/10, 
8/10, and 8/9 in females) (McCauley et al. 1995).  Depletion of colloid density in the thyroid was 
characterized by decreased follicular size with scant colloid and follicles lined by cells that were cuboidal 
to columnar.  The severity of the colloid density depletion generally ranged from mild to moderate, 
increased with dose level, and was greater in males than females.  Incidences of male rats with thyroid 
colloidal density depletion of moderate or marked severity were significantly increased at 
≥147 mg/kg/day (0/10, 0/10, 2/10, 5/9, and 6/8). 
Pituitary effects included significantly (p≤0.05) increased incidences of cytoplasmic vacuolization in the 
pars distalis in male rats at ≥147 mg/kg/day (2/10, 6/10, 6/10, 10/10, and 7/7).  The vacuoles were 
variably sized, irregularly shaped, and often poorly defined, and the severity of the lesions (i.e., number of 
cells containing vacuoles) ranged from minimal to mild and generally increased with increasing dose 
level. Incidences of male rats with pituitary cytoplasmic vacuolization of moderate or marked severity
were significantly increased at 588 mg/kg/day (1/10, 0/10, 2/10, 3/9, and 7/7).  The pituitary lesion was 
reported to be similar to "castration cells" found in gonadectomized rats and considered to be an indicator 
of gonadal deficiency.  No compound-related pituitary lesions were observed in female rats.  Serum
cholesterol was significantly increased in males at ≥9 mg/kg/day and in females at ≥37 mg/kg/day in a 
dose-related manner, and serum calcium was significantly increased in both sexes at ≥37 mg/kg/day.  The 
investigators suggested that these serum chemistry changes might reflect a disruption of hormonal 
feedback mechanisms, or target organ effects on the pituitary, hypothalamus, and/or other endocrine 
organs. 
Hepatic effects occurred in both sexes at 147 and 588 mg/kg/day, including significantly increased 
relative liver weight and incidences of liver lesions (McCauley et al. 1995).  Absolute organ weights were 
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homogeneous inclusions), and hepatocellular necrosis.  Liver lesions that were significantly (p≤0.05) 
increased included hepatocellular cytoplasmic alterations of minimal to mild severity in males at 
≥147 mg/kg/day (1/10, 2/10, 1/10, 6/10, and 7/9) and females at 588 mg/kg/day (0/10, 2/10, 0/10, 1/10, 
and 7/9), and necrotic hepatocyte foci of minimal severity at 588 mg/kg/day in both males (1/10, 2/10, 
1/10, 2/10, and 5/9) and females (0/10, 0/10, 0/10, 3/10, and 5/9).  Other statistically significant liver-
associated effects included significantly increased serum AST levels (90–100% higher than controls) in 
males at ≥9 mg/kg/day and females at ≥37 mg/kg/day.  Serum cholesterol levels were significantly 
increased in males at ≥9 mg/kg/day and females at ≥37 mg/kg/day, but might be pituitary-related, as 
indicated above. Serum LDH levels were reduced in males at ≥9 mg/kg/day and BUN levels were 
reduced in both sexes at 588 mg/kg/day, but the biological significance of decreases in these indices is 
unclear. 
To derive a point of departure for MRL derivation, BMD analysis was conducted using data for thyroid 
and pituitary lesion incidences and serum AST and cholesterol levels.  Continuous variable models in the 
EPA Benchmark Dose Software (Version 1.3.2) were fit to serum AST levels in the male rats and the 
serum cholesterol levels in the male and female rats using a one standard deviation change from the 
control mean as the BMR.  Dichotomous variable models in the BMD software were fit to the incidence 
data for thyroid lesions (reduced follicular colloidal density) and pituitary lesions (cytoplasmic
vacuolation in the pars distalis) in the male rats.  A summary of the predicted BMDs and BMDLs for all 
of the end points, as well as details of the BMD modeling, are presented in Appendix A.  None of the 
models provided an adequate fit for the serum AST, serum cholesterol, or thyroid lesion data.  For the 
pituitary lesion incidence data, all of the models provided adequate fit.  The probit model provided the 
best fit, but nearly identical fits were provided by three other models (gamma, quantal-linear, and 
Weibull). Because the BMD10 of 4.08 mg/kg/day and associated BMDL10 of 2.10 mg/kg/day from the 
gamma, quantal-linear, and Weibull models are lower than those from the probit model (BMD10 = 
7.79 mg/kg/day; BMDL10 = 4.46 mg/kg/day), a conservative health protective approach was taken and the 
lower BMDL10 of 2.10 mg/kg/day was selected as the point of departure for deriving the MRL.  The 
BMDL10 of 2.1 mg/kg/day was divided by an uncertainty factor of 100 (10 for extrapolation from animals 
to humans and 10 for human variability) to derive an MRL of 0.02 mg/kg/day for intermediate-duration 
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Chronic-Duration Exposure. 
No MRL was derived for chronic-duration oral exposure to 1,3-DCB due to a lack of chronic oral studies. 
1,4-Dichlorobenzene 
Acute-Duration Exposure. No acute-duration oral MRL was derived for 1,4-DCB due to insufficient 
data. Information on effects of non-lethal acute-duration oral exposures to 1,4-DCB is essentially limited 
to hepatic and renal changes of unclear toxicological significance observed in studies designed to 
elucidate mechanisms of liver and kidney toxicity in rats and mice.  Acute liver damage, as assessed by
histopathology and serum enzyme/biochemical indicators following gavage exposure, was not induced by
high levels of 1,4-DCB in rat given single doses of ≤2790 mg/kg (Allis et al. 1992), rats and mice given 
single doses of ≤1,200 mg/kg/day (Eldridge et al. 1992), or rats and mice administered ≤300 and 
≤600 mg/kg/day, respectively, 5 days/week for 1 week (Lake et al. 1997).  Porphyria, manifested as 
increased porphyrin levels in liver and urine and suggestive of hepatic damage, was reported in rats that 
were orally exposed to 770 mg/kg/day for 5 days (Rimington and Ziegler 1963).  Although there was no 
clear evidence of liver injury in acute studies, similar dose levels of 1,4-DCB are toxic following 
intermediate- and chronic-duration exposures. 
Increased hepatocelluar proliferation, as measured by increased incorporation of bromodeoxyridine 
(BrdU) or [3H] thymidine into DNA-synthesizing liver cells, has been demonstrated in rats and mice at 
doses ≥150 mg/kg/day in a number of single dose and short-term oral studies that found no histological or 
other indications of overt liver damage (Eldridge et al. 1990, 1992; Hasmall et al. 1997; Lake et al. 1997; 
Sherman et al. 1998; Umemura et al. 1992, 1996).  The induction of liver cell proliferation in the absence 
of manifest hepatoxicity suggests that the proliferation is a response to mitogenic stimulation rather than 
compensatory regeneration to cytotoxicity.  Cellular proliferation and other changes have also been 
demonstrated in the kidney tubular epithelia of male rats, but not in female rats or mice of either sex, 
following short-term oral exposures to doses ≥150 mg/kg/day (Eldridge et al. 1992; Lake et al. 1997;
Sherman et al. 1998; Umemura et al. 1992).  The renal effects are consistent with the induction of 
α2µ-globulin nephropathy in male rats by similar doses of 1,4-DCB in other acute oral studies 
(Charbonneau et al. 1989b; Dietrich and Swenberg 1991; Saito et al. 1996), but are not relevant to 
humans.  Induction of hepatic microsomal xenobiotic metabolizing enzymes appears to be the most 
sensitive effect of acute/short-term exposure to 1,4-DCB (Elovaara 1998).  For example, oral exposure to 
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hydroxylase, and enzymes involved in the detoxification of O-ethyl-O-nitrophenyl phenylphos­
phorothionate (EPN) in rats (Carlson and Tardiff 1976).  Induction of hepatic microsomal enzymes is not 
necessarily adverse, but does indicate that the liver is sensitive to relatively low doses of 1,4-DCB. 
The toxicological significance of the hepatic microsomal enzyme changes is unclear and the information 
on other liver effects is insufficient to identify a reliable NOAEL or LOAEL for acute/short-term oral 
exposure to 1,4-DCB.  The lack of adequate data on the threshold of adverse effects precludes derivation 
of an MRL for acute duration oral exposure. 
Intermediate-Duration Exposure. 
•	 An MRL of 0.07 mg/kg/day has been derived for intermediate-duration (15–364 days) oral 
exposure to 1,4-DCB. 
Information on the systemic toxicity of intermediate-duration oral exposure to 1,4-DCB is available from
a number of studies conducted in rodents, mainly rats and mice, as well as one study in dogs.  Liver and 
kidney effects are the most consistently observed, best characterized, and most sensitive findings in these 
studies. The lowest observed adverse effect level is for liver toxicity in dogs, although reproductive and 
developmental studies in rats indicate that offspring are particularly sensitive to 1,4-DCB toxicity during 
the postnatal preweaning period. 
Hepatic effects induced by intermediate-duration oral exposures to 1,4-DCB ranged from increased liver 
weight and hepatocyte enlargement to hepatocellular degeneration, lesions, necrosis, and tumors in rats, 
mice, rabbits, and dogs.  Increases in serum levels of enzymes and alterations in other end points (e.g., 
serum cholesterol and triglycerides) indicative of hepatocellular damage or liver dysfunction have also 
been induced. Increased liver weight is the most sensitive hepatic end point in intermediate-duration 
studies in rats, observed at doses as low as 150 mg/kg/day for 4–13 weeks and 188 mg/kg/day for 
192 days (Hollingsworth et al. 1956; Lake et al. 1997; Umemura et al. 1998).  There was no indication of 
early liver damage in rats exposed to 150 mg/kg/day for 4 weeks using an immunohistochemical marker 
of centrilobular hepatocyte injury (Umemura et al. 1998), and increases in liver porphyrins in rats 
exposed to 50–200 mg/kg/day for 120 days were not considered to be toxicologically significant (Carlson 
1977).  Hepatocellular hypertrophy and decreased serum triglycerides occurred in rats exposed to 
≥300 mg/kg/day for 13 weeks (Lake et al. 1997; NTP 1987).  Higher dose levels of 1,4-DCB induced 
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necrosis) (Hollingsworth et al. 1956) or 1,200 mg/kg/day for 13 weeks (hepatocyte degeneration and 
necrosis) (NTP 1987).  In mice, hepatocellular degeneration was induced at doses ≥600 mg/kg/day for 
13 weeks (NTP 1987), and rabbits had cloudy swelling and minimal focal necrosis in the liver after 
exposure to 500 mg/kg/day for 367 days (Hollingsworth et al. 1956).  Dogs are more sensitive to hepatic 
effects of intermediate-duration 1,4-DCB exposure than the other species because serum enzyme levels 
were increased following exposure to doses as low as 50 mg/kg/day for 6 months (Naylor and Stout 
1996).
Renal changes, including hyaline droplet accumulation, increased kidney weights, and tubular lesions, are 
characteristically observed effects of subchronic and chronic oral exposure to 1,4-DCB in male rats at 
doses ≥75 mg/kg/day (Bomhard et al. 1988; Lake et al. 1997; NTP 1987).  These findings are not 
considered for MRL derivation because there is a scientific consensus that they are related to the 
α2µ-globulin nephropathy syndrome, which is specific to male rats and not relevant to humans.  
Subchronic studies in female rats found increased kidney weight, but no indications of nephrotoxic action 
(i.e., no histopathology or effects on urinary indices of renal function), following exposure to 
≥188 mg/kg/day for 192 days or 600 mg/kg/day for 13 weeks (Bomhard et al. 1988; Hollingsworth et al. 
1956). 
Developmental toxicity studies provide no indications that 1,4-DCB is teratogenic in rats at oral doses as 
high as 1,000 mg/kg/day during gestation, although fetotoxicity occurred at maternally toxic levels 
≥500 mg/kg/day (Giavini et al. 1986; Ruddick et al. 1983).  Decreased maternal weight gain and 
increased incidences of extra ribs, a skeletal variation attributable to the maternal toxicity, occurred in rats 
at gestational dose levels ≥500 mg/kg/day, but not at 250 mg/kg/day (Giavini et al. 1986).  In a two-
generation study, reproductive and developmental toxicity were evaluated in male and female rats that 
were orally exposed to 30, 90, or 270 mg/kg/day of 1,4-DCB (Bornatowicz et al. 1994).  No effects on 
mating and fertility indices were observed at any level, although toxicity occurred in the offspring at 
doses ≥90 mg/kg/day. Effects at ≥90 mg/kg/day included reduced birth weight in F1 pups and increased 
total number of deaths from birth to postnatal day 4 in F1 and F2 pups, clinical manifestations of dry and
scaly skin (until approximately postnatal day 7) and tail constriction with occasional partial tail loss 
(during postnatal days 4–21) in F1 and F2 pups, reduced neurobehavioral performance (draw-up reflex 
evaluated at weaning) in F2 pups, and increased relative liver weight in adult F1 males. No exposure-
related changes were found at 30 mg/kg/day, indicating that this is the NOAEL for reproductive and 
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As discussed above, liver, kidney, and perinatal developmental toxicity are main effects of concern for 
intermediate-duration oral exposure to 1,4-DCB in animals.  The dog is the most sensitive tested species, 
as liver effects were induced by exposure to doses as low as 50 mg/kg/day for 6 months (Naylor and Stout 
1996), which are below subchronic LOAELs of approximately 150–200 mg/kg/day for liver and kidney
effects in rats and mice.  The two-generation study in rats demonstrates that oral exposure to 1,4-DCB can 
cause perinatal developmental toxicity, including reduced birth weight and neonatal survival in F1 and 
F2 pups, at doses ≥90 mg/kg/day (Bornatowicz et al. 1994).  Although this finding indicates that perinatal 
developmental toxicity is an additional sensitive end point for 1,4-DCB exposure, the lower 50 mg/kg/day  
LOAEL for liver effects in dogs (Naylor and Stout 1996) is a more appropriate basis for MRL derivation. 
In the dog study, groups of five male and five female beagles were orally administered 1,4-DCB by
capsule in dose levels of 0, 10, 50, or 75 mg/kg/day on 5 days/week for 1 year (Naylor and Stout 1996).
Complete details on the experimental design and results of the study are provided in the section on the 
chronic oral MRL for 1,4-DCB.  As summarized below, 6-month interim liver enzyme findings are 
consistent with liver enzyme, liver weight, and histopathological changes observed at 1 year.  Hepatic end 
points evaluated at 6 months were limited to clinical chemistry indices, including serum ALT, AST, 
GGTP, and AP, whereas the 1-year end-of-study evaluations included liver weight and histology in 
addition to clinical chemistry.  Effects on serum enzymes included statistically significantly increased AP 
in males at 50  mg/kg/day after 6 and 12 months, females at 50 mg/kg/day after 6 and 12 months, and 
females at 75 mg/kg/day after 6 and 12 months.  Serum AP levels were not statistically significantly 
increased in the 75 mg/kg/day males at months 6 or 12, but only three animals were evaluated in this dose 
group. As detailed in the chronic MRL summary, the increases in serum AP were similar in magnitude 
after 6 and 12 months, ranging from 330 to 761% higher than control values.  Other clinical chemistry
findings included significantly increased serum ALT (75 mg/kg/day females at month 12) and GGTP 
(75 mg/kg/day females at months 6 and 12), and significantly decreased albumin (50 and 75 mg/kg/day in 
males at months 6 and 12, and 75 mg/kg/day in females at month 6).  Absolute and relative liver weights 
were significantly increased in both sexes at 50 and 75 mg/kg/day (except absolute liver weight in 
50 mg/kg/day males).  Hepatic lesions included hepatocellular hypertrophy (diffuse or multifocal in all 
males and females at 50 and 75 mg/kg/day, and one female at 10 mg/kg/day), hepatocellular pigment 
deposition (two males and one female each at 50 and 75 mg/kg/day), bile duct/ductule hyperplasia (one 
male and one female at 75 mg/kg/day), and hepatic portal inflammation (periportal accumulation of 
neutrophils in one male at 50 mg/kg/day and two males at 75 mg/kg/day).  The 50 mg/kg/day dose is a 
intermediate-duration LOAEL based on the increases in serum AP at 6 months.  This serum enzyme
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similar in magnitude to those observed after 1 year and associated with increased liver weight and liver 
lesions; the latter effects likely developed earlier in the study but could not be detected due to the lack of 
organ weight and histology examinations before 1 year.   
To derive a point of departure for MRL derivation, BMD analysis was conducted using the Naylor and 
Stout (1996) data for changes in serum AP levels in female dogs.  Mean serum AP levels in the female 
dogs exhibited a dose-response relationship and were significantly increased in the 50 and 75 mg/kg/day
groups. Although significantly increased mean serum AP levels were noted in the 50 mg/kg/day male
dogs, the increase was not significant in the 75 mg/kg/day males; only three males in this dose group were 
available for the assessment of serum AP levels.  Therefore, the male serum AP data were not modeled.  
Continuous variable models in the EPA Benchmark Dose Software (Version 1.3.2) were fit to serum AP 
data in the female dogs using a one standard deviation change from the control mean as the BMR.  A 
summary of the predicted BMDs and BMDLs, as well as details of the BMD modeling, are presented in 
Appendix A.  The best fit was provided by the polynomial model, which resulted in a BMD1sd of 
12.48 mg/kg/day and a BMDL1sd of 9.97 mg/kg/day.  The BMDL1sd of 9.97 mg/kg/day was adjusted for 
intermittent experimental exposure (5 days/7 days) to give a duration-adjusted BMDL1sd of 7 mg/kg/day, 
and divided by an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human 
variability) to derive an intermediate-duration oral MRL of 0.07 mg/kg/day for 1,4-DCB.   
Chronic-Duration Exposure. 
•	 An MRL of 0.07 mg/kg/day has been derived for chronic-duration (365 days or more) oral 
exposure to 1,4-DCB. 
Information on the chronic oral effects of 1,4-DCB is available from one study each in rats, mice, rabbits, 
and dogs.  Observed effects included nephropathy in rats (including tubular degeneration and atrophy in
females) exposed to ≥150 mg/kg/day on 5 days/week for 103 weeks (NTP 1987), hepatocellular 
degeneration and nephropathy in mice exposed to ≥300 mg/kg/day on 5 days/week for 103 weeks (NTP 
1987), and cloudy swelling and minimal focal necrosis in rabbits exposed to 500 mg/kg/day in 263 doses 
in 367 days (Hollingsworth et al. 1956).  The lowest chronic LOAEL in these studies was 150 mg/kg/day 
for kidney effects in female rats (NTP 1987).  Liver and kidney effects were induced in dogs at doses 
below the LOAELs in the other species.  As summarized below, doses as low as 50 mg/kg/day for 1 year 
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In the dog study, groups of five male and five female beagles were orally administered 1,4-DCB by
capsule in dose levels of 0, 10, 50, or 75 mg/kg/day for 1 year (Naylor and Stout 1996).  Based on the 
summarized design of a 4-week dose range-finding study, it is presumed that dosing was 5 days/week.  
The 75 mg/kg/day dose is a time-weighted average level reflecting dose decreases at the beginning of the 
study in response to unexpected severe toxicity.  An initial high dose of 150 mg/kg/day was adjusted to 
100 mg/kg/day for males during week 3, and a further decrease to 75 mg/kg/day was made for both sexes 
at the beginning of week 6.  Both high-dose males and females were untreated during weeks 4 and 5 to 
allow for recovery.  End points evaluated throughout the study included clinical observations (daily),
body weight (weekly), and food consumption (weekly).  Ophthalmoscopic examinations were performed 
prior to study start and just prior to study completion.  Hematology (11 indices, including activated partial 
thromboplastin time), clinical chemistry (18 indices, including ALT, AST, GGTP, AP, and creatinine 
phosphokinase), and urinalysis (10 indices) were performed at month 6 and study completion (month 12).
Organ weights, gross pathology, and histology were evaluated at month 12. 
Mortality occurred the first 25 days of the study before dose reduction; exposure to 150 mg/kg/day caused 
one male dog to be sacrificed in extremis on day 12, one male death on day 25, and one female death on 
day 24 (Naylor and Stout 1996).  A control male died on day 83, but all other dogs survived to the end of 
the study.  Treatment-related clinical signs were primarily limited to severely affected high-dose dogs and 
the control male that died; these included hypoactivity, dehydration, decreased defecation, blood-like 
fecal color, emesis, emaciation, and/or pale oral mucosa.  There were no significant group differences in 
mean body weight at the end of the study.  Body weight gain was significantly reduced during the first 
month of the study, but recovered following dose reduction and adjustment of food availability.  A mild 
anemia was observed at month 6 (significantly reduced red blood cells in females and HCT in males) at 
75 mg/kg/day, but it resolved by the end of the study.  The mild anemia correlated with histologic 
findings of bone marrow erythroid hyperplasia in females, and splenic excessive hematopoiesis and 
megakaryocyte proliferation in both sexes, indicating a compensatory response to the earlier anemia.  
Hepatic effects occurred at ≥50 mg/kg/day in both sexes as shown by changes in liver enzymes, increased 
liver weight, and histopathology.  Effects on serum enzyme levels included significantly increased AP in 
males at 50 mg/kg/day at months 6 and 12 (731 and 620% higher than controls, respectively), females at 
50 mg/kg/day at months 6 and 12 (525 and 330% higher), and females at 75 mg/kg/day at months 6 and
12 months (761 and 680% higher).  Serum AP was also increased in males at 75 mg/kg/day after 6 and 
12 months, but the changes were not statistically significant, possibly due to a reduced group size of 
3 males at 75 mg/kg/day. Other clinical chemistry findings included significantly increased ALT in 






















2. RELEVANCE TO PUBLIC HEALTH 
75 mg/kg/day at months 6 and 12 (131 and 161% higher), and decreased albumin in males at 50 and 
75 mg/kg/day at month 6 (16 and 18% lower than controls) and females at 75 mg/kg/day at month 6 (19%
lower). Absolute and relative liver weights were significantly increased (40–70% higher than controls) in 
both sexes at 50 and 75 mg/kg/day (except absolute liver weight in 50 mg/kg/day males).  Hepatocellular 
hypertrophy (diffuse or multifocal) occurred in all males and females at 50 and 75 mg/kg/day and in one 
female at 10 mg/kg/day.  The study authors (Naylor and Stout 1996) considered the hepatocellular 
hypertrophy (multifocal) in the single 10 mg/kg/day female dog to be an adaptive response to a xenobiotic 
agent rather than a direct treatment related effect.  Other liver lesions considered to be treatment-related 
included hepatocellular pigment deposition (two males and one female each at 50 and 75 mg/kg/day), bile 
duct/ductule hyperplasia (one male and one female at 75 mg/kg/day), and hepatic portal inflammation 
(periportal accumulation of neutrophils in one male at 50 mg/kg/day and two males at 75 mg/kg/day). 
Kidney effects included collecting duct epithelial vacuolation in one male at 75 mg/kg/day and at all dose 
levels in females (one each at 10 and 50 mg/kg/day and two at 75 mg/kg/day). The renal lesion was 
considered to be a possible effect of treatment at ≥50 mg/kg/day, because it was accompanied by
increased relative kidney weight in females at ≥50 mg/kg/day and grossly observed renal discoloration in 
two females at 75 mg/kg/day.  The highest chronic NOAEL and lowest LOAEL are 10 and 50 mg/kg/day, 
respectively, based on the hepatic effects in dogs (increased liver weight, changes in liver enzymes, and 
histopathology). 
To derive a point of departure for MRL derivation, BMD analysis was performed on the serum AP level 
and relative liver weight data for the female dogs. The incidences of hepatocellular hypertrophy in the 
females (0/5, 1/5, 5/5, and 5/5 at 0, 10, 50, and 75 mg/kg/day) and males (0/5, 0/5, 5/5, and 5/5) are 
inappropriate for BMD modeling due to actual or effective responses of 0% in the control and low dose 
groups and 100% in the higher dose groups.  The response in the low-dose female dog is effectively 0%
because the authors implied that the hypertrophy in this single animal was not a hepatotoxic response.  
The incidences of the other dog liver lesions were not subjected to BMD analysis due to the low numbers 
of responders and group sizes.  Continuous variable models in the EPA Benchmark Dose Software 
(Version 1.3.2) were fit to serum AP and relative liver weight data in the female dogs using a one 
standard deviation change from the control mean as the BMR.  A summary of the predicted BMDs and 
BMDLs, as well as details of the BMD modeling, are presented in Appendix A.  The relative liver weight 
data were judged to be unsuitable for BMD analysis due to inadequate modeling of variance.  The best fit 
for the serum AP data was provided by the polynomial model, which resulted in a BMD1sd of 
15.40 mg/kg/day and a BMDL1sd of 12.32 mg/kg/day.  The BMDL1sd of 12.32 mg/kg/day was rounded to
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give a duration-adjusted BMDL1sd of 7 mg/kg/day, and divided by an uncertainty factor of 100 (10 for 
animal to human extrapolation and 10 for human variability) to derive a chronic-duration oral MRL of 






















3. HEALTH EFFECTS 
3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of dichlorobenzenes.  
It contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 





















3. HEALTH EFFECTS 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of 
dichlorobenzenes are indicated in Tables 3-1 and 3-5 and Figures 3-1 and 3-5.   
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
3.2.1 Inhalation Exposure 
Descriptive data are available from reports of humans exposed to 1,2- and 1,4-DCB by inhalation (and 
possibly dermal contact).  It is important to note that the case studies discussed in this section should be 
interpreted with caution since they reflect incidents in which individuals have reportedly been exposed to 
1,2- and 1,4-DCB, and they assume that there has been no other exposure to potentially toxic or infectious 
agents. There is usually little or no verification of these assumptions, and often no estimate of the level of 
exposure which may have occurred.  With only rare exceptions, case studies in general are not 
scientifically equivalent to carefully designed epidemiological studies or to adequately controlled and 
monitored laboratory experiments.  Thus, the case studies described below should be considered only as 
providing supplementary evidence that 1,2- and 1,4-DCB may cause the reported human effects.  The 
highest NOAEL and all reliable LOAEL values after inhalation exposure to 1,2- and 1,4-DCB are 
recorded in Tables 3-1 and 3-2, respectively, and plotted in Figures 3-1 and 3-2, respectively.  No LSE 
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3. HEALTH EFFECTS 
3.2.1.1 Death 
1,2-Dichlorobenzene. No studies were located regarding death in humans following inhalation exposure 
to 1,2-DCB.
Inhalation LC50 values of 1,532 and 1,236 ppm were determined for rats and mice, respectively, that were 
exposed to 1,2-DCB for 6 hours and observed for the following 14 days (Bonnet et al. 1982).  No 
mortality was observed in rats that were exposed to 1,2-DCB in concentrations of 977 ppm for 0.5–1 hour
or 539 ppm for 3 hours (Hollingsworth et al. 1958). 
1,3-Dichlorobenzene. No studies were located regarding death in humans or animals following 
inhalation exposure to 1,3-DCB.
1,4-Dichlorobenzene. Only one report of human death attributed to 1,4-DCB inhalation exposure has 
been located in the literature. A 60-year-old man and his wife died within months of each other due to 
acute yellow atrophy of the liver (also known as massive hepatic necrosis or fulminant hepatitis; 
diagnosis was not verified histologically) (Cotter 1953).  Their home had been "saturated" with 1,4-DCB 
moth ball vapor for a period of about 3–4 months, but no air measurements were available.  Clinical 
symptoms included severe headache, diarrhea, numbness, clumsiness, slurred speech, weight loss 
(50 pounds in 3 months in the case of the husband), and jaundice.  The wife died within a year of the 
initial exposure; however, it was not clear if 1,4-DCB was the primary cause of death.  This case study
did not address whether these individuals consumed excessive amounts of alcohol or had previous 
medical problems, such as a chronic liver infection. 
Several studies were located regarding death in animals after inhalation exposure to 1,4-DCB.  In an 
acute-duration study, two of six male CD-1 mice exposed to 1,4-DCB at an air concentration of 640 ppm, 
6 hours/day for 5 days died on the fifth day; no deaths were reported at an exposure level of 320 ppm
(Anderson and Hodge 1976). 
Mortality data were also reported in intermediate-duration studies using rats, guinea pigs, and rabbits.  In 
studies performed by Hollingsworth et al. (1956), rats, guinea pigs, and rabbits were exposed to 1,4-DCB 
vapors for 9–12 weeks at an air concentration of 798 ppm, 8 hours/day, 5 days/week.  In that study, 4 of 
34 rats, 2 of 23 guinea pigs, and 4 of 16 rabbits died during the study period.  The exact number of 





























3. HEALTH EFFECTS 
In a chronic-duration study, there was no evidence of a treatment effect on mortality in Wistar rats 
exposed to 1,4-DCB at concentrations up to 490–499 ppm for 5 hours/day, 5 days/week for 76 weeks 
(Riley et al. 1980a). 
Another chronic study found that survival was significantly reduced in male rats (F344/DuCrj) that were 
exposed 300 ppm 1,4-DCB for 6 hours/day, 5 days/week for 104 weeks (Aiso et al. 2005b; Japan 
Bioassay Research Center 1995).  Survival in the male rats was noticeably lower than controls beginning 
at approximately study week 80, and terminal survival in the 0, 20, 75, and 300 ppm groups of the study
were 66% (33/50), 68% (34/50), 58% (29/50), and 36% (18/50), respectively.  There were no effects on 
survival in similarly exposed female rats.  Male mice (Crj:BDF1) that were similarly exposed to the same 
levels of 1,4-DCB had slightly reduced survival at all levels of exposure (80% [39/49], 63% [31/49], 64%
[32/50], and 61% [30/49] at 0, 20, 75, and 300 ppm, respectively), but the decreases were not
significantly different from controls or dose-related.  Survival in female mice was similar to controls.   
3.2.1.2 Systemic Effects  
Respiratory Effects. 
1,2-Dichlorobenzene. Periodic industrial hygiene surveys and medical examinations were conducted in a 
plant where an unreported number of men were exposed to 1,2-DCB at an average level of 15 ppm (range 
1–44 ppm) for an unreported duration (Hollingsworth et al. 1958).  No nasal or eye irritation was 
attributable to exposure. Additionally, Hollingsworth et al. (1958) noted that his researchers detected 
1,2-DCB odor at a concentration of 50 ppm without eye or nasal irritation during repeated vapor 
inhalation experiments on animals.  An earlier source (Elkins 1950) referenced by Hollingsworth (1958) 
reported that occupational exposure to 100 ppm of 1,2-DCB caused irritation of the eyes and respiratory
passages. 
No changes in absolute lung weight or lung histology were reported in rats (20/sex), guinea pigs (8/sex), 
rabbits (2/sex), or monkeys (2 females) exposed to 93 ppm 1,2-DCB for 7 hours/day, 5 days/week for 6– 
7 months, or in mice (10 females) similarly exposed to 49 ppm 1,2-DCB (Hollingsworth et al. 1958).  
Relative lung weight was not determined.  The scope of histological evaluations was not specifically

























3. HEALTH EFFECTS 
Histological examinations of the upper and lower respiratory tract were conducted in groups of 10 male 
Swiss OF1 mice that were exposed to 1,2-DCB in actual mean concentrations of 0, 64, or 163 ppm (0, 
385, or 980 mg/m3) for 6 hours/day, 5 days/week for 4, 9, or 14 days (Zissu 1995).  Histological 
examinations were performed on the upper and lower respiratory tracts.  Nonrespiratory tissues were not 
evaluated. Histopathologic lesions were observed in the olfactory epithelium of the nasal cavity at 
≥64 ppm.  The olfactory epithelial lesions were graded as very severe following the 4-day exposure and 
moderate after the 14-day exposure, indicating to the authors that a repair mechanism may take place 
despite continued exposure.  The more severe cases were characterized by a complete loss of olfactory
epithelium, which left only the partially denuded basement membrane.  No histological alterations were 
observed in the respiratory epithelium of the nasal cavity, or in the trachea or lungs.  The results suggest 
that the upper respiratory tract is a target for inhalation exposures to 1,2-DCB. 
1,3-Dichlorobenzene. No studies were located regarding respiratory effects in humans or animals 
following inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. A case of pulmonary granulomatosis was reported to have occurred in a 53-year­
old woman who, for 12–15 years, had been inhaling 1,4-DCB crystals that were scattered on a weekly
basis on the carpets and furniture of her home.  A lung biopsy revealed the presence of 1,4-DCB crystals 
with the surrounding lung parenchyma being distorted by fibrosis, thickening of the alveolar walls, and 
marked infiltrates of lymphocytes and mononuclear phagocytes.  Also, there was some thickening of the 
muscular walls of small arteries and focal fibrous thickening of the pleura (Weller and Crellin 1953).
These effects are most likely related to the physical interaction of 1,4-DCB crystals (or any crystals when 
inhaled) with lung tissue, rather than to chemical toxicity.  This conclusion by the authors of the study
was based on exposure history of the patient, radiography, and histological examination of the lung tissue 
which showed the presence of birefringent crystals and a clear granulatomous reaction.   
A study of 58 men occupationally exposed for 8 hours/day, 5 days/week, continually or intermittently, for 
8 months to 25 years (average, 4.75 years) to 1,4-DCB found that the odor was faint at 15–30 ppm and 
strong at 30–60 ppm (Hollingsworth et al. 1956).  Painful irritation of the nose and eyes was usually
experienced at 50–80 ppm, although the irritation threshold was higher (80–160 ppm) in workers 
acclimated to exposure.  At levels >160 ppm, the air was considered not breathable for unacclimated 
persons. The results of this study indicate that nose and eye irritation are critical effects of acute and 






















3. HEALTH EFFECTS 
prevent irritation caused by 1,4 DCB (Hollingsworth et al. 1956), 15 ppm was designated a NOAEL for 
irritant effects and used to derive an MRL of 2 ppm for acute inhalation exposure to 1,4-DCB. 
Associations between blood concentrations of 1,4-DCB and 10 other volatile organic compounds (VOCs) 
and pulmonary function were evaluated in 953 adult participants in the Third National Health and 
Nutrition Examination Survey (NHANES III) (1988–1994) of the general population who had both blood 
VOC and pulmonary function measurements (Elliot et al. 2006). The mean age of the subjects was 
36.6 years (range 20–59), 43.1% were female, and 26.3% were current smokers.  Pulmonary function 
measures included forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), peak 
expiratory flow rate (PEFR), and maximum mid-expiratory flow rate (MMEFR).  Least squares 
regression models were used to evaluate the association between each VOC and each pulmonary function 
outcome.  The models used natural log transformations of VOC concentrations, and were adjusted for 
race/ethnicity, age, standing height, body mass index, sex, smoking, and emphysema to account for 
differences in pulmonary function based on these characteristics.  In the models unadjusted for smoking 
variables, reductions in at least one pulmonary function outcome were statistically significant for 
1,4-DCB, benzene, ethylbenzene, styrene, and toluene.  When the models were adjusted for smoking 
variables, 1,4-DCB was the only VOC that was statistically significantly associated with reduced 
pulmonary function.  Among all 1,4-DCB participants (n=846), there was a statistically significant 
(p<0.05) inverse relationship between 1,4-DCB level and FEV1 and MMEFR. The linear regression 
coefficient (β) was -96 mL (95% CI -182 to -11) for FEV1 and -198 mL/sec (95% CI -388 to -8) for 
MMEFR. The β coefficient estimates the expected change in lung function as the concentration of 
1,4-DCB increases from the 10th to 90th percentile (3.76 µg/L) on the natural log scale. Analysis by race 
and sex showed statistically significant results for FEV1 in non-Hispanic white females [β=-266 mL (95%
CI -488 to -43)] and African-American males [β=-282 mL (95% CI -497 to -66)].  Analyses conducted in
534 subjects using urinary concentrations of 1,4-DCB and its major metabolite, 2,5-dichlorophenol, 
showed statistically significant β coefficients for FEV1 for both 1,4-DCB (-96 mL, 95% CI not reported) 
and 2,5-dichlorophenol (-134 mL, 95% CI not reported).  Analyses were also performed using non-
logarithmically transformed blood concentrations of 1,4-DCB that were categorized into deciles.  Tests 
for linear trend across deciles were statistically significant for FEV1 and MMEFR. Compared with 
subjects in the lowest decile of 1,4-DCB concentration (0.10 ppb), subjects in the highest decile 
(>4.40 ppb) had FEV1 decrements of -153 mL (95% CI -297 to -8) and MMEFR decrements of 
-346 mL/sec (95% CI -667 to -24).  The authors concluded that the findings of this study suggest that 























3. HEALTH EFFECTS 
In pregnant Alderley-Park rats, whole-body exposure to 1,4-DCB at air concentrations of 74.7, 198.6, or 
508.4 ppm, 6 hours/day on gestation days (Gd) 6–15 produced no adverse clinical or pathological signs in 
the lung tissues of the dams (Hodge et al. 1977).  Mild histopathological changes of interstitial edema, 
congestion, and alveolar hemorrhage were observed in the lungs of male (but not female) rats, female 
guinea pigs, and one female rabbit after 16 days of exposure to 1,4-DCB at 173 ppm (Hollingsworth et al. 
1956).  Congestion and emphysema were also reported in the lungs of two rabbits exposed to 798 ppm for 
12 weeks (Hollingsworth et al. 1956). These observations were derived from a large study using several 
species of laboratory animals; however, interspecies comparisons are difficult to make due to the various 
experimental designs used in this study.  For example, at 798 ppm, 10 male rats, 15 female rats, 16 male 
guinea pigs, seven female guinea pigs, and 8 rabbits of each sex were exposed up to 62 times; at 173 ppm, 
five rats of each sex, five guinea pigs of each sex, and one rabbit of each sex were exposed for 16 days.  
These reported observations provide only qualitative evidence of respiratory effects as a result of 
intermediate-duration inhalation exposure to 1,4-DCB. 
An intermediate-duration study was conducted in which F344 rats and BDF1 mice were chamber–exposed 
to 25, 55, 120, 270, or 600 ppm of 1,4-DCB for 6 hours/day, 5 days/week for 13 weeks (Aiso et al. 
2005a). No histological changes in the respiratory tract were reported.  This study apparently conformed 
to (OECD) (1981) testing guidelines for a 90-day inhalation toxicity study, indicating that the histological 
examinations included naso-pharyngeal tissues and lungs. 
In a chronic-duration study, male and female Wistar rats were exposed to 1,4-DCB at air concentrations 
of 75 or 490–499 ppm, 5 hours/day, 5 days/week for 76 weeks (Riley et al. 1980a).  Rats in the high-
exposure group showed a small but significant increase in absolute lung weight at termination of the 
study (112 weeks).  This response was not observed in rats sacrificed on week 76 or in rats exposed to 
75 ppm 1,4-DCB for 112 weeks.  No treatment-related histological alterations were observed in the 
larynx, trachea, or lungs in this study.
Another chronic inhalation study was conducted in which groups of 50 male and female F344/DuCrj rats, 
and 50 male and 50 female Crj:BDF1 mice, were exposed to 1,4-DCB in concentrations of 0, 20, 75, or 
300 ppm for 6 hours/day, 5 days/week for 104 weeks (Aiso et al. 2005b; Japan Bioassay Research Center 
1995). Histological examinations of the respiratory tract (nasal cavity, trachea, and lung) showed nasal 
epithelial effects in rats and mice.  The nasal lesions in rats mainly included eosinophilic changes of 
moderate or greater severity in the olfactory epithelium in male rats at 300 ppm and female rats at 




















3. HEALTH EFFECTS 
rats, and 28/50, 29/50, 39/50, and 47/50 in the female rats.  The increases were significantly (p≤0.05) 
different than the control values and there was a trend of increasing response with increasing dose in both 
sexes. Additionally observed were significantly increased incidences of eosinophilic changes of the 
respiratory epithelium and respiratory metaplasia in the 300 ppm female rats only.  The nasal lesions in 
mice included significantly increased incidences of respiratory metaplasia in the nasal gland (moderate 
severity) in males at 75 ppm (9/49, 12/49, 18/50, 11/49) and olfactory epithelium (slight severity) in 
males at 75 ppm (23/49, 30/49, 37/50, 22/49) and females at 300 ppm (7/50, 6/50, 2/49, 20/50), but the 
effects in the males were not dose-related (i.e., incidences were increased at 75 ppm but not at 300 ppm).  
The nasal lesions in female rats, the more sensitive species and sex, were selected as the critical effect for 
deriving a chronic-duration inhalation MRL of 0.01 ppm for 1,4-DCB.   
Cardiovascular Effects.
1,2-Dichlorobenzene. No studies were located regarding cardiovascular effects in humans following 
inhalation exposure to 1,2-DCB.
No changes in absolute heart weight or heart histology were reported for rats (20/sex), guinea pigs 
(8/sex), rabbits (2/sex), or monkeys (2 females) following exposure to 93 ppm 1,2-DCB for 7 hours/day, 
5 days/week for 6–7 months, or in mice (10 females) that were similarly exposed to 49 ppm 1,2-DCB 
(Hollingsworth et al. 1958).  Relative heart weight was not determined.  The scope of histological 
evaluations was not specifically reported; organs that were weighed are inferred to have been 
histologically examined.   
1,3-Dichlorobenzene. No studies were located regarding cardiovascular effects in humans or animals 
following inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. No studies were located regarding cardiovascular effects in humans following 
inhalation exposure to 1,4-DCB. 
Limited information is available regarding cardiovascular effects in animals.  No alterations in relative 
heart weight were observed in rats or guinea pigs exposed to 1,4-DCB at an air concentration of 173 ppm, 
7 hours/day, 5 days/week for up to 12 exposures (Hollingsworth et al. 1956).  Similar results were 


























3. HEALTH EFFECTS 
exposure protocol (Hollingsworth et al. 1956); no other cardiovascular end points were evaluated in this 
study.
In pregnant Alderley-Park rats, whole-body exposure to 1,4-DCB at air concentrations of 74.7, 198.6, or 
508.4 ppm, 6 hours/day from Gd 6 to 15 produced no adverse clinical or pathological signs in the heart 
tissues of the dams (Hodge et al. 1977). 
A significant increase in absolute heart weight was reported in male and female rats exposed to 1,4-DCB 
at air concentrations of 490–499 ppm, 5 hours/day, 5 days/week for 76 weeks and allowed to recover until 
week 112 (Riley et al. 1980a).  This effect was not seen at the 76-week interim sacrifice or at the lower-
exposure concentration of 75 ppm.  Examination of the heart and aorta at interim sacrifices or at 
termination of the study revealed no significant histological alterations related to 1,4-DCB treatment. 
Gastrointestinal Effects.     
1,2-Dichlorobenzene. No studies were located regarding gastrointestinal effects in humans or animals 
following inhalation exposure to 1,2-DCB. 
1,3-Dichlorobenzene. No studies were located regarding gastrointestinal effects in humans or animals 
following inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. Two case reports provide evidence of gastrointestinal effects in humans after 
exposure to unknown concentrations of 1,4-DCB.  A 60-year-old man who had been exposed to vapors of
1,4-DCB in his home for 3–4 months reported having several bowel movements a day with loose tarry
stools for 10 days before being admitted to a hospital (Cotter 1953).  The second case is that of a 34-year­
old woman who had been exposed to vapors of 1,4-DCB at work and became acutely ill with nausea and 
vomiting, and was hospitalized with hemorrhage from the gastrointestinal tract (Cotter 1953).  The 
physical and chemical findings led to the diagnosis of subacute yellow atrophy and cirrhosis of the liver 
from 1,4-DCB exposure.  No further information was located. 
Limited information regarding gastrointestinal effects in animals is provided in a chronic-duration study.  
In that study (Riley et al. 1980a), the investigators found no effect on the organ weight or on gross and 
























3. HEALTH EFFECTS 
stomach in male and female Wistar rats exposed to 1,4-DCB at air concentrations of up to 490–499 ppm, 
5 hours/day, 5 days/week for 76 weeks.  
Hematological Effects. 
1,2-Dichlorobenzene. Periodic industrial hygiene surveys and medical examinations were conducted in a 
plant where an unreported number of men were exposed to 1,2-DCB at an average level of 15 ppm (range 
1–44 ppm) for an unreported duration (Hollingsworth et al. 1958).  No effects on clinical hematology
indices (red blood cell count, total and differential white blood cell counts, hemoglobin, hematocrit, and 
mean corpuscular volume) were attributable to exposure. 
Red blood cell (RBC), total white blood cell (WBC), and leucocyte differential cell counts were assessed 
in groups of five male Sprague-Dawley rats that were exposed to 0, 5, 10, 16, or 29 ppm 1,2-DCB for 
4 hours (Brondeau et al. 1990).  Total WBC counts were significantly (p≤0.05) reduced at ≥10 ppm
without any changes in WBC differential or RBC counts.  The effect of 1,2-DCB on total WBC count 
was further assessed in groups of 10 male Sprague-Dawley rats that were normal or adrenalectomized and 
exposed to 0 or 24 ppm for 4 hours.  Adrenalectomy caused a significant increase in total WBCs (39.9% 
higher than normal controls), although exposure did not significantly affect WBC count in the 
adrenalectomized rats.  Because the adrenal-dependent leucopenia was similar to that observed after 
exposure to various irritant stressors, and is thought to be a secondary manifestation of increased secretion 
of glucocorticosteroids, the authors considered the effect to be an associative response to sensory
irritation. 
No hematological changes were reported in rabbits (2/sex) or monkeys (2 females) that were exposed to 
93 ppm 1,2-DCB for 7 hours/day, 5 days/week for 6–7 months (Hollingsworth et al. 1958). The 
hematology end points that were evaluated were not specified. 
1,3-Dichlorobenzene. No studies were located regarding hematological effects in humans or animals 
following inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. Two reports of hematological effects in humans after inhalation exposure to 
1,4-DCB were located in the literature.  Based on results from blood counts, anemia was diagnosed in two 
men; one had been exposed to unknown concentrations of 1,4-DCB vapors at home for 3–4 months and 























3. HEALTH EFFECTS 
manner was diagnosed with borderline anemia (Cotter 1953).  Early industrial hygiene surveys found no 
evidence of adverse hematological effects attributable to exposure to 1,4-DCB in workers at air 
concentrations ranging from 10 to 550 ppm for 8 months to 25 years (average 4.75 years) (Hollingsworth 
et al. 1956). 
Information regarding hematological effects in animals is scant.  No hematologic effects (specific tests 
not provided) were observed in rats and rabbits exposed to 1,4-DCB vapors at concentrations of 96 or 
158 ppm, respectively, dosed for durations of 7 hours/day, 5 days/week for 5–7 months (Hollingsworth et 
al. 1956).  In another intermediate-duration study, F344 rats and BDF1 mice were chamber-exposed to 25, 
55, 120, 270, or 600 ppm of 1,4-DCB for 6 hours/day, 5 days/week for 13 weeks (Aiso et al. 2005a).  
Hematological changes suggestive of microcytic anemia occurred in the male rats; effects included 
significantly decreased RBC count and hemoglobin concentration at ≥120 ppm, hematocrit at ≥270 ppm, 
and MCV and MCH at 600 ppm.  The effects were not accompanied by any anemia-associated
histopathological changes in hematopoietic tissues (e.g., increased extramedullary hematopoiesis or 
hemosiderosis in the spleen) and did not occur in the female rats or mice of either sex, leading the 
investigators to suggest that they were secondary to male rat-specific α2µ-globulin nephropathy-related 
effects on erythropoietin synthesis in the renal tubules. 
A chronic-duration study reported that some changes in blood chemistry and hematologic parameters 
were seen in rats exposed 5 hours/day, 5 days/week to 1,4-DCB at air concentrations of up to 490– 
499 ppm for 76 weeks; however, the reported changes showed no consistent trend with dose, sex, or 
exposure duration that would indicate treatment-related effects (Riley et al. 1980a). 
Musculoskeletal Effects. 
1,2-Dichlorobenzene. No studies were located regarding musculoskeletal effects in humans following 
inhalation exposure to 1,2-DCB.
1,3-Dichlorobenzene. No studies were located regarding musculoskeletal effects in humans or animals 
following inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. No studies were located regarding musculoskeletal effects in humans after 
























3. HEALTH EFFECTS 
One study was located that examined the musculoskeletal effects in laboratory animals after inhalation 
exposure to 1,4-DCB.  No gross or histological alterations in skeletal muscle (unspecified parameters) 
were detected in rats exposed to 1,4-DCB at air concentrations of up to 490–499 ppm, 5 hours/day,
5 days/week for 76 weeks (Riley et al. 1980a). 
Hepatic Effects. 
1,2-Dichlorobenzene. No studies were located regarding hepatic effects in humans following inhalation 
exposure to 1,2-DCB.
Increased liver weight and marked central lobular necrosis occurred in rats that were exposed to 1,2-DCB 
at a concentration of 977 ppm for 0.5 or 1 hour, but not to 539 ppm for 3 hours (Hollingsworth et al. 
1958).  No changes in absolute liver weight or hepatic histology were reported for rats (20/sex), guinea 
pigs (8/sex), rabbits (2/sex), or monkeys (2 females) exposed to 93 ppm 1,2-DCB for 7 hours/day, 
5 days/week for 6–7 months, or in mice (10 females) similarly exposed to 49 ppm 1,2-DCB 
(Hollingsworth et al. 1958).   
1,3-Dichlorobenzene. No studies were located regarding hepatic effects in humans or animals following 
inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. Hepatic effects have been reported in humans following long-term exposure to 
1,4-DCB via inhalation. A 60-year-old man and his wife who were exposed to moth ball vapor that 
"saturated" their home for 3–4 months both died of liver failure (acute liver atrophy) within a year of the 
initial exposure (Cotter 1953). Yellow atrophy and cirrhosis of the liver were reported in a 34-year-old 
woman who demonstrated 1,4-DCB products in a department store and in a 52-year-old man who used 
1,4-DCB occupationally in a fur storage plant for about 2 years (Cotter 1953).  Duration of exposure was 
not estimated for the 34-year-old woman, but was indicated in the report to be >1 year.  No estimates of 
the 1,4-DCB exposure levels (other than the use of the term “saturated”) were provided in any of these 
reports, nor was it verified that 1,4-DCB exposure was the only factor associated with the observed 
effects. History of alcohol consumption or prior liver disease factors were not mentioned for any of the 
cases reported by Cotter (1953).  These case studies indicate that the liver is a target organ for 1,4-DCB in



















3. HEALTH EFFECTS 
In an acute-duration study using pregnant Alderley-Park rats, whole-body exposure to 1,4-DCB at air 
concentrations of 74.7, 198.6, or 508.4 ppm, 6 hours/day from Gd 6 to 15 produced no adverse clinical or 
pathological signs in the hepatic tissues of the dams (Hodge et al. 1977).  In a similar study, New Zealand 
White rabbits exposed whole-body to 1,4-DCB 6 hours/day on Gd 6–18 experienced no adverse effects 
on absolute or relative maternal liver weights at air concentrations up to 800 ppm (Hayes et al. 1985). 
An intermediate-duration study was conducted in which F344 rats and BDF1 mice were chamber-exposed 
to 0, 25, 55, 120, 270, or 600 ppm of 1,4-DCB for 6 hours/day, 5 days/week for 13 weeks (Aiso et al. 
2005a). Hepatic effects in the rats included increases in absolute and relative liver weight (>10%) in 
males at ≥270 ppm and females at 600 ppm, serum total cholesterol and phospholipid in males at 
≥270 ppm and females at 600 ppm, serum albumin in females at ≥270 ppm and males at 600 ppm, total 
protein in both sexes at 600 ppm, and centrilobular hepatocellular hypertrophy in males at 600 ppm.  
Hepatic effects in the mice included increases in absolute and relative liver weight (>10%) in males at 
≥270 ppm and females at 600 ppm, serum ALT in males at ≥270 ppm and females at 600 ppm, serum
AST in males at 600 ppm, serum total cholesterol and total protein in both sexes at 600 ppm, and 
centrilobular hepatocellular hypertrophy in males at ≥270 ppm and females at 600 ppm.  The mouse liver 
was more responsive to 1,4-DCB than the rat liver as shown by the histological and serum enzyme
changes. Hepatocellular hypertrophy occurred at a lower exposure level in the mice (270 ppm compared 
to 600 ppm in rats); incidences in the 0, 25, 120, 270, and 600 ppm male mice were 0/10, 0/10, 0/10, 
0/10; 10/10 and 10/10, respectively.  At 600 ppm, the severity of the hepatocellular hypertrophy was 
classified as moderate in the mice and slight in the rats.  Affected hepatocytes in the mice were 
characterized by cell enlargement, varying nuclear size and shape, and coarse chromatin and inclusion 
bodies in the nucleus, whereas such nuclear changes were not observed in the hypertrophic hepatocytes of 
the rats. Additionally, the hepatocellular hypertrophy in the mice was accompanied by single cell 
necrosis (both sexes, incidence not reported) and focal necrosis (2/10 males) at 600 ppm, as well as the 
increases in serum ALT at ≥270 ppm and AST at 600 ppm, whereas none of these indicators of 
hepatocellular damage occurred in the rats.   
In a cross-species comparative study, exposure to 1,4-DCB at air concentrations up to 158 ppm, 
7 hours/day, 5 days/week for 5–7 months produced no treatment-related effects on liver weight or 
microscopic appearance in male and female mice; in contrast, various hepatic effects were noted in rats, 
guinea pigs, and rabbits exposed to 1,4-DCB at various levels and durations of exposure (Hollingsworth 
et al. 1956). There was considerable variability in the species of animals exposed at each dose, the 























3. HEALTH EFFECTS 
798 ppm of 1,4-DCB intermittently for 2–12 weeks, several hepatic effects were observed.  Relative liver 
weight was increased in rats exposed to 173 ppm; histopathological examination at this exposure level 
revealed slight congestion and granular degeneration in female rats.  At 798 ppm, liver changes included 
cloudy swelling and central necrosis in both sexes of rats and rabbits.  In the same study, when rats 
inhaled 158–341 ppm 1,4-DCB intermittently for 5–7 months, male and female rats displayed cloudy
swelling and central zone degeneration of the hepatic parenchymal cells in the liver, and increased 
relative liver weights at 158 ppm.  These changes were not seen at a concentration of 96 ppm.  In the 
same study, guinea pigs that were exposed to 341 ppm for a comparable duration or to 798 ppm for 2– 
4.5 weeks had focal necrosis and slight cirrhosis (in some animals) as well as hepatocyte swelling and 
degeneration. 
In a 2-generation study of the effects of inhalation exposure to 1,4-DCB in Sprague-Dawley rats, males 
and females were exposed to 0, 66.3, 211, or 538 ppm 1,4-DCB 6 hours/day for 10 weeks prior to mating.  
The females were also exposed during mating, and on Gd 0–19 and postnatal days 5–27; males were 
exposed throughout the study.  Marked hepatocellular hypertrophy, localized in the centrilobular area, 
was noted in F0 and F1 males and females in the 538 ppm dose group; no such effects were seen in the 
low- and mid-dose groups.  Liver weights were significantly elevated in F0 males at the 211 and 538 ppm
doses and in F0 females at the 538 ppm dose; liver weights were also significantly elevated in F1 males 
and females at the 538 ppm dose (Tyl and Neeper-Bradley 1989).  The increased liver weight in F0 male
rats was selected as the critical effect for deriving an intermediate-duration inhalation MRL of 0.2 ppm
for 1,4-DCB. 
In a long-term inhalation study in rats, exposure to 1,4-DCB at air concentrations of 490–499 ppm
5 hours/day, 5 days/week for 76 weeks resulted in an increase in absolute liver weight throughout the 
study in males and at weeks 27 and 112 in females (Riley et al. 1980a).  This effect was not accompanied 
by histological alterations or by increased serum transaminase activities.  No hepatic effects were noted at 
75 ppm.  None of the adverse hepatic effects reported at lower concentrations of 1,4-DCB for shorter 
durations (Hollingsworth et al. 1956), as described above, were identified in the 76-week study.   
In another chronic study, groups of 50 male and female F344/DuCrj rats and 50 male and 50 female 
Crj:BDF1 mice were exposed to 1,4-DCB in concentrations of 0, 20, 75, or 300 ppm for 6 hours/day,
5 days/week for 104 weeks (Aiso et al. 2005b; Japan Bioassay Research Center 1995).  Histological 
























3. HEALTH EFFECTS 
hepatocellular hypertrophy was significantly increased in male mice at 300 ppm, as shown by incidences 
of 0/49, 0/49, 0/50, and 34/49 in the control to high dose groups.  
Renal Effects. 
1,2-Dichlorobenzene. Periodic industrial hygiene surveys and medical examinations were conducted in a 
plant where an unreported number of men were exposed to 1,2-DCB at an average level of 15 ppm (range 
1–44 ppm) for an unreported duration (Hollingsworth et al. 1958).  No effects on clinical renal indices 
(blood urea nitrogen, sedimentation rate, or urinalysis) were attributable to exposure. 
No changes in absolute kidney weight or kidney histology were reported for rats (20/sex), guinea pigs 
(8/sex), rabbits (2/sex), or monkeys (2 females) exposed to 93 ppm 1,2-DCB for 7 hours/day, 
5 days/week for 6–7 months, or in mice (10 females) similarly exposed to 49 ppm 1,2-DCB 
(Hollingsworth et al. 1958).  Relative kidney weight was not determined.  The scope of histological 
evaluations was not specifically reported; organs that were weighed are inferred to have been 
histologically examined.  Limited urinalysis was performed in the species exposed to 93 ppm; BUN 
determinations and qualitative tests for sugar, albumin, sediment, and blood showed no abnormalities. 
1,3-Dichlorobenzene. No studies were located regarding renal effects in humans or animals following 
inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. No studies were located regarding renal effects in humans after inhalation 
exposure to 1,4-DCB. 
In an acute-duration study using pregnant Alderley-Park rats, whole-body exposure to 1,4-DCB at air 
concentrations of 74.7, 198.6, or 508.4 ppm, 6 hours/day from Gd 6 to 15 produced no adverse clinical or 
pathological signs in the kidney tissues of the dams (Hodge et al. 1977).  In a similar study, pregnant New 
Zealand White rabbits exposed whole-body to 1,4-DCB 6 hours/day on Gd 6–18 experienced no adverse 
effects with regard to either absolute or relative maternal kidney weights at air concentrations up to
800 ppm (Hayes et al. 1985). 
In an intermediate-duration study, F344 rats and BDF1 mice were chamber-exposed to 25, 55, 120, 270, 
or 600 ppm of 1,4-DCB for 6 hours/day, 5 days/week for 13 weeks (Aiso et al. 2005a).  Histological 

























3. HEALTH EFFECTS 
tubular cell necrosis, cytoplasmic basophila, and papillary mineralization) in the male rats at ≥270 ppm. 
There were no histological changes in the kidneys of the female rats or mice of either sex.  Other renal 
effects included increased relative and/or absolute kidney weights in male rats and male mice at 
≥270 ppm and female rats and female mice at 600 ppm, and increased serum BUN in male rats and male 
mice at 600 ppm. 
In rats, mice, and rabbits exposed by inhalation to 1,4-DCB at air concentrations ranging from 96 to 
798 ppm, 7 or 8 hours/day, for periods as long as 7 months, no renal effects were noted in mice or rabbits, 
while both male and female rats experienced increased relative kidney weights at the 173 ppm dose level.  
In addition, a slight cloudy swelling of the tubular epithelium was noted in female rats exposed to 
798 ppm.  In the same study, inhalation of 1,4-DCB at 158 or 341 ppm intermittently for 5–7 months by
rats caused a slight increase in relative kidney weight in males but not females (Hollingsworth et al. 
1956).  This effect was not observed in groups of guinea pigs, in one monkey, or in two rabbits under the 
same experimental conditions (Hollingsworth et al. 1956).  The findings in this study are consistent with 
those reported by Riley et al. (1980a) in a 76-week study in rats, described below. 
In a 2-generation study of the effects of inhalation exposure to 1,4-DCB in Sprague-Dawley rats, males 
and females were exposed to 0, 66.3, 211, or 538 ppm 1,4-DCB 6 hours/day for 10 weeks prior to mating.  
The females were also exposed during mating, and on Gd 0–19 and postnatal days 5–27; males were 
exposed throughout the study.  An increased incidence of nephrosis was seen in F0 males of all dose 
groups and in F1 males of the 211 and 538 ppm dose groups; lesions consisted of hyaline droplets, tubular 
protein nephrosis, granular cast formation, and interstitial nephritis.  No renal lesions were noted in F0 or 
F1 females. Kidney weights were significantly elevated in F0 males at all doses and in F1 males at the 
538 ppm dose.  In females, kidney weights were significantly elevated in the F0 generation at the 538 ppm
dose, but were not elevated in the F1 generation (Tyl and Neeper-Bradley 1989). 
In a chronic-duration inhalation study in Wistar rats, exposure to 1,4-DCB at air concentrations of 490– 
499 ppm, 5 hours/day, 5 days/week for 76 weeks resulted in an increase in absolute kidney weight in 
males throughout the study and in females at weeks 27 and 112 weeks.  Exposure to 75 ppm 1,4-DCB had 
no effect on kidney weight, and neither exposure level caused histopathological alterations in the kidneys
(Riley et al. 1980a).  In another chronic study, groups of 50 male and female F344/DuCrj rats and 50 male 
and 50 female Crj:BDF1 mice were exposed to 1,4-DCB in concentrations of 0, 20, 75, or 300 ppm for 
6 hours/day, 5 days/week for 104 weeks (Aiso et al. 2005b; Japan Bioassay Research Center 1995).  




























3. HEALTH EFFECTS 
mineralization of the renal papilla and hyperplasia of the urothelium were significantly increased.  In 
general, the renal effects observed in inhalation studies of 1,4-DCB are mild in contrast with the severe 
renal effects observed in oral studies as described in Section 3.2.2.2. 
Endocrine Effects. 
1,2-Dichlorobenzene. No studies were located regarding endocrine effects in humans or animals 
following inhalation exposure to 1,2-DCB.
1,3-Dichlorobenzene. No studies were located regarding endocrine effects in humans or animals 
following inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. No studies were located regarding endocrine effects in humans following 
inhalation exposure to 1,4-DCB. 
The only information regarding endocrine effects in animals after inhalation exposure to 1,4-DCB is from
a chronic-duration study in rats.  In that study (Riley et al. 1980a), no gross or histopathological effects 
were observed in the adrenal, thyroid, or pituitary glands of male or female rats exposed to 1,4-DCB at air 
concentrations up to 490–499 ppm, 5 hours/day, 5 days/week for 76 weeks.  No further information 
regarding endocrine effects was located. 
Dermal Effects.     
1,2-Dichlorobenzene. No studies were located regarding dermal effects in humans or animals following 
inhalation exposure to 1,2-DCB.
1,3-Dichlorobenzene. No studies were located regarding dermal effects in humans or animals following 
inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. Dermal effects resulting from 1,4-DCB exposure were reported in a 69-year-old 
man who had been exposed for approximately 3 weeks to 1,4-DCB used in his home, including on a chair 
on which he had been sitting.  He gradually developed petechiae (small red spots), purpura (purple or 
























3. HEALTH EFFECTS 
indirect basophil degranulation test that showed a strongly positive reaction (degenerative changes in 62% 
of his basophils when tested with 1,4-DCB, compared with a 6% reaction of normal serum with 1,4-DCB) 
(Nalbandian and Pearce 1965).  The authors suggested that these effects were probably immunologically 
mediated. In a study of 58 men occupationally exposed to up to 725 ppm 1,4-DCB, 8 hours/day, 
5 days/week continually or intermittently for 8 months to 25 years (average:  4.75 years), medical 
examinations revealed no evidence of dermatological effects (Hollingsworth et al. 1956). 
No studies were located regarding dermal effects in animals after inhalation exposure to 1,4-DCB. 
Ocular Effects.     
1,2-Dichlorobenzene. Periodic industrial hygiene surveys and medical examinations were conducted in a 
plant where an unreported number of men were exposed to 1,2-DCB at an average level of 15 ppm (range 
1–44 ppm) for an unreported duration (Hollingsworth et al. 1958).  No eye or nasal irritation was 
attributable to exposure. Additionally, Hollingsworth et al. (1958) noted that his researchers detected 
1,2-DCB odor at a concentration of 50 ppm without eye or nasal irritation during repeated vapor 
inhalation experiments on animals.  An earlier source (Elkins 1950) referenced by Hollingsworth (1958) 
reported that occupational exposure to 100 ppm of 1,2-DCB caused irritation of the eyes and respiratory
passages. 
1,3-Dichlorobenzene. No studies were located regarding ocular effects in humans or animals following 
inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. In a report on 58 men who had worked for 8 months to 25 years (average exposure 
4.75 years) in a plant that used 1,4-DCB, painful irritation of the nose and eyes were reported at levels 
ranging from 80 to 160 ppm (Hollingsworth et al. 1956).  At levels >160 ppm, the air was considered 
unbreathable by unacclimated persons.  Neither cataracts nor any other lens changes were found upon 
examination of their eyes. 
There is no clear, quantitative evidence of ocular effects resulting from inhalation exposure to 1,4-DCB in 
animal studies.  Ocular effects, described as reversible, nonspecific eye ground changes (changes in the 
fundus or back of the eye), were seen in two rabbits exposed to 1,4-DCB at 798 ppm, 8 hours/day, 
5 days/week for 12 weeks (Hollingsworth et al. 1956). In the same study, no lens changes were observed 
























3. HEALTH EFFECTS 
tested. Ocular effects occurring during and/or after exposure to chemicals in air are likely to be due to 
direct contact of the chemical with the eye.   
A chronic-duration inhalation study in male and female Wistar rats reported no histopathological 
alterations in the eyes of rats exposed to 1,4-DCB at air concentrations up to 490–499 ppm, 5 hours/day, 
5 days/week for 76 weeks (Riley et al. 1980a).  No further data were located.  
Body Weight Effects.     
1,2-Dichlorobenzene. Groups of male and female albino rats (20/sex) were exposed to 0, 49, or 93 ppm
(0, 290, or 560 mg/m3, respectively) of 1,2-DCB (99% pure) vapor for 7 hours/day, 5 days/week for 6– 
7 months (Hollingsworth et al. 1958).  No compound related effects were found at 49 ppm.  Effects 
observed at 93 ppm consisted of statistically significant (p≤0.05) decreased final body weight in the males 
(8.9% lower than controls). There were no body weight changes in guinea pigs (8/sex), rabbits (2/sex), or 
monkeys (2 females) similarly exposed to 93 ppm 1,2-DCB, or in mice (10 females) similarly exposed to
49 ppm 1,2-DCB (Hollingsworth et al. 1958). 
1,3-Dichlorobenzene. No studies were located regarding body weight effects in humans or animals 
following inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. A 60-year-old man who was exposed to vapors of 1,4-DCB in his home for 3– 
4 months was reported to have lost approximately 50 pounds in body weight in 3 months (Cotter 1953).  
His wife, who received similar exposure, also lost weight.  A third case reported by the same author 
(Cotter 1953) is that of a 52-year-old man who was exposed to 1,4-DCB by using the chemical for 
preserving raw furs. On examination, this individual was described as being emaciated.  Information 
regarding food consumption was not available in any of these cases.  In the case of the 60-year-old man, 
persistent diarrhea may have contributed to the weight loss.   
In an acute-duration study using pregnant Alderley-Park rats, whole-body exposure to 1,4-DCB at air 
concentrations of 74.7, 198.6, or 508.4 ppm, 6 hours/day from Gd 6 to 15 had no effect on maternal body
weight gain (Hodge et al. 1977). 
Body weight data are available for various animal species after exposure to 1,4-DCB 7–8 hours/day, 























3. HEALTH EFFECTS 
and guinea pigs experienced weight loss when exposed to 798 ppm, 8 hours/day, 5 days/week.  Rats 
exposed to up to 341 ppm 1,4-DCB for 5–7 months grew at a rate similar to that of unexposed controls.  
Similar results were obtained in rabbits exposed to 173 ppm for 16 days or to 158 ppm for about 
200 days.  Slight growth depression was observed in male and female guinea pigs exposed to 158 ppm
1,4-DCB for 157 days, but only males showed a slight delay in growth when the exposure level was 
341 ppm for 6 months.  In male and female mice and in one female monkey, there were no effects on 
body weight after exposure to 1,4-DCB at air concentrations up to 158 ppm for as long as 7.1 months.  In 
another intermediate-duration study, there were no effects on body weight gain in F344 rats and 
BDF1 mice that were exposed to 25, 55, 120, 270, or 600 ppm of 1,4-DCB for 6 hours/day, 5 days/week 
for 13 weeks (Aiso et al. 2005a). 
In a 2-generation study of the effects of inhalation exposure to 1,4-DCB in Sprague-Dawley rats, males 
and females were exposed to 0, 66.3, 211, or 538 ppm 1,4-DCB 6 hours/day for 10 weeks prior to mating.  
The females were also exposed during mating, and on Gd 0–19 and postnatal days 5–27; males were 
exposed throughout the study. Male F0 body weight and body weight gain were significantly reduced in 
the 538 ppm group.  Body weight gain was also significantly reduced in the 211 ppm group; however, the 
effect was seen at fewer observation periods.  Female F0 body weights were equivalent across all 
treatment groups during the entire prebreeding period.  The F1 generation males and females exposed to 
538 ppm 1,4-DCB had lower body weights than did controls; however, these decreases were accompanied 
by decreased food consumption (Tyl and Neeper-Bradley 1989).  
A chronic-duration inhalation study in male and female Wistar rats found that body weight was not 
significantly altered after exposure to 1,4-DCB at air concentrations up to 490–499 ppm, 5 hours/day,
5 days/week for 76 weeks (Riley et al. 1980a). 
Other Systemic Effects.     
1,2-Dichlorobenzene. No studies were located regarding other systemic effects in humans or animals 
following inhalation exposure to 1,2-DCB. 
1,3-Dichlorobenzene. No studies were located regarding other systemic effects in humans or animals 
























3. HEALTH EFFECTS 
1,4-Dichlorobenzene. No studies were located regarding other effects in humans following inhalation 
exposure to 1,4-DCB.  Ascites, esophageal varices, hemorrhoids, and tarry stools are all secondary effects 
of subacute, yellow atrophy and cirrhosis of the liver (Cotter 1953).
A chronic-duration inhalation study in male and female Wistar rats found that food and water 
consumption was not significantly altered after exposure to 1,4-DCB at air concentrations up to 490– 
499 ppm, 5 hours/day, 5 days/week for 76 weeks (Riley et al. 1980a). 
In a 2-generation study of the effects of inhalation exposure to 1,4-DCB in Sprague-Dawley rats, males 
and females were exposed to 0, 66.3, 211, or 538 ppm 1,4-DCB 6 hours daily for 10 weeks prior to 
mating. The females were also exposed during mating, and on Gd 0–19 and postnatal days 5–27; males 
were exposed throughout the study.  Exposure of the F0 and F1 generations to 538 ppm 1,4-DCB resulted 
in clinical signs of toxicity such as decreased grooming, unkempt appearance, decreased food 
consumption, and dehydration (Tyl and Neeper-Bradley 1989).  
3.2.1.3 Immunological and Lymphoreticular Effects  
1,2-Dichlorobenzene. No studies were located regarding immunological effects in humans following 
inhalation exposure to 1,2-DCB.
No changes in absolute spleen weight or spleen histology were reported for rats (20/sex) or guinea pigs 
(8/sex) that were exposed to 93 ppm 1,2-DCB for 7 hours/day, 5 days/week for 6–7 months 
(Hollingsworth et al. 1958).  Relative spleen weight was not determined.  The scope of histological 
evaluations was not specifically reported; organs that were weighed appear to have been examined.  
1,3-Dichlorobenzene. No studies were located regarding immunological effects in humans or animals 
following inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. As mentioned in Section 3.2.1.2, dermal effects observed in a 69-year-old man 
who had been exposed to 1,4-DCB in his home for approximately 3 weeks (Nalbandian and Pearce 1965) 
may have been mediated by immunological mechanisms.  In addition to petechiae, purpura, and swelling 
of his hands and feet, his serum showed a strong positive reaction to 1,4-DCB in an indirect basophil 
degranulation test. The authors stated that, to their knowledge, this was the first reported case of allergic 























3. HEALTH EFFECTS 
woman who had been exposed to 1,4-DCB in her home for 3–4 months and in a man who used 1,4-DCB 
to preserve raw furs (Cotter 1953).  This, however, was most likely a secondary response to 
hematological disturbances rather than an immunological effect. 
A slight decrease in relative spleen weight was observed in male guinea pigs exposed to 1,4-DCB at an 
air concentration of 173 ppm, 7 hours/day, 5 days/week for 16 days (Hollingsworth et al. 1956); no effect 
was seen in rats under the same experimental conditions.  In a chronic-duration inhalation study, groups 
of male and female Wistar rats exposed to 1,4-DCB 5 hours/day, 5 days/week for 76 weeks exhibited no
gross or histopathological alterations in the cervical, thoracic, and mesenteric lymph nodes; spleen; or 
thymus at air concentrations up to 500 ppm (Riley et al. 1980a).  No other immunological end points were 
evaluated. 
No effects were found in an immunotoxicity study in which groups of 10 male SPF Hartley guinea pigs 
were exposed to 1,4-DCB by inhalation in concentrations of 0, 2, or 50 ppm for 12 weeks (schedule not 
specified) (Suzuki et al. 1991). The animals were sensitized with ovalbumin after 4 and 8 weeks of 
exposure to evaluate effects on antibody production. Determinations of serum IgE titers (passive 
cutaneous anaphylaxis test) and serum IgG and IgM titers (enzyme-linked immunosorbent assay) against 
ovalbumin, performed 1 and 2 weeks after the first sensitization and 1, 2, and 4 weeks after the second 
sensitization, showed no significant differences between the exposed and control groups.  The passive 
cutaneous anaphylaxis test was also conducted with antiserum from the 50 ppm exposure group (collected 
1 and 2 weeks after the first sensitization and 1, 2, and 4 weeks after the second sensitization) to 
determine if IgE antibodies were produced against 1,4-DCB; no antibodies against the compound were 
detected. Active systemic anaphylaxis was also evaluated in the 0 and 50 ppm exposure groups.  An 
antigen mixture of 1,4-DCB and guinea pig serum albumin did not cause an anaphylactic reaction when 
intravenously injected in the animals 14 days after the last exposure.  This study was reported in the 
Japanese literature; relevant information was obtained from the English abstract and data tables. 
3.2.1.4 Neurological Effects 
1,2-Dichlorobenzene. No studies were located regarding neurological effects in humans or animals 
following inhalation exposure to 1,2-DCB.
1,3-Dichlorobenzene. No studies were located regarding neurological effects in humans or animals 
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1,4-Dichlorobenzene. Information regarding neurological effects in humans exposed to 1,4-DCB via 
inhalation is limited to several case reports.  A 60-year-old man whose home had been saturated with 
1,4-DCB moth ball vapor for 3 or 4 months complained of persistent headache, numbness, clumsiness, 
and a burning sensation in his legs (consistent with peripheral nerve damage); he also showed slurred 
speech (Cotter 1953).  In a more recent case study, a 25-year-old woman was exposed to high 
concentrations of 1,4-DCB from her bedroom, bedding, and clothing.  She had used this compound
liberally as an insect repellant for 6 years.  The subject sought medical assistance because of severe 
ataxia, speech difficulties, and moderate weakness of her limbs.  Brainstem auditory-evoked potentials 
(BAEPs) showed marked delays of specific brainwave patterns.  Her symptoms gradually improved over 
the next 6 months after cessation of exposure and the BAEPs examined 8 months later had returned to 
normal.  This study suggests that there may be measurable but reversible neurological effects associated 
with human inhalation exposure to 1,4-DCB (Miyai et al. 1988). The level of 1,4-DCB exposure was 
neither known nor estimated in either of the human case studies.  In addition, there is no certainty that 
exposure to 1,4-DCB was the only factor associated with the toxic effects reported. 
Neurological signs including marked tremors, weakness, and loss of consciousness were observed in rats, 
rabbits, and guinea pigs exposed to 798 ppm 1,4-DCB 8 hours/day, 5 days/week (Hollingsworth et al. 
1956).  In a chronic-duration study in rats, exposure to up to 500 ppm 1,4-DCB 5 hours/day, 5 days/week 
for 76 weeks did not cause gross or histological alterations in the brain, sciatic nerve, or spinal cord, but 
absolute brain weight was slightly decreased at the termination of the study (Riley et al. 1980a).  Adult 
rats exposed 6 hours/day for 10 weeks to 538 ppm 1,4-DCB during a 2-generation study displayed 
symptoms associated with compound neurotoxicity, including tremors, ataxia, and hyperactivity (Tyl and
Neeper-Bradley 1989).  The animals also decreased their grooming behavior and developed an unkempt 
appearance. At sacrifice, the relative brain weights of the males, but not the females, were significantly 
increased compared to the controls. 
3.2.1.5 Reproductive Effects  
1,2-Dichlorobenzene. No studies were located regarding reproductive effects in humans or animals 
following inhalation exposure to 1,2-DCB.
A 2-generation inhalation reproduction study was conducted in which groups of Charles River CD 
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394 ppm (Bio/dynamics 1989).  F0 adults were exposed for 6 hours/day, 7 days/week for a 10-week 
premating period and during mating.  Following mating, F0 males were exposed 6 hours/day, 7 days/week 
until sacrifice at 3–4 weeks postmating.  Bred F0 females were exposed for 6 hours/day on gestation days
0–19 and lactation days 5–28, then sacrificed postweaning. F1 pups (29 days old) received similar 
exposures throughout an 11-week premating period, mating, gestation, and lactation.  There were no 
exposure-related effects on reproductive performance or fertility indices in either generation. 
No changes in absolute testicular weight or testicular histology were reported for male rats or guinea pigs 
that were exposed to 93 ppm 1,2-DCB for 7 hours/day, 5 days/week for 6–7 months (Hollingsworth et al. 
1958).  Relative testicular weight was not determined.  The scope of histological evaluations in this study
was not specifically reported; organs that were weighed also appear to have been examined. 
1,3-Dichlorobenzene. No studies were located regarding reproductive effects in humans or animals 
following inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. No studies were located regarding reproductive effects in humans after inhalation 
exposure to 1,4-DCB. 
In an acute-duration study using pregnant Alderley-Park rats, whole-body exposure to 1,4-DCB at air 
concentrations up to 508.4 ppm, 6 hours/day from Gd 6 to 15 did not adversely affect the number of 
implantations, resorptions, viable fetuses, corpora lutea, or sex ratios (Hodge et al. 1977).  A similar study
in inseminated New Zealand White rabbits exposed whole-body to 1,4-DCB at air concentrations of 100, 
300, or 800 ppm, 6 hours/day on Gd 6–18 found no differences between treated and control groups in the 
mean number of corpora lutea per dam, the mean number of implantation sites per dam, the mean number 
of resorptions per litter, or the number of totally resorbed litters.  At 300 ppm, there was a significant 
increase (p≤0.05) in the percentage of resorbed implantations per litter and in the number of litters with 
resorptions; however, the results at 800 ppm were comparable to controls, and the percentage of litters 
with resorptions reported in the 300 ppm group was within the range reported for historical controls, 
suggesting this effect was not chemical- or dose-related (Hayes et al. 1985). 
Exposure of rats and guinea pigs to 1,4-DCB at an air concentration of 173 ppm, 7 hours/day,
5 days/week for 2 weeks did not significantly alter relative testis weight.  The same results were obtained 
after intermittently exposing rats and guinea pigs to 1,4-DCB at air concentrations up to 158 ppm for 5– 
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of male or female Wistar rats exposed to 1,4-DCB at concentrations up to 490–499 ppm, 5 hours/day, 
5 days/week for 76 weeks (Riley et al. 1980a).  The evaluation of reproductive end points included organ
weights and histopathology. 
In another chronic inhalation study, groups of 50 male and female F344/DuCrj rats and 50 male and 
50 female Crj:BDF1 mice were exposed to 1,4-DCB in concentrations of 0, 20, 75, or 300 ppm for 
6 hours/day, 5 days/week for 104 weeks (Aiso et al. 2005b; Japan Bioassay Research Center 1995).  
Histological examinations included reproductive system tissues in both sexes (testis, epididymis, seminal 
vesicle, prostate, ovary, uterus, vagina, and mammary gland), but there were no exposure-related adverse 
findings in either species or sex (Aiso 2006). 
The effects of 1,4-DCB vapors on the reproductive performance of Sprague-Dawley rats was assessed in 
a 2-generation study in which animals of both sexes were exposed before and during mating (Tyl and 
Neeper-Bradley 1989).  The females were then exposed on Gd 0–19 and postnatal days 5–27.  Effects on 
body weight, liver and kidney weight, and hepatocellular hypertrophy were found in the adult rats at 
exposure concentrations of 211 and 538 ppm and were indicative of toxicity to the breeding animals.  
These effects did not occur with the 66.3 ppm exposure concentration.  Both generations of offspring 
exposed to the 538 ppm concentration had lower body weights than the controls at lactation day 4; 
average litter size and survival rates were decreased.  When selected animals from the first filial 
generation were allowed to recover from the 1,4-DCB exposure for a 5-week period, body weights of the 
538 ppm exposure group remained lower than those for the controls.  The authors concluded that parental 
toxicity was the cause of the increased risk to offspring rather than inherent effects of 1,4-DCB on 
reproductive processes.  In addition, no reduction in reproductive performance (as measured by the 
percentage of males successfully impregnating females) was observed in an inhalation study in which 
male mice were exposed to 1,4-DCB at 75–450 ppm for 6 hours/day for 5 days before being mated with 
virgin females (Anderson and Hodge 1976).  These data are consistent with the data from the males used 
in the 2-generation study discussed above. 
3.2.1.6 Developmental Effects 
1,2-Dichlorobenzene. No studies were located regarding developmental effects in humans or animals 
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1,3-Dichlorobenzene. No studies were located regarding developmental effects in humans or animals 
following inhalation exposure to 1,3-DCB. 
1,4-Dichlorobenzene. No studies were located regarding developmental effects in humans after 
inhalation exposure to 1,4-DCB. 
Exposure of pregnant Alderley-Park rats to 1,4-DCB via inhalation at levels up to 508 ppm for 
6 hours/day on Gd 6–15 did not result in developmental effects in the offspring (Hodge et al. 1977).  End
points examined included the number of viable fetuses, fetal weight, litter weight, sex ratio, external 
abnormalities, and skeletal and visceral abnormalities. 
In a 2-generation study of the effects of inhalation exposure to 1,4-DCB in Sprague-Dawley rats, males 
and females that were exposed to 0, 66.3, 211, or 538 ppm 1,4-DCB 6 hours daily for 10 weeks prior to 
mating were assessed.  The females were also exposed during mating, and on Gd 0–19 and postnatal days
5–27; males were exposed throughout the study.  F1 and F2 pup body weights in the 538 ppm group were 
significantly reduced from postnatal day 0 to 28.  The number of F1 and F2 pups that died during the 
perinatal period was significantly elevated in the 538 ppm group (Tyl and Neeper-Bradley 1989).  
The developmental effects of 1,4-DCB have been evaluated in New Zealand White rabbits (Hayes et al. 
1985).  Pregnant rabbits were exposed to 1,4-DCB by inhalation at 800 ppm for 6 hours/day on Gd 6–18.
At 300 ppm, there was a significant increase in the number of litters with resorptions and the percentages 
of resorbed implantations per litter; however, this effect was not seen at 800 ppm and was thus probably 
not treatment-related. An increased incidence of retroesophageal right subclavian artery present in the 
offspring was noted; it was not considered to constitute a teratogenic response to exposure to 1,4-DCB, 
but was considered only a minor variation.   
3.2.1.7 Cancer 
1,2-Dichlorobenzene. No studies were located regarding cancer in humans or animals following 
inhalation exposure to 1,2-DCB.
1,3-Dichlorobenzene. No studies were located regarding cancer in humans or animals following 



















3. HEALTH EFFECTS 
1,4-Dichlorobenzene. No studies were located regarding cancer in humans after inhalation exposure to 
1,4-DCB. 
No evidence of carcinogenicity was observed in a long-term inhalation study in rats that were exposed to 
1,4-DCB at 75 or 500 ppm intermittently for 76 weeks (Riley et al. 1980a).  The reported lack of 
extensive organ toxicity in this study (compared with results seen in oral studies described in 
Section 3.2.2.2) strongly suggests that a maximum tolerated dose (MTD) was not achieved.  In addition, a 
less-than-lifetime dosing regimen was used.  The experimental design limitations preclude reliable 
evaluation of potential inhalation carcinogenicity based on this study. 
The carcinogenicity of 1,4-DCB was more recently evaluated in groups of 50 male and female
F344/DuCrj rats, and 50 male and 50 female Crj:BDF1 mice, following exposure to concentrations of 0, 
20, 75, or 300 ppm for 6 hours/day, 5 days/week for 104 weeks (Aiso et al. 2005b; Japan Bioassay
Research Center 1995).  Comprehensive histological evaluations (including nasal cavity, trachea, and 
lungs) showed no compound-related neoplastic changes in rats, although incidences of liver and lung 
tumors were elevated in mice.  The liver tumors were induced in mice of both sexes, generally increased 
only at 300 ppm, and were comprised of several tumor types.  Liver tumors reported to be significantly 
increased (p≤0.05, Fisher’s Exact test) in male mice were hepatocellular carcinoma (12/49, 17/49, 16/50, 
38/49; p≤0.01 at high dose), hepatoblastoma (0/49, 2/49, 0/50, 8/49; p≤0.01 at high dose) and hepatic 
histiocytic sarcoma (0/49, 3/49, 1/50, 6/49; p≤0.05 at high dose).  Liver tumors reported to be 
significantly increased in female mice were hepatocellular carcinoma (2/50, 4/50, 2/49, 41/50; p≤0.01 at 
high dose), hepatocellular adenoma (2/50, 10/50, 6/49, 20/50; p≤0.05 at low and high doses), 
hepatocellular carcinoma or adenoma (4/50, 13/50, 7/49, 45/50; p≤0.05 at low and high doses), and 
hepatoblastoma (0/50, 0/50, 0/49, 6/50; p≤0.05 at high dose).  Although the hepatocellular adenomas 
were increased in female mice at 20 and 300 ppm, the relevance of the increase at 20 ppm is unclear 
given the lack of significant change at 75 ppm.  Lung bronchoalveolar adenoma and carcinoma were 
significantly increased in female mice (1/50, 4/50, 2/49, 7/50; p≤0.05 at high dose).  Except for 
hepatoblastoma, all of the aforementioned liver and lung tumor incidences were reported to have a 
significant positive linear trend by the Peto test and/or Cochran-Armitage test. 
3.2.2 Oral Exposure  
Most of the data described in this section were derived from laboratory studies in which 1,2-, 1,3-, and 
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consumption are described.  Case studies are not generally scientifically equivalent to well-conducted 
epidemiologic studies or laboratory experiments and should be viewed only as providing contributory 
evidence that 1,4-DCB may have caused the reported effects.  The available case studies do not provide 
unequivocal proof that 1,4-DCB is solely responsible for the reported toxicological effects in humans.  
The highest NOAEL and all reliable LOAEL values after oral exposure to 1,2-, 1,3-, and 1,4-DCB are 
recorded in Tables 3-3, 3-4, and 3-5, respectively, and plotted in Figures 3-3, 3-4, and 3-5, respectively. 
3.2.2.1 Death 
1,2-Dichlorobenzene.  No studies were located regarding death in humans after oral exposure to 
1,2-DCB. 
Single-dose LD50 values of 500 and 1,516 mg/kg have been reported for 1,2-DCB in rats administered the 
compound in oil by gavage (Ben-Dyke et al. 1970; Monsanto 1989).  Rats that were gavaged with a 25%
solution of 1,2-DCB in peanut oil at a dose of 675 mg/kg/day for 3 days were considered unlikely to 
survive further exposures (DuPont 1982).  Guinea pigs that were treated with a single gavage dose of 
1,2-DCB as a 50% solution in olive oil had no deaths at 800 mg/kg and 100% mortality at 2,000 mg/kg 
(Hollingsworth et al. 1958). 
Rats that were administered 1,2-DCB in oil by gavage for 14 consecutive days and observed until 
day 20 experienced 100% mortality at 1,000 mg/kg/day and no deaths at 500 mg/kg/day and lower doses 
(NTP 1985). Mice that were similarly treated with 1,2-DCB for 14 days had 80% mortality in both sexes 
at 250 mg/kg/day (lowest tested dose) and 80–100% mortality at ≥500 mg/kg/day (NTP 1985).  The 
reliability of the 14-day findings is uncertain because there were no clear effects of gavage exposure to 
1,2-DCB in oil on survival in rats or mice exposed to ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 
1985), rats exposed to 400 mg/kg/day on 7 days/week for 90 days (Robinson et al. 1991), or rats or mice 
exposed to ≤120 mg/kg/day, 5 days/week for 103 weeks (NTP 1985).  Information in the longer-term
NTP (1985) studies suggests that gavage error might have contributed to some of the deaths in the 14-day
studies. 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3. HEALTH EFFECTS 
Acute oral LD50 values of 1,200 and 1,000 mg/kg were determined in male and female Sprague-Dawley
rats, respectively, administered a single dose of 1,3-DCB by gavage and observed for the following 
14 days (Monsanto 1980). 
No mortality or overt signs of toxicity occurred in male or female Sprague-Dawley rats that were exposed 
to 1,3-DCB in corn oil by gavage in doses as high as 735 mg/kg/day for 10 consecutive days, or 
588 mg/kg/day for 90 consecutive days (McCauley et al. 1995). 
1,4-Dichlorobenzene. No studies were located regarding death in humans after oral exposure to 
1,4-DCB. 
Animal mortality data for 1,4-DCB are available from acute-, intermediate-, and chronic-duration studies.  
In acute-duration animal studies, a single dose by gavage in olive oil of 1,000 mg/kg to rats and 
1,600 mg/kg to guinea pigs resulted in no deaths, while a single dose of 4,000 mg/kg to rats and 
2,800 mg/kg to guinea pigs resulted in 100% mortality (Hollingsworth et al. 1956).  Similar results were 
seen in groups of adult male albino rats administered various doses of 1,4-DCB in corn oil once daily for 
14 days; administration of 1,4-DCB at doses up to 600 mg/kg did not result in any deaths (Carlson and 
Tardiff 1976).  Oral LD50 (lethal dose, 50% kill) values for adult Sherman rats administered 1,4-DCB in 
peanut oil were calculated to be 3,863 and 3,790 mg/kg for males and females, respectively (Gaines and 
Linder 1986).  In contrast, groups of male F344 rats (n=1/group) were administered 13–27,900 mg/kg 
body weight in corn oil via gavage.  Twenty-four hours after dosing, the animals were weighed and 
exsanguinated. No mortality among the 1,4-DCB-treated rats was observed (Allis et al. 1992). 
In one series of studies (NTP 1987), the lethality data for 1,4-DCB, when administered for 14 days by 
gavage in corn oil to F344 rats and B6C3F1 mice, were rather inconsistent.  In one of these studies, no 
1,4-DCB-related deaths occurred in rats of either sex that received doses up to 1,000 mg/kg/day; however, 
in the second rat study, four of five females (80%) at 1,000 mg/kg/day died, and all rats dosed at 
>2,000 mg/kg/day died.  In one 14-day study in mice, no 1,4-DCB-related deaths occurred in either sex at 
levels up to 1,000 mg/kg/day; however, in a second 14-day mouse study, 70% of mice at 1,000 mg/kg/day 
died, and all mice that received 4,000 mg/kg/day died within 4 days.  At 1,200 mg/kg/day, 5 of 10 male 
and 1 of 10 female rats died.  No deaths occurred at 600 mg/kg/day.  
In 13-week gavage studies, 17 of 20 rats (8 of 10 males and 9 of 10 females) dosed with 1,4-DCB in corn 
























3. HEALTH EFFECTS 
10 male and 1 of 10 female rats died.  No deaths occurred at doses of ≤600 mg/kg/day (NTP 1987).  
Mortality rates in mice were somewhat lower; 8 of 20 (3 of 10 males and 5 of 10 females) animals dosed 
with 1,500 mg/kg/day 1,4-DCB in corn oil 5 days/week died.  No deaths occurred in males or females at 
doses up to 900 and 1,000 mg/kg/day, respectively (NTP 1987). 
High mortality was reported in male rats that received 1,4-DCB 5 days/week by gavage in corn oil in a 
2-year study (NTP 1987). At 300 mg/kg/day, 26 of 50 males (52%) died; however, survival of female 
rats at 600 mg/kg/day was comparable to controls.  There was no excess mortality in mice of either sex 
that received 1,4-DCB 5 days/week by gavage in corn oil for 2 years at levels up to 600 mg/kg/day (NTP 
1987).  The high rate of mortality in male rats was probably related, in part, to the severe nephrotoxic 
effects and renal tumors that were reported in these animals and are described in more detail in 
Sections 3.2.2.2 and 3.2.2.7. 
Groups of five male and five female Beagle dogs were administered 1,4-DCB by capsule in dose levels of 
0, 10, 50, or 75 mg/kg/day, 5 days/week for 1 year (Naylor and Stout 1996).  The 75 mg/kg/day dose is a 
time-weighted average level reflecting decreases from an initial high level of 150 mg/kg/day in response 
to severe toxicity.  The main early effect was mortality during the first 25 days of the study; exposure to 
150 mg/kg/day caused one male dog to be sacrificed in extremis on day 12, one male death on day 25, and
one female death on day 24.  With the exception of one control male that died on day 83, all remaining 
dogs survived exposure to 75 mg/kg/day. 
3.2.2.2 Systemic Effects  
Respiratory Effects. 
1,2-Dichlorobenzene. No studies were located regarding respiratory effects in humans after oral 
exposure to 1,2-DCB.
No gross or histological changes were observed in the respiratory tract (nasal cavity, trachea, lungs, 
and/or bronchi) of Sprague-Dawley or F344 rats that were administered 1,2-DCB in corn oil by gavage in 
doses of 300 mg/kg/day for 10 consecutive days (Robinson et al. 1991), 400 mg/kg/day for 
90 consecutive days (Robinson et al. 1991), ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985), or 


























3. HEALTH EFFECTS 
the respiratory system of B6C3F1 mice that were similarly treated with ≤500 mg/kg/day, 5 days/week for 
13 weeks (NTP 1985), or ≤120 mg/kg/day, 5 days/week for 103 weeks (NTP 1985). 
1,3-Dichlorobenzene. No studies were located regarding respiratory effects in humans after oral 
exposure to 1,3-DCB. 
No gross or histological changes were observed in the respiratory tract (nasal cavity and turbinates, lungs, 
and lower half of trachea) in male or female Sprague-Dawley rats that were exposed to 1,3-DCB in corn 
oil by gavage in doses of 735 mg/kg/day for 10 consecutive days or 588 mg/kg/day for 90 consecutive 
days (McCauley et al. 1995).
1,4-Dichlorobenzene. No studies were located regarding respiratory effects in humans after oral 
exposure to 1,4-DCB. 
In a series of dose range-finding studies, groups of F344 rats were administered 1,4-DCB at 
concentrations ranging from 37.5 to 1,500 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks 
(NTP 1987). At sacrifice, animals were examined grossly and major tissues were examined 
histologically.  No compound-related effects were observed in the lungs at any dose up to 900 mg/kg/day, 
while rats treated with 1,200 mg/kg/day or higher exhibited epithelial necrosis of the nasal turbinates 
(NTP 1987). In parallel studies, B6C3F1 mice were administered 1,4-DCB at concentrations ranging from
84.4 to 1,800 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks.  No compound-related effects 
were observed in the lungs at any dose level (NTP 1987). 
In 2-year exposure studies in F344 rats, no respiratory effects were reported in males or females that 
received 1,4-DCB by gavage in corn oil at levels up to 300 or 600 mg/kg/day, respectively (NTP 1987).  
In similarly dosed B6C3F1 mice, no respiratory effects were reported in either sex at doses up to 
600 mg/kg/day (NTP 1987). 
Cardiovascular Effects. 

























3. HEALTH EFFECTS 
Mutifocal mineralization of the myocardial fibers of the heart (as well as skeletal muscle) was found in 
B6C3F1 mice that were administered 500 mg/kg/day of 1,2-DCB in corn oil by gavage 5 days/week for 
13 weeks (NTP 1985); this effect does not appear to have occurred in controls or lower dose groups 
(≤250 mg/kg/day).  No gross or histological changes were observed in the heart of B6C3F1 mice that were 
similarly treated with ≤120 mg/kg/day, 5 days/week for 103 weeks (NTP 1985), or in Sprague-Dawley or 
F344 rats that were similarly treated with 300 mg/kg/day for 10 consecutive days (Robinson et al. 1991), 
400 mg/kg/day for 90 consecutive days (Robinson et al. 1991), ≤500 mg/kg/day, 5 days/week for 
13 weeks (NTP 1985), or ≤120 mg/kg/day, 5 days/week for 103 weeks (NTP 1985). 
1,3-Dichlorobenzene. No studies were located regarding cardiovascular effects in humans after oral 
exposure to 1,3-DCB. 
No gross or histological changes in the aorta were observed in male or female Sprague-Dawley rats that 
were exposed to 1,3-DCB in corn oil by gavage in doses of 735 mg/kg/day for 10 consecutive days or
588 mg/kg/day for 90 consecutive days (McCauley et al. 1995).
1,4-Dichlorobenzene. No studies were located regarding cardiovascular effects in humans after oral 
exposure to 1,4-DCB. 
In a series of dose range-finding studies, groups of F344 rats were administered 1,4-DCB at 
concentrations ranging from 37.5 to 1,500 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks 
(NTP 1987). At sacrifice, animals were examined grossly and major tissues were examined 
histologically.  No compound-related cardiovascular effects were observed at any dose level.  In parallel 
studies, B6C3F1 mice were administered 1,4-DCB at concentrations ranging from 84.4 to 
1,800 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks.  As with the rats, no compound-related 
cardiovascular effects were observed in mice at any of the doses used (NTP 1987). 
In 2-year exposure studies in F344 rats, no cardiovascular effects were reported in males or females that 
received 1,4-DCB by gavage in corn oil at levels up to 300 or 600 mg/kg/day, respectively (NTP 1987).  
In similarly dosed B6C3F1 mice, no cardiovascular effects were reported in either sex at doses up to 



























3. HEALTH EFFECTS 
No gross or histological changes were found in the aorta or heart of Beagle dogs (5/sex/level) that were 
administered 1,4-DCB by capsule in doses as high as 75 mg/kg/day, 5 days/week for 1 year (Naylor and 
Stout 1996).
Gastrointestinal Effects.     
1,2-Dichlorobenzene. No studies were located regarding gastrointestinal effects in humans after oral 
exposure to 1,2-DCB.
No gross or histological changes were observed in the gastrointestinal tract (esophagus, stomach, small 
intestine, colon, and/or other tissues) of Sprague-Dawley or F344 rats that were administered 1,2-DCB in 
corn oil by gavage in doses of 300 mg/kg/day for 10 consecutive days (Robinson et al. 1991), 
≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985), or ≤120 mg/kg/day, 5 days/week for 103 weeks 
(NTP 1985). Additionally, there were no gross or histological effects in the gastrointestinal tract of 
B6C3F1 mice that were similarly treated with ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985), or 
≤120 mg/kg/day, 5 days/week for 103 weeks (NTP 1985).
1,3-Dichlorobenzene. No studies were located regarding gastrointestinal effects in humans after oral 
exposure to 1,3-DCB. 
No gross or histological changes were observed in the gastrointestinal tract (esophagus, stomach, 
duodenum, jejunum, ileum, colon, cecum, rectum, tongue) in male or female Sprague-Dawley rats that 
were exposed to 1,3-DCB in corn oil by gavage in doses of 735 mg/kg/day for 10 consecutive days, or 
588 mg/kg/day for 90 consecutive days (McCauley et al. 1995).
1,4-Dichlorobenzene. No studies were located regarding gastrointestinal effects in humans after oral 
exposure to 1,4-DCB. 
In a series of dose range-finding studies, groups of F344 rats were administered 1,4-DCB at 
concentrations ranging from 37.5 to 1,500 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks 
(NTP 1987). At sacrifice, animals were examined grossly and major tissues were examined 
histologically.  Gastrointestinal effects were observed at doses of 1,200 mg/kg/day or more and consisted 
of epithelial necrosis and villar bridging of the mucosa of the small intestines.  No gastrointestinal effects 






























3. HEALTH EFFECTS 
studies with B6C3F1 mice, no compound-related gastrointestinal effects were observed after 
administration of 1,4-DCB at concentrations ranging from 84.4 to 1,800 mg/kg/day by gavage in corn oil
5 days/week for 13 weeks (NTP 1987). 
In 2-year exposure studies in Fischer 344 rats, no gastrointestinal effects were reported in males or 
females that received 1,4-DCB by gavage in corn oil at levels up to 300 or 600 mg/kg/day, respectively
(NTP 1987). In similarly dosed B6C3F1 mice, no gastrointestinal effects were reported in either sex at 
doses up to 600 mg/kg/day (NTP 1987). 
No gross or histological changes were found in the gastrointestinal tract of Beagle dogs (5/sex/level) that 
were administered 1,4-DCB by capsule in doses as high as 75 mg/kg/day, 5 days/week for 1 year (Naylor 
and Stout 1996).  Nine regions of the gastrointestinal tract were examined. 
Hematological Effects. 
1,2-Dichlorobenzene.  No studies were located regarding hematological effects in humans after oral 
exposure to 1,2-DCB.
No hematological changes were observed in Sprague-Dawley or F344 rats that were administered 
1,2-DCB in corn oil by gavage in doses of ≤300 mg/kg/day for 10 consecutive days (Robinson et al. 
1991), ≤400 mg/kg/day for 90 consecutive days (Robinson et al. 1991), or ≤500 mg/kg/day, 5 days/week 
for 13 weeks (NTP 1985). Additionally, there were no hematological effects in B6C3F1 mice that were 
similarly treated with ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985).
1,3-Dichlorobenzene.  No studies were located regarding hematological effects in humans after oral 
exposure to 1,3-DCB. 
No hematological changes (numbers of erythrocytes and leukocytes, hemoglobin level, hematocrit, or 
mean corpuscular volume) were observed in male or female Sprague-Dawley rats that were exposed to 
1,3-DCB in corn oil by gavage in doses of 735 mg/kg/day for 10 consecutive days, or 588 mg/kg/day for 
90 consecutive days (McCauley et al. 1995).
1,4-Dichlorobenzene. A 21-year-old pregnant woman who had eaten 1–2 blocks of 1,4-DCB toilet air 






















3. HEALTH EFFECTS 
excessive polychromasia and marginal nuclear hypersegmentation of the neutrophils.  Heinz bodies were 
seen in a small number of the red cells.  After she discontinued this practice (at about 38 weeks of 
gestation), her hemoglobin levels began to rise steadily.  She gave birth to a normal infant with no 
hematological problems, and her own red blood cells were again normal at the final check 6 weeks after 
delivery (Campbell and Davidson 1970).  Acute hemolytic anemia and were reported to have occurred in 
a 3-year-old boy who had played with 1,4-DCB crystals (Hallowell 1959).  It is not clear whether this 
child had actually ingested any of the 1,4-DCB crystals. 
Hematological effects reported in animal studies mainly concern effects on red cells in rats and on white 
cells in mice.  Groups of male F344 rats (n=1/group) were administered 13–2,790 mg/kg body weight of 
1,4-DCB once via corn oil gavage.  Twenty-four hours after dosing, the animals were weighed and 
exsanguinated. No hematological alterations were noted in any of the treated rats (Allis et al. 1992). 
No adverse effects on hemoglobin levels or hematocrit were seen in adult male albino rats dosed with 
1,4-DCB by gavage in corn oil at levels up to 40 mg/kg/day for 90 days (Carlson and Tardiff 1976).
In F344 rats administered 1,4-DCB by gavage in corn oil, 7 days/week for 13 weeks at doses of 75– 
600 mg/kg/day, no compound-related hematological effects were noted (Bomhard et al. 1988).  In a series 
of experiments performed by Hollingsworth et al. (1956), male rats were administered 1,4-DCB by
gavage in olive oil at doses of 10–500 mg/kg/day, 5 days/week for 4 weeks; female rats received 
1,4-DCB in like manner at doses of 18.8–376 mg/kg/day, 5 days/week for 192 days; and male and female 
rabbits received 500 mg/kg/day 1,4-DCB, 5 days/week for 367 days.  Administration of 1,4-DCB 
produced no hematological effects at any dose.  
In another 13-week study in F344 rats, male rats that received 1,4-DCB at 300 mg/kg/day and above had 
decreased hematocrit levels, red blood cell counts, and hemoglobin concentrations (NTP 1987).  None of 
these hematologic effects were consistently seen in female rats at the same dosage level; however, a 
decrease in mean corpuscular volume was noted in females at doses of 600 mg/kg/day or more.  In a 
parallel study in male and female B6C3F1 mice dosed with 84.4–900 mg/kg/day 1,4-DCB for 13 weeks, 
no hematological effects were noted in male or female mice at doses up to 900 mg/kg/day (NTP 1987); 
however, in another study, B6C3F1 mice dosed with 600–1,800 mg/kg/day 1,4-DCB for 13 weeks showed 
hematologic effects including 34–50% reductions in the white cell counts in all male dose groups; these 
decreases were accompanied by 26–33% decreases in lymphocytes and 69–82% decreases in neutrophils. 



























3. HEALTH EFFECTS 
No hematologic effects were reported in 2-year studies in which male F344 rats received 1,4-DCB at 
levels up to 300 mg/kg/day/day and female rats received levels up to 600 mg/kg/day (NTP 1987).  Similar 
results were reported in B6C3F1 mice of both sexes exposed to 600 mg/kg/day 1,4-DCB for 2 years (NTP 
1987).
Hematology was evaluated in groups of five male and five female Beagle dogs that were administered 
1,4-DCB by capsule in doses of 0, 10, 50, or 75 mg/kg/day, 5 days/week for 1 year (Naylor and Stout 
1996). Ten routine indices and one blood clotting measurement (activated partial thromboplastin time) 
were evaluated at 6 and 12 months.  A mild anemia, as indicated by significantly reduced red blood cell 
count in females and hematocrit in males, was observed after 6 months at 75 mg/kg/day, but resolved by
the end of the study.  Histological findings in the bone marrow (erythroid hyperplasia in females) and 
spleen (excessive hematopoiesis and megakaryocyte proliferation in both sexes) at 75 mg/kg/day
indicated a compensatory response to the earlier anemia. 
Musculoskeletal Effects. 
1,2-Dichlorobenzene. No studies were located regarding musculoskeletal effects in humans after oral 
exposure to 1,2-DCB. 
Mutifocal mineralization of the myocardial fibers of the heart and skeletal muscle was found in 
B6C3F1 mice (3/10 males, 8/10 females) that were administered 500 mg/kg/day of 1,2-DCB in corn oil by
gavage 5 days/week for 13 weeks (NTP 1985); this effect does not appear to have occurred in controls or 
lower dose mice (≤250 mg/kg/day).  No gross or histological changes were observed in muscle of 
B6C3F1 mice that were similarly treated with ≤120 mg/kg/day, 5 days/week for 103 weeks (NTP 1985), 
or in Sprague-Dawley or F344 rats that were similarly treated with 300 mg/kg/day for 10 consecutive 
days (Robinson et al. 1991), ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985), or ≤120 mg/kg/day, 
5 days/week for 103 weeks (NTP 1985). 
No gross or histological changes in bone were observed in any of the rat or mouse 10-day, 13-week, or 
103-week studies summarized above (NTP 1985; Robinson et al. 1991).
1,3-Dichlorobenzene. No studies were located regarding musculoskeletal effects in humans after oral 

























3. HEALTH EFFECTS 
No gross or histological changes were observed in thigh muscle or sternebrae in male or female Sprague-
Dawley rats that were exposed to 1,3-DCB in corn oil by gavage in doses of 735 mg/kg/day for 
10 consecutive days or 588 mg/kg/day for 90 consecutive days (McCauley et al. 1995).
1,4-Dichlorobenzene. No studies were located regarding musculoskeletal effects in humans after oral 
exposure to 1,4-DCB. 
In a series of dose range-finding studies, groups of F344 rats were administered 1,4-DCB at 
concentrations ranging from 37.5 to 1,500 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks.  At 
sacrifice, animals were examined grossly and major tissues were examined histologically.  No 
musculoskeletal effects were noted in any of the 1,4-DCB-treated rats.  In parallel studies with 
B6C3F1 mice, no compound-related musculoskeletal effects were observed after administration of 
1,4-DCB at concentrations ranging from 84.4 to 1,800 mg/kg/day by gavage in corn oil 5 days/week for 
13 weeks (NTP 1987). 
In 2-year exposure studies in F344 rats, no musculoskeletal effects were reported in males or females that 
received 1,4-DCB by gavage in corn oil at levels up to 300 or 600 mg/kg/day, respectively.  In similarly
dosed B6C3F1 mice, no musculoskeletal effects were reported in either sex at doses up to 600 mg/kg/day
(NTP 1987). 
No gross or histological changes were found in skeletal muscle or bone of Beagle dogs (5/sex/level) that 
were administered 1,4-DCB by capsule in doses as high as 75 mg/kg/day, 5 days/week for 1 year (Naylor 
and Stout 1996). 
Hepatic Effects. 
1,2-Dichlorobenzene. No studies were located regarding hepatic effects in humans after oral exposure to 
1,2-DCB. 
The liver is a main target of toxicity in animals following oral exposure to 1,2-DCB.  Necrosis and other 
degenerative hepatic changes were observed in acute-duration studies in which 1,2-DCB was 
administered in oil by gavage.  A single 1,500 mg/kg dose (a lethal level) caused central necrosis of the 
























3. HEALTH EFFECTS 
intense necrosis and fatty changes, occurred in three male rats administered 455 mg/kg/day for 
15 consecutive days (Rimington and Ziegler 1963).  Other hepatic effects in this study included 
porphyria, manifested as increased mean peak urinary levels of coproporphyrin, uroporphyrin, 
porphobilinogen (PBG), and γ-aminolevulinic acid (ALA) that were approximately 10-fold higher than 
levels in controls. Liver changes in other acute-duration studies included necrosis and increased serum
ALT in rats given 300 mg/kg/day for 10 consecutive days (Robinson et al. 1991).  The necrosis was slight 
in severity and significantly (p=0.04) increased in males at 300 mg/kg/day [4/10 compared to 0/10 in
controls; incidences in lower dose groups (37.5, 75, and 150 mg/kg/day) were not specifically reported 
and are assumed to be 0/10].  Incidences of other hepatic lesions were not significantly increased but 
included inflammation (characterized by lymphocyte and macrophage infiltrates) and degeneration of 
hepatocytes (characterized varying degrees of fibrillar or vacuolated cytoplasm and swelling with intact 
cell membranes).  Liver weight was increased in females at ≥150 mg/kg/day and males at 300 mg/kg/day;
the increased liver weight in female rats in this study (Robinson et al. 1991) was selected as the critical 
effect for deriving an acute-duration oral MRL of 0.7 mg/kg/day for 1,2-DCB.  No liver histopathology 
was observed in male or female rats that were given doses as high as 500 or 1,000 mg/kg/day for 
14 consecutive days (NTP 1985).  The inconsistency between these findings and those of Robinson et al. 
(1991) might be due to a small number of animals (5 rats/sex/dose level) in the NTP (1985) study and 
mild response (low incidence and severity of lesions) in the Robinson et al. (1991) study.  Hepatic 
degeneration and necrosis were observed in mice exposed to 250 or 500 mg/kg/day for 14 consecutive 
days (NTP 1985), but this study is also limited by small numbers of animals (3–4 mice/sex/group). 
Liver histopathology was also the predominant finding in intermediate-duration studies of rats and mice 
exposed to 1,2-DCB (Hollingsworth et al. 1958; NTP 1985; Robinson et al. 1991).  The compound was 
administered in oil vehicle by gavage in all of these studies.  Slight to moderate cloudy swelling of the 
liver was found in female rats (strain not specified) dosed with 376 mg/kg/day, 5 days/week for 138 doses 
in 192 days, but not at lower dose levels of 18.8 or 188 mg/kg/day (Hollingsworth et al. 1958).  The 
incidence of the lesion was not reported.  Liver weight was increased at ≥188 mg/kg/day, but it is unclear 
whether this is an adaptive change or adverse effect due to the lack of histological or other evidence of 
tissue damage.   
Administration of 400 mg/kg/day for 90 consecutive days caused significantly increased incidences of 
lesions in Sprague-Dawley rats, including centrilobular degeneration, centrilobular hypertrophy, and 
single cell necrosis in 10/10, 9/10, and 7/10 males, respectively, and 8/10, 10/10, and 5/10 females, 





















3. HEALTH EFFECTS 
100 mg/kg/day), although no lesions occurred in controls of either sex.  Absolute and relative liver 
weights and serum levels of ALT were significantly increased at ≥100 mg/kg/day, but the increases in 
ALT were not dose-related and other liver-associated enzymes (AST, LDH, AP) were not increased.  The 
400 mg/kg/day dose is a LOAEL for hepatic effects based on histopathology. A reliable NOAEL cannot 
be identified because histology was not evaluated at lower doses, the increase in serum ALT was not 
dose-related or supported by changes in other serum indicators of liver damage, and an increase in liver 
weight without clear evidence of tissue damage is considered to be an adaptive response. 
NTP (1985) conducted subchronic studies in F344/N rats and B6C3F1 mice to determine doses to be used 
in chronic bioassays.  Groups of 10 males and 10 females of each species were administered 1,2-DCB in 
doses of 0, 30, 60, 125, 250, or 500 mg/kg/day, 5 days/week for 13 weeks.  Histology examinations of the 
liver were limited to the control and three highest dose groups.  Degenerative lesions were significantly
(p≤0.05) increased in both species at ≥250 mg/kg/day.  Changes in the rats included necrosis of individual 
hepatocytes at ≥250 mg/kg/day and centrilobular degeneration at 500 mg/kg/day; total incidences of these 
lesions at 0, 125, 250, and 500 mg/kg/day were 0/10, 1/10, 4/9, and 8/10 in males, respectively, and 0/10,
3/10, 5/10, and 7/8 in females, respectively.  Relative liver weight was significantly increased at
≥125 mg/kg/day in both sexes, but there were no increases in serum levels of liver enzymes (ALT, AP, or 
gamma-glutamyltranspeptidase [GGPT]) at any dose.  Serum cholesterol was significantly increased in 
males at ≥30 mg/kg/day (50.0, 17.6, 26.5, 70.6, and 109% higher than controls in the low to high dose 
groups, not significant at 42.9 mg/kg/day) and females at ≥125 mg/kg/day (12.2, 12.2, 32.6, 26.5, and 
51.0%).  Urinary concentrations of uroporphyrin and coproporphyrin were 3–5 times higher than controls 
in the 500 mg/kg/day males and females, but this increase was not considered indicative of porphyria 
because total porphyrin concentration in the liver was not altered at any dose level and no pigmentation 
indicative of porphyria was observed by ultraviolet light at necropsy.  The increases in relative liver 
weight seen in male and female rats at 125 mg/kg/day are believed to represent the beginning of adverse 
hepatic effects, indicating that 125 mg/kg/day is a minimal LOAEL for this study.  The increased liver 
weight in the female rats in this study (NTP 1985) was selected as the critical effect for deriving an 
intermediate-duration oral MRL of 0.6 mg/kg/day for 1,2-DCB.  In the mice, no compound-related 
histopathological changes were observed in either sex at 0 and 125 mg/kg/day, or in females at 
250 mg/kg/day.  Lesions that were significantly increased included necrosis of individual hepatocytes, 
hepatocellular degeneration and/or pigment deposition in 4/10 males at 250 mg/kg/day, and centrilobular 
necrosis, necrosis of individual hepatocytes, and/or hepatocellular degeneration in 9/10 males and 
9/10 females at 500 mg/kg/day.  Relative liver weights were significantly increased at 500 mg/kg/day in 




















3. HEALTH EFFECTS 
sex at any dose (no other clinical chemistry indices were examined in the mice). The hepatic 
histopathology findings indicate that the NOAEL and LOAEL for liver effects in mice are 125 and 
250 mg/kg/day, respectively. 
In the NTP (1985) chronic study, groups of 50 male and 50 female F344/N rats and B6C3F1 mice were 
administered 1,2-DCB in corn oil by gavage in doses of 0, 60, or 120 mg/kg/day, 5 days/week for 
103 weeks. Histopathological examinations were performed in all animals, although liver weights and 
clinical chemistry indices were not evaluated.  There were no exposure-related nonneoplastic liver lesions 
in either species, indicating that 125 mg/kg/day is the chronic NOAEL for liver effects in both rats and 
mice. 
1,3-Dichlorobenzene. No studies were located regarding hepatic effects in humans after oral exposure to 
1,3-DCB. 
Liver toxicity was evaluated in groups of 10 male and 10 female Sprague-Dawley rats that were exposed 
to 1,3-DCB in corn oil by daily gavage, in doses of 0, 37, 147, 368, or 735 mg/kg/day for 10 consecutive 
days, or 9, 37, 147, or 588 mg/kg/day for 90 consecutive days (McCauley et al. 1995).  Study end points 
included serum chemistry indices (AP, AST, ALT, LDH, cholesterol), liver weight, and gross appearance 
and histology of the liver.  As discussed below, hepatic changes were found at ≥147 mg/kg/day in the 
10-day study and ≥9 mg/kg/day in the 90-day study. 
Hepatic effects in the 10-day rat study included significantly (p≤0.05) increased relative liver weight in 
males at ≥147 mg/kg/day and females at ≥368 mg/kg/day (absolute organ weight not reported), and 
histopathology at ≥368 mg/kg/day in both sexes.  Increased liver weight in this study (McCauley et al. 
1995) was selected as the critical effect for deriving an acute-duration oral MRL of 0.4 mg/kg/day for 
1,3-DCB. The main hepatic histological change was dose-related centrilobular hepatocellular 
degeneration, characterized by varying degrees of cytoplasmic vacuolization and swelling with intact 
membranes.  Respective incidences of this lesion at 368 and 735 mg/kg/day were 2/10 and 9/10 in males, 
and 6/10 and 10/10 females; incidences in the other groups were not reported, but are presumed to be 
0/10.  Other hepatic alterations included hepatocellular necrosis that was sporadically noted in the 147, 
368, and 735 mg/kg/day groups.  This change was usually minimal to mild, and tended to increase in 
incidence and severity in the males in a dose-related manner; however, incidences were not reported.  






















3. HEALTH EFFECTS 
cholesterol was significantly increased at 368 and 735 mg/kg/day in both sexes, but this change could be 
pituitary-related (see discussion of the 90-day study in Endocrine Effects).   
Hepatic effects in the 90-day study included significantly increased relative liver weight (absolute weight 
not reported) and histopathological changes at ≥147 mg/kg/day in both sexes.  The liver lesions included 
inflammation, hepatocellular alterations (characterized by spherical, brightly eosinophilic homogeneous 
inclusions), and hepatocellular necrosis. Liver lesions that were significantly increased included 
hepatocellular cytoplasmic alterations of minimal to mild severity in males at ≥147 mg/kg/day 
(incidences in the control to high dose groups were 1/10, 2/10, 1/10, 6/10, and 7/9) and females at 
588 mg/kg/day (0/10, 2/10, 0/10, 1/10, and 7/9), and necrotic hepatocyte foci of minimal severity in both 
sexes at 588 mg/kg/day (1/10, 2/10, 1/10, 2/10, and 5/9 in males, and 0/10, 0/10, 0/10, 3/10, and 5/9 in 
females).  Other statistically significant liver-associated effects included significantly increased serum
AST levels (90–100% higher than controls) in males at ≥9 mg/kg/day and females at ≥37 mg/kg/day.  
Serum LDH levels were also reduced in males at ≥9 mg/kg/day, but the biological significance of a 
decrease in liver enzymes is unclear.  Serum cholesterol values were significantly increased in males at 
≥9 mg/kg/day and females at ≥37 mg/kg/day, but this change could be pituitary-related (see Endocrine 
Effects). 
1,4-Dichlorobenzene. A single case study was located regarding hepatic effects in humans after oral 
exposure to 1,4-DCB. In this case report, the author describes a 3-year-old boy who had been playing 
with crystals containing 1,4-DCB for 4–5 days before being admitted to the hospital.  On admission, the 
boy was jaundiced and his mucous membranes were pale.  After a blood transfusion, the child gradually
improved.  It was unclear whether the boy actually ingested any of the 1,4-DCB (Hallowell 1959). 
The acute hepatotoxicity and response of hepatic cytochrome P-450 in response to dosing with 1,4-DCB 
were evaluated in groups of male F344 rats (n=1/group) given one dose of 13–2,790 mg/kg body weight 
by corn oil gavage.  Twenty-four hours after dosing, the animals were weighed and sacrificed.  Serum
was collected and analyzed for total bilirubin, cholesterol, AST, alanine aminotransferase (ALT), and 
alkaline phosphatase.  The liver was weighed and slices examined histopathologically.  Liver microsomes 
were prepared and assayed for P-450, in addition to liver protein determinations.  1,4-DCB did not 
produce liver necrosis at any dose.  There was also no effect observed on serum levels of ALT and AST.  
Hepatic cytochrome P-450 levels were increased about 30% by 1,4-DCB beginning at 380 mg/kg and 



















3. HEALTH EFFECTS 
hepatobiliary damage, serum cholesterol, serum alkaline phosphatase, and total bilirubin (Allis et al. 
1992). 
The effects of 1,4-DCB were compared in male F344 rats given 0 (corn oil control), 25, 75, 150, and 
300 mg/kg/day 1,4-DCB (n=6–8/group/time) by daily oral gavage 5 days/week for 1 week.  Replicative 
DNA synthesis was studied using subcutaneously implanted osmotic pumps containing 5-bromo­
2'-deoxyuridine (BrdU) to determine the hepatocyte labeling index.  Livers were removed, weighed, and 
then immunostained.  Morphological examination of the liver sections from all lobes was performed from
control and 300 mg/kg group rats.  1,4-DCB treatment for 1 week did not produce morphological changes 
in the rat livers.  1,4-DCB produced significant dose-related increases in relative liver weight in the rats, 
which were also associated with mild centrilobular hypertrophy.  At 300 mg/kg, relative liver weight was 
significantly increased.  Significant dose-related increases in microsomal cytochrome P-450 content were 
observed in rats given 150 and 300 mg/kg 1,4-DCB for 1 week, with a significant dose-related induction 
of microsomal 7-pentoxyresorufin O-depentylase activity observed in rats given 75–300 mg/kg 1,4-DCB.  
The hepatocyte labeling index values were only increased in animals given 300 mg/kg 1,4-DCB (225% of 
controls) (Lake et al. 1997). 
In a series of experiments, Eldridge et al. (1992) studied the acute hepatotoxic effects of 1,4-DCB and the 
role of cell proliferation in hepatotoxicity in B6C3F1 mice and F344 rats. Mice and rats received a single 
dose of 1,4-DCB by gavage in corn oil of 600, 900, or 1,200 mg/kg/day.  At 1, 2, 4, and 8 days after 
1,4-DCB treatment, selected animals were injected intraperitoneally with BrdU 2 hours prior to sacrifice 
to monitor cell proliferation.  Other groups of mice and rats were sacrificed 24 or 48 hours after dosing, 
blood was collected for liver enzyme analysis, and liver sections were collected for histopathology.  In 
mice dosed with 600 mg/kg/day 1,4-DCB, liver weights were significantly increased 48 hours after 
dosing.  Labeling index (LI), indicative of cell proliferation, peaked 24 hours after dosing in females and 
48 hours in males.  Activities of serum enzymes associated with liver damage (ALT, AST, LDH, sorbitol 
dehydrogenase) were not affected by 1,4-DCB.  Twenty-four and 48 hours after administration of 
1,4-DCB, the livers of males showed periportal hepatocytes with vacuolated cytoplasm and centrilobular 
hepatocytes with granulated basophilic cytoplasm; the severity of these changes was dose-related at 
48 hours, but not at 24 hours.  Similar but less pronounced effects were seen in females at 24 hours.  In 
rats, liver weights were significantly increased at all time points after administration of 600 mg/kg/day 
1,4-DCB. The LI peaked 24 hours after dosing and was still elevated after 48 hours.  Necrosis was not 






















3. HEALTH EFFECTS 
In pregnant CD rats administered 1,4-DCB in corn oil at doses of 250–1,000 mg/kg/day on Gd 6–15, no 
differences in maternal liver weight were noted (Giavini et al. 1986); however, hepatic effects have been 
reported in other oral studies in which 1,4-DCB has been administered to test animals by gavage 
(discussed below).  These effects have ranged from temporary elevation of hepatic enzymes to hepatic 
degeneration and necrosis. 
The effects of 1,4-DCB were compared in male B6C3F1 mice given 0 (corn oil control), 300, and 
600 mg/kg/day 1,4-DCB (n=6–8/group/time) by daily oral gavage 5 days/week for 1 week.  Replicative 
DNA synthesis was studied using subcutaneously implanted osmotic pumps containing BrdU to assess 
the hepatocyte labeling index.  Livers were removed, weighed, and immunostained.  Morphological 
examination of the liver sections was performed for control and 600 mg/kg groups.  Biochemical analysis 
of liver whole homogenates was performed.  1,4-DCB produced significant dose-related increases in 
relative liver weight, which were associated with marked centrilobular hypertrophy.  Relative liver 
weights were increased for mice in both the 300 and 600 mg/kg groups at all time points, with minimal 
centrilobular hypertrophy observed in 600 mg/kg group mice.  No other histological abnormalities were 
observed in the liver sections.  Administration of 1,4-DCB also produced a sustained induction of 
microsomal cytochrome P-450 content and 7-pentoxyresorufin O-depentylase activity.  Significant dose-
related induction of microsomal cytochrome P-450 content was induced in mice given 600 but not 
300 mg/kg 1,4-DCB.  Microsomal 7-pentoxyresorufin O-depentylase activity was significantly induced in 
mouse liver microsomes at doses of 300 and 600 mg/kg 1,4-DCB.  Western immunoblotting studies 
demonstrated that 1,4-DCB induced CYP2B isoenzyme(s) in mouse liver microsomes at 300 and 
600 mg/kg 1,4-DCB.  The hepatocyte labeling index values were also significantly increased in mice 
given 300 and 600 mg/kg 1,4-DCB (Lake et al. 1997). 
In male B6C3F1 mice, single doses of 600, 1,000, or 1,800 mg/kg/day 1,4-DCB administered by gavage 
in corn oil resulted in significantly elevated BrdU labeling of hepatocytes at the 1,000 and
1,800 mg/kg/day doses.  In addition, single doses of 1,800 mg/kg resulted in a 4.5-fold increase in serum
ALT activity and severe centrilobular hepatocyte swelling.  In a companion time-course study, single 
doses of 1,800 mg/kg 1,4-DCB administered by gavage in corn oil resulted in significantly elevated BrdU 
labeling in hepatic samples on days 2, 3, and 4, but not days 1 or 7.  ALT activity was significantly
elevated in 1,4-DCB-treated mice on day 2 only.  In all other aspects, hepatic toxicity was not evident in 






















3. HEALTH EFFECTS 
1,4-DCB has been shown to produce disturbances in porphyrin metabolism after high-level/acute-duration 
exposure. Increased excretion of porphyrins, especially coproporphyrin and uroporphyrin, are considered 
to be indicators of liver damage.  Administration of 1,4-DCB in liquid paraffin to male rats at gradually
increasing doses, until a dose level of 770 mg/kg/day was maintained for 5 days, resulted in high 
porphyrin excretion (Rimington and Ziegler 1963).  Mean peak values of urinary coproporphyrin 
increased to about 10–15-fold above levels in controls.  A 37–100-fold increase in urinary uroporphyrin 
levels occurred; porphobilinogen levels increased 200–530-fold; and a 10-fold increase in 
δ-aminolevulinic acid (δ-ALA) levels was observed. In the liver itself, coproporphyrin levels were 
similar to controls, uroporphyrin levels were increased 46-fold, and protoporphyrin levels were increased 
6-fold. These dramatic increases, which suggest severe damage to the liver, were not observed when 
1,4-DCB was administered to rats at higher levels (850 mg/kg/day) in 1% cellofas (Rimington and 
Ziegler 1963) or at lower levels for a longer period of time in another study (Carlson 1977), as discussed 
below. Also, Trieff et al. (1991) have used animal data on porphyrogenicity from various chlorinated 
benzenes to perform a QSAR study allowing prediction of ambient water criteria. 
Changes in other markers of liver function including cytochrome P-450 levels, and activities of some 
drug-metabolizing enzymes (aminopyrine N-demethylase and aniline hydroxylase) were investigated in 
rats treated with of 1,4-DCB by gavage at 250 mg/kg/day for up to 3 days (Ariyoshi et al. 1975).  Activity
of δ-ALA synthetase, an enzyme used in synthesis of the heme moiety found in cytochromes, was 
increased 42% by treatment with 1,4-DCB.  However, the cytochrome P-450 content did not change, 
although the microsomal protein content of liver preparations was increased.  The toxicological 
significance of these findings is not clear since δ-ALA synthetase activity did not correlate with
cytochrome P-450 concentration. 
Effects on hepatic enzyme activities were reported to have occurred in adult male rats that were given 
1,4-DCB by gavage for 14 days (Carlson and Tardiff 1976).  Significant decreases in hexobarbital 
sleeping time and a 6.5-fold increase in serum isocitrate dehydrogenase activity were observed after a 
14-day treatment regimen at 650 mg/kg/day.  In addition, even at considerably lower levels (20 or 
40 mg/kg/day), increases were observed in the activities of hepatic microsomal xenobiotic metabolic 
systems including levels of glucuronyl transferase, and benzpyrene hydroxylase and O-ethyl-O-nitro­
phenyl phenylphosphorothionate (EPN) detoxification to nitrophenol.  In a 90-day study at the same 
dosage levels, significant increases were seen in EPN detoxification, benzpyrene hydroxylase, and 
azoreductase levels. The former two levels were still elevated at 30 days after the cessation of 
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3. HEALTH EFFECTS 
studies; however, azoreductase levels were elevated even at 10 mg/kg/day (Carlson and Tardiff 1976).  
These observations are important because they demonstrate that hepatic effects occur at levels of 
1,4-DCB that are far below those associated with severe histopathology.
The effects of 1,4-DCB were compared in male F344 rats given 0 (corn oil control), 25, 75, 150, and 
300 mg/kg/day 1,4-DCB (n=6–8/group/time) by daily oral gavage 5 days/week for 4 and 13 weeks.  
Replicative DNA synthesis was studied using subcutaneously implanted osmotic pumps containing BrdU 
during study weeks 3–4 and 12–13.  Livers were removed, weighed, and then immunostained.  
Morphological examination of the liver sections was performed from control and 300 mg/kg group rats in 
the 13-week exposure group. 1,4-DCB treatment produced a mild centrilobular hypertrophy seen in rats 
given 300 mg/kg 1,4-DCB for 13 weeks.  No other histological abnormalities were observed in the liver 
sections. 1,4-DCB produced significant dose-related increases in relative liver weight in the rats, which 
were associated with mild centrilobular hypertrophy.  At 300 mg/kg, relative liver weight was 
significantly increased.  Significant increases in relative liver weight were observed in rats given 75 and 
150 mg/kg 1,4-DCB for 4 weeks and 150 mg/kg 1,4-DCB for 13 weeks.  Administration of 1,4-DCB also 
produced a sustained induction of microsomal cytochrome P-450 content and 7-pentoxyresorufin 
O-depentylase activity.  Significant dose-related increases in microsomal cytochrome P-450 content were 
observed in rats given 25–300 mg/kg 1,4-DCB for 4 weeks and 75–300 mg/kg 1,4-DCB for 13 weeks.  A 
significant dose-related induction of microsomal 7-pentoxyresorufin O-depentylase activity was observed 
in rats given 75–300 mg/kg 1,4-DCB for 4 weeks and 25–300 mg/kg 1,4-DCB for 13 weeks.  Western 
immunoblotting studies demonstrated that 1,4-DCB induced CYP2B isoenzyme(s) in rat liver 
microsomes at 75 and 300 mg/kg 1,4-DCB (Lake et al. 1997). 
Histopathological effects in the liver, including cloudy swelling and centrilobular necrosis, were observed 
after gavage administration of 1,4-DCB in rats (two per group) at 500 mg/kg/day for 4 weeks; similar 
results (cloudy swelling, focal caseous necrosis) were obtained in rabbits (five per group) given 92 doses 
of 1,000 mg/kg/day 1,4-DCB in olive oil over a 219-day period (Hollingsworth et al. 1956). The 
interpretation of this study is limited by the size of the test groups and the fact that observations in 
controls were not presented. Histopathological changes were also reported in a 13-week study in which 
rats received 1,4-DCB by gavage (NTP 1987).  Doses of 1,200 or 1,500 mg/kg/day produced 
degeneration and necrosis of hepatocytes.  Serum cholesterol levels were increased by doses of 
600 mg/kg/day or more in male rats and by ≥900 mg/kg/day in female rats, while serum triglycerides and 
protein levels were reduced at doses of ≥300 mg/kg/day in male rats.  Urinary porphyrins were increased 


























3. HEALTH EFFECTS 
to indicate mild porphyrinuria rather than hepatic porphyria.  Liver porphyrins were not increased at any
dose. In a second 13-week study in the same laboratory, hepatic effects were not observed in rats at 
dosage levels up to 600 mg/kg/day (NTP 1987). 
Similar hepatic effects were reported in two 13-week gavage studies in mice (NTP 1987).  Hepatocellular 
degeneration was observed in both sexes at all doses (600–1,800 mg/kg/day).  Serum cholesterol levels 
were increased in male mice at doses of 900 mg/kg/day or more, and serum protein and triglycerides were
increased at doses of 1,500 mg/kg/day or more.  These changes were thought by the authors to reflect the 
hepatic effects of this compound.  Hepatic porphyria was not found in mice at any dose level in this study. 
Because hepatic effects were seen in mice in all dose groups in the first 13-week study, a second 13-week 
study was conducted at lower dosage levels.  Hepatocellular cytomegaly was observed in mice at doses of
675 mg/kg/day and above.  The lowest level at which hepatic effects were observed in mice was 
600 mg/kg/day (in the first study).  
Other intermediate-duration oral studies with 1,4-DCB have reported liver toxicity.  In female rats dosed 
with 1,4-DCB by gavage for about 6 months, doses of 188 mg/kg/day and above resulted in increased 
liver weights. At 376 mg/kg/day, slight cirrhosis and focal necrosis of the liver were also observed 
(Hollingsworth et al. 1956).  No effects on the liver were seen at a dose of 18.8 mg/kg/day.   
The ability of 1,4-DCB to induce porphyria was investigated in female rats that were administered 
1,4-DCB by gavage for up to 120 days (Carlson 1977).  Slight but statistically significant increases in 
liver porphyrins were seen in all dosed rats (50–200 mg/kg/day) at 120 days.  Urinary excretion of 
δ-ALA, porphobilinogen, or porphyrins was not increased over control levels.  These results indicated 
that 1,4-DCB had only a slight potential for causing porphyria at these doses in female rats compared with 
the far more pronounced porphyrinogenic effects reported earlier in male rats that received 
770 mg/kg/day for 5 days in a study by Rimington and Ziegler (1963).  However, sex-related differences 
in susceptibility to 1,4-DCB's effects on these parameters cannot be ruled out in a comparison of these 
two studies. 
The role of cell proliferation in liver toxicity induced by 1,4-DCB was examined in groups of mice (5– 
7 per sex per dose level) administered 0 (vehicle only), 300, or 600 mg/kg 1,4-DCB in corn oil by gavage 
5 days/week for 13 weeks (Eldridge et al. 1992).  The liver toxicity induced by 1,4-DCB was also 
examined in groups of female rats (5–7 per dose level) administered 0 (vehicle only) or 600 mg/kg 
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implanted with osmotic pumps to deliver BrdU.  Liver weights were significantly increased in high-dose 
male and female mice and in female rats throughout the 13-week study.  Treated male mice showed a 
centrilobular pattern of labeled hepatocytes, whereas females were labeled throughout the lobules.  At the 
lower-dose level, liver weight was increased in male and female mice at weeks 6 and 13.  In a group of 
mice in which treatment with 600 mg/kg/day ceased after 5 weeks and the animals were allowed to 
recover for 1 week, liver weight returned to control values.  The authors concluded that 1,4-DCB induced 
a mitogenic stimulation of cell proliferation in the liver rather than a regenerative response following 
cytotoxicity.  This was evidenced by an increase in liver weight without increase in liver-associated 
plasma enzymes (Eldridge et al. 1992).
The effects of 1,4-DCB were determined in male B6C3F1 mice given 0 (corn oil control), 300, and 
600 mg/kg/day 1,4-DCB (n=6–8/group/time) by daily oral gavage 5 days/week for 4 and 13 weeks.  
Replicative DNA synthesis was studied using subcutaneously implanted osmotic pumps containing BrdU 
during study weeks 3–4 and 12–13.  Livers were removed, weighed, and immunostained.  Morphological 
examination of the livers was performed for control and 600 mg/kg group mice at 13 weeks.  Biochemical 
analysis of liver whole homogenates was also performed.  1,4-DCB produced significant dose-related 
increases in relative liver weight in the mice, which were associated with marked centrilobular 
hypertrophy.  Relative liver weights were increased for mice in both the 300 and 600 mg/kg groups at all 
time points. At 13 weeks, a marked centrilobular hypertrophy was observed in the 600 mg/kg group.  No 
other histological abnormalities were observed in the liver.  Administration of 1,4-DCB also produced a 
sustained induction of microsomal cytochrome P-450 content and 7-pentoxyresorufin O-depentylase 
activity.  Significant dose-related induction of microsomal cytochrome P-450 content was induced in 
mice given 600 but not 300 mg/kg 1,4-DCB for treatments of 4 and 13 weeks.  Microsomal 
7-pentoxyresorufin O-depentylase activity was significantly induced in mouse liver microsomes at doses 
of 300 and 600 mg/kg 1,4-DCB.  Western immunoblotting studies demonstrated that 1,4-DCB induced 
CYP2B isoenzyme(s) in mouse liver microsomes at 300 and 600 mg/kg 1,4-DCB.  Hepatocyte labeling 
index values were significantly increased in mice given 300 and 600 mg/kg 1,4-DCB for 4 weeks 
(420 and 395% of controls, respectively) (Lake et al. 1997). 
A 1-year study in dogs indicates that this species is more sensitive than rats or mice to hepatic effects of  
1,4-DCB. Groups of five male and five female Beagle dogs were administered 1,4-DCB by capsule in 
dose levels of 0, 10, 50, or 75 mg/kg/day, 5 days/week for 1 year (Naylor and Stout 1996).  Liver effects 
occurred after 6 and 12 months at ≥50 mg/kg/day in both sexes as shown by changes in liver enzymes, 
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after 6 and 12 months.  Statistically significant increases were found for serum AP in males at 
50 mg/kg/day, and females at 50 and 75 mg/kg/day, at months 6 and 12 (330–761% higher than controls); 
ALT in females at 75 mg/kg/day and month 12 (253% higher than controls); and GGT in females at 
75 mg/kg/day and months 6 and 12 (131–161% higher than controls).  Serum albumin was significantly 
decreased in males at ≥50 mg/kg/day (months 6 and 12) and females at 75 mg/kg/day (month 6).  
Absolute and relative liver weights were significantly increased in both sexes at 50 and 75 mg/kg/day
(except absolute liver weight in 50 mg/kg/day males).  Hepatic lesions included hepatocellular 
hypertrophy in all males and females at 50 and 75 mg/kg/day (as well as one female at 10 mg/kg/day), 
hepatocellular pigment deposition at 50 and 75 mg/kg/day (two males and one female at each level), bile 
duct/ductule hyperplasia at 75 mg/kg/day (one male and one female), and hepatic portal inflammation at 
50 and 75 mg/kg/day (periportal accumulation of neutrophils in an unspecified number of males).  The 
6- and 12-month increased serum AP levels in dogs (Naylor and Stout 1996) were used to derive 
intermediate- and chronic-duration oral MRLs of 0.07 mg/kg/day for 1,4-DCB. 
Studies of the hepatic effects of chronic 1,4-DCB exposure are sparse.  The toxicity of 1,4-DCB was 
evaluated in a group of seven rabbits administered 1,4-DCB in olive oil at a dose of 500 mg/kg/day a total 
of 263 times over a 367-day period.  Slight changes in the liver (cloudy swelling and a few areas of focal 
caseous necrosis) were noted at sacrifice (Hollingsworth et al. 1956). 
In the only study of lifetime oral exposure to 1,4-DCB in laboratory animals, groups of male and female 
F344 rats were administered 1,4-DCB by gavage in corn oil 5 days/week for 103 weeks at doses of 150 or
300 mg/kg/day (males) or 300 or 600 mg/kg/day (females).  Groups of male and female B6C3F1 mice
were administered 1,4-DCB at doses of 300 or 600 mg/kg/day by gavage in corn oil, 5 days/week for 
103 weeks. No hepatic effects were seen in rats; in mice, the incidence of hepatocellular degeneration 
was greatly increased in treated mice (in males:  0/50 control, 36/49 low-dose, 39/50 high-dose; in 
females 0/50 control, 8/48 low-dose, 36/50 high-dose).  The primary degenerative change was cellular 
swelling with clearing or vacuolation of the cytoplasm.  Individual hepatocytes had pyknotic or
karyorrhectic nuclei and condensed eosinic cytoplasm.  Some necrotic hepatocytes formed globular 
eosinophilic masses in the sinusoids (NTP 1987). 
Renal Effects. 


























3. HEALTH EFFECTS 
A single 1,500 mg/kg gavage dose of 1,2-DCB in peanut oil (a lethal level) caused accumulation of 
albuminous fluid and casts in the renal tubules of rats (number and gender not reported) (DuPont 1982).  
Sprague-Dawley rats (10/sex/level) that were administered 1,2-DCB in corn oil by gavage in doses of 
300 mg/kg/day for 10 consecutive days or 400 mg/kg/day for 90 consecutive days (Robinson et al. 1991).  
In subchronic studies performed by NTP (1985), F344 rats and B6C3F1 mice (10/sex/level/species) were 
administered 1,2-DCB in doses of 0, 30, 60, 125, 250, or 500 mg/kg/day in corn oil by gavage 
5 days/week for 13 weeks.  Histology examinations of the kidneys were limited to the 0 and 
≥125 mg/kg/day dose groups in the rats and 0 and 500 mg/kg/day groups in the mice.  Renal effects 
occurred only in the 500 mg/kg/day male rats; these included tubular degeneration (6/10 incidence 
compared to 0/10 in lower dose and control groups) and increased urine volume (57% higher than 
controls). There were no exposure-related increases in BUN in either species.  In chronic studies 
performed by NTP (1985), there were no nonneoplastic tissue changes in the kidneys of male or female 
F344 rats (50/sex/level) exposed to 0, 60, or 120 mg/kg/day in corn oil by gavage for 5 days/week for 
103weeks. In similarly-exposed B6C3F1 mice (50/sex/level) exposure to 120 mg/kg/day, but not to 
60 mg/kg/day, resulted in a significantly increased incidence of renal tubular regeneration (controls:  
8/48; low dose: 12/50; high dose: 17/49) relative to controls.  The incidence data for renal tubular 
regeneration in mice (NTP 1985) were used to derive a chronic-duration oral MRL of 0.3 mg/kg/day for 
1,2-DCB. Renal end points other than histology were not assessed in the chronic studies. 
1,3-Dichlorobenzene. No studies were located regarding renal effects in humans after oral exposure to 
1,3-DCB. 
No gross or histological changes were observed in the kidneys or urinary bladder in male or female 
Sprague-Dawley rats that were exposed to 1,3-DCB in corn oil by gavage in doses of 735 mg/kg/day for 
10 consecutive days or 588 mg/kg/day for 90 consecutive days (McCauley et al. 1995).  Blood urea 
nitrogen (BUN) and kidney weight was measured in both studies, although only relative organ weights 
were reported.  There was a statistically significant increase in relative kidney weight at ≥147 mg/kg/day
in males and 735 mg/kg/day in females in the 90-day study, but this is not considered to be an adverse 
effect due to decreases in body weight gain and lack of changes in BUN and renal histology. 






















3. HEALTH EFFECTS 
The role of cell proliferation in kidney toxicity induced by 1,4-DCB was examined in groups of male and 
female B6C3F1 mice and F344 rats (Umemura et al. 1992).  Mice were administered 300 or 600 mg/kg 
1,4-DCB; in rats, males received 150 or 300 mg/kg 1,4-DCB while females received 300 or 600 mg/kg 
1,4-DCB. All doses were administered by gavage in corn oil for 4 consecutive days.  Cell proliferation 
was evaluated by means of immunohistochemical measurement of BrdU-labeled cells.  In mice, kidney
weights and cell proliferation in the kidney tubules were not altered by 1,4-DCB treatment; in rats, kidney
weight was significantly increased in male rats at both dose levels, but was not affected in females.  Cell 
proliferation was greatly increased in the proximal convoluted tubule from high-dose males.  A lesser 
increase was seen in the proximal straight tubule from high-dose males; no increase was observed in the 
distal tubule from males or in any kidney region from treated female rats.  
The effects of 1,4-DCB were compared in male F344 rats given 0 (corn oil control), 25, 75, 150, and 
300 mg/kg/day 1,4-DCB (n=6–8/group/time) and male B6C3F1 mice given 0 (corn oil control), 300, and 
600 mg/kg/day 1,4-DCB (n=6–8/group/time) by daily oral gavage 5 days/week for 1 week.  Replicative 
DNA synthesis was studied using subcutaneously implanted osmotic pumps containing 5-bromo­
2'-deoxyuridine during study weeks 0–1, 3–4, and 12–13.  After sacrifice, the kidneys were removed, 
weighed, and immunostained.  In rats, significant increases in relative kidney weight were observed in 
those rats administered 150 and 300 mg/kg 1,4-DCB for 4 and 13 weeks.  1,4-DCB treatment produced 
significant increases in rat renal P1/P2 proximal tubule cell labeling index values at all time points.  
Significant increases were seen in the following groups:  75 mg/kg 1,4-DCB at 4 weeks (250% of 
controls); 150 mg/kg 1,4-DCB at 4 and 13 weeks (400 and 440% of controls, respectively); and
300 mg/kg 1,4-DCB at 1, 4, and 13 weeks (170, 475, and 775% of controls, respectively).  A significant 
increase in rat P3 renal proximal tubule cell labeling index values was observed in 300 mg/kg 1,4-DCB 
group rats at weeks 4 (185% of controls) and 13 (485% of controls).  In contrast, some reduction in rat 
P3 renal proximal tubule cell labeling index values was observed in 75–300 mg/kg 1,4-DCB group rats at 
1 week. In contrast, 1,4-DCB treatment produced little effect on mouse renal P1/P2 proximal tubule cell 
labeling index values at all time points tested.  No significant increase was seen in 300 or 600 mg/kg 
1,4-DCB groups for 1 and 13 weeks, but significant increases were seen at 4 weeks (205 and 170% of 
controls, respectively).  Neither 300 nor 600 mg/kg 1,4-DCB for 1, 4, or 13 weeks had much effect on 
mouse P3 renal proximal tubule cell labeling index values (Lake et al. 1997). 
In a study that examined the role of the protein α2µ-globulin in 1,4-DCB-induced nephrotoxicity in male 
rats, NCI-Black-Reiter (NBR) rats, known not to synthesize the hepatic form of the α2µ-globulin, were




















3. HEALTH EFFECTS 
consisted of F344 male rats treated with lindane; the results were also compared with those obtained in a 
group of female F344 rats treated with lindane.  End points examined consisted of kidney lesions and 
protein droplet evaluation.  α2µ-Globulin was detected in kidney sections from male F344 rats, but not in
male NBR or female F344 rats.  No lesions or hyaline droplets were detected in treated or control male 
NBR and female F344 rats (Dietrich and Swenberg 1991). 
Renal tubular degeneration has been observed in male but not female F344 rats in two 13-week gavage 
studies (NTP 1987). These effects were severe in male rats receiving ≥300 mg/kg/day in the first study, 
but in the second study, only slight changes were seen at 300 mg/kg/day, while moderate tubular 
degeneration was present at 600 mg/kg/day.  Renal effects reported in another intermediate-duration 
gavage study in rats included increased renal weights at doses of ≥188 mg/kg/day (Hollingsworth et al. 
1956).  Renal effects were not observed in mice in either of two 13-week gavage studies using dosage 
regimens of 600–1,800 and 84.4–900 mg/kg/day (NTP 1987). 
In a study designed to investigate the mechanism of renal toxicity for 1,4-DCB reported in the NTP 
(1987) studies, 1,4-DCB administered by gavage to male F344 rats at 7 daily doses of 120 or 
300 mg/kg/day significantly increased the level of protein droplet formation in the kidneys of males but 
not females (Charbonneau et al. 1987). Administration of a single dose of 14C-1,4-DCB by gavage at 
500 mg/kg gave similar results.  An analysis of the renal tissue of animals administered radio-labeled 
1,4-DCB indicated that it was reversibly associated with the protein α2µ-globulin.  In a study designed to 
correspond to the experimental conditions of the 13-week NTP (1987) study in rats, 1,4-DCB was 
administered to F344 rats by gavage at 75–600 mg/kg/day for 13 weeks; interim sacrifices were
performed at 4 weeks (Bomhard et al. 1988).  At 4 weeks, females had no structural damage to the 
kidneys, while males experienced damage at the corticomedullary junction at doses of 150 mg/kg or 
more; damage consisted of dilated tubules with granular and crystalline structures, hyaline droplets, and 
desquamated epithelia.  At all dose levels in the males, hyaline bodies were seen in the proximal tubule 
epithelial cells.  At 13 weeks, males exhibited an increase urinary excretion of LDH and of epithelial cells 
over the entire dose range tested. These changes did not always appear to be dose-related.  No signs of 
structural damage were seen in the females' kidneys.  In males, a dose-dependent incidence of hyaline 
droplets in the cortical tubular epithelium was seen at 75 mg/kg/day and above.  At ≥150 mg/kg/day,
single-cell necrosis was observed, and at 300 and 600 mg/kg/day, epithelial desquamation of longer parts 


























3. HEALTH EFFECTS 
In the only available study of chronic-duration oral exposure to 1,4-DCB, renal effects were observed to 
occur preferentially in male rats.  Male F344 rats exposed to 1,4-DCB at 150 and 300 mg/kg/day by
gavage for 2 years exhibited the following effects with greater severity and in greater numbers:  
nephropathy, epithelial hyperplasia of the renal pelvis, mineralization of the collecting tubules in the renal 
medulla, and focal hyperplasia of renal tubular epithelium (NTP 1987).  There was also increased 
incidence of nephropathy in female rats dosed with 1,4-DCB at 300 and 600 mg/kg/day, but there was 
minimal hyperplasia of the renal pelvis or tubules.  Administration of 1,4-DCB at 300 and 600 mg/kg/day
for 2 years also increased the incidence of nephropathy in male B6C3F1 mice.  Renal tubular degeneration 
was noted in female mice, but these changes occurred at a lower frequency and were qualitatively
different from those in male rats (NTP 1987). 
In a study with dogs, groups of five male and five female Beagles were administered 1,4-DCB by capsule 
in dose levels of 0, 10, 50, or 75 mg/kg/day, 5 days/week for 1 year (Naylor and Stout 1996).
Histopathological changes were observed in the kidneys that included collecting duct epithelial 
vacuolation in one male at 75 mg/kg/day, and in females at all dose levels (one at 10 mg/kg/day, one at 
50 mg/kg/day, and two at 75 mg/kg/day).  This renal lesion was considered to be a possible effect of 
treatment at ≥50 mg/kg/day where it was accompanied by increased relative kidney weight (50 mg/kg/day
females) and gross observed renal discoloration (two females at 75 mg/kg/day).  No gross or histological 
changes were found in the urinary bladder. 
Endocrine Effects. 
1,2-Dichlorobenzene. No studies were located regarding endocrine effects in humans after oral exposure 
to 1,2-DCB. 
No gross or histological changes were observed in the adrenal or pancreas of Sprague-Dawley rats that 
were administered 1,2-DCB in corn oil by gavage in a dose of 300 mg/kg/day for 10 consecutive days, or 
in the adrenal (pancreas not examined) in rats similarly exposed to 400 mg/kg/day for 90 consecutive 
days (Robinson et al. 1991).  No gross or histological changes were observed in the adrenal, pancreas, 
thyroid, parathyroid, or pituitary of F344 rats or B6C3F1 mice that were treated with 1,2-DCB in corn oil
by gavage in doses ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985), or ≤120 mg/kg/day,
























3. HEALTH EFFECTS 
1,3-Dichlorobenzene. No studies were located regarding endocrine effects in humans after oral exposure 
to 1,3-DCB. 
Gross and histological examinations of adrenals, pancreas, pituitary, thyroid, parathyroids, and gonads 
were performed in groups of 10 male and 10 female Sprague-Dawley rats that were exposed to 1,3-DCB 
in oil by daily gavage, in doses of 0 or 735 mg/kg/day for 10 consecutive days or 588 mg/kg/day for 
90 consecutive days (McCauley et al. 1995).  The 90-day study additionally included examinations of 
thyroid and pituitary at lower dose levels of 9, 37, and 147 mg/kg/day.  No compound-related endocrine 
effects were observed in the 10-day study.  As discussed below, the 90-day study found histological 
effects in the thyroid at ≥9 mg/kg/day and the pituitary at ≥147 mg/kg/day.  The only other tissue with 
histological changes in the 90-day study was the liver (see Hepatic Effects). 
Inflammatory and degenerative lesions in the McCauley et al. (1995) 90-day study were graded on a 
relative scale from one to four depending on severity (minimal, mild, moderate, or marked).  In the 
thyroid, colloidal density in the follicular cells was significantly (p≤0.05) increased in male rats at 
≥9 mg/kg/day and female rats at ≥37 mg/kg/day.  The incidences of this lesion in the 0, 9, 37, 147, and 
588 mg/kg/day dose groups were 2/10, 8/10, 10/10, 8/9, and 8/8 in males and 1/10, 5/10, 8/10, 8/10, and
8/9 in females.  Depletion of colloid density in the thyroid was characterized by decreased follicular size 
with scant colloid and follicles lined by cells that were cuboidal to columnar.  The severity of the colloid 
density depletion generally ranged from mild to moderate, increased with dose level, and was greater in 
males than females. For example, in the 147 and 588 mg/kg/day groups, severity was classified as 
moderate in males and mild for the females.  Incidences of male rats with thyroid colloidal density 
depletion of moderate or marked severity were significantly increased at ≥147 mg/kg/day (0/10, 0/10, 
2/10, 5/9, and 6/8).  The lowest tested dose, 9 mg/kg/day, is considered to be a minimal LOAEL because
the morphological alterations (reduced colloidal density in follicles) are unlikely to be associated with 
functional changes in the thyroid.  The pituitary effect was cytoplasmic vacuolization in the pars distalis
and only found in the male rats.  Incidences of this lesion were significantly (p≤0.05) increased in males 
at ≥147 mg/kg/day (2/10, 6/10, 6/10, 10/10, and 7/7); incidences in the 9 and 37 mg/kg/day groups were 
marginally increased (p=0.085).  The vacuoles were variably sized, irregularly shaped, and often poorly
defined, and severity (number of cells containing vacuoles) ranged from minimal to mild.  The severity of 
the lesions generally increased with increasing dose level, and incidences of male rats with pituitary 
cytoplasmic vacuolization of moderate or marked severity were significantly increased at 588 mg/kg/day
(1/10, 0/10, 2/10, 3/9, and 7/7).  The pituitary lesion was reported to be similar to “castration cells” found 
























3. HEALTH EFFECTS 
pituitary lesions were observed in female rats.  The incidences of pituitary lesions in male rats (McCauley
et al. 1995) were used to derive an intermediate-duration oral MRL of 0.02 mg/kg/day for 1,3-DCB.  
Other effects in this 90-day study included significant increases in serum cholesterol in males at 
≥9 mg/kg/day and females at ≥37 mg/kg/day, and serum calcium in both sexes at ≥37 mg/kg/day.  The 
study authors suggested that these serum chemistry changes might reflect a disruption of hormonal 
feedback mechanisms, or target organ effects on the pituitary, hypothalamus, and/or other endocrine 
organs. 
1,4-Dichlorobenzene. No studies were located regarding endocrine effects in humans after oral exposure 
to 1,4-DCB. 
In a series of dose range-finding studies, groups of F344 rats were administered 1,4-DCB at 
concentrations ranging from 37.5 to 1,500 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks.  At 
sacrifice, animals were examined grossly and major tissues were examined histologically.  No endocrine 
organs were affected in any of the 1,4-DCB-treated rats.  In parallel studies with B6C3F1 mice, no 
compound-related endocrine effects were observed after administration of 1,4-DCB at concentrations 
ranging from 84.4 to 1,800 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks (NTP 1987). 
In the only study of lifetime oral exposure to 1,4-DCB in laboratory animals (NTP 1987), groups of male 
and female F344 rats were administered 1,4-DCB by gavage in corn oil, 5 days/week for 103 weeks at 
doses of 150 or 300 mg/kg/day (males) or 300 or 600 mg/kg/day (females).  Groups of male and female 
B6C3F1 mice were administered 1,4-DCB at doses of 300 or 600 mg/kg/day by gavage in corn oil, 
5 days/week for 103 weeks.  In the F344 rats, an increased incidence of parathyroid hyperplasia was 
observed in males (4/42 controls, 13/42 low-dose, 20/38 high-dose), while no effect was seen in females.  
In mice, the incidence of thyroid follicular cell hyperplasia increased with dose in males (1/47 control, 
4/48 low-dose, 10/47 high-dose), but not in females.  The incidence of adrenal medullary hyperplasia and 
focal hyperplasia of the adrenal gland capsule also increased with dose in males (controls, 11/47; low-
dose, 21/48; high-dose, 28/49). 
No gross or histological changes were found in the adrenal, thyroid, parathyroid, pancreas, or pituitary
glands of Beagle dogs (5/sex/level) that were administered 1,4-DCB by capsule in doses as high as 






























3. HEALTH EFFECTS 
Dermal Effects.     
1,2-Dichlorobenzene. No studies were located regarding dermal effects in humans after oral exposure to 
1,2-DCB. 
No gross or histological changes were observed in the skin of Sprague-Dawley or F344 rats that were 
administered 1,2-DCB in corn oil by gavage in doses of 300 mg/kg/day for 10 consecutive days 
(Robinson et al. 1991), ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985), or ≤120 mg/kg/day,
5 days/week for 103 weeks (NTP 1985). Additionally, there were no gross or histological effects in the 
skin of B6C3F1 mice that were similarly treated with ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 
1985) or ≤120 mg/kg/day, 5 days/week for 103 weeks (NTP 1985). 
1,3-Dichlorobenzene. No studies were located regarding dermal effects in humans after oral exposure to 
1,3-DCB. 
No gross or histological changes were observed in the skin in male or female Sprague-Dawley rats that 
were exposed to 1,3-DCB in corn oil by gavage in doses of 735 mg/kg/day for 10 consecutive days or
588 mg/kg/day for 90 consecutive days (McCauley et al. 1995). 
1,4-Dichlorobenzene. A 19-year-old black woman who had been eating 4–5 moth pellets made of 
1,4-DCB daily for 2.5 years developed symmetrical, well demarcated areas of increased pigmentation in a 
bizarre configuration over various parts of her body.  After she discontinued this practice, the skin 
discolorations gradually disappeared over the next 4 months (Frank and Cohen 1961). 
In laboratory animals, groups of F344 rats were administered 1,4-DCB at concentrations ranging from
37.5 to 1,500 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks.  No dermal effects were noted 
in any of the 1,4-DCB-treated rats.  In parallel studies with B6C3F1 mice, no compound-related dermal 
effects were observed after administration of 1,4-DCB at concentrations ranging from 84.4 to
1,800 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks (NTP 1987). 
In the only study of lifetime oral exposure to 1,4-DCB in laboratory animals (NTP 1987), groups of male 
and female F344 rats were administered 1,4-DCB by gavage in corn oil, 5 days/week for 103 weeks at 
doses of 150 or 300 mg/kg/day (males) or 300 or 600 mg/kg/day (females).  Groups of male and female 
























3. HEALTH EFFECTS 
5 days/week for 103 weeks.  No dermal effects have been reported in rats or mice at any of the studied 
doses. 
No gross or histological changes were found in the skin of Beagle dogs (5/sex/level) that were 
administered 1,4-DCB by capsule in doses as high as 75 mg/kg/day, 5 days/week for 1 year (Naylor and 
Stout 1996). 
Ocular Effects.     
1,2-Dichlorobenzene.  No studies were located regarding ocular effects in humans after oral exposure to 
1,2-DCB. Opthalmoscopic examinations showed no effects in Sprague-Dawley rats that were dosed with 
400 mg/kg/day of 1,2-DCB in corn oil by gavage for 90 consecutive days (Robinson et al. 1991).  No 
gross or histological changes were observed in eyes of F344 rats or B6C3F1 mice that were similarly
exposed to ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985) or ≤120 mg/kg/day, 5 days/week for 
103 weeks (NTP 1985). 
1,3-Dichlorobenzene. No studies were located regarding ocular effects in humans or animals after oral 
exposure to 1,3-DCB. 
1,4-Dichlorobenzene. No studies were located regarding the ocular effects in humans after oral exposure 
to 1,4-DCB. 
In a series of intermediate-duration studies, groups of F344 rats were administered 1,4-DCB at 
concentrations ranging from 37.5 to 1,500 mg/kg/day by gavage in corn oil 5 days/week for 13 weeks.  
Ocular discharge was noted prior to death in males dosed with 1,200 mg/kg and in all rats exposed to 
1,500 mg/kg.  In parallel studies with B6C3F1 mice, no compound-related ocular effects were observed 
after administration of 1,4-DCB at concentrations ranging from 84.4 to 1,800 mg/kg/day by gavage in 
corn oil 5 days/week for 13 weeks (NTP 1987). 
The ocular effects of oral administration of 1,4-DCB were examined in groups of white (strain not 
reported) female rats and male and female rabbits.  Rats received 1,4-DCB in olive oil at doses of 18.8– 
376 mg/kg/day, 5 days/week for 192 days; rabbits received 1,4-DCB in olive oil at a dose of 
1,000 mg/kg/day for 219 days.  Under the study conditions, administration of 1,4-DCB did not produce 






























3. HEALTH EFFECTS 
In chronic-duration toxicity studies in laboratory animals, Hollingsworth et al. (1956) found no evidence 
of cataract formation in rabbits administered a total of 263 doses of 500 mg/kg/day 1,4-DCB in olive oil 
over a 367-day period.
In two lifetime oral exposure studies (NTP 1987), groups of male and female F344 rats were administered
1,4-DCB by gavage in corn oil, 5 days/week for 103 weeks at doses of 150 or 300 mg/kg/day (males) or 
300 or 600 mg/kg/day (females); groups of male and female B6C3F1 mice were administered 1,4-DCB at 
doses of 300 or 600 mg/kg/day by gavage in corn oil, 5 days/week for 103 weeks.  In both species, no 
ocular effects were noted at any of the studied doses. 
Opthalmoscopic examination showed no ocular effects in Beagle dogs (5/sex/level) that were 
administered 1,4-DCB by capsule in doses as high as 75 mg/kg/day, 5 days/week for 1 year (Naylor and 
Stout 1996). 
Body Weight Effects.     
1,2-Dichlorobenzene. No studies were located regarding body weight effects in humans after oral 
exposure to 1,2-DCB. 
Gavage exposure to 1,2-DCB in oil has adversely affected body weight gain in rodent at doses that also 
caused other signs of toxicity.  Decreases in body weight gain in the range of 10–20% were observed in 
rats exposed to 300 mg/kg/day for 10 consecutive days (Robinson et al. 1991), 400 mg/kg/day for 
90 consecutive days (Robinson et al. 1991), 1,000 mg/kg/day for 14 consecutive days (NTP 1985), and 
500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985), as well as in mice exposed to 500 mg/kg/day, 
5 days/week for 13 weeks (NTP 1985).
1,3-Dichlorobenzene. No studies were located regarding body weight effects in humans after oral 
exposure to 1,3-DCB. 
Body weight was measured in groups of 10 male and 10 female Sprague-Dawley rats that were exposed 
to 1,3-DCB in corn oil by daily gavage, in doses of 0, 37, 147, 368, or 735 mg/kg/day for 10 consecutive 
days, or 9, 37, 147, or 588 mg/kg/day for 90 consecutive days (McCauley et al. 1995).  Decreases in body

























3. HEALTH EFFECTS 
weights at 735 mg/kg/day were 20 and 13% lower than controls in males and females, respectively.  The 
weight loss was progressive throughout the exposure period and, in males, accompanied by significantly
reduced food consumption (12%, normalized by body weight).  In the 90-day study, final body weights at 
588 mg/kg/day were 24 and 10% lower than controls in males and females, respectively.  The weight loss 
was progressive throughout the exposure period, and occurred despite increased food and water 
consumption. 
1,4-Dichlorobenzene. No studies were located regarding body weight effects in humans after oral 
exposure to 1,4-DCB. 
The effects of acute exposure to 1,4-DCB on body weight were examined in female Wistar rats given 
1,4-DCB suspended in 2% tragacanth gum solution (a suspending agent obtained from the dried gummy
exudation of Astragalus gummifer) at a dose of 250 mg/kg/day for 3 days.  Under these conditions, no 
effects on body weight were seen (Ariyoshi et al. 1975).  Male and female mice and female rats dosed 
once with 600 mg/kg/day 1,4-DCB also showed no discernible changes in body weight (Eldridge et al. 
1992).  Male rats administered 770 mg/kg/day of 1,4-DCB once a day for 5 days showed no changes in 
body weight (Rimington and Ziegler 1963).  Pregnant CD rats that were administered 250– 
1,000 mg/kg/day 1,4-DCB in corn oil on Gd 6–15 experienced a reversible loss in maternal body weight 
(Giavini et al. 1986). 
Body weight changes were observed in three studies in rats and mice (NTP 1987).  In the first, both sexes 
of mice and female rats dosed at concentrations up to 1,000 mg/kg/day for 14 days by gavage 
demonstrated no changes in body weight during the test period.  Male rats dosed at 500 mg/kg/day also 
showed no changes in body weight; however, a 7–12% decrease in body weight was noted in the 
1,000 mg/kg/day dose group.  In the second study (same route and duration as the first), male mice 
experienced a 13.3% decrease in body weight at the 250 mg/kg/day dose and a 14.7% decrease in body 
weight at the 2,000 mg/kg/day dose; however, results of intermediate doses demonstrated that there was 
no observable dose-response relationship for body weight changes.  Neither male nor female rats dosed 
with 500 mg/kg/day showed any effects on body weights; however, a dose of 1,000 mg/kg/day resulted in 
a 13.5% decrease in weight for males and a 16.7% decrease in females.  In the third study, male rats 
gavaged with 0, 25, 75, or 150 mg/kg of 1,4-DCB in corn oil for 7 days showed no changes in body 
weight; however, rats dosed at 300 mg/kg showed an approximately 10% decrease in body weight gain
(Lake et al. 1997). The same study in male mice dosed with 0, 300, or 600 mg/kg of 1,4-DCB in corn oil 


























3. HEALTH EFFECTS 
In intermediate-duration studies, no compound-related effects on weight gain were noted in albino or 
F344 rats administered 1,4-DCB by gavage in corn oil at doses up to 600 mg/kg/day, 7 days/week for 
13 weeks (Bomhard et al. 1988; Carlson and Tardiff 1976).  Male rats gavaged with 0 or 25 mg/kg of 
1,4-DCB in corn oil for 7 days showed no changes in body weight; however, rats dosed at 75, 150, or 
300 mg/kg showed an approximately 10% decrease in body weight gain (Lake et al. 1997).  The same 
study in male mice dosed with 0, 300, or 600 mg/kg of 1,4-DCB in corn oil for 7 days showed no changes 
in body weight at any dose level (Lake et al. 1997). Male and female mice and female rats dosed with 
concentrations of 600 mg/kg/day 1,4-DCB 5 days/week for 13 weeks also showed no discernible changes 
in body weight (Eldridge et al. 1992).  In a series of dose range-finding studies, groups of F344 rats were 
administered 1,4-DCB at concentrations ranging from 37.5 to 1,500 mg/kg/day by gavage in corn oil,
5 days/week for 13 weeks (NTP 1987).  In the first of these studies, there were no treatment-related 
effects on body weight at doses up to 600 mg/kg/day.  In the second study, final body weight was 
decreased by 11% in low-dose males (300 mg/kg/day) relative to controls; in high-dose males 
(1,500 mg/kg/day), the reduction was 32%.  The effect was less marked in females (6% reduction at 
900 mg/kg/day; 11% reduction at 1,200 mg/kg/day).  In parallel studies with B6C3F1 mice, no compound-
related effects on body weight were observed after administration of 1,4-DCB at concentrations up to
900 mg/kg/day; however, in the second study, final body weight was reduced in all males receiving 
1,4-DCB (11.4% at 1,500 mg/kg/day to 13.9% at 600 mg/kg/day) and in females at 600 mg/kg/day 
(10.3%) (NTP 1987). 
In two lifetime oral exposure studies, groups of male and female F344 rats and B6C3F1 mice were
administered 1,4-DCB by gavage in corn oil, 5 days/week for 103 weeks.  Fischer 344 rats were 
administered 1,4-DCB at doses of 150 or 300 mg/kg/day (males) or 300 or 600 mg/kg/day (females); 
mice were administered 1,4-DCB at doses of 300 or 600 mg/kg/day (NTP 1987).  In mice, no effects on 
body weight attributable to treatment with 1,4-DCB were observed at doses up to 600 mg/kg/day.  In rats, 
body weight gain was depressed by 12.5% in high-dose males (300 mg/kg/day) and by 12.4% in high-
dose females (600 mg/kg/day) relative to vehicle controls. 
There were no adverse body weight changes in Beagle dogs (5/sex/level) that were administered 1,4-DCB 
























3. HEALTH EFFECTS 
3.2.2.3 Immunological and Lymphoreticular Effects  
1,2-Dichlorobenzene. No studies were located regarding immunological or lymphoreticular effects in 
humans after oral exposure to 1,2-DCB.  
Immunological function has not been assessed in animals orally exposed to 1,2-DCB.  No gross or 
histological changes were observed in the spleen, thymus, or lymph nodes of male or female Sprague-
Dawley rats that were administered 1,2-DCB in corn oil by gavage in doses of 300 mg/kg/day for 
10 consecutive days or 400 mg/kg/day for 90 consecutive days (Robinson et al. 1991).  Gross and 
histological examinations of lymph nodes, spleen, thymus, and bone marrow were performed in F344 rats
and B6C3F1 mice that were exposed to 1,2-DCB in corn oil by gavage 5 days/week in doses 
≤500 mg/kg/day for 13 weeks or ≤120 mg/kg/day for 103 weeks (NTP 1985). The only changes in these 
tissues occurred at 500 mg/kg/day in the 13-week study; effects included lymphoid depletion in the 
thymus (4/10 male rats, 2/10 male mice, 2/10 female mice) and spleen (4/10 male mice, 2/10 female 
mice). 
1,3-Dichlorobenzene. No studies were located regarding immunological or lymphoreticular effects in 
humans after oral exposure to 1,3-DCB. 
Immunological function has not been assessed in animals orally exposed to 1,3-DCB.  No gross or 
histological changes were observed in the spleen, thymus, or mandibular and mesenteric lymph nodes of 
male or female Sprague-Dawley rats that were exposed to 1,3-DCB in corn oil by gavage in doses of 
735 mg/kg/day for 10 consecutive days, or 588 mg/kg/day for 90 consecutive days (McCauley et al. 
1995).  Spleen and thymus weight was measured in both studies, although only relative organ weights 
were reported.  In the 10-day study, relative spleen weight was significantly decreased in females at 
≥368 mg/kg/day and males at 735 mg/kg/day, and relative thymus weight was significantly decreased in 
both sexes at 735 mg/kg/day.  These changes are not considered adverse because body weight gain was 
decreased and they were not observed after 90 days or accompanied by histological alterations.
1,4-Dichlorobenzene.  No studies were located regarding immunological effects in humans after oral 
exposure to 1,4-DCB.  Symmetrical lesions with a bizarre pattern of skin pigmentation over most of her 
body were reported in the case study of a 19-year-old black woman who ingested 4–5 moth pellets of 





























3. HEALTH EFFECTS 
cessation. The described lesions may have been the result an immunological response to 1,4-DCB.  
However, this possibility was not addressed by the authors. 
Groups of F344 rats were administered 1,4-DCB at concentrations ranging from 300 to 1,500 mg/kg/day
by gavage in corn oil, 5 days/week for 13 weeks (NTP 1987).  Treatment-related immunological and 
lymphoreticular effects noted in the study included hypoplasia of the bone marrow and lymphoid 
depletion of the spleen and thymus in males and females at doses of 1,200 mg/kg/day and above.  In 
parallel studies with B6C3F1 mice administered 1,4-DCB at concentrations ranging from 300 to 
1,500 mg/kg/day, lymphoid necrosis in the thymus, lymphoid depletion in the spleen, and hematopoietic 
hypoplasia of the spleen and bone marrow were noted in both males and females at doses of 
1,500 mg/kg/day and above (NTP 1987). 
Minimal lymphoreticular changes were noted in a chronic-duration study (NTP 1987).  Male rats 
administered doses of 150 or 300 mg/kg/day and female rats given 300 or 600 mg/kg/day of 1,4-DCB by
gavage 5 days/week for 2 years showed no discernible changes in the lymphoreticular system; however, 
mice dosed in a similar fashion and at a dose of 600 mg/kg/day showed an increased incidence of lymph 
node hyperplasia. 
No gross or histological changes were found in spleen, thymus, or lymph nodes of Beagle dogs 
(5/sex/level) that were administered 1,4-DCB by capsule in doses as high as 75 mg/kg/day, 5 days/week 
for 1 year (Naylor and Stout 1996). 
3.2.2.4 Neurological Effects 
1,2-Dichlorobenzene. No studies were located regarding neurological effects in humans after oral 
exposure to 1,2-DCB.  
Neurobehavioral function has not been assessed in animals orally exposed to 1,2-DCB.  Ataxia and clonic 
contractions were observed in a small group of rats (three males) administered 1,2-DCB in liquid paraffin 
by gavage in a porphyrinogenic dose regimen of 455 mg/kg/day for 15 consecutive days (Rimington and 
Ziegler 1963).  No clinical signs of neurotoxicity or histological changes in the brain were found in 
Sprague-Dawley or F344 rats that were administered 1,2-DCB in corn oil by gavage in doses of 
300 mg/kg/day for 10 consecutive days (Robinson et al. 1991), 400 mg/kg/day for 90 consecutive days






















3. HEALTH EFFECTS 
5 days/week for 103 weeks (NTP 1985). The 10-day rat study also found no histological changes in 
sciatic nerve tissue, and the 90-day rat study also found no changes in absolute or relative brain weight 
(Robinson et al. 1991).  Additionally, there were no signs of neurotoxicity or histological effects in the 
brain of B6C3F1 mice that were gavaged with ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985) or 
≤120 mg/kg/day, 5 days/week for 103 weeks (NTP 1985). 
1,3-Dichlorobenzene. No studies were located regarding immunological effects in humans after oral 
exposure to 1,3-DCB. 
Neurobehavioral function has not been assessed animals orally exposed to 1,3-DCB.  No clinical signs of 
neurotoxicity, or histological changes in the nervous system (brain or sciatic nerve), occurred in male or 
female Sprague-Dawley rats that were exposed to 1,3-DCB in corn oil by gavage in doses of 
735 mg/kg/day for 10 consecutive days, or 588 mg/kg/day for 90 consecutive days (McCauley et al. 
1995).
1,4-Dichlorobenzene.  Two case studies have reported neurological effects in humans exposed to 
1,4-DCB via ingestion have been reported in two case studies.  A 21-year-old pregnant woman developed 
pica (a craving for unnatural substances) for 1,4-DCB toilet bowl deodorizer blocks, which she consumed 
at the rate of 1–2/week throughout pregnancy (Campbell and Davidson 1970). Reported neurological 
effects included fatigue, dizziness, and mild anorexia.  These effects, however, are common general 
symptoms that occur in many women during normal pregnancy.  A 19-year-old black woman who 
ingested 4–5 pellets of 1,4-DCB daily for about 2.5 years developed tremors and unsteadiness after she 
stopped eating this chemical.  However, in the opinion of the neurologist who evaluated the woman in 
this case report, the effects were considered to be psychological rather than the physiological effects of 
withdrawal from 1,4-DCB (Frank and Cohen 1961). 
Two studies in laboratory animals indicate that oral exposure to 1,4-DCB may result in adverse 
neurological effects.  In a study performed by Rimington and Ziegler (1963), three male albino rats were 
administered daily doses of 1,4-DCB in liquid paraffin at gradually increasing doses until a dose was 
reached (770 mg/kg/day), which resulted in high porphyrin excretion with very few fatalities; this dose 
was given for 5 days.  Clinical symptoms associated with highly porphyric rats included extreme 
weakness, ataxia, clonic contractions, and slight tremors (a rarity).  One rat receiving 1,4-DCB developed 
left-sided hemiparesis. In F344 rats administered 1,4-DCB by gavage in corn oil 5 days/week for 
























3. HEALTH EFFECTS 
both sexes at 1,500 mg/kg/day.  However, administration of 1,4-DCB had no effect on brain weight or on
the microscopical appearance of the brain, sciatic nerve, or spinal cord (NTP 1987). 
In a chronic-duration study (NTP 1987), no neurological effects were noted either in rats dosed with 
300 mg/kg/day of 1,4-DCB, 5 days/week for 2 years, or in mice dosed with 600 mg/kg/day, 5 days/week 
for 2 years. 
No gross or histological changes were found in the brain, spinal cord (three levels), or peripheral or optic 
nerves of Beagle dogs (5/sex/level) that were administered 1,4-DCB by capsule in doses as high as 
75 mg/kg/day, 5 days/week for 1 year (Naylor and Stout 1996). 
3.2.2.5 Reproductive Effects  
1,2-Dichlorobenzene. No studies were located regarding reproductive effects in humans after oral 
exposure to 1,2-DCB. 
Reproductive function has not been assessed in animals orally exposed to 1,2-DCB.  No gross or 
histological changes were observed in the testes, seminal vesicles, prostate, or ovaries of Sprague-Dawley
rats that were administered 1,2-DCB in corn oil by gavage in a dose of 300 mg/kg/day for 10 consecutive 
days (Robinson et al. 1991).  There were no changes in testis or ovary weight (absolute or relative) or 
histology in Sprague-Dawley rats that were similarly exposed to 400 mg/kg/day for 90 consecutive days
(Robinson et al. 1991).  Additionally, no gross or histological changes occurred in reproductive tissues of 
male (prostate, testes) or female (ovaries, uterus) F344 rats and B6C3F1 mice that were similarly exposed 
to ≤500 mg/kg/day, 5 days/week for 13 weeks (NTP 1985) or ≤120 mg/kg/day, 5 days/week for 
103 weeks (NTP 1985).  
1,3-Dichlorobenzene. No studies were located regarding reproductive effects in humans after oral 
exposure to 1,3-DCB.   
Reproductive function has not been assessed in animals orally exposed to 1,3-DCB.  No histological 
changes occurred in male or female reproductive tissues (testes, seminal vesicles, prostate, preputial 
gland, clitoral gland, ovaries, or mammary gland).of Sprague-Dawley rats that were exposed to 1,3-DCB 
in corn oil by gavage in doses of 735 mg/kg/day for 10 consecutive days or 588 mg/kg/day for 





























3. HEALTH EFFECTS 
although only relative organ weights were reported.  There was a statistically significant but small 
decrease (10.6% less than controls) in relative testes weight at 735 mg/kg/day in the 10-day study, but this 
is not considered to be an adverse effect because the magnitude of change was small, body weight gain 
was decreased, and there were no accompanying testicular histological alterations.
1,4-Dichlorobenzene. No studies were located regarding reproductive effects in humans after oral 
exposure to 1,4-DCB.   
1,4-DCB was administered to female CD rats by gavage in corn oil on Gd 6–15 in a developmental 
toxicity study (Giavini et al. 1986).  Doses up to 1,000 mg/kg/day had no adverse effect on the mean 
number of corpora lutea, mean number of implantations, mean percentage of pre- or postimplantation 
losses, or mean percentage of dams with resorptions (Giavini et al. 1986).  In another developmental 
toxicity study of 1,4-DCB, female Wistar rats were exposed to a reported estimated dietary dose of 
2 mg/kg/day from gestation day (Gd) 1 to postnatal day (Pnd) 21 for a total of 42 days (Makita 2005). 
There were no exposure-related effects on fertility, litter size, or sex ratio, and examinations of the pups at 
6 weeks of age showed no changes in serum levels of reproductive hormones (leutinizing hormone [LH]
and follicle stimulating hormone [FSH] in both sexes, testosterone in males) or weight or histology of 
reproductive tissues (testes, epididymides, prostate, seminal vesicles, ovaries, and uterus).   
Intermediate- and chronic-duration toxicity studies were conducted in which F344/N and B6C3F1 mice 
were treated with 1,4-DCB in corn oil by gavage 5 days/week (NTP 1987).  No gross or histological 
changes were observed in reproductive tissues (testis, ovary, uterus, or mammary gland) of rats exposed 
to ≤1,500 mg/kg/day for 13 weeks or ≤300 mg/kg/day for 103 weeks, or mice exposed to 
≤1,800 mg/kg/day for 13 weeks or ≤600 mg/kg/day for 103 weeks.  No gross or histological changes 
were found in the testes, ovaries, or uterus of Beagle dogs that were administered 1,4-DCB by capsule in 
doses as high as 75 mg/kg/day, 5 days/week for 1 year (Naylor and Stout 1996). 
In a 2-generation study, 1,4-DCB was administered by daily gavage in olive oil to male and female 
Sprague-Dawley rats at dose levels of 0, 30, 90, or 270 mg/kg/day (Bornatowicz et al. 1994).  Groups of 
24 F0 rats/sex/ dose were treated for 77 days (males) and 14 days (females) before mating, followed by
exposure of both sexes for 21 days during mating and females during gestation.  Groups of 
24 F1 weanlings/sex/dose were treated for 84 days before mating, followed by exposure of both sexes for 
30 days during mating and females during gestation (21 days) and lactation (21 days).  There were no 

























3. HEALTH EFFECTS 
copulation, and fertility index (percentage of pregnant animals out of the number of inseminated animals).  
Additional reproductive indices were not evaluated as the emphasis of the study was on postnatal 
developmental toxicity.  As discussed in Section 3.2.2.6, developmental effects included reduced birth 
weight in F1 pups and increased F2 pup deaths between birth and postnatal day 4 at ≥90 mg/kg/day. 
3.2.2.6 Developmental Effects 
1,2-Dichlorobenzene. No studies were located regarding developmental effects in humans after oral 
exposure to 1,2-DCB.   
A limited amount of information is available on the prenatal developmental effects of 1,2-DCB in 
animals.  In a gavage study inadequately reported as an abstract, Sprague-Dawley rats were administered 
50, 100, or 200 mg/kg/day of 1,2-DCB on days 6–15 of gestation (Ruddick et al. 1983).  Maternal end 
points included body weight gain, 15 unspecified biochemical parameters, and histology.  Fetal toxicity
was assessed by evaluating litter size, fetal weight, deciduoma, and skeletal, visceral, and histological 
changes. The maternal and fetal histological examinations included liver and thyroid; other tissues were 
not specified. No teratological effects or maternal toxicity were reported.  Additional relevant 
information on the design and results of this study was not included in the abstract. 
1,3-Dichlorobenzene. No studies were located regarding developmental effects in humans after oral 
exposure to 1,3-DCB.   
The developmental toxicity study of 1,3-DCB is from a gavage study inadequately reported as an abstract 
(Ruddick et al. 1983).  Sprague-Dawley rats were administered 50, 100, or 200 mg/kg/day of 1,2-DCB on 
days 6–15 of gestation (use of controls not specified).  Maternal end points included body weight gain, 
15 unspecified biochemical parameters, and histology.  Fetal toxicity was assessed by evaluating litter 
size, fetal weight, deciduoma, and skeletal, visceral, and histological changes.  The maternal and fetal 
histological examinations included liver and thyroid; other tissues were not specified.  No teratological 
effects or maternal toxicity were reported.  Additional relevant information on the design and results of 
this study was not included in the abstract.  
1,4-Dichlorobenzene. No studies were located regarding developmental effects in humans after oral 

























3. HEALTH EFFECTS 
A dose-related increase in the incidence of an extra rib was observed in the fetuses of pregnant CD rats 
administered 1,4-DCB by gavage on Gd 6–15 at doses of 500, 750, and 1,000 mg/kg/day (Giavini et al. 
1986).  A reduction in fetal weight was observed at 1,000 mg/kg/day.  The reduction in fetal weight was 
not considered to be a fetotoxic effect since it was associated with a decrease in maternal weight gain at 
the same dosage level.  The structural anomaly observed in these fetuses was dose-dependant, but was not 
considered to be a true adverse effect by the authors. However, these results raise the question of whether 
1,4-DCB ingested by the dams reached developing fetal tissue and elicited a developmental effect.  
Additional information on prenatal developmental effects of orally administered 1,4-DCB is available 
from a gavage study inadequately reported as an abstract (Ruddick et al. 1983). Sprague-Dawley rats 
were administered 50, 100, or 200 mg/kg/day of 1,4-DCB on days 6–15 of gestation (use of controls not 
specified). Maternal end points included body weight gain, 15 unspecified biochemical parameters, and 
histology. Fetal toxicity was assessed by evaluating litter size, fetal weight, deciduoma, and skeletal, 
visceral, and histological changes. The maternal and fetal histological examinations included liver and 
thyroid; other tissues were not specified.  No teratological effects or maternal toxicity were reported.  
Additional relevant information on the design and results of this study was not included in the abstract. 
In a dietary study of 1,4-DCB, female Wistar rats were exposed to a reported estimated dose of 
2 mg/kg/day from Gd 1 to Pnd 21 for a total of 42 days (Makita 2005).  There were no maternal effects as
shown by clinical signs or changes in body weight and food consumption.  No fetal examinations were 
performed but perinatal evaluations showed no gross external malformations or effects on litter size, sex 
ratio, or pup viability on Pnd 1.  Postnatal assessments of the offspring until 6 weeks of age showed no 
effects on body weight gain, anogenital distance, times of eye and vaginal opening and preputial 
separation, or serum levels of reproductive hormones (LH and FSH in both sexes and testosterone in 
males at 6 weeks). Examination of the liver, kidneys, spleen, thymus, testes, epididymides, prostate, 
seminal vesicles, ovaries, uterus, and thymus at 6 weeks showed no effects on organ weight or histology, 
except for increased absolute thymus weight (approximately 20% higher than controls) in the female
pups. The biological significance of this effect is unclear because it did not occur in the male offspring 
and was not accompanied by any histological changes.
A 2-generation study was conducted in which 1,4-DCB in olive oil was administered by daily gavage to 
male and female Sprague-Dawley rats at dose levels of 0, 30, 90, or 270 mg/kg/day (Bornatowicz et al. 
1994).  Groups of 24 F0 rats/sex/dose were treated for 77 days (males) and 14 days (females) before 






















3. HEALTH EFFECTS 
Exposure in the F0 females was continued throughout lactation until weaning of the F1 pups on postnatal 
day 21.  Groups of 24 F1 weanlings/sex/dose were treated for 84 days before mating, followed by
exposure of both sexes for 30 days during mating, and of females during gestation and lactation.  The 
study was ended following weaning of the F2 pups on postnatal day 21.  The F0 and F1 males were 
sacrificed 21 days after the end of the mating period (it is unclear if exposure continued postmating), and 
the F0 and F1 females were sacrificed after their pups were weaned.  Study end points included clinical 
observations in adults and pups, body weight and food consumption in maternal animals (during gestation 
and lactation) and pups (from birth to day 21), reproductive indices, gestation length, litter size, numbers 
of live and dead pups, postnatal survival, postnatal developmental milestones (times to erect ears and 
eyelid separation), and neurobehavioral effects in pups at weaning (auricle reflex, orientation reaction, 
grasping, and draw-up reflexes). Necropsies were performed on all adult males and females, as well as on 
pups that died during the first 4 days or were killed on day 4 (i.e., those not selected for continuation in
the study).  Liver, kidney, and spleen weights were measured in males and females of both generations.  
Histopathological examinations were performed on selected tissues (liver, kidneys, spleen, vagina, cervix, 
uterus, ovaries, mammary gland, testes, epididymides, penis, prostate, seminal vesicles, and spermatic 
cord) from F0 and F1 adult animals that had no living young, died prematurely, or were killed as moribund, 
as well as on gross lesions in all animals.
There were no exposure-related effects in adult rats or pups at 30 mg/kg/day (Bornatowicz et al. 1994).  
Body weight was significantly reduced in F1 pups at birth at ≥90 mg/kg/day (4.4, 5.7, and 22.6% lower 
than control group at 30, 90, and 270 mg/kg/day), in F1 pups on postnatal days 7–21 at 270 mg/kg/day, 
and in F2 pups at birth and on postnatal days 4–21.  The total number of deaths from birth to postnatal 
day 4 was significantly increased in F1 pups at 270 mg/kg/day and F2 pups at ≥90 mg/kg/day (33, 467, and 
1,033% higher than controls at 30, 90, and 270 mg/kg/day).  None of the data in this study were reported 
on a per-litter basis or analyzed for dose-related trends.  Decreased offspring survival at 270 mg/kg/day is 
also indicated by reduced total number of live F1 and F2 pups at birth, increased total dead F1 and F2 pups 
at birth, and increased total dead F1 and F2 pups during postnatal days 5–21.  Other postnatal effects in the 
offspring included delayed eye opening (first day of appearance or day shown in all pups) in F1 and 
F2 pups at 270 mg/kg/day, delayed ear erection (day shown in all pups) in F2 pups at 270 mg/kg/day, and
reduced percentage of rats per litter with a positive draw-up reflex in the F1 pups at 270 mg/kg/day and in
F2 pups at ≥90 mg/kg/day.  Clinical manifestations occurred in pups of both generations at 
≥90 mg/kg/day, including dry and scaly skin until approximately postnatal day 7 (0, 0, ≈70, and 100% of 
the litters at 0, 30, 90, and 270 mg/kg/day), and tail constriction that appeared between days 4 and 21 in























3. HEALTH EFFECTS 
Additionally, the number of F1 pups described as cyanotic after birth was increased (not quantified) at 
270 mg/kg/day.   
Effects in adult animals were generally not quantified, but included reduced average body weight in 
F1 males and females at 270 mg/kg/day at all time points during gestation and lactation, increased relative 
liver weight in F1 males at ≥90 mg/kg/day, and changes in absolute and/or relative organ weights in 
kidneys (increased) and spleen (reduced) in F1 males at 270 mg/kg/day.  There were no effects on organ 
weights in female rats of either generation. The only histopathological finding attributed to exposure was 
unspecified kidney damage in both generations (effect levels, possible male specificity, and other 
information not reported).  There were no effects on mating and fertility indices in any group (see 
Section 3.2.2.5). 
3.2.2.7 Cancer 
1,2-Dichlorobenzene. No studies were located regarding carcinogenic effects in humans after oral 
exposure to 1,2-DCB. 
Carcinogenicity was evaluated in groups of 50 male and 50 female F344/N rats and 50 male and 
50 female B6C3F1 mice that were exposed to 1,2-DCB (>99% pure) in corn oil by gavage in doses of 0, 
60, or 120 mg/kg, 5 days/week for 103 weeks (NTP 1985).  Evaluations in both species included clinical 
signs, body weight, and necropsy and histology on all animals.  As discussed below, no exposure-related 
tumors were found in either species, although it is unclear whether a maximum tolerated dose (MTD) was 
achieved in either species. 
In rats, survival to termination in the high-dose males was significantly reduced compared with controls 
(19/50 vs. 42/50, p<0.001), but NTP (1985) concluded that the difference was likely mainly from causes 
incidental to treatment.  Due to the probable gavage-related deaths in the high-dose male rats, the lower 
survival of this group does not necessarily mean that the MTD was either reached or exceeded.  No 
clinical signs were reported.  Mean body weight was slightly reduced (≈5% less than controls) in males 
throughout the study at 85.7 mg/kg/day; the only effect in females was a small increase compared to 
controls after week 32 in both dose groups (final body weights were 11–12% increased at 42.9 and 
85.7 mg/kg/day).  There were no exposure-related increased tumor incidences in the rats.  The incidence 
of adrenal gland pheochromocytomas was significantly (p≤0.05) increased in low-dose males by the life 
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groups, respectively), but not statistically significant by the incidental tumor test, which was considered to 
be the more appropriate mortality-adjusted test for analysis of nonfatal types of tumors.  The increased 
incidence of pheochromocytomas in the low-dose males also was not significant in the Fisher Exact test 
(without mortality adjustment), and there was no significant dose-related trend in the Cochran-Armitage 
test. No increase in pheochromocytomas was seen in high-dose males.  The increased incidence of 
pheochromocytomas in the low-dose male rats was discounted by NTP (1985) because there was no dose-
response trend or high-dose effect, no increased incidence in females, no observation of malignant 
pheochromocytomas, and questionable toxicological significance of the life table test results 
(pheochromocytomas were not considered to be a life-threatening condition).  Incidences of interstitial-
cell tumors of the testis were elevated in control and treated groups (47/50, 49/50, 41/50), and occurred 
with a significant positive trend when analyzed by the life-table test.  However, the increase detected by
the life-table test was discounted by NTP because this tumor is not considered to be life threatening, and 
no significant results were obtained by the incidental tumor test, which is the more appropriate test for 
nonfatal tumors.  The Cochran-Armitage test showed a significant negative trend for the interstitial cell 
tumors. 
There were no clinical signs or effects on body weight or survival in the mice, indicating that it is unclear 
whether an MTD was achieved in this species (NTP 1985).  There were no clear compound-related 
increased incidences of neoplasms in the mice.  Incidences of malignant histiocytic lymphomas showed a 
significant positive dose-related trend in male mice (0/50, 1/50, 4/50) and female mice (0/49, 0/50, 3/49), 
but NTP considered numbers of animals with all types of lymphomas to be a more appropriate basis for 
comparison.  Because malignant lymphocytic lymphomas occurred in male mice (7/50, 0/50, 0/50) with a 
significant negative dose-related trend, and the combined incidence of all types of lymphomas was not 
significantly different than that in controls for the male mice (8/50, 2/50, 4/50) or female mice (11/49, 
11/50, 13/49) by any of the statistical tests, the increase in histiocytic lymphomas was discounted by
NTP. Alveolar/bronchiolar carcinomas were significantly increased in the high dose male mice (4/50, 
2/50, 10/50).  The incidences showed a significant positive increasing trend by the Cochran-Armitage 
test, but not by the life-table or incidental tumor test.  The increase in alveolar/bronchiolar carcinomas 
was discounted by NTP because the more appropriate combined incidence of male mice with 
alveolar/bronchiolar adenomas or carcinomas (8/50, 8/50, 13/50) was not significantly greater than 
controls in any of the tests. 
1,3-Dichlorobenzene. No studies were located regarding carcinogenic effects in humans or animals after 




















3. HEALTH EFFECTS 
1,4-Dichlorobenzene. No studies were located regarding carcinogenic effects in humans after oral 
exposure to 1,4-DCB. 
1,4-DCB was found to be carcinogenic in B6C3F1 mice and male (but not female) F344 rats exposed to 
1,4-DCB for 2 years in a carcinogenesis bioassay (NTP 1987).  1,4-DCB was administered by gavage to 
male rats at doses of 150 or 300 mg/kg/day and female rats at doses of 300 or 600 mg/kg/day. Significant 
dose-related increases in the incidence of renal tubular cell adenocarcinomas were reported in male rats 
(controls, 2%; low-dose, 6%; high-dose, 14%).  Spontaneous tumors of this type are uncommon in male 
F344 rats; they have been diagnosed in only 4 of 1,098 (0.4%) of the corn oil-gavage controls in previous 
NTP studies. There were no tubular cell tumors in dosed or vehicle-control female rats.  There also was a 
marginal increase in the incidence of mononuclear cell leukemia in dosed male rats that was only slightly
higher than the incidence in historical controls from the same laboratory.  The NTP study concluded that 
1,4-DCB was carcinogenic in male rats, but not in female rats. 
In a 2-year bioassay in B6C3F1 mice that received 1,4-DCB at 300 or 600 mg/kg/day (NTP 1987), 
increased incidences of hepatocellular carcinomas were observed in high-dose male mice (controls, 28%; 
low-dose, 22.5%; high-dose, 64%) and high-dose female mice (controls, 10%; low-dose, 10.4%; high-
dose, 38%). Hepatocellular adenomas were increased in high- and low-dose male mice (controls, 10%; 
low-dose, 26.2%; high-dose, 32%) and in high-dose female mice (controls, 20%; low-dose, 12.5%; high-
dose, 42%). Female control mice in this bioassay had a substantially higher incidence of liver tumors 
than did historical controls.  Hepatoblastomas (a rare form of hepatocellular carcinoma) were observed in 
four high-dose male mice along with other hepatocellular carcinomas.  This tumor type had not been 
previously observed in 1,091 male vehicle-control mice in NTP studies.  An increase in thyroid gland 
follicular cell hyperplasia was observed in dosed male mice, and there was a marginal positive trend in 
the incidence of follicular cell adenomas of the thyroid gland in female mice.  The incidence of 
pheochromocytomas (tumors of chromaffin tissue of the adrenal medulla or sympathetic pregangliar, 
benign and malignant, combined) of the adrenal gland was 0 of 47 (control), 2 of 48 (low dose), and 3 of 
49 (high dose), and the incidence of adrenal gland medullary hyperplasia and focal hyperplasia of the 
adrenal gland capsule were increased as well in dosed male mice. 
The observation that kidney tumors are induced in male rats, but not female rats, in response to exposure 
to certain chemicals has been the subject of recent research.  It has been hypothesized that the male rat 
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has not been found at significant levels in either female rats, or in mice and humans of either sex 
(Charbonneau et al. 1987, 1989a, 1989b).  Chemicals like 1,4-DCB, which reversibly bind to this protein, 
cause the formation of hyalin droplets in the proximal convoluted tubules of male rats.  The hyalin 
droplet-protein complex is resistant to degradation by lysosomal enzymes and accumulates in the tubule, 
leading to localized hyperplasia of the epithelium (Borghoff et al. 1991; EPA 1991i).  It is hypothesized 
that the resulting cellular damage and cell proliferation enhances tumor formation via a mechanism not 
yet elucidated.  It has also been demonstrated that the same effects can be elicited in male rats 
administered other α2µ-globulin-binding chemicals such as [hexachloroethane, d-limonene 1-methyl­
4(1-methylethenyl)cyclohexene], unleaded gasoline, and pentachloroethane (EPA 1991i). Based on these 
data, EPA (1991) concluded that tumors associated with α2µ-globulin and hyalin droplets are specific to 
species that produce this protein in large quantities, and that these tumors should be distinguished from
other renal tumors. 
The finding of hepatocellular carcinomas and adenomas in mice in the NTP (1987) study has been the 
subject of scientific debate. There was a high incidence of these tumors in both male and female control 
animals, but this is fairly common in mice.  However, in this case, the tumor incidence in the female
controls was substantially higher than the historical control value.  In addition, 1,4-DCB has not been 
demonstrated to be mutagenic in any of the microbial or mammalian systems tested (NTP 1987), 
suggesting that the liver tumors are not the result of genotoxicity. Hepatocellular degeneration with 
resultant initiation of tissue repair was present in both male and female treated mice.  This led NTP 
(1987) to speculate that 1,4-DCB acted as a tumor promotor rather than a tumor initiator during the 
formation of the liver tumors found in male and female mice. 
As shown in Table 3-5, 300 mg/kg/day is the cancer effect level (CEL) for renal tubular cell adenomas in 
male rats and 600 mg/kg/day is the CEL for hepatocellular carcinomas and hepatoblastomas in mice 
(NTP 1987). 
3.2.3 Dermal Exposure  
3.2.3.1 Death 
1,2-Dichlorobenzene. No studies were located regarding death in humans or animals after dermal 





















3. HEALTH EFFECTS 
1,3-Dichlorobenzene.  No studies were located regarding death in humans or animals after dermal 
exposure to 1,3-DCB. 
1,4-Dichlorobenzene. No studies were located regarding death in humans after dermal exposure to 
1,4-DCB. 
The dermal LD50 for 1,4-DCB in Sherman rats was >6,000 mg/kg/day (Gaines and Linder 1986).  It is not 
clear how many rats died after dermal exposure to 1,4-DCB in this study, and there are no toxicokinetic 
data that address the question of absorption of 1,4-DCB by the dermal route. 
3.2.3.2 Systemic Effects  
1,2-Dichlorobenzene.  No studies were located regarding systemic toxicity in humans or animals after 
dermal exposure to 1,2-DCB. 
Application of two drops of undiluted 1,2-DCB into the eyes of rabbits caused some pain and slight 
irritation of the conjunctival membranes, which healed completely within 1 week (Hollingsworth et al. 
1958).  The irritation was reduced by prompt rinsing with water.  Additional relevant information was not 
reported. 
1,3-Dichlorobenzene.  No studies were located regarding systemic effects in humans or animals after 
dermal exposure to 1,3-DCB. 
1,4-Dichlorobenzene. No studies were located regarding systemic effects in humans or animals after 
dermal exposure to 1,4-DCB.   
Industrial experience indicates that solid particles of 1,4-DCB are painful in the eyes of humans 
(Hollingsworth et al. 1956).  Solid 1,2-DCB has a negligible irritating action on intact, uncovered human 
skin, but can produce a burning sensation when held in close dermal contact for an unspecified excessive 
period of time (Hollingsworth et al. 1956).  Prolonged and repeated contact to strong solutions of 




























3. HEALTH EFFECTS 
No studies were located regarding the following health effects in humans or animals after dermal 
exposure to 1,2-, 1,3-, or 1,4-DCB: 
3.2.3.3 Immunological and Lymphoreticular Effects  
3.2.3.4 Neurological Effects 
3.2.3.5 Reproductive Effects  
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
3.3 GENOTOXICITY  
In vivo and in vitro genotoxicity studies of DCBs are summarized in Tables 3-6 and 3-7, respectively.
1,2-Dichlorobenzene.  No studies were located regarding genotoxic effects in humans after inhalation, 
oral, or dermal exposure to 1,2-DCB. 
A limited amount of information is available on the genotoxicity of 1,2-DCB in animals.  Micronuclei 
were induced in bone marrow erythrocytes of mice that were administered two 93.5–375 mg/kg doses by
intraperitoneal injection 24 hours apart; lower dose levels were not tested (Mohtashamipur et al. 1987).  A 
single 0.4 mg/kg intraperitoneal dose of 1,2-DCB caused covalent binding to liver, lung, kidney, and 
stomach DNA in rats and mice (Colacci et al. 1990). 
In vitro reverse mutation assays of 1,2-DCB in microbial systems were negative in Salmonella 
typhimurium with or without metabolic activation (Connor et al. 1985; NTP 1985; Shimizu et al. 1983; 
Waters et al. 1982), negative in Escherichia coli without metabolic activation (Waters et al. 1982), and 
positive results in Saccharomyces cerevisiae with metabolic activation (Paolini et al. 1998). In mouse 
lymphoma cells, 1,2-DCB was negative for forward mutation without metabolic activation, but positive 
with S9 activation mixture (Myhr and Caspary 1991). In vitro exposure to 1,2-DCB induced DNA 
damage in E. coli and S. cerevisiae, but not in Bacillus subtilis (Waters et al. 1982), and did not cause 
replicative DNA synthesis in cultured human lymphocytes (Perocco et al. 1983) or increased DNA repair 
in primary rat hepatocytes (Williams et al. 1989).  1,2-DCB did not cause chromosomal aberrations, 
either with or without metabolic activation, in Chinese hamster ovary (CHO) cells, but did induce sister-










































3. HEALTH EFFECTS 
Table 3-6. Genotoxicity of Dichlorobenzenes In Vivo 
Species (test system) End point Results Reference 
1,2-Dichlorobenzene 
Mammalian cells 
Mouse bone marrow 
erythrocytesa 
Micronucleus formation  + Mohtashampir et al. 1987 
Rat liver, lung, kidney and 
stomach cellsb 
Covalent binding to DNA + Colacci et al. 1990 
Mouse liver, lung, kidney 
and stomach cellsb 
Covalent binding to DNA + Colacci et al. 1990 
1,3-Dichlorobenzene 
Mammalian cells 




Rat bone marrow cellsd Chromosomal aberrations – Anderson and Richardson 1976 
Mouse bone marrow cells Micronucleus formation – Shelby and Witt 1995 
 Mouse erythrocytese Micronucleus formation – NTP 1987 
Rat kidney cellsf Unscheduled DNA synthesis – Steinmetz and Spanggord 1987b 
Increased DNA replication +g
 Mouse hepatocytesh Unscheduled DNA synthesis – Steinmetz and Spanggord 1987a 
Rat kidney cellsi Increased DNA replication + Charbonneau et al. 1989b 
Mouse bone marrow Micronucleus formation + Mohtashamipur et al. 1987
erythrocytesj 
Rat renal tubular cells Cumulative replicating fraction – Umemura et al. 1998 
and hepatocytesk 
Mouse renal tubular cells Cumulative replicating fraction + Umemura et al. 1998 
and hepatocytesk 
aExposed to 1,2-dichlorobenzene via two intraperitoneal injections of 93.5, 187.5, 281, or 375 mg/kg (24 hours apart) 

and sacrificed 6 hours after the second injection.  Males only were tested. 

bExposed to 1,2-dichlorobenzene via one intraperitoneal injection of 0.4 mg/kg. 

cExposed to 1,3-dichlorobenzene via two intraperitoneal injections of 87.5, 175, 262.5, or 700 mg/kg (24 hours apart) 

and sacrificed 6 hours after the second injection.  Males only were tested. 

dExposed to 1,4-dichlorobenzene via inhalation for 2 hours at 299 or 682 ppm; for 5 days, 5 hours/day at 75 or 

500 ppm; or for 3 months, 5 days/week, 5 hours/day at 75 or 500 ppm. 

eExposed to 1,4-dichlorobenzene via gavage for 13 weeks, 5 days/week at 600–1,800 mg/kg/day.
 
fExposed to 1,4-dichlorobenzene via gavage in corn oil at 300, 600, or 1,000 mg/kg at 16 hours before sacrifice for 

unscheduled DNA synthesis experiment or at 96 hours before sacrifice for DNA replication experiment. 

gResults were positive for male rats only in which a significant S-phase response was induced. 





iExposed to 1,4-dichlorobenzene via gavage in corn oil at 120 or 300 mg/kg/day for 7 days and sacrificed 24 hours 

after the last dose. 

jExposed to 1,4-dichlorobenzene via two intraperitoneal injections of 355, 710, 1,065, or 1,420 mg/kg (24 hours 

apart) and sacrificed 6 hours after the second injection.  Males only were tested. 

kExposed to 1,4-dichlorobenzene via gavage for 1 week or 4 weeks at 150, 300, or 600 mg/kg/day. 



















   
  
   
 
 













3. HEALTH EFFECTS 
Table 3-7. Genotoxicity of Dichlorobenzenes In Vitro 
Results 
With Without 
Species (test system) End point activation activation Reference 
1,2-Dichlorobenzene 
Microbial systems 
 Salmonella Gene mutation ND – Waters et al. 1982 
typhimurium TA98, 
TA100, TA1535, 
TA1537, and TA1538 
S. typhimurium TA98, Gene mutation – – Connor et al. 1985 
TA100, UTH8413, and 
UTH8414 
S. typhimurium TA98, Gene mutation – – NTP 1985 





S. typhimurium TA98, Gene mutation – – Shimizu et al. 1983 
TA100, TA1535, 
TA1537, and TA1538 
S. typhimurium	 Gene induction (umu) – – Nakamura et al. 1987 
Escherichia coli   	 Prophage lambda   DeMarini and Brooks 
induction 1992 
E. coli WP2 uvra	 Gene mutation ND – Waters et al. 1982 
E. coli polA- DNA damage ND + Waters et al. 1982 
Bacillus subtilis recA- DNA damage ND + Waters et al. 1982 
 Saccharomyces Gene mutation – ND Paolini et al. 1998 
cerevisiae
S. cerevisiae D3	 DNA damage ND + Waters et al. 1982 
Mammalian cells 
Mouse lymphoma cells Gene mutation + – Myhr and Caspary 1991 
Chinese hamster ovary Chromosomal aberrations – – Loveday et al. 1990 
cells 
Chinese hamster ovary Sister-chromatid + – Loveday et al. 1990 
cells exchange 
 Rat primary Increased DNA repair ND – Williams et al. 1989 
hepatocytes 
Human lymphocytes Replicative DNA synthesis – – Perocco et al. 1983 
1,3-Dichlorobenzene
Microbial systems 
S. typhimurium TA98, Gene mutation ND – Waters et al. 1982 
TA100, TA1535, 
TA1537, and TA1538
S. typhimurium TA98, Gene mutation – – Connor et al. 1985 
















   
   
   





   
   
   
   
   
   






   
  
198 DICHLOROBENZENES
3. HEALTH EFFECTS 
Table 3-7. Genotoxicity of Dichlorobenzenes In Vitro 
Results 
With Without 
Species (test system) End point activation activation Reference 
S. typhimurium TA98, Gene mutation – – Shimizu et al. 1983 
TA100, TA1535, 
TA1537, and TA1538
E. coli WP2 uvra Gene mutation ND – Waters et al. 1982 
E. coli polA- DNA damage ND + Waters et al. 1982 
B. subtilis recA- DNA damage ND + Waters et al. 1982 
S. cerevisiae D3 DNA damage ND – Waters et al. 1982 
Mammalian cells 




TA98, TA100, TA1535, 
and TA1538
S. typhimuriumb





TA98, TA100, TA1535, 
TA1537, and TA1538 
S. typhimurium













S. cerevisiae D3 
Mammalian cells 
mouse lymphoma cells 
L5178Y/TK± 
mouse lymphoma cells 
L5178Y/TK± 
Chinese hamster lung 
cells 
Chinese hamster ovary 
cells 
Gene mutation – – 
Gene mutation – – 
Gene mutation + – 
Gene mutation – – 
Gene mutation – – 
Gene mutation – – 
Gene mutation ND – 
DNA damage ND -
DNA damage ND -
Gene mutation + ND 
DNA damage ND -
Gene mutation (=) – 
Gene mutation + (=) 
Gene mutation – – 




Shimizu et al. 1983; 
Waters et al. 1982 
Haworth et al. 1983; NTP 
1987 
Connor et al. 1985 
Waters et al. 1982 
Waters et al. 1982 
Waters et al. 1982 
Paolini et al. 1998 
Waters et al. 1982 
NTP 1987 
McGregor et al. 1988 
Instituto di Ricerche
Biomediche 1986b 


































3. HEALTH EFFECTS 
Table 3-7. Genotoxicity of Dichlorobenzenes In Vitro 
Results 
With Without 
Species (test system) End point activation activation Reference 
Chinese hamster ovary Sister chromatid – – Anderson et al. 1990; 
cells exchanges NTP 1987 
Rat hepatocytes DNA fragmentation ND - Canonero et al. 1997 
Rat hepatocytes Micronucleus formation ND (=) Canonero et al. 1997 
Rat kidney cells DNA damage ND + Robbiano et al. 1997 
Rat kidney cells Micronucleus formation ND + Robbiano et al. 1997 
Human kidney cells DNA damage ND + Robbiano et al. 1997 
Human kidney cells Micronucleus formation ND + Robbiano et al. 1997 
Human hepatocytes DNA fragmentation ND - Canonero et al. 1997 
Human hepatocytes Micronucleus formation ND - Canonero et al. 1997 
Human lymphocytes Replicative DNA synthesis – – Perocco et al. 1983 
 Human lymphocytes Sister-chromatid – – Carbonell et al. 1991 
exchanges 
 Human lymphocytes Unscheduled DNA – – Perocco et al. 1983; 
synthesis Instituto di Ricerche
Biomediche 1987 
 HeLa cells Unscheduled DNA – – Instituto di Ricerche 
synthesis Biomediche 1986a 
Plant systems 
Root tips (16 species of Chromosomal aberrations ND + Sharma and Battachary 
dicotyledons and 1956 
monocotyledons) 
Lens esculenta (L.) Mitotic abnormalities ND + Sarbhoy 1980 
Moench 
Aspergillus nidulans Back mutation frequency ND + Prasad 1970
Tribe viceae Chromosomal aberrations ND + Srivastava 1966 
aExposed to 1,4-dichlorobenzene gas. 
bExposed to 1,4-dichlorobenzene in DMSO. 























3. HEALTH EFFECTS 
1,3-Dichlorobenzene.  No studies were located regarding genotoxic effects in humans after inhalation, 
oral, or dermal exposure to 1,3-DCB. 
A limited amount of information is available on the genotoxicity of 1,3-DCB.  Micronuclei were induced 
in bone marrow erythrocytes of mice following administration of two 87.5–700 mg/kg doses by
intraperitoneal injection 24 hours apart; lower dose levels were not tested (Mohtashamipur et al. 1987).  
In vitro exposure to 1,3-DCB did not induce reverse mutations in S. typhimurium (Connor et al. 1985; 
Shimizu et al. 1983; Waters et al. 1982) or E. coli (Waters et al. 1982).  1,3-DCB caused DNA damage in 
E. coli, but not in B. subtilis or S. cerevisiae (Waters et al. 1982), and did not increase replicative DNA 
synthesis in cultured human lymphocytes (Perocco et al. 1983). 
1,4-Dichlorobenzene. No studies were located regarding genotoxic effects in humans after inhalation, 
oral, or dermal exposure to 1,4-DCB. 
Cytogenetic studies have been conducted using bone marrow cells of rats following inhalation exposure 
to 1,4-DCB (Anderson and Richardson 1976).  Three series of exposures were carried out:  (1) one 
exposure at 299 or 682 ppm for 2 hours; (2) exposures at 75 or 500 ppm, 5 hours/day for 5 days; and 
(3) exposures to 75 or 500 ppm, 5 hours/day, 5 days/week for 3 months.  Bone marrow cells from both 
femurs were examined for chromosome or chromatid gaps, chromatid breaks, fragments, or other 
complex abnormalities.  In all three experiments, exposure to 1,4-DCB failed to induce any effects 
indicative of chromosomal damage.   
Gavage administration of 1,4-DCB to B6C3F1 mice and F344 rats at single doses of 300–1,000 mg/kg/day 
did not result in unscheduled deoxyribonucleic acid (DNA) synthesis in the mouse hepatocytes or in the 
renal tissue of the rats in an in vivo/in vitro assay (Steinmetz and Spanggord 1987a, 1987b).  However, 
1,4-DCB at the highest level did induce an increase in DNA replication (S-phase of cell division) in the 
renal tissue of the male rats and in the hepatocytes of the male mice.  Based on a comparison with 
historical controls, the authors concluded that levels of DNA replication were also significantly elevated 
in the hepatocytes of female mice. 
No evidence of a clastogenic effect was found in mouse bone marrow erythroblasts after a single gavage 
administration of 1,4-DCB at 2,500 mg/kg/day (Herbold 1986a).  Similarly, no evidence of clastogenic 

























3. HEALTH EFFECTS 
(the major metabolite of 1,4-DCB) at 1,500 mg/kg/day (Herbold 1986b).  2,5-Dichlorophenol with or 
without metabolic activation did not induce an increase in mutagenic response in the Chinese hamster 
ovary HGPRT forward mutation assay (Litton Bionetics 1986a).  This compound was also inactive in the 
Balb/3T3 in vitro transformation assay (Litton Bionetics 1985). 
Cytogenetic effects were not found in bone marrow cells from mice treated with 1,4-DCB by gavage at 
levels up to 1,800 mg/kg/day in a 13-week study (NTP 1987).  No increase in micronucleated cells 
occurred even at levels that were extremely toxic to the test animals, resulting in liver toxicity and 
decreased survival rates. As noted by the authors of that study, the observed carcinogenic activity of
1,4-DCB cannot be adequately predicted on the basis of the available genotoxicity data; all of the 
available information strongly suggests that 1,4-DCB acts as a tumor promoter rather than as a mutagen.   
However, gavage administration of a single 1,000 mg/kg/day dose of 1,4-DCB to mice and rats resulted 
in an increase in DNA replication in the renal tissue of the male rats and in the hepatocytes of mice of 
both sexes (Steinmetz and Spanggord 1987a, 1987b).  Increased 3H-thymidine incorporation into renal 
DNA has also been demonstrated in rats dosed with 1,4-DCB by gavage at 120 mg/kg/day for 7 days
(Charbonneau et al. 1989b). These observations suggest that 1,4-DCB promotes cell division, a finding 
that may help to elucidate the mechanism of carcinogenic action of 1,4-DCB in male rat kidneys and 
mouse liver in the NTP (1987) bioassay.  However, it is important to note that in these studies; only
kidney tissue was tested in the rat for increased DNA replication, and in the mouse, only liver tissue was 
tested. Therefore, it is not clear whether increased cell replication also occurs in other tissue in each 
species or is limited to the tissues in which the carcinogenic effects occurred. 
The in vivo genotoxicity of 1,4-DCB is summarized in Table 3-6.  As discussed above, the in vivo testing 
showed positive results for increased DNA replication in the livers of orally exposed mice (Steinmetz and 
Spanggord 1987a) and in the kidneys of orally exposed rats (Charbonneau et al. 1989b; Steinmetz and 
Spanggord 1987b), and mixed positive and negative findings for induction of micronuclei in bone marrow 
cells of orally exposed mice (Mohtashampir et al. 1987; NTP 1987).   
In vitro genotoxicity studies of 1,4-DCB are summarized in Table 3-7.  Microbial reverse mutation tests 
were predominantly negative in S. typhimurium (Anderson 1976; Connor et al. 1985; NTP 1987; Shimizu
et al. 1983; Waters et al. 1982) and E. coli (Waters et al. 1982), but positive in S. cerevisiae (Paolini et al. 
1998). Assays for DNA damage in E. coli, B. subtilis, and S. cerevisiae were negative (Waters et al. 

























3. HEALTH EFFECTS 
(Canonero et al. 1997) in rat and human hepatocytes, although DNA damage was increased in rat and 
human kidney cells (Robbiano et al. 1999).  Forward mutation assays in mouse lymphoma cells were 
equivocal (McGregor et al. 1988; NTP 1987), and mixed positive and negative results were found for 
chromosomal aberrations and sister-chromatid exchanges in CHO cells (Anderson et al. 1990; Carbonell 
et al. 1991; NTP 1987).  Tests for micronucleus formation were equivocal in human and rat hepatocytes 
(Canonero et al. 1997) and positive in human and rat kidney cells (Robbiano et al. 1999).  In vitro testing 
in plant systems showed genotoxic effects that included chromosomal aberrations, mitotic abnormalities, 
and back mutations (Prasad 1970; Sarbhoy 1980; Sharma and Battacharya 1956; Srivastava 1966).
3.4 TOXICOKINETICS 
1,2-DCB is quickly and extensively absorbed through both the gastrointestinal tract and the respiratory
tract; studies describing the absorption of 1,2-DCB following dermal exposure are not available.  
Following absorption, 1,2-DCB is distributed throughout the body, but tends to be found in greatest levels 
in the fat, kidney, and liver.  1,2-DCB is initially metabolized by cytochrome P-450 enzymes, specifically
P4502E1, to an active epoxide followed by hydrolysis to 2,3-dichlorophenol or 3,4-dichlorophenol.  The 
dichlorophenols may be further oxidized or, more often, be conjugated to glutathione, sulfate, or to form
the glucuronide; conjugation occurs extensively, with virtually no unconjugated metabolites reported in 
the available studies. Metabolism is believed to occur mainly in the liver, but may occur at lower levels 
in other tissues, such as the kidney or lung.  Elimination of 1,2-DCB from the body is rapid, with the 
majority of a single dose being removed within the first 75 hours postexposure; elimination occurs 
primarily in the urine as metabolites. 
Information on the quantitative absorption of 1,3-DCB in humans and animals is not available for any
route of exposure; however, absorption of the compound can be inferred from studies that have detected 
1,3-DCB or metabolites in the breast milk, blood, and fat of humans and in the bile and urine of exposed 
animals.  Distribution is believed to be similar to the other DCB isomers, but data demonstrating this are 
not presently available.  Similar to the other DCB isomers, 1,3-DCB is initially metabolized by
cytochrome P-450 enzymes, followed by extensive conjugation, primarily to glutathione, has been 
reported. 1,3-DCB is eliminated mainly in the urine, similar to the other DCB isomers. 
Absorption of 1,4-DCB is rapid and essentially complete following inhalation or oral exposure.  
Information on the quantitative absorption of 1,4-DCB following dermal exposure are not available; 

























3. HEALTH EFFECTS 
in rats, and on a lack of systemic effects in humans who held solid 1,4-DCB in their hands.  Similar to the 
other dichlorobenzene isomers, 1,4-DCB is distributed throughout the body, but tends to be found in 
greatest levels in fat, liver, and kidney.  Metabolism of 1,4-DCB is similar to that of 1,2-DCB, with an 
initial oxidation to an epoxide, followed by hydrolysis to 2,5-dichlorophenol.  Extensive phase II 
metabolism occurs subsequently, with eliminated metabolites found mainly as the sulfate, glucuronide, or 
mercapturic acid.  1,4-DCB is eliminated almost exclusively in the urine, primarily as conjugates of 
2,5-dichlorophenol. 
3.4.1 Absorption
3.4.1.1 Inhalation Exposure 
1,2-Dichlorobenzene. Quantitative data on the absorption of 1,2-DCB in humans following inhalation 
exposure are not available. However, evidence for absorption of 1,2-DCB in humans comes from
numerous studies that have detected 1,2-DCB in human tissues, including the blood (Bristol et al. 1982), 
urine (Kumagai and Matsunaga 1995, 1997; Zenser et al. 1997), adipose tissue (Jan 1983), and in breast 
milk (Jan 1983; Mes et al. 1986). While these studies do not provide a quantitative measure of the rate or 
extent of 1,2-DCB and cannot provide information concerning possible exposure route, they provide 
evidence of 1,2-DCB absorption in humans. 
Quantitative data on the absorption of 1,2-DCB in animals are similarly not available.  However, 
numerous studies presenting evidence of systemic toxicity (see Section 3.2) following inhalation of 
1,2-DCB provide qualitative evidence for the absorption of 1,2-DCB.  
1,3-Dichlorobenzene. Quantitative data on the absorption of 1,3-DCB in humans following inhalation 
exposure are not available. However, evidence for absorption of 1,3-DCB in humans comes from studies 
that have detected 1,3-DCB in breast milk (Mes et al. 1986), blood (Bristol et al. 1982), and adipose 
tissue (Jan 1983). While these studies do not provide a quantitative measure of the rate or extent of 
1,3-DCB and cannot provide information concerning possible exposure route, they provide evidence of 
1,3-DCB absorption in humans. 
Quantitative inhalation absorption data for 1,3-DCB are not available, but absorption characteristics are 
























3. HEALTH EFFECTS 
1,4-Dichlorobenzene. Quantitative data on the absorption of 1,4-DCB in humans following inhalation 
exposure are not available. However, evidence for absorption of 1,4-DCB in humans comes from
numerous studies that have detected 1,4-DCB in human tissues, including the blood (Bristol et al. 1982;
Hill et al. 1995), urine (Ghittori et al. 1985; Hill et al. 1995; Pagnotto and Walkley 1965), adipose tissue 
(Jan 1983), and breast milk (Jan 1983).  While these studies do not provide a quantitative measure of the 
rate or extent of 1,4-DCB and cannot provide information concerning possible exposure route, they 
provide evidence that 1,4-DCB is absorbed by humans. 
Studies presenting quantitative data on the rate and/or extent of absorption of 1,4-DCB following 
inhalation exposure in animals are not available.  However, numerous studies presenting evidence of 
systemic toxicity (see Section 3.2) following inhalation exposure provide qualitative evidence for the 
absorption of 1,4-DCB.  Additional evidence comes from studies that have reported the presence of the 
compound or its metabolites in peripheral tissues following inhalation exposure. Following a single or 
multiple 3-hour inhalation exposures of radiolabeled 1,4-DCB in rats, label was detected in all evaluated 
tissues (liver, kidneys, lungs, muscle, fat, and blood plasma), indicating that considerable absorption had 
occurred (Hawkins et al. 1980). Levels of label in tissues did not appreciably increase with increasing the 
number of exposures beyond one (Hawkins et al. 1980).  Similarly, following a single 24-hour inhalation 
exposure in rats, 1,4-DCB levels in the liver, kidney, fat, and blood increased sharply during the first 
6-hour evaluation period, then rose slowly but steadily for the remainder of the exposure period 
(Umemura et al. 1998), indicating an initial rapid absorption, followed by a slower total absorption as 
equilibration of body and blood levels is approached. 
3.4.1.2 Oral Exposure  
1,2-Dichlorobenzene. Quantitative data on the absorption of 1,2-DCB in humans following oral 
exposure are not available. However, absorption of 1,2-DCB in humans can be concluded based on the 
results of numerous studies that have detected 1,2-DCB in human tissues, including the blood (Bristol et 
al. 1982), urine (Kumagai and Matsunaga 1995, 1997; Zenser et al. 1997), and in breast milk (Jan 1983; 
Mes et al. 1986). While these studies do not provide a quantitative measure of the rate or extent of 
1,2-DCB and cannot provide information concerning possible exposure route, they provide evidence of 
1,2-DCB absorption in humans. 
In male Wistar rats given single oral doses of 5, 50, and 250 mg/kg body weight of 14C-labeled 1,2-DCB, 






















3. HEALTH EFFECTS 
the radioactivity for administered doses, respectively (Hissink et al. 1996a).  Radioactivity in feces 
accounted for about 16, 12, and 7% of the respective administered doses.  These results indicate 
absorption of at least 75–84% of the administered dose (assuming that none of fecal radioactivity was 
absorbed) occurred, and up to 82–96% of the dose (assuming that all radiolabel in the feces was first 
absorbed and later excreted in the bile) may have been absorbed.  Rapid absorption was indicated since 
peak levels of radioactivity in blood samples occurred at about 6, 10, and 24 hours after administration of 
5, 50, and 250 mg/kg doses, respectively (Hissink et al. 1996a).  Other studies have identified the 
presence of metabolites of 1,2-DCB in the urine following oral exposure (Azouz et al. 1955; Hissink et al. 
1996c). 
1,3-Dichlorobenzene. Quantitative data on the absorption of 1,3-DCB in humans following oral 
exposure are not available. However, evidence for absorption of 1,3-DCB in humans comes from studies 
that have detected 1,3-DCB in breast milk (Mes et al. 1986), blood (Bristol et al. 1982), and adipose 
tissue (Jan 1983). While these studies do not provide a quantitative measure of the rate or extent of 
1,3-DCB and cannot provide information concerning possible exposure route, they provide evidence of 
1,3-DCB absorption in humans. 
Evidence for absorption of 1,3-DCB following oral exposure of animals comes from the detection of 
metabolites in the urine and bile.  Kimura et al. (1992) identified at least 12 metabolites in the bile of rats 
given 1,3-DCB by gavage, indicating that absorption and transport to the liver had occurred.  In rabbits 
given oral 1,3-DCB, glucuronide, sulfur esters, mercapturic acid, and catechol metabolites were identified 
in the urine (Parke and Williams 1955), and suggested that 50–75% of the compound was absorbed, based 
on the presence of these metabolites. 
1,4-Dichlorobenzene. Quantitative data on the absorption of 1,4-DCB in humans following oral 
exposure are not available. However, evidence for absorption of 1,4-DCB in humans comes from
numerous studies that have detected 1,4-DCB in human tissues, including the blood (Bristol et al. 1982;
Hill et al. 1995), urine (Hill et al. 1995; Ghittori et al. 1985; Pagnotto and Walkley 1965), adipose tissue 
(Jan 1983), and breast milk (Jan 1983).  While these studies do not provide a quantitative measure of the 
rate or extent of 1,4-DCB and cannot provide information concerning possible exposure route, they 
provide evidence that 1,4-DCB is absorbed by humans. 
Evidence for absorption of 1,4-DCB in animals includes studies demonstrating toxicity following oral 

























3. HEALTH EFFECTS 
peripheral tissues following one or more oral exposures that indicate that 1,4-DCB is rapidly and nearly
completely absorbed.  Following a single or multiple oral exposures of radiolabeled 1,4-DCB in rats, 
label was detected in all evaluated tissues (liver, kidneys, lungs, muscle, fat, and blood plasma), 
indicating that considerable absorption had occurred (Hawkins et al. 1980).  Additional support for a 
near-complete absorption comes from data showing that levels in tissues were similar following 10 oral 
exposures or 10 subcutaneous injections of 250 mg/kg.  Levels of label in tissues did not appreciably
increase with increasing the number of exposures beyond one (Hawkins et al. 1980).  Similarly, Hissink 
et al. (1996b) reported that 70–85% of a single radiolabeled dose of 1,4-DCB was eliminated in the urine 
within 72 hours of exposure, indicating that 1,4-DCB was rapidly and extensively absorbed.  By contrast, 
Klos and Dekant (1994) reported that ~41% of a labeled oral dose of 1,4-DCB was recovered in the urine 
72 hours postexposure. 
3.4.1.3 Dermal Exposure  
1,2-Dichlorobenzene. Studies examining the absorption of 1,2-DCB in humans or animals following 
dermal exposure are not available. 
1,3-Dichlorobenzene. Studies examining the absorption of 1,3-DCB in humans or animals following 
dermal exposure are not available. 
1,4-Dichlorobenzene. No studies were located that specifically address the rate or amount of absorption 
of 1,4-DCB by humans or animals after dermal exposure to 1,4-DCB.  Solid 1,4-DCB produces a burning 
sensation when held closely to the skin for an excessive period of time, but it does not produce irritation 
or systemic effects (Hollingsworth et al. 1956).  In a study of the acute dermal toxicity of 1,4-DCB in 
adult Sherman rats, the dermal LD50 was estimated to be >6,000 mg/kg/day in both sexes (Gaines and 
Linder 1986). These data do not indicate that 1,4-DCB is absorbed to any extent after dermal exposure; 




























3. HEALTH EFFECTS 
3.4.2 Distribution  
1,2-Dichlorobenzene. Quantitative data on the distribution of 1,2-DCB in humans are not available.  
1,2-DCB has been detected in the blood (Bristol et al. 1982), urine (Kumagai and Matsunaga 1995, 1997; 
Zenser et al. 1997), and breast milk (Jan 1983; Mes et al. 1986) of humans. 
The most comprehensive animal study of the distribution of 1,2-DCB following a single oral 
administration (10 mg/kg) is the study of Hissink et al. (1996a), which followed the distribution of the 
compound in exposed rats for up to 75 hours in 19 tissues, as well as the residual carcass and 
gastrointestinal tract. The results are presented in Table 3-8.  1,2-DCB was detected in all evaluated 
tissues, but at greatest concentrations in the urinary bladder, kidney, fat, and liver. Retention half-times 
ranged from 8.7 hours (urinary bladder) to 19.3 hours (brain), with only small levels of activity detectable 
in any tissue at 75 hours postexposure.  In a separate study in the same manuscript, approximately 60% of 
an oral dose was found in the bile, indicating that considerable enterohepatic circulation occurs. 
Twenty-two hours after a single intraperitoneal injection in Wistar rats or BALB/c mice, 1,2-DCB was 
found covalently bound to DNA, RNA, and proteins of liver, kidney, lung, and stomach (Colacci et al. 
1990). 
1,3-Dichlorobenzene. Quantitative data on the distribution of 1,3-DCB in humans are not available.  
However, 1,3-DCB has been detected in breast milk (Mes et al. 1986), blood (Bristol et al. 1982), and 
adipose tissue (Jan 1983), suggesting a wide distribution throughout the body. 
Data are not available on the distribution of 1,3-DCB following inhalation exposure in animals.  Kimura 
et al. (1983) reported the presence of 1,3-DCB or metabolites in the liver and kidney following oral 
exposure. Following oral exposure, 1,3-DCB undergoes enterohepatic circulation, as demonstrated by the 
data of Kimura et al. (1992), who identified at least 12 biliary metabolites in rats exposed to 1,3-DCB by
gavage. 
1,4-Dichlorobenzene. Quantitative data on the distribution of 1,4-DCB in humans are not available.  
However, 1,4-DCB has been detected in the blood (Bristol et al. 1982; Hill et al. 1995), urine (Hill et al. 
1995; Ghittori et al. 1985; Pagnotto and Walkley 1965), adipose tissue (Jan 1983), and breast milk (Jan 



























3. HEALTH EFFECTS 
Table 3-8. Tissue Concentrations (nmol/g tissue) of Radioactivity in Male Wistar 
Rats at Four Time Points after Oral Administration of 10 mg/kg 14C-Labeled 
1,2-Dichlorobenzene in Corn Oil 
Tissue 6 hours 15 hours 30 hours 75 hours t1/2 (hours) 
Liver 32.7±3.4 9.4±1.9 3.1±1.1 1.4±0.4 17.0 
Kidney 132.5±107 15.7±4.8 3.8±0.7 1.5±0.4 13.1 
Spleen 8.0±5.3 2.0±0.9 0.59±0.14 0.2±0.07 15.2 
Pancreas 9.5±5.6 2.6±0.9 1.11±0.4 0.26±0.08 14.5 
Lung 6.6±0.6 3.4±0.9 1.02±0.12 0.29±0.11 16.0 
Heart 4.7±0.8 2.6±0.8 0.7±0.08 0.18±0.03 15.1 
Brain 1.1±0.1 0.7±0.08 0.3±0.08 0.08±0.04 19.3 
Skin 18.8±10.9 2.9±1.1 1.11±0.46 0.41±0.12 15.1 
Femur 5.2±2.6 1.3±0.4 0.55±0.18 0.14±0.0 15.1 
Skeletal muscle 4.7±3.1 1.3±0.6 0.45±0.2 0.09±0.04 13.5 
Perirenal fat 33.4±12.1 14.0±2.6 2.18±0.3 0.18±0.03 9.4 
Testis 3.6±0.8 1.9±0.4 1.13±0.9 0.2±0.07 17.2 
Urinary bladder 183±121 17.3±13.6 6.6±6.4 0.32±0.04 8.7 
Stomach 6.5±1.7 1.7±0.2 0.98±0.46 0.16±0.03 14.3 
Small intestine 29.1±9.3 10.7±0.6 3.5±2.4 0.43±0.28 11.6 
Caecum 16.4±4.8 16.7±1.1 2.8±2.2 0.27±0.07 11.1 
Colon 7.5±2.2 12.0±2.4 1.4±0.9 0.20±0.07 12.0 
Plasma 22.3±2.0 8.8±3.0 1.8±0.1 0.41±0.14 12.5 
Red blood cells 9.2±1.0 3.4±0.6 1.6±0.4 0.57±0.22 18.8 
Residual carcass 13±3% 4±2% 1±0.2% 0.3±0.07% No data 
Gastrointestinal tract contents 13±4% 15±4% 2±1% 0.1±0.04% No data 























3. HEALTH EFFECTS 
Studies in animals indicate that following absorption, 1,4-DCB is rapidly distributed throughout the body. 
Initially, 1,4-DCB accumulates in adipose tissue, but is not retained long-term.  While distributed rapidly
throughout the body, studies have demonstrated that very little of a dose of 1,4-DCB remains in tissues 
72 hours postexposure (Hissink et al. 1996b; Klos and Dekant 1994; Umemura et al. 1998). 
Following a single 24-hour inhalation exposure in rats, serum concentrations of 1,4-DCB rose sharply
during the first 6 hours, then slowly for the next 18 hours.  A sharp increase was seen in serum 1,4-DCB 
levels during the first 3 hours postexposure, which decreased rapidly thereafter.  The greatest tissue 
concentrations of 1,4-DCB were found in the fat; concentrations in fat increased rapidly for the first 
12 hours, then leveled off, remaining more or less steady until 6 hours postexposure, at which time they
declined sharply (Umemura et al. 1990).  Levels in the liver and kidney were approximately equivalent, 
although 10- to 20-fold lower than those in fatty tissues; in both liver and kidney, there was a steady
increase in 1,4-DCB concentration for the 24 hours of exposure.  In parallel with serum 1,4-DCB levels, 
there was a sharp, unexplained jump in the concentration of 1,4-DCB in both liver and kidney at 3 hours 
postexposure that resolved by 6 hours postexposure; concentrations fell rapidly thereafter.  Following 
single or multiple inhalation exposures to radiolabeled 1,4-DCB, the greatest concentrations of label were 
found in the fat, with levels 10- to 20-fold greater than any other examined tissue (Hawkins et al. 1980).  
In nonfat tissues, the kidney showed the greatest amounts of label, on a per gram of tissue basis, followed 
by the liver, blood plasma, lungs, and muscle (Hawkins et al. 1980). 
Following single or multiple oral exposures to radiolabeled 1,4-DCB, the greatest concentrations of label 
were found in the fat, with levels 6- to 15-fold greater than any other examined tissue (Hawkins et al. 
1980).  In nonfat tissues, the kidney showed the greatest amounts of label, on a per gram of tissue basis, 
followed by the liver, blood plasma, lungs, and muscle (Hawkins et al. 1980).  Hissink et al. (1997a) 
reported that after a single oral dose of radiolabeled 1,4-DCB, a steady increase in radiolabel found in the 
blood, and in the plasma compartment, was seen for the first 8–10 hours, after which concentrations 
decreased steadily for the next 40 hours. 
Within 12 hours after exposure of male rats to a single oral dose of 1,4-DCB, two sulfur-containing 
metabolites, 2,5-dichlorophenyl methyl sulfoxide, and 2,5-dichlorophenyl methyl sulfone (M2), were 
found in the blood, urine, fat, liver, and kidneys (Kimura et al. 1979).  These metabolites remained in the 
blood after most of the 1,4-DCB had fallen below the detection limits of the assay.  The maximum 
concentration of 2,5-dichlorophenyl methyl sulfoxide in blood was reached 15 hours after dosing and 























3. HEALTH EFFECTS 
48 hours after dosing, which suggested to the authors that 2,5-dichlorophenyl methyl sulfone might 
undergo enterophepatic circulation.  Changes in the levels of these metabolites in blood and tissues over a 
120-hour period led the authors to suggest that 2,5-dichlorophenyl methyl sulfone might arise from
2,5-dichlorophenyl methyl sulfoxide. 
3.4.3 Metabolism 
Fisher et al. (1995) compared the metabolism and toxicity of the DCB isomers in liver slices prepared 
from human donor tissues, and from male Sprague-Dawley and F344 rats.  At 2 and 6 hours, the 
metabolism of 1,4-DCB in human liver slices was similar to that seen in Sprague-Dawley and F344 rats.  
In human and F344 rat liver slices, the metabolism of 1,4-DCB was intermediate to that of 1,3- and 
1,2-DCB at 2 hours; at 6 hours, the metabolism of 1,4-DCB was lower than that of 1,3- or 1,2-DCB.  In 
Sprague-Dawley rats, the hepatic metabolism of 1,4-DCB was greater than that of 1,3- and 1,2-DCB at 
2 hours, while at 6 hours, the metabolism of 1,4-DCB was intermediate to that of 1,3- or 1,2-DCB.  In all 
three species, the metabolism of 1,4-DCB was not linear over time; the amount metabolized at 6 hours 
was only slightly higher than that metabolized after 2 hours.  At both 2 and 6 hours, the amount of 
glucuronide and sulfate conjugates produced from 1,4-DCB was similar across all of the tested species. 
1,2-Dichlorobenzene. The initial step in the metabolism of 1,2-DCB is metabolism by cytochrome
P-450 isozymes, mainly P4502E1, to an active epoxide.  This epoxide can either react directly with 
cellular components, be conjugated to glutathione or glucuronic acid, or be hydrolyzed to form
2,3-dichlorophenol or 3,4-dichlorophenol.  The dichlorophenol metabolites can be further metabolized by
conjugation with glutathione, glucuronic acid, or sulfate, or further oxidized to catechols.  An additional 
oxidation to form dichlorohydroquinone metabolites has also been proposed. 
Microsomal studies have implicated cytochrome P-450, and particularly P4502E1, as a major component 
of 1,2-DCB metabolism, resulting in the formation of dichlorophenols, dichlorocatechols, and 
dichlorohydroquinones.  After exposure to 1,2-DCB in rat liver microsomes, dichlorohydroquinone 
metabolites>dichlorophenol metabolites>dichlorocatechol metabolites (den Besten et al. 1992).  
Increasing dose results in a greater formation of dichlorohydroquinone metabolites, with less 
dichlorophenol and dichlorocatechol metabolites, and a greater covalent binding to proteins.  When 
1,2-DCB was added to hepatic microsomes from animals treated with P-450 inducers, the major 
metabolites were dichlorophenols and dichlorohydroquinones (den Besten et al. 1992).  1,2-DCB in this 
























3. HEALTH EFFECTS 
decreased the binding to protein by 68% (den Besten et al. 1992).  Microsomes from rats and mice 
pretreated with benzene to induce cytochrome P-450 resulted in greater levels of metabolism of 1,2-DCB, 
both to soluble or covalently-bound products, than in untreated animals (Nedelcheva et al. 1998).  
Addition of diethyldithiocarbamate, a P-450 inhibitor, decreased 1,2-DCB metabolism by ≥90% in both 
normal and pretreated hepatic microsomes from rats and mice, and in normal human liver microsomes. 
Addition of glutathione to the reaction mixture containing human or rat microsomes results in 
considerable (50–70%) formation of the glutathione-epoxide conjugate; addition of glutathione 
S-transferase enhances this proportion (Hissink et al. 1996c). 
The metabolism of 1,2-DCB by isolated microsomes containing human cytochrome P-450 isozymes is 
accomplished mainly by cytochrome P4502E1 (Hissink et al. 1996a, 1996b).  Incubation of 1,2-DCB 
with microsomes from cells expressing human cytochrome P-450 enzymes indicated that the 
3,4-dichlorophenol was formed in greater amounts than the 2,3-dichlorophenol, and that in both cases, 
cytochrome P4502E1 was the most active isozyme (Bogaards et al. 1995). 
Experiments using rat and human liver slices have detected the presence of sulfatase, glucuronide, and 
glutathione/cysteine conjugates following exposure to 1,2-DCB (Fisher et al. 1990, 1995).  Covalent 
binding of 1,2-DCB metabolites to proteins has also been shown in experiments using rat and liver slices 
(Fisher et al. 1990, 1995). 
Fisher et al. (1990) reported that in rat liver slices, the majority (>70%) of 1,2-DCB was found conjugated 
to glutathione, or as a cysteine conjugate, with only small amounts of the glucuronide or sulfate detected; 
only the conjugation status of the metabolite was reported.  In human liver slices, the pattern was 
different, with approximately equal distribution of glucuronide and glutathione conjugates, and only
minor amounts of the sulfate.  Human liver slices metabolized approximately 50% more 1,2-DCB than 
did slices from F344 rats, and approximately 4-fold as much as slices from Sprague-Dawley rats (Fisher 
et al. 1995). Human liver slices formed 7–30-fold greater levels of glucuronide conjugates, 1.5–2-fold
more sulphatase conjugates, and 1.5–2-fold more glutathione/cysteine conjugates of 1,2-DCB than rat 
liver slices (Fisher et al. 1995).  Human fetal liver slices metabolized 1,2-DCB only about 10% as much 























3. HEALTH EFFECTS 
Azouz et al. (1955) identified urinary metabolites of 1,2-DCB in rabbits exposed to a single in vivo dose; 
2,3- and 3,4-dichlorophenol were detected, as were considerable levels of glucuronide and sulfate 
conjugates; the presence of dihydroquinone metabolites was not reported.  Pretreatment of F344 rats with 
inducers of cytochrome P-450 (phenobarbital, β-naphthoflavone, or pyridine) resulted in an increased 
toxicity of intraperitoneal 1,2-DCB while treatment with piperonyl butoxide, a P-450 inhibitor, reduced 
the toxicity of 1,2-DCB (Valentovic et al. 1993b).  Evidence for binding of 1,2-DCB or its metabolites to 
glutathione includes the depletion of hepatic glutathione following a single intraperitoneal injection of 
3.6 mmol/kg of 1,2-DCB in F344 or SD rats (Younis et al. 2000); depletion was nearly complete at 
8 hours postinjection, and remained nearly complete at 12 hours postinjection.  Fischer 344 rats recovered 
by 24 hours postinjection, but SD rats remained depleted. 
Kumagai and Matsunaga (1995, 1997) reported that in occupationally-exposed humans, conjugated 
urinary metabolites of 1,2-DCB consisted of 3,4- and 4,5-dichlorocatechol and 2,3- and 
3,4-dichlorophenol; there was a linear correlation between exposure concentration and the levels of these 
four metabolites in the urine. 
1,3-Dichlorobenzene. Data on the metabolism of 1,3-DCB are less available than for the other two 
isomers of DCB.  However, the available studies indicate that 1,3-DCB is metabolized by cytochrome
P-450 to an epoxide and later to a dichlorophenol, followed by considerable secondary metabolism,
similar to 1,2- and 1,4-DCB.   
Fisher et al. (1990) reported that in rat liver slices, the majority (~70%) of 1,3-DCB was found conjugated 
to glutathione, or as a cysteine conjugate, with only small amounts of the glucuronide or sulfate detected.  
In human liver slices, the pattern was different, with approximately equal distribution (~40% each) of 
glucuronide and glutathione conjugates, and ~20% of the metabolites as the sulfate.   
Human liver slices metabolized greater amounts of 1,3-DCB than did slices from F344 or Sprague-
Dawley rats (Fisher et al. 1995).  Human liver slices formed 2–9-fold greater levels of glucuronide 
conjugates, 1–4-fold greater levels of sulphatase conjugates, and 1–4-fold greater levels of 
glutathione/cysteine conjugates of 1,3-DCB than rat liver slices (Fisher et al. 1995). 
Following in vivo exposure of rats to 1,3-DCB, the major sulfur-containing metabolites in the urine were 
2,4- and 3,5-dichlorophenyl methyl sulfoxides and 3,5- and 2,4-dichlorophenyl methyl sulfones (Kimura 
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dose of 1,3-DCB; these were all heavily conjugated dichlorophenyl metabolites, with evidence of both 
mono- and diol formation, but no conjugated quinone derivatives.   
Parke and Williams (1955) reported that following administration of 1,3-DCB to rabbits, the major 
urinary metabolites were 3,5-dichlorophenol and 2,4-dichlorophenol; the urine also contained 
2,4-dichlrophenylmercapturic acid. 
1,4-Dichlorobenzene. In general, the basic steps in metabolism of 1,4-DCB are similar to those of the 
other DCB isomers. The initial metabolic step is oxidation by cytochrome P-450, primarily P4502E1, to 
an epoxide and further to 2,5-dichlorophenol.  The dichlorophenol may be further oxidized to
dichlorocatechols, or possibly a dichlorohydroquinone, or may be conjugated by several phase II 
metabolism pathways.  Support for the cytochrome P-450-mediated oxidation of 1,4-dichlorophenol, and 
subsequent conjugation reactions, comes from studies in isolated microsomes, liver slices, and exposures 
in vivo. 
Analysis of the urine specimens of a 3-year-old boy who had been playing with 1,4-DCB yielded 
2,5-dichlorophenol as well as four other unidentified phenols.  These compounds were shown to be 
conjugated with glucuronic and sulfuric acids (Hallowell 1959). 
After treatment of F344 rats with 1,4-DCB, the major biotransformation reaction is P-450-dependent 
oxidation to 2,5-dichlorophenol, which is then primarily conjugated to sulphate or glucuronic acid and 
eliminated in the urine (Hissink et al. 1996b; Klos and Dekant 1994); mercapturic acids were also 
identified in the urine of exposed rats.  Following a single oral exposure of 1,4-DCB to male Wistar rats, 
the main sulfur-containing metabolites found in the urine were 2,5-dichlorophenyl methyl sulfoxide (M1) 
and 2,5-dichlorophenyl methyl sulfone (M2); levels of M2 in the blood were greater, and more persistant, 
following a single oral dose of 1,4-DCB (Kimura et al. 1979).   
Hissink et al. (1997a) exposed male Wistar rats to 0, 10, 50, or 250 mg/kg of 1,4-DCB.  Approximately
90% of the DCB was metabolized to the 2,5-dichlorophenol, which was detected in the urine as its sulfate 
(50–60%), glucuronide (20–30%), and the free form (5–10%); in the bile, the major metabolite was the 
glucuronide of 2,5-dichlorophenol.  The remaining metabolites consisted of N-acetyl-cysteine-S-dihydro­
hydroxy-1,4-DCB and N-acetyl-cysteine-S-1,4-DCB.  No evidence for the formation of hydroquinones 
















3. HEALTH EFFECTS 
Following oral administration to Chinchilla rabbits, 1,4-DCB was also oxidized, principally to 
2,5-dichlorophenol.  A very high percentage of this metabolite was eliminated in the urine as conjugates 
of glucuronic or sulfuric acids (Azouz et al. 1955).  Sulfur metabolites (methyl sulfides and methyl 
sulfones) of 2,5-dichlorophenol have been shown to induce cytochrome P450 activity (Kimura et al. 
1983). 
Fisher et al. (1990) reported that in rat liver slices, the majority (>60%) of 1,4-DCB was found conjugated 
to glutathione, or as a cysteine conjugate, with small amounts of the sulfate detected as well (~10% of 
total metabolites). In human liver slices, the pattern was different, with glutathione still being the 
predominant metabolite (~55%), but with an approximately equal distribution of glucuronide and sulfate 
conjugates (22–24%).  In a later study, Fisher et al. (1995) reported that the total metabolism of 1,4-DCB 
was similar in liver slices from F344 rats, Sprague-Dawley rats, and humans.  Human liver slices formed 
greater levels (~20–50%) of glucuronide conjugates of 1,4-DCB than rat liver slices; levels of formation 
of sulphatase and glutathione conjugates were similar in rats and humans (Fisher et al. 1995). 
After a single exposure to 1,4-DCB in rat liver microsomes, dichlorohydroquinone metabolites were 
formed at greater levels than dichlorophenol metabolites, which in turn were more prevalent than 
dichlorocatechol metabolites (den Besten et al. 1992).  Increasing the concentration does not change the 
percent formation of 2,5-dichlorohydroquinone, but decreases the formation of dichlorophenols in favor 
of increased covalent binding to proteins.  Hissink et al. (1997b) reported that incubation of 1,4-DCB with 
microsomes of rat or mouse liver, in the presence of glutathione but lacking ascorbic acid or glutathione 
transferase enzymes, resulted primarily in the formation of S-glutathionyl-dichlorocatechol metabolites, 
2,5-dichlorophenol, and 2,5-dichlorohydroquinone; rats appeared to be more efficient at forming a 
glutathione conjugate of the 2,3-epoxide than did mice, and formed less unconjugated 2,5-dichlorophenol 
and 2,5-dichlorhydroquinone.   
Incubation of 1,4-DCB with microsomes from cells expressing human cytochrome P-450 enzymes 
indicated that the 2,5-dichlorophenol was the only isomer formed, and that cytochrome P4502E1 was the 
most active isozyme in its formation (Bogaards et al. 1995; Hissink et al. 1996a, 1996b).  In human 
microsomes, metabolism of 1,4-DCB was lower than in rodents, with 2,5-dichlorophenol as the major 
metabolite, even in the presence of added GSH (Hissink et al. 1997b).  Using cell lines expressing 
individual human cytochrome P-450 isozymes, it was revealed that CYP2E1, and not 1A1, 1A2, 2B6, 

























3. HEALTH EFFECTS 
Addition of diethyldithiocarbamate, a P-450 inhibitor, decreased 1,2-DCB metabolism by ≥90% in both 
normal or pretreated hepatic microsomes from rats and mice, and in normal human liver microsomes 
(Nedelcheva et al. 1998), providing additional evidence for the involvement of cytochrome P-450 in
1,4-DCB metabolism. 
3.4.4 Elimination and Excretion 
1,2-Dichlorobenzene. Following absorption, 1,2-DCB is eliminated primarily in the urine of both 
humans and animals, as metabolites rather than as the parent compound.  Studies have detected the 
metabolites of 1,2-DCB in the urine of occupationally exposed humans (Kumagai and Matsunaga 1995, 
1997; Zenser et al. 1997). While a linear correlation between airborne concentration and urinary
metabolite levels has been demonstrated, a quantitative assessment of the percent urinary elimination has 
not been determined. 
Quantitative data on elimination of 1,2-DCB comes from the study of Hissink et al. (1996a), which 
reported that following a single oral exposure to radiolabeled 1,2-DCB, 75–84% of the activity was 
detected in the urine 175 hours postexposure, with 7–16% being detected in the feces.  Azouz et al. 
(1955) has also reported the elimination of 1,2-DCB and metabolites in the urine of exposed animals, 
although quantitative assessments of elimination were not presented. 
1,3-Dichlorobenzene. Data on the elimination of 1,3-DCB in humans are not available. 
Following a single dose of 1,3-DCB in rabbits, 50–75% of the compound was detected as urinary
metabolites, indicating that the major route of elimination for 1,3-DCB is via the urine (Parke and 
Williams 1955).  Kumura et al. (1984) also reported the presence of urinary metabolites of 1,3-DCB, 
although quantitative data were not presented.  Additional data on the elimination of 1,3-DCB are not 
available. 
1,4-Dichlorobenzene. Quantitative data on the elimination of 1,4-DCB in humans are not available.  
However, metabolites of 1,4-DCB have been detected in the urine of exposed humans (Ghittori et al. 































3. HEALTH EFFECTS 
Animal studies of 1,4-DCB elimination have demonstrated that the compound is eliminated mainly in the 
urine, regardless of exposure route; elimination occurs in the form of metabolites, rather than as the parent 
compound. Male Wistar rats given single oral doses of 10, 50, or 250 mg/kg of 14C-1,4-DCB excreted the 
majority of 14C derived from 1,4-DCB in the urine as either the sulfate conjugate (60%) or the 
glucuronide (30%). Bile contained 5 and 30% of the total radioactivity after the low and high doses, 
respectively.  Only minor amounts of mercapturic acid were found (Hissink et al. 1996b).  In a later study,
Hissink et al. (1997a) reported that following a single oral dose of 1,4-DCB in male Wistar rats, 75–85%
of the dose was recovered in the urine, with only 2–5% being detected in the feces; clearance half-times 
did not vary with increasing dose level.  Biliary excretion was dose-related, ranging from <5% at 
10 mg/kg to 30% at 250 mg/kg (Hissink et al. 1997a). In male and female F344 rats administered a single 
dose of 900 mg/kg/day 14C-1,4-DCB by gavage in corn oil, the excretion of radioactivity in the urine 
reached a peak in both males and females between 24 and 36 hours after dosing.  Seventy-two hours after 
dosing, 41.3 and 3.6% of the dose was found in the urine and feces, respectively, of males; corresponding 
values in the urine and feces of females were 41.3 and 3.6% (Klos and Dekant 1994).  Following oral or
inhalation exposure in rats, levels of 1,4-DCB and its metabolites decreased only slightly over the first 
8 hours postexposure in the liver, kidneys, fat, and plasma, but then fell rapidly and were nearly 
undetectable 120 hours after the final exposure (Hawkins et al. 1980).  Elimination was primarily urinary,
with 97% of the total recovered label found in the urine (Hawkins et al. 1980).  Elimination in the expired 
air was negligible, being 1% of the total or less (Hawkins et al. 1980). 
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
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Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps:  (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-6 shows a conceptualized representation of a PBPK model. 
If PBPK models for dichlorobenzenes exist, the overall results and individual models are discussed in this 




















3. HEALTH EFFECTS 
Figure 3-6. Conceptual Representation of a Physiologically Based 

Pharmacokinetic (PBPK) Model for a  













































 Chemicals in air 
contacting skin 
Source: adapted from Krishnan et al. 1994 
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by























3. HEALTH EFFECTS 
PBPK models are available for 1,2-DCB in rats and humans (Hissink et al. 1997b).  No PBPK models 
have been developed for 1,3- or 1,4-DCB. 
The rat and human PBPK models for 1,2-DCB were developed for oral exposure and do not include 
respiratory or dermal portals of entry (Hissink et al. 1997b).  Both models have four compartments 
connected by blood flows:  rapidly perfused tissues including the lung, kidneys, and spleen; slowly
perfused tissues comprising muscle and skin; fat; and the liver, the only compartment in which 
metabolism is assumed to take place.  The models assume that gastrointestinal tract uptake proceeds as a 
dose-dependent first-order kinetic process in which 1,2-DCB is deposited directly in the liver. For each 
of the nonmetabolizing compartments, differential equations describe the influx and efflux of 1,2-DCB.  
Equations are also used for the liver compartment to accounted for 1,2-DCB metabolism and reduced 
glutathione (GSH) synthesis, turnover, and consumption.  Physiologic parameters, partition coefficients, 
biochemical parameters, and absorption rate constants used in the models are shown in Table 3-9.  
Absorption rate constants were estimated by fitting of the parameters to data for rats exposed to 5, 50, or 
250 mg/kg 1,2-DCB. 
Metabolism in the model is described as the initial, P-450-mediated, saturable formation of an epoxide, 
followed by epoxide transformation via three competing pathways that are assumed to independently
follow pseudo first-order kinetics (i.e., are non-saturable):  (1) conversion into dichlorophenol; 
(2) covalent binding to cellular macromolecules; and (3) conjugation with GSH.  Michaelis-Menten 
constants, Vmax and Km, for the saturable cytochrome-P-450 oxidation of 1,2-DCB were initially
estimated (in units of nmol/min-mg protein) from in vitro experiments with rat and human liver 
microsomes (Table 3-9).  Scaling for use in the models assumed rat and human values of 45 and 77 mg
microsomal protein/g liver, respectively.  However, in order to obtain adequate fits to rat data for blood 
concentrations of parent material or total amount of metabolites, a “best-fit” Vmax value of 17 µmol/hour 
was used, along with the in vitro Km of 4.8 µM (Table 3-9).  This “best-fit” value was about 4-fold higher 
than the rat in vitro Vmax scaled to units of µmol/hour (4.3 µmol/hour; see Table 3-9).  Based on the rat 
data analysis, a factor of four was used to derive a “best-fit” Vmax value of 10,840 µmol/hour from the 
human in vitro Vmax (2,742 µmol/hour; see Table 3-9).  The ratio of rate constants for the three epoxide­
transforming pathways in rats (5:30:65) was estimated based on the relative amounts of in vitro covalent 
binding (5%), in vitro and in vivo dichlorophenol formation (25 and 30%), and in vitro and in vivo GSH 
conjugation (70 and 60%).  For the rat model, the first-order rate constant for covalent binding was 

























3. HEALTH EFFECTS 
Table 3-9. Parameters in PBPK Models for 1,2-Dichlorobenzene 
Parameter Rat Human 
Physiologic parameters (as per Gargas et al. 1986) 
Body weight (kg) 0.258 70 
Percentages of body weight 
Liver 4 3.14 
Fat 7 23.1 
 Rapidly perfused 5 2.66 
 Slowly perfused 75 62.1 
Flows (L/hour) [QC or QP= 15 L/hour (body weight)0.74] 
Cardiac output (QC) 5.50 348.0 
Alveolar ventilation (QP) 5.50 348.0 
Percentages of cardiac output 
Liver 25 25 
Fat 9 9 
 Rapidly perfused 51 51 
 Slowly perfused 15 15 
Partition coefficients 
[calculated by methods of Droz et al. (1989) based on water:air, oil:air, and blood:air partition 
coefficients] 
Blood:air 423 423 
Liver:blood 2.7 2.7 
Fat:blood 66.4 66.4 
Rapidly perfused:blood 2.7 2.7 
Slowly perfused:  blood 1.3 1.3 
Biochemical parameters 
1,2-Dichlorobenzene oxidation 
Vmax (nmol/min-mg) (in vitro derived) 0.142 (4.3 µmol/hour) 0.27 (2,742 µmol/hour) 
Km (µM) (in vitro derived) 4.8 7.5 
Vmax (µmol/hour) (“best-fit” values) 17 10,840 
GSH conjugation of epoxide (hour-1) 650 650 
Formation of dichlorophenol (hour-1) 300 360 
Formation of reactive metabolites (hour-1) 50 5 
GSH turnover rate (hour-1) 0.14 0.14 
Absorption rate constants
(estimated by fitting parameters to data for rats at indicated dose levels) 
Ka (hour-1) 
5 mg/kg 0.5 No data 
50 mg/kg 0.18 No data 
 250 mg/kg 0.06 0.06 
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were 300 and 650 hour-1, respectively (Table 3-9).  In vitro data with human microsomes similarly formed 
the basis of the rate constants for these pathways:  5 hour-1 for covalent binding, 360 hour-1 for 
dichlorophenol formation, and 650 hour-1 for GSH conjugation (Table 3-9).  A GSH turnover rate of 
0.14 hour-1, determined in another study with rats (Potter and Tran 1993), was used in both the rat and 
human models (see Table 3-9). 
The rat model was used to predict hepatic concentrations of covalently bound metabolites following an 
oral dose of 250 mg/kg 1,2-DCB that was expected to be toxic to the liver (Hissink et al. 1997b).  The 
hepatic concentration in rats, 24 hours after dosing, was 1,459 µM.  Versions of the human model using 
different Vmax values predicted that this administered dose level produced much lower hepatic 
concentrations of covalently bound metabolites in humans.  Increasing the human in vitro-derived Vmax 
values by a factor of 10 did not increase the predicted human hepatic concentrations, 24 hours after 
dosing, to a value above about 240 µM.  Therefore, the models predicted that equivalent administered 
doses in rats and humans would produce rat hepatic concentrations of covalently bound metabolites that 
are at least 6-fold higher in rats than humans. 
The PBPK models were also used to predict hepatic concentrations of GSH (expressed as a percentage of 
an assumed baseline concentration of 6.5 mM) following an oral dose of 250 mg/kg 1,2-DCB (Hissink et 
al. 1997b).  The rat model predicted that maximum depletion of GSH (about 70% depletion) occurred at 
15 hours after dosing with 250 mg/kg.  In contrast, the human model (using a Vmax value of 
10,840 µmol/hour; see Table 3-9) predicted that maximum depletion of GSH (essentially 100% depletion) 
occurred at 10 hours after dosing.  The models therefore predicted that humans may be more susceptible 
to 1,2-DCB depletion of hepatic GSH levels than are rats.  Hissink et al. (1997b) noted that (1) if 
depletion of GSH is the only factor involved in acute 1,2-DCB hepatotoxicity, the models predict that 
humans may be more susceptible than rats at the same administered dose levels, and (2) if covalent 
binding of reactive metabolites is the critical factor, humans may be less susceptible to 1,2-DCB acute 
hepatotoxicity than rats. However, at present, the majority of parameters of the human model are based 
on direct scaling from the rodent data, rather than having been calibrated and validated using human data.  




















3. HEALTH EFFECTS 
3.5 MECHANISMS OF ACTION  
3.5.1 Pharmacokinetic Mechanisms 
Absorption.    Quantitative inhalation, oral, or dermal absorption studies in humans are not available for 
1,4-DCB. In the few studies available in laboratory animals, absorption was demonstrated to occur 
during a 3-hour inhalation exposure to 1,000 ppm of 1,4-DCB (Hawkins et al. 1980) as evidenced by
accumulation of 14C in liver, kidney, plasma, and adipose tissue.  No studies were located that described 
the absorption characteristics of 1,4-DCB after oral exposure; however, given the structural and 
physicochemical similarity to benzene, oral absorption is thought to be at or near 100% (EPA 1987a; 
Hawkins et al. 1980).  A study assessing dermal absorption reported a dermal LD50 of >6,000 mg/kg/day
in rats (Gaines and Linder 1986).  Given the physicochemical properties, similarity to benzene, and lipid-
soluble properties of 1,4-DCB, absorption by the inhalation, oral, and dermal routes of exposure is most 
likely by simple diffusion across cellular lipid membranes.  No information is available that describes 
site-specific absorption within the respiratory tract (nasal epithelial absorption as opposed to alveolar 
absorption) or in the gastrointestinal tract.  
Distribution.    Quantitative inhalation, oral, or dermal distribution studies in humans are not available 
for 1,4-DCB.  1,4-DCB has been detected in human blood, adipose tissue, and breast milk after an 
assumed inhalation exposure in Tokyo residents (Morita and Ohi 1975; Morita et al. 1975), as well as 
people in some parts of the United States (EPA 1983b, 1986f).  The available data indicate that after 
inhalation, oral, and subcutaneous exposure, 1,4-DCB preferentially distributes to the fat tissue and 
organ-specific sites within the body (Hawkins et al. 1980), following the order:  adipose > kidney > liver 
> blood (Charbonneau et al. 1989b; Hawkins et al. 1980).  Although 1,4-DCB is originally distributed 
primarily to adipose tissue, significant amounts of 1,4-DCB are not retained in that tissue after exposure 
ceases. Regardless of exposure route, most of the 1,4-DCB falls to near- or below-detectable assay limits 
in all tissues of the body except adipose tissues 48–72 hours after exposure, depending on the dose 
(Charbonneau et al. 1989b; Kimura et al. 1979).  1,4-DCB was detected in adipose tissue at 120 hours 
after exposure (Charbonneau et al. 1989b).  In the kidney, 50% of the 1,4-DCB appears to localize within 
the cytosol in male F344 rats (Charbonneau et al. 1987).  1,4-DCB also does not appear to bind to tissue 
proteins (Klos and Dekant 1994). 
Metabolism/Excretion. Quantitative inhalation, oral, or dermal metabolism and excretion studies in 
humans are not available for 1,4-DCB.  One case study involving a 3-year-old boy who may have 
























3. HEALTH EFFECTS 
laboratory animal studies have indicated that 1,4-DCB is metabolized by phase I metabolism to 2,5-di­
chlorophenol (probably by cytochrome P-450), which then undergoes phase II metabolism/conjugation to 
the glucuronide or sulfate (Azouz et al. 1955; Hawkins et al. 1980; Hissink et al. 1996a; Kimura et al. 
1979; Klos and Dekant 1994).  Minor amounts of 2,4-dichlorohydroquinone may also be present (Klos 
and Dekant 1994). Metabolism occurs in the liver.  None of the detected metabolites have been reported 
to be associated with the toxic effects seen with 1,4-DCB.  Metabolites are excreted mostly in the urine 
(Azouz et al. 1955; Hissink et al. 1996a; Kimura et al. 1979); however, some metabolites (mainly the 
glucuronide conjugate) may also be excreted in the bile and feces (Hissink et al. 1996a).  The role of 
enterohepatic circulation in the metabolism and excretion of metabolites is not completely known; 
however, it has been suggested that enterohepatic circulation may occur with some sulfated metabolites 
(Kimura et al. 1979).  This phase I and II metabolic pathway mechanism (see below) seems plausible, in 
that other chemicals with similar (halogenated- and lipid-soluble) physicochemical properties undergo 
very similar metabolic routines to become more water-soluble and excreted.  The data suggest that 
metabolism and excretion are similar in several species.  It is likely that human metabolic pathways are 
similar, if not identical, to those established in laboratory animals. 
3.5.2 Mechanisms of Toxicity
The precise mechanism of 1,4-DCB oxidation to 2,5-dichlorophenol has not thoroughly been 
investigated. 1,4-DCB is known to be metabolized by cytochrome P-450 (Azouz et al. 1955; Hawkins et 
al. 1980) in order to be presented to phase II metabolic pathways to increase its water solubility for 
excretion. A proposed metabolic pathway involving cytochrome P-450 with intermediate formations of 
metabolites has been outlined for 1,4-DCB (Den Besten et al. 1992).  No information was available 
regarding specific or altered mechanisms of action for 1,4-DCB in children.  The hepatotoxicity and 
nephrotoxicity observed in laboratory animals are likely due to the formation of toxic intermediates 
formed while converting 1,4-DCB to 2,5-dichlorophenol by cytochrome P-450, or by depletion of GSH at 
higher doses of 1,4-DCB, or both.  Some indirect evidence of this was provided by Mizutani et al. (1994). 
In mice pretreated with DL-buthionine sulfoximine (BSO), a glutathione synthesis inhibitor, a single dose 
of 300 mg/kg 1,4-DCB caused significant elevations of ALT and liver calcium, both peaking between 
24 and 32 hours after dosing and declining thereafter, indicative of hepatic damage.  Necrotic changes 
were observed at those times as well as hemorrhage, fatty changes, and appearance of altered eosinophilic 
cells. A single 1,200 mg/kg dose of 1,4-DCB did not significantly alter ALT or liver calcium, but doses 
of 100 mg/kg or higher in mice pretreated with BSO produced dose-related alterations in these 
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of 1,4-DCB and BSO. In addition, pretreatment with microsomal cytochrome P-450-dependent 
monooxygenase inhibitors also protected the liver from the combined toxicity of 1,4-DCB and BSO.  
Pretreatment with the P-450 inducer beta-naphthoflavone did not significantly alter the effect of 1,4-DCB 
plus BSO. Pretreatment with phenobarbital partially blocked the effect of 1,4-DCB plus BSO on ALT 
and completely prevented the increase in liver calcium. PCBs prevented the effect on both ALT and liver 
calcium.  Treatment with BSO alone or in combination with 1,4-DCB (300 mg/kg) greatly decreased 
hepatic GSH concentration, the effect being more pronounced with the combination.  1,4-DCB alone had 
no such effect. Depletion of GSH also has been reported to increase the toxicity of 1,4-DCB in rats (Stine 
et al. 1991). The data provide a strong indication that the mechanism behind the hepatic (and probably 
renal) toxicity of 1,4-DCB lies in the intermediate steps of metabolite formation and conjugation by 
cytochrome P-450.  Formation of 2,5-dichlorophenol from 1,4-DCB via cytochrome P-450 metabolism
likely produces some intracellular, intermediate metabolite(s) that are also hepatotoxic when sufficient 
amounts accumulate intracellularly.  These yet unidentified metabolites are detoxified by GSH, but when 
GSH depletion occurs, which is likely to occur at higher oral doses, toxicity is enhanced.  Hepatocytes 
respond to these insults by releasing intracellular enzymes (Carlson and Tardiff 1976; Umemura et al. 
1996), degeneration, vacuolation (Eldridge et al. 1992; NTP 1987; Rimington and Ziegler 1963), 
necrosis, and increases in gross liver weight (Hollingsworth et al. 1956; Riley et al. 1980a).  However, 
these changes are not specific to 1,4-DCB and likely occur in a dose-responsive manner.  At lower doses, 
cellular proliferation in the liver in the absence of these toxic-type responses has been observed (Eldridge 
et al. 1992; Umemura et al. 1996); however, the mechanism behind this response needs to be more clearly
defined. Exposure to 1,4-DCB likely follows similar metabolic pathways in the kidneys and would be 
responsible for the toxicity (increased organ weight, tubular degeneration, nephropathy) observed in that 
organ, and may also be linked to the known formation of cancer-linked α2µ-globulin in male rats.  
The metabolism of 1,4-DCB could involve the formation of an arene oxide intermediate, as has been 
proposed to occur in the oxidative metabolism of many halogenated aromatic hydrocarbons (Jerina and 
Daly 1974). 1,4-DCB has not been shown to be mutagenic in microbial or mammalian systems, a result 
that may be viewed as further suggestive evidence that an arene oxide intermediate is not involved in its 
metabolism. 
1,4-DCB has also been reported to produce hematological effects associated with exposure in humans and 
laboratory animals.  These findings have been limited to red and white blood cell anomalies (NTP 1987) 
in rats and mice, and may take place within the bone marrow at the time of red and white cell formation, 
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anemia and methemoglobinemia reportedly occurred in a 3-year-old boy who had played with, and 
possibly ingested, 1,4-DCB crystals (Hallowell 1959).  A 21-year-old pregnant woman who had eaten 1– 
2 blocks of 1,4-DCB toilet air freshener per week throughout pregnancy developed severe microcytic, 
hypochromic anemia with excessive polychromasia and marginal nuclear hypersegmentation of the 
neutrophils. Heinz bodies were seen in a small number of the red cells.  After she discontinued this 
practice (at about 38 weeks of gestation), her hemoglobin levels began to rise steadily.  The mechanism
behind these findings in the human exposures is unknown, but it appears that 1,4-DCB may have some 
local effect on the hemoglobin content of the red blood cell (hemolysis, methemoglobinemia, Heinz 
bodies). These are rare events in humans and only occur at very high exposure doses in laboratory
animals.  The clinical finding of Heinz-body formation in red blood cells and methemoglobinemia 
suggest that some form of oxidative stress is occurring to produce these findings, although the 
mechanisms behind these end points are not known.  While there may not be any direct evidence, it is not 
unreasonable to suspect that oxidant metabolites of 1,4-DCB may inhibit glucose-6-phosphate
dehydrogenase (G6PD), as do metabolites of aniline, leading to Heinz body production, 
methemoglobinemia, and hemolysis (Trieff et al. 1993).  The effect on the red and white blood cell 
production processes in the bone marrow (anemia, polychromasia) is quite likely an effect related to 
blood loss associated with bleeding from esophageal varices which form secondary to liver cirrhosis.   
3.5.3 Animal-to-Human Extrapolations 
No studies were identified that specifically addressed the use of animal data applied to human exposure 
issues specifically related to 1,4-DCB.  No physiologically based pharmacokinetic models are available to 
estimate risk associated with human exposure to 1,4-DCB.  It is difficult to compare the toxicity of 
1,4-DCB in laboratory animals to the toxicity observed in humans, since little reliable human data are 
available for examination (see Section 3.2).  From the little data available, it appears that humans do have 
the potential to exhibit the same toxicological features of 1,4-DCB toxicosis as demonstrated or observed 
in the laboratory animal models studied.  Although the mechanisms have not been outlined, human 
hematological responses (Campbell and Davidson 1970) and liver responses (Hallowell 1959) to 
1,4-DCB have been similar to the responses of laboratory animals tested (Hollingsworth et al. 1956; NTP 
1987).  (However, the human hematological responses were vague and quite possibly unrelated.)  
Although the data are not sufficient to make direct comparisons, the possibility strongly exists that human 
responses may be similar to those of laboratory animals, and animal data should be taken into 
consideration until better human data become available.  With the exception of the α2µ-globulin
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laboratory animal models are present in humans.  This means that humans are likely to detoxify 1,4-DCB 
in a similar or identical manner to that of the laboratory animals, and suggests that humans are susceptible
to the liver and possibly the renal lesions outlined for the laboratory animals studied (see Section 3.5.2).  
Due to the lack of acceptable dosing and exposure data in humans, it is not possible at present to 
definitively determine the magnitude of these human toxicological responses, the dose-response 
relationship, or whether humans are more or less susceptible to these effects on a mg/kg/day (oral and 
dermal) or ppm (inhalation) basis.  It is also unknown whether the sex predilection found in male rats to 
1,4-DCB renal or endocrine toxicity occurs in the human male. 
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992) and again by Colborn et al. (1993), was also used in 
1996 when Congress mandated the EPA to develop a screening program for “...certain substances [which]
may have an effect produced by a naturally occurring estrogen, or other such endocrine effect[s]...”.  To 
meet this mandate, EPA convened a panel called the Endocrine Disruptors Screening and Testing 
Advisory Committee (EDSTAC), and in 1998, the EDSTAC completed its deliberations and made 
recommendations to EPA concerning endocrine disruptors. In 1999, the National Academy of Sciences 
released a report that referred to these same types of chemicals as hormonally active agents. The 
terminology endocrine modulators has also been used to convey the fact that effects caused by such 
chemicals may not necessarily be adverse.  Many scientists agree that chemicals with the ability to disrupt 
or modulate the endocrine system are a potential threat to the health of humans, aquatic animals, and 
wildlife. However, others think that endocrine-active chemicals do not pose a significant health risk, 
particularly in view of the fact that hormone mimics exist in the natural environment.  Examples of 
natural hormone mimics are the isoflavinoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et 
al. 1992).  These chemicals are derived from plants and are similar in structure and action to endogenous 
estrogen. Although the public health significance and descriptive terminology of substances capable of 
affecting the endocrine system remains controversial, scientists agree that these chemicals may affect the 
synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body responsible 
for maintaining homeostasis, reproduction, development, and/or behavior (EPA 1997c).  Stated 
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a result, these chemicals may play a role in altering, for example, metabolic, sexual, immune, and 
neurobehavioral function. Such chemicals are also thought to be involved in inducing breast, testicular, 
and prostate cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992). 
Concern has been raised that many industrial chemicals, including DCBs, are endocrine-active 
compounds capable of having widespread effects on humans and wildlife (Colborn et al. 1993; Crisp et al. 
1998; Daston et al. 1997; Safe and Zacharewski 1997; Versonnen et al. 2003).  Particular attention has 
been paid to the possibility of these compounds mimicking or antagonizing the action of estrogen.  
Estrogen influences the growth, differentiation, and functioning of many target tissues, including female
and male reproductive systems, such as mammary gland, uterus, vagina, ovary, testes, epididymis, and 
prostate. Most estrogenic chemicals have a ring structure included in the molecule, and para-substituted 
phenols generally bind better to the estrogen receptor and are more likely to exert xenoestrogenic effects 
than ortho- or meta-substituted compounds.  In addition, there is evidence that some of these chemicals 
alter the thyroid hormone system, which is an important system for normal structural and functional 
development of sexual organs and the brain. 
Insufficient information is available to adequately assess the endocrine disruptor potential of DCBs.  
Testing of 1,2-, 1,3-, and 1,4-DCB in the in vitro yeast estrogen screen (YES) assay showed that the 1,3- 
and 1,4- isomers were active in a concentration-responsive manner, although estrogenic potency was 
extremely weak (Versonnen et al. 2003).  The relative potency relative to 17β-estradiol was 1.04x10-8 for
1,3-DCB and 2.2x10-7 for 1,4-DCB.  The negative results for 1,2-DCB in this system are consistent with a 
lack of estrogenic activity of 1,2-DCB in in vitro yeast two-hybrid assays (Eguchi et al. 2003; Nishihara 
et al. 2000). The in vivo estrogenic activity of 1,2-, 1,3-, and 1,4-DCB was tested by measuring plasma 
vitellogenin (VTG) production in zebrafish (Danio rerio) that were exposed to each isomer for 14 days
(Versonnen et al. 2003).  VTG is a yolk protein precursor in teleosts and other oviparous vertebrates that 
is synthesized in response to estradiol stimulation.  Elevated VTG levels were found in fish exposed to 
≥10 mg/L of 1,4-DCB, but estrogenic potency was weak in comparison to ethynylestradiol, which 
increased VTG at ≥5 ng/L. 
Histopathological changes occurred in the thyroid and pituitary glands of rats orally exposed to 1,3-DCB 
for 90 days (McCauley et al. 1995).  Effects in the thyroid occurred at ≥9 mg/kg/day, the lowest tested 
dose, and included depletion of colloid density, characterized by decreased follicular size with scant 
colloid and follicles lined by cells that were cuboidal to columnar.  Effects in the pituitary occurred at 
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cholesterol and serum calcium also occurred and were also believed to be related to effects on endocrine 
end points, possibly reflecting a disruption of hormonal feedback mechanisms, or target organ effects on 
the pituitary, hypothalamus, and/or other endocrine organs.  Histopathological changes in endocrine 
tissues were not observed in intermediate- and chronic-duration studies of 1,2-DCB (NTP 1985; 
Robinson et al. 1991) or 1,4-DCB (Aiso et al. 2005b; Japan Bioassay Research Center 1995; Naylor and 
Stout 1996; NTP 1987) in rats, mice, or dogs.  Measurements of thyroid and other endocrine hormones 
have not been conducted in any study of DCBs. 
Effects of 1,2- and 1,3-DCB on reproductive function have not been investigated.  There were no effects 
on fertility or mating in 2-generation studies of 1,4-DCB in rats exposed orally to ≤270 mg/kg/day
(Bornatowicz et al. 1994) or by inhalation to ≤211 ppm (Tyl and Neeper-Bradley 1989).  No adverse 
histopathological changes in reproductive tissues were observed in intermediate- and chronic-duration 
oral studies of 1,2-DCB (NTP 1985; Robinson et al. 1991), 1,3-DCB (McCauley et al. 1995), and 
1,4-DCB (Naylor and Stout 1996; NTP 1987). 
3.7 CHILDREN’S SUSCEPTIBILITY  
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
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and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
There is little credible scientific information available on the susceptibility and toxicological effects of 
1,4-DCB in children. The risk for exposure is apparently high.  A study by Hill et al. (1995) measured 
blood levels of 1,4-DCB and urine levels of its metabolites in 1,000 adults, finding that exposure to 
1,4-DCB was widespread, with 98% of the adults having measurable concentrations of 1,4-DCB 
metabolites in their urine.  There is no evidence to indicate that children are likely to be exposed to lower 
amounts of 1,4-DCB from everyday living, suggesting that children are perhaps equally at risk for 























3. HEALTH EFFECTS 
Some information on possible health effects of DCBs in children is available from two case reports of 
1,4-DCB exposure. Campbell and Davidson (1970) reported a case of a 21-year-old woman eating 1– 
2 toilet air-freshener blocks per week while pregnant.  The mother developed hematological aberrations 
(hypochromic, microcytic anemia, polychromasia); however, she delivered an apparently normal female 
infant with no apparent hematological problems.  Another report describes a 3-year-old boy who had been 
playing with crystals containing 1,4-DCB for 4–5 days before being admitted to the hospital.  On 
admission, the boy was jaundiced, his mucous membranes were pale, and he was diagnosed with anemia 
and methemoglobinemia.  After a blood transfusion, the child gradually improved, but it was unclear 
whether the boy actually ingested any of the 1,4-DCB (Hallowell 1959).  These case reports are consistent 
with an expectation that health effects in children and adults are similar.  Although there are no known 
differences in the toxicity of DCBs between adults and children, there is no evidence to substantiate the 
presumption.
Information on the reproductive toxicity of DCBs is essentially limited to a 2-generation oral study of 
1,4-DCB in rats (Bornatowicz et al. 1994).  There were no effects on mating or fertility in either 
generation, as assessed by a minimal number of end points (duration between mating and successful 
copulation and fertility index).  The is a report of morphologically abnormal sperm in rats exposed to a 
high dose of 1,4-DCB by intraperitoneal injection (Murthy et al. 1987), but there are no studies that 
investigated transgenerational effects of exposure to DCBs. 
Information on the developmental toxicity of 1,2-, 1,3-, and 1,4-DCB is available from oral and inhalation
studies in rats and rabbits (Bio/dynamics 1989; Bornatowicz et al. 1994; Giavini et al. 1986; Hayes et al. 
1985; Hodge et al. 1977; Ruddick et al. 1983; Tyl and Neeper-Bradley 1989).  These studies provide no 
indications that DCBs are teratogenic, although fetotoxicity occurred at exposure levels that were also 
maternally toxic.  A multigeneration study in rats that were orally exposed to 1,4-DCB found toxic effects 
in the pups during the nursing period, including increased neonatal mortality, dermal effects and other 
clinical manifestations, and reduced neurobehavioral performance (Bornatowicz et al. 1994). The 
postnatal developmental toxicity occurred at dose levels that were not maternally toxic and below those 
causing systemic toxicity in other animal studies.  The results of this study indicate that postnatal 
developmental toxicity is the most sensitive end point in animals, and suggest a basis for potential 






















3. HEALTH EFFECTS 
No studies are available that describe potential differences in the toxicokinetics or the mechanism of 
action of 1,4-DCB in children. No data are available that specifically describe whether 1,4-DCB or its 
major metabolites will cross the placenta; however, all three DCB isomers have been detected in placental 
tissues (Erickson et al. 1980; Pellizzari et al. 1982; Reichrtova et al. 1999).  Because 1,4-DCB is not 
known to be genotoxic, it poses no threat to the DNA in parental germ cells.  No PBPK models are 
available for children, fetuses/pregnant women, or infants/lactating women exposed to 1,4-DCB. 
As discussed in Section 3.4, Toxicokinetics, the specific toxicokinetic behavior of 1,4-DCB in children 
(and immature laboratory animals) has not been reported.  Based on its physicochemical properties, it is 
anticipated that the absorption, distribution, metabolism, and excretion of 1,4-DCB and its metabolites 
would be quite similar to that of the adult human (or animal), even when taking into account differences 
in body weight, total body water, body fat, volumes of distribution (VD), and perhaps lower activities of 
some metabolizing enzymes (cytochrome P-450) during the natal and neonatal periods.  1,4-DCB is a 
lipid-soluble toxicant and is likely to pass across the placental membranes.  It will likely accumulate in 
many of the same tissues in the fetus that it would normally be expected to accumulate in the adult, with 
the possible exception of fat storage in the fetus (Li et al. 1995).  Some amount of 1,4-DCB accumulates 
in human breast milk (EPA 1983b), given its high lipid (milk fat) content, thereby providing a potential 
route of exposure to a nursing child, although there is no concrete data to support this relay exposure 
hypothesis.  Some studies have noted that 1,4-DCB will preferentially distribute to adipose tissues in 
relatively high amounts, compared to accumulations in the liver and kidneys (Charbonneau et al. 1989b; 
Hawkins et al. 1980; Klos and Dekant 1994).  Loss of maternal body fat may potentially mobilize 
1,4-DCB from fat storage deposits in exposed mothers.  This mobilization could result in increased blood 
levels and/or excretion of 1,4-DCB and its metabolites from the mother, as well as redistribution to other 
fat deposition sites, such as the high fat content found in breast milk. 
No studies have described the interactions of 1,4-DCB with other chemicals in children, or the means by
which to reduce peak absorption of 1,4-DCB after exposure. 
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 



























3. HEALTH EFFECTS 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to dichlorobenzenes are discussed in Section 3.8.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by dichlorobenzenes are discussed in Section 3.8.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible. 
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Dichlorobenzenes  
Exposure to DCBs can be identified by measuring levels of the isomers in blood (Bristol et al. 1982; Hill 























3. HEALTH EFFECTS 
et al. 1995; Kumagai and Matsunaga 1995, 1997; Zenser et al. 1997), adipose tissue (Jan 1983), and 
breast milk (Jan 1983; Mes et al. 1986).  Toxicokinetic studies (Section 3.4) indicate that DCBs are 
present in blood for a limited time after exposure and eliminated from the body over a period of several 
days, primarily in the urine as metabolites (Hissink et al. 1996a, 1996b; Kimura et al. 1979; Parke and 
Williams 1955).  Measurement of urinary metabolites is likely to provide a better indication of recent 
exposure than blood or other measurements since DCBs can be excreted for several days post-exposure 
(Hallowell 1959). Urinary 2,5-dichlorophenol is a well-documented biomarker for monitoring worker 
exposure to 1,4-DCB (McKinney et al. 1970; Pagnotto and Walkley 1965).  Urinary 2,3- and
3,4-dichlorophenols, as well as 3,4- and 4,5-dichlorocatechols, have been shown to be useful indicators of 
exposure to 1,2-DCB (Kumagai and Matsunaga 1997).  Because the basic steps in the metabolism of the 
three DCB isomers are similar, likely biomarkers of exposure to 1,3-DCB include 2,4- and 3,5-dichloro­
phenols (Kimura et al. 1992). The presence of a DCB isomer and/or its conjugates in urine is not 
completely specific for exposure to the DCB.  For example, several chlorophenols, including
2,5-dichlorophenol, have been identified as metabolites of lindane in laboratory animals.  Because DCBs 
tend to accumulate in fat, measurements of adipose levels of the parent isomers are likely to provide 
useful information on long-term exposures (Jan 1983; Morita et al. 1975).  There are currently no data 
available to assess a potential correlation between the values obtained with these measurements and the 
toxic effects observed in humans or laboratory animal species.  Information on the analytical methods 
commonly used to detect and quantify 1,4-DCB in biological samples is presented in Section 6.1. 
No information is available describing specific biomarkers of exposure to 1,4-DCB in children. 
3.8.2 Biomarkers Used to Characterize Effects Caused by Dichlorobenzenes  
There are no known specific biomarkers of effects for 1,2-, 1,3-, or 1,4-DCB because none of the health 
effects identified in humans or animals appear to be uniquely associated with exposure to any isomer.  
Biomarkers of effects for DCBs are likely to be common to the general class of halogenated aromatic 
hydrocarbons because DCBs and other structurally similar chemicals cause generally similar effects.  For 
example, DCBs and other chlorinated aromatics induce a similar spectrum of hepatic effects ranging from
liver enlargement and increased microsomal enzyme activities at lower levels of exposure to degenerative 
lesions at higher doses. 
It is well documented that 1,4-DCB induces hyaline droplet formation and tubular degeneration in the 























3. HEALTH EFFECTS 
oral treatment with 1,4-DCB on the urinary excretion of kidney-type α2µ-globulin (aG-K) in male 
Sprague-Dawley rats.  Groups of 3 rats received placebo or 1,4-DCB (1.5 mmol/kg/day; 220 mg/kg/day)
by gavage in corn oil for 7 days.  Concentrations of aG-K in the urine of 1,4-DCB-treated rats ranged 
from 0.04 to 0.18 mg/mL; urine concentrations increased steadily throughout the study.  In contrast, aG-K 
concentrations were undetectable in the urine of controls at all time points.  The mean concentration of 
aG-K in the kidneys of rats treated with 1,4-DCB was 1.15 mg/mg of soluble protein, compared to 
0.35 mg/mg protein in the control group.  The authors concluded that measurement of urinary aG-K
would be a good indicator of 1,4-DCB exposure; however, this response is neither unique to 1,4-DCB nor 
applicable to human exposure cases.  As discussed earlier in Section 2.5, this particular protein is 
produced in large amounts by male rats, accounting for 26% of their total urinary protein, but not in 
human males, where it was found to be present at 1% of the amount measured in male rats (Olson et al. 
1990).  Also, this protein is produced in only minimal quantities by females of any species or the males of 
other laboratory species including mice (EPA 1991i). These observations have led to suggestions that 
humans are probably not at risk for the type of nephropathy induced by 1,4-DCB in male rats, and that the 
α2µ-globulin biomarker is inappropriate to use in humans (EPA 1991i). 
No information was available describing specific biomarkers of effect in children to 1,4-DCB. 
For more information on biomarkers for renal and hepatic effects of chemicals see ATSDR/CDC 
Subcommittee Report on Biological Indicators of Organ Damage (1990) and for information on 
biomarkers for neurological effects, see OTA (1990).
3.9 INTERACTIONS WITH OTHER CHEMICALS  
Little information is available regarding possible interactions of 1,2-, 1,3-, or 1,4-DCB with other 
chemicals.  Because DCBs are liver toxins, they might interact with other chemicals that are liver 
toxicants. These toxicants are many, and include ethanol, halogenated hydrocarbons (chloroform, carbon 
tetrachloride, etc.), benzene, and other haloalkanes and haloalkenes.  DCB hepatotoxicity could also be 
exacerbated by concurrent exposure to acetaminophen, heavy metals (copper, iron, arsenic), aflatoxins, 
pyrrolizidine alkaloids (from some types of plants), high levels of vitamin A, and hepatitis viruses.  Such 
interactions are likely to be additive or synergistic.  One study found that pretreatment with DCB 























3. HEALTH EFFECTS 
Regarding the effect of 1,4-DCB on hemolysis and formation of Heinz bodies, methemaglobinemia, and 
hemolytic anemia, it is likely that additive or synergistic interaction would occur with other oxidants, 
such as aniline and acrolein, which are known to inhibit G6PD.  A human case study reported a possible 
interactive effect between DCB and naphthalene in a woman who developed aplastic anemia (EPA 
1985a). 
Perinatal evaluations were performed in offspring of female Wistar rats were exposed to diets containing 
25 ppm 1,4-DCB (estimated dose 2 mg/kg/day) alone or combined with 125 ppm p,p’-dichlorodiphenyl­
dichloroethylene (p,p’-DDE) from Gd 1 to Pnd 21 for a total of 42 days (Makita 2005).  There were no 
maternal effects in either group as shown by clinical signs or changes in body weight and food
consumption.  Perinatal evaluations showed no gross external malformations or effects on litter size, sex 
ratio, or pup viability on Pnd 1 in either group.  Assessments of the offspring until 6 weeks of age showed 
no postnatal effects on body weight gain, anogenital distance, times of eye and vaginal opening and 
preputial separation, or serum levels of reproductive hormones (LH and FSH in both sexes and 
testosterone in males at 6 weeks) in either group.  Examination of the liver, kidneys, spleen, thymus, 
testes, epididymides, prostate, seminal vesicles, ovaries, uterus, and thymus at 6 weeks showed no effects 
on organ weight or histology in either group, except for increased absolute thymus weight (approximately
20% higher than controls) in female pups exposed to 1,4-DCB alone.  The biological significance of this 
effect is unclear because it did not occur in the male offspring and was not accompanied by any
histological changes. There was no effect on thymus weight or histology in male or female pups exposed 
to the mixture of 1,4-DCB and p,p’-DDE.   
No information was located on interactions between DCBs and other chemicals in children. 
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to dichlorobenzenes than will most 
persons exposed to the same level of dichlorobenzenes in the environment.  Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
These parameters result in reduced detoxification or excretion of dichlorobenzenes, or compromised 
function of organs affected by dichlorobenzenes.  Populations who are at greater risk due to their 
























3. HEALTH EFFECTS 
No population has been identified as exhibiting an unusual susceptibility to the effects of exposure to 
1,4-DCB. However, based on data from studies in humans and animals, individuals with compromised 
liver function, infants and children with immature liver function (Hallowell 1959), and elderly people 
(Cotter 1953; Nalbandian and Pearce 1965) may be more at risk than the general population.  Individuals 
having a genetic susceptibility to methemoglobin formation (such as those individuals with a deficiency
of G6PD in their red blood cells) may also be at increased risk from inhalation or oral exposure to 
1,4-DCB. 
No information was available describing specific susceptibilities of children to 1,4-DCB.  There is no 
direct evidence that children differ in their susceptibility to the health effects of 1,4-DCB from adults.  It 
should be noted that postnatal neurodevelopmental toxicity is a sensitive end point in 1,4-DCB-exposed 
rats (Bornatowicz et al. 1994), suggesting a basis for potential concern in exposed children.  This issue is 
discussed in detail in Section 3.7 Children’s Susceptibility.
The extent to which men and women may differ in susceptibility to DCBs is not known.  Available 
animal data do not provide a clear pattern for gender differences in the toxicity of DCBs, although some
subchronic and chronic studies found that males were more sensitive than females for some end points.  
For example, a multigeneration inhalation study of 1,4-DCB in rats observed increases in adult liver 
weight that were more pronounced in males than females (Tyl and Neeper-Bradley 1989).  In a 
subchronic oral study of 1,3-DCB in rats, histopathological changes in the thyroid were generally more 
severe in males than in females (McCauley et al. 1995).  This study also found histopathology in the 
pituitary of male rats, but not female rats.  The pituitary lesion was reported to be similar to those induced 
in gonadectomized rats and was considered to be an indicator of gonadal deficiency (McCauley et al. 
1995). Though these animal studies provide an indication that males may be more sensitive to DCBs 
exposure, the evidence is insufficient for extrapolating to humans. 
3.11 METHODS FOR REDUCING TOXIC EFFECTS  
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to dichlorobenzenes. However, because some of the treatments discussed may be experimental 
and unproven, this section should not be used as a guide for treatment of exposures to dichlorobenzenes.  

























3. HEALTH EFFECTS 
consulted for medical advice.  The following texts provide specific information about treatment following
exposures to dichlorobenzenes:   
Aaron CK, Howland MA, eds. 1994.  Goldfrank's toxicologic emergencies.  Norwalk, CT: Appleton and 
Lange. 
Dreisback RH, ed. 1987.  Handbook of poisoning.  Norwalk, CT: Appleton and Lange. 
Ellenhorn MJ, Barceloux, DG, eds.  1997.  Medical toxicology:  Diagnosis and treatment of human 
poisoning.  New York, NY:  Elsevier Publishing. 
Grossel TA, Bricker JD.  1994. Principles of clinical toxicology.  3rd edition, New York, NY:  Raven 
Press. 
Haddad LM, Winchester JF, eds. 1990.  Clinical management of poisoning and drug overdose.  2nd 
edition, Philadelphia, PA:  WB Saunders. 
3.11.1 Reducing Peak Absorption Following Exposure  
Human exposure to 1,4-DCB can occur by inhalation, ingestion, or dermal contact.  General 
recommendations for reducing absorption of 1,4-DCB following acute-duration inhalation exposure have 
included moving the patient to fresh air and administration of 100% humidified supplemental oxygen 
with assisted ventilation (HSDB 1996).  General recommendations for reducing absorption following 
acute ingestion exposure have included inducing vomiting (unless the patient is or could rapidly become 
obtunded, comatose, or convulsing, and considering the risk of aspiration of vomitus), gastric lavage, or 
administration of a charcoal slurry (HSDB 1996).  Intake of fatty foods, which would promote absorption,
should be avoided.  In the case of eye exposure, irrigation with copious amounts of water has been 
recommended (HSDB 1996).  For dermal exposure, and to minimize dermal absorption, the removal of 
contaminated clothing and a thorough washing of any exposed areas with soap and water has been 
recommended (HSDB 1996). 
3.11.2 Reducing Body Burden  
1,4-DCB distributes to fatty tissues and is probably retained there at low concentrations (EPA 1986d; 
Hawkins et al. 1980; Morita and Ohi 1975; Morita et al. 1975).  However, most of an absorbed dose is 
excreted within 5 days of exposure (Hawkins et al. 1980), and there is no evidence suggesting that the low
























3. HEALTH EFFECTS 
methods for enhancing elimination of 1,4-DCB shortly after high-dose exposure could reduce toxic 
effects; however, no such methods have been identified.  Methods that could enhance the elimination of 
1,4-DCB after high- or low-dose exposure in humans or laboratory animals have not been reported. 
While it might be possible to develop methods to alter metabolism of 1,4-DCB to promote formation of 
metabolites that are more easily excreted, this could be difficult because the current lack of knowledge of
the specific metabolic pathways of 1,4-DCB precludes speculation concerning which pathways it might 
be most beneficial to stimulate or inhibit.  One pathway for which stimulation may be contraindicated is 
sulfate conjugate formation (Kimura et al. 1979).  Methylation of 1,4-DCB sulfate conjugates can occur, 
and these methylated conjugates are excreted less rapidly than nonmethylated conjugates (Kimura et al. 
1979). Since little is known concerning the toxicity of these conjugates, it is presently not possible to 
determine the consequences of promoting formation of these metabolites. 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects  
The mechanism of action for liver effects of 1,4-DCB has not been clearly delineated; however, based on 
in vitro experiments, induction of P-450 metabolism by pretreatment with phenobarbital may enhance 
hepatotoxicity (Fisher et al. 1991a).  This suggests that one mechanism of hepatotoxicity may be the 
production of reactive intermediates through phase I P-450-mediated oxidation, although it should be 
noted that the P-450 inhibitors metyrapone and SKF 525-A did not block hepatotoxicity of 1,4-DCB in 
human liver tissue in vitro (Fisher et al. 1991a). Lattanzi et al. (1989) provide evidence indicating that the 
microsomal mixed-function oxidase system and microsomal glutathione transferases and, to a lesser 
degree, cytosolic glutathione transferases, can be involved in the bioactivation of 1,4-DCB.  More 
information concerning the mechanism of action for hepatic effects is needed before methods for blocking 
that mechanism and reducing toxic effects can be developed. 
The mechanisms of action for nephrotoxic (with the exception of α2µ-globulin-mediated nephropathy
specific to male rats) or hematotoxic effects have not been clearly delineated, and with the available 
information, it is difficult to speculate how 1,4-DCB might cause such effects.  More information 
concerning the mechanisms of action for blood and kidney effects are needed before methods for 






















3. HEALTH EFFECTS 
3.12 ADEQUACY OF THE DATABASE
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of dichlorobenzenes is available.  Where adequate information 
is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to 
assure the initiation of a program of research designed to determine the health effects (and techniques for 
developing methods to determine such health effects) of dichlorobenzenes. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Health Effects of Dichlorobenzenes 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
dichlorobenzenes are summarized in Figures 3-7, 3-8, and 3-9.  The purpose of this figure is to illustrate 
the existing information concerning the health effects of dichlorobenzenes.  Each dot in the figure 
indicates that one or more studies provide information associated with that particular effect.  The dot does 
not necessarily imply anything about the quality of the study or studies, nor should missing information in 
this figure be interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for 
Identifying Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic 
Substances and Disease Registry 1989), is substance-specific information necessary to conduct 
comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly as any 
substance-specific information missing from the scientific literature.
Some limited information (i.e., anecdotal, single acute-duration exposure, and workplace exposure) is 
available on the health effects of human exposure to 1,2- and 1,4-DCB via inhalation and 1,4-DCB by the 
oral route. For persons exposed via inhalation, there is information on death, systemic effects, neurologic 
effects. There is also information on systemic effects in humans resulting from acute-, intermediate-, and 
chronic-duration oral exposure.  It is important to note that most of this oral information was obtained 











































































































































































































































































































































































3. HEALTH EFFECTS 
Data available on health effects of DCBs in animals are more extensive than in humans.  Most of the 
information is for 1,2- and 1,4-DCB, whereas all data on 1,3-DCB are from one oral study.  The most 
extensively studied isomer is 1,4-DCB.  Information is available on the developmental, reproductive, 
genotoxic, and carcinogenic effects of inhalation exposure to 1,4-DCB, as well as on the systemic effects 
resulting from intermediate-duration exposure.  In studies using oral exposure, information is available on 
death; systemic effects resulting from acute-, intermediate-, and chronic-duration exposure; and 
developmental, genotoxic, and carcinogenic effects.  Only data on the lack of a lethal effect are available 
in studies using dermal exposure. 
3.12.2 Identification of Data Needs 
Acute-Duration Exposure.    A limited amount of information is available on health effects in people 
who were occupationally exposed to 1,2-DCB (Hollingsworth et al. 1958).  This information includes 
exposure levels associated with eye and respiratory tract irritation and results of periodic medical 
examinations, but the data are insufficient for identifying sensitive systemic end points in humans or for 
inhalation MRL derivation purposes. The limited information on irritation effects of 1,2-DCB in humans 
is consistent with histological findings of nasal olfactory epithelial lesions in mice that were intermittently
exposed to 1,2-DCB vapor for up to 14 days (Zissu 1995).  The severity of the nasal lesions ranged from
moderate to severe in severity and occurred at concentrations lower than those that caused acute systemic
effects (liver and kidney lesions) in rats (DuPont 1982; Hollingsworth et al. 1958) or developmental 
effects in rats and rabbits (Hayes et al. 1985).  A NOAEL was not identified for the serious nasal effects, 
precluding derivation of an acute inhalation MRL.  Additional studies could characterize the threshold 
region for nasal effects, confirm that the nasal cavity is more sensitive than systemic end points, and 
provide a sufficient basis for inhalation MRL derivation.  
There is no information on the toxicity of 1,2-DCB in orally-exposed humans.  Information on effects of 
acute oral exposure to 1,2-DCB in animals essentially consists of findings in three systemic toxicity
studies in rats and mice (NTP 1985; Rimington and Ziegler 1963; Robinson et al. 1991) and one 
developmental toxicity study in rats (Ruddick et al. 1983).  These studies collectively identify the liver as 
the most sensitive target, but two are limited by small numbers of animals and lack of a NOAEL due a 
single dose level (Rimington and Ziegler 1963) or lack of histopathology evaluations at doses lower than 
the LOAEL (NTP 1985). The third systemic toxicity study (Robinson et al. 1991) is well designed, 





















3. HEALTH EFFECTS 
Additional studies are needed to establish whether liver toxicity is the most sensitive end point for acute 
exposure and the most appropriate basis for the MRL.  The oral database for 1,2-DCB particularly lacks 
adequate assessments of neurotoxicity, immunotoxicity, and end points shown to be sensitive to other 
DCB isomers (e.g., thyroid and pituitary). 
No inhalation toxicity data are available for 1,3-DCB in humans or animals, indicating that a well-
designed inhalation toxicity study could provide a basis for an acute inhalation MRL.  The acute oral 
database for 1,3-DCB essentially consists of one well-designed 10-day systemic toxicity study (McCauley
et al. 1995) that was sufficient for estimation of an MRL.  Additional studies could determine whether the 
critical effect in this study, increased liver weight, is the most appropriate and sensitive end point for 
MRL derivation. 
A limited amount of information is available on the toxicity of inhaled 1,4-DCB in humans.  Case reports 
of people who inhaled 1,4-DCB provide indications that the liver and nervous system are systemic targets 
of inhalation toxicity in humans, but are limited by lack of adequate quantitative exposure information 
and/or verification that 1,4-DCB was the only factor associated with the effects (Cotter 1953; Miyai et al. 
1988; Reygagne et al. 1992).  An occupational health survey identified odor detection and eye/nose 
irritation thresholds for 1,4-DCB (Hollingsworth et al. 1956).  Information on effects of acute-duration 
inhalation exposure to 1,4-DCB in animals is available from short-term systemic toxicity studies in rats 
and guinea pigs (Hollingsworth et al. 1956), a male reproduction study rats (Anderson and Hodge 1976), 
and developmental toxicity studies in rats and rabbits (Hayes et al. 1985; Hodge et al. 1977).  These 
animal studies identified the lung as the target of concern, and are consistent with chronic inhalation data 
(Aiso et al. 2005b; Japan Bioassay Research Center 1995) as well as the human occupational experience 
(Hollingsworth et al. 1956), but are insufficient for deriving an acute inhalation MRL.  Studies in animals 
investigating potentially sensitive systemic end points (e.g., respiratory, endocrine, neurological, 
immunological) are needed to identify an appropriate end point and effect level for MRL derivation. 
Information on effects of non-lethal acute-duration oral exposures to 1,4-DCB is essentially limited to 
hepatic and renal changes of unclear toxicological significance observed in animal studies designed to 
elucidate mechanisms of liver and kidney toxicity in rats and mice. Appropriately designed acute oral 
studies are needed to provide a suitable basis for MRL derivation.
The only available study using the dermal route is a lethality study that attempted to determine a dermal 






















3. HEALTH EFFECTS 
have examined absorption of 1,4-DCB via the dermal route.  If dermal absorption and systemic
distribution of 1,4-DCB could be demonstrated, acute-duration studies using this route would be useful 
since humans are commonly exposed to it by handling various consumer products in the home and being 
exposed to the vapor form.   
Intermediate-Duration Exposure.    Information on the toxicity of intermediate-duration inhalation 
exposure to 1,2-DCB is limited to the findings of a multispecies subchronic study (Hollingsworth et al. 
1958) and a 2-generation reproduction study in rats (Bio/dynamics 1989).  These studies identified 
NOAELs and LOAELs for liver and body weight effects, but possible effects in the nasal cavity, a known 
sensitive target of 1,2-DCB based on acute data, were not evaluated.  Derivation of an intermediate-
duration inhalation MRL for 1,2-DCB is precluded because the acute-duration serious LOAEL for nasal 
effects (Zissu 1995) is lower than the available intermediate-duration LOAELs for systemic and 
developmental effects.  Additional studies could verify the nasal cavity is more sensitive than systemic 
end points and provide exposure-response data useful for inhalation MRL derivation. 
No information was located regarding the toxicity of inhaled 1,3-DCB in humans or animals, indicating 
that appropriate studies are needed to provide a basis for derivation of an intermediate-duration inhalation 
MRL for this isomer.  The database for intermediate-duration oral exposure to 1,3-DCB consists of one  
well-designed 90-day systemic toxicity study (McCauley et al. 1995) that was sufficient for estimation of 
an intermediate oral MRL. The thyroid, pituitary, and liver were identified as sensitive targets and 
incidences of pituitary lesions were used to derive an intermediate oral MRL. 
Case studies are available on humans exposed to 1,4-DCB via inhalation and the oral route for
intermediate-duration exposure.  These include the report of a 69-year-old man who developed skin 
discolorations and swelling of his hands and feet after about 3 weeks of exposure to 1,4-DCB in his home
(Nalbandian and Pearce 1965), the cases of a 60-year-old man and his wife who both died of liver atrophy
after their home had been saturated with moth ball vapor for 3–4 months (Cotter 1953), and the case of a 
21-year-old woman who developed hypochromic, microcytic anemia as a result of ingesting 1,4-DCB 
toilet air freshener blocks throughout pregnancy (Campbell and Davidson 1970).  All of these case studies 
lack critical dosing amounts and durations.  It would be helpful if future reports of accidental or 
intentional exposure included dose information (measured or estimated) that could be used to help 























3. HEALTH EFFECTS 
Information on effects of intermediate-duration inhalation exposure to 1,4-DCB in animals is available 
from a multispecies subchronic toxicity study (Hollingsworth et al. 1956), a 13-week toxicity study in rats 
and mice (Aiso et al. 2005a), and a 2-generation reproductive/developmental toxicity study in rats (Tyl
and Neeper-Bradley 1989).  The 13-week and 2-generation studies identified a NOAEL and LOAEL for 
increased relative liver weight, and increased liver weight was used to derive an MRL.  A chronic 
inhalation study (Aiso et al. 2005b; Japan Bioassay Research Center 1995) found that nasal lesions in rats 
and testicular effects in mice were more sensitive than liver effects.  No nasal or testicular lesions were 
reported in the 13-week rat and mouse study, and these tissues were not examined in the multispecies 
subchronic study.  Additional studies could verify that liver weight is the most appropriate basis for the 
intermediate inhalation. 
Information on the systemic toxicity of intermediate-duration oral exposure to 1,4-DCB is available from
a number of studies conducted in rodents, mainly rats and mice, as well as one study in dogs (Bomhard et 
al. 1988; Hollingsworth et al. 1956; NTP 1985; Lake et al. 1997; Naylor and Stout 1996; Umemura et al. 
1998).  Liver and kidney effects were the most consistently observed, best characterized, and most 
sensitive findings in these studies. Liver effects were used as the basis for intermediate-duration oral 
MRLs for 1,2-DCB (NTP 1985) and 1,4-DCB (Naylor and Stout 1996). 
Studies using the dermal route for intermediate-duration exposure would be useful if absorption and 
systemic distribution of 1,4-DCB by this route could first be demonstrated in toxicokinetic studies.   
Chronic-Duration Exposure and Cancer.    No studies were located regarding the chronic 
inhalation toxicity of 1,2-DCB in humans or animals, indicating that data are needed to provide a basis for 
estimation of an inhalation MRL.  Regarding chronic oral toxicity of 1,2-DCB, the only available study is 
a two-dose-level NTP (1985) bioassay that was conducted in rats and mice.  The only exposure-related 
effect in either species was a significantly increased incidence of renal tubular regeneration in male mice.  
A NOAEL and LOAEL were identified for this lesion and incidences of renal tubular regeneration were 
used to derive a chronic oral MRL for 1,2-DCB.  No information is available on the carcinogenicity of 
1,2-DCB in humans. Data on cancer in animals are limited to the NTP (1985) chronic bioassay, in which 
no exposure-related tumors were found in male and female rats and mice exposed to two dose levels of 
1,2-DCB for 103 weeks. This is a well-designed chronic study with respect to exposure duration and 
scope of histological examinations, but it is uncertain whether an MTD was achieved in either species.  
Additional studies that include multiple dose levels and clear MTDs, as well as toxicity end points that 




















3. HEALTH EFFECTS 
if the MRL is based on the most appropriate effect level and also provide an better assessment of 
carcinogenic potential. 
No studies were located regarding the chronic inhalation or oral toxicity of 1,3-DCB in humans or 
animals, indicating that data are needed to provide the bases for chronic MRL and carcinogenicity
assessments. 
Several case studies of chronic human exposure to 1,4-DCB have been reported.  Reported effects 
resulting mainly from chronic inhalation included pulmonary granulomatosis in a 53-year-old woman 
who had been inhaling 1,4-DCB crystals in her home for 12–15 years (Weller and Crellin 1953); atrophy 
and cirrhosis of the liver in a 34-year-old woman who was exposed to 1,4-DCB-containing products in a 
small enclosed booth in a department store for 1 or more years (Cotter 1953); jaundice and liver atrophy
in a 52-year-old man after 2 years of exposure to 1,4-DCB in the fur storage plant where he worked 
(Cotter 1953); and ataxia, speech difficulties, limb weakness, and altered brainwave activity in a 25-year­
old woman who had been exposed to high concentrations of 1,4-DCB in her bedroom, bedding, and 
clothes for about 6 years (Miyai et al. 1988).  A limited occupational health survey reported that nasal and 
ocular irritation, but no major systemic health effects, were the only 1,4-DCB-related complaints 
(Hollingsworth et al. 1956).  Further occupational health data on individuals exposed chronically to 
1,4-DCB would be useful for both cancer and noncancer health effect end points already mentioned.  The 
only data located relating to chronic oral human exposure to 1,4-DCB come from a case report of a 
19-year-old black woman who developed an increase in skin pigmentation as a result of eating 1,4-DCB 
moth pellets daily for about 2.5 years (Frank and Cohen 1961).  All of these case studies lacked dosing 
amounts and durations, which makes it difficult to characterize dose-response relationships for effects in 
humans exposed to 1,4-DCB.  No studies of chronic dermal exposure to 1,4-DCB were located, although 
it seems likely that chronic inhalation and oral exposure scenarios, both in the home and in the workplace, 
have also involved dermal contact with 1,4-DCB. 
A limited amount of additional information is available on the chronic toxicity of inhaled 1,4-DCB in 
humans.  Periodic health examinations of workers who were exposed to 1,4-DCB for an average of 
4.75 years (range, 8 months to 25 years) showed no changes in standard blood and urine indices 
(Hollingsworth et al. 1956).  The data from this occupational study are inadequate for chronic MRL 
derivation due to poor characterization of exposure levels, insufficient investigation of systemic health 
end points, and poor reporting as well as other study deficiencies.  However, eye and nose irritation 























3. HEALTH EFFECTS 
Information on the chronic inhalation toxicity of 1,4-DCB in animals is available from two studies in rats 
and mice (Aiso et al. 2005b; Japan Bioassay Research Center 1995; Riley et al. 1980a, 1980b).  One of 
these studies (Aiso et al. 2005b; Japan Bioassay Research Center 1995) identified nasal lesions in rats and 
provided a sufficient basis for MRL estimation. 
Information on the chronic oral effects of 1,4-DCB is available from one study each in rats, mice, and 
rabbits (Hollingsworth et al. 1956; NTP 1987).  Lesions were observed in the kidneys and liver, and the 
lowest tested dose was a LOAEL for renal effects in rats (NTP 1987).  Naylor and Stout (1996) identified 
liver effects (increased liver weight, changes in liver enzymes, and histopathology) in dogs administered 
1,4-DCB for 1 year; these liver effects provided a sufficient basis for chronic oral MRL estimation.  
Information on carcinogenicity of 1,4-DCB is available from the chronic oral and inhalation studies in 
rats and mice.  The oral study (NTP 1987) found evidence of carcinogenicity based on increased tumor 
incidences in male rat kidneys and in the livers of male and female mice.  The kidney tumors are not 
relevant to humans because the mechanism (α2µ-globulin nephropathy) is specific to male rats.  One of the 
inhalation studies (Aiso et al. 2005b; Japan Bioassay Research Center 1995) similarly showed tumor 
induction in the livers of male and female mice, although there was no tumor formation in either sex of 
rats. The other inhalation study (Riley et al. 1980a, 1980b) found no neoplastic changes in rats or mice, 
but the adequacy of the study for carcinogenicity evaluation is limited by failure to reach the maximum
tolerated dose, less-than-lifetime exposure durations, and short observation periods in both species.  There 
is sufficient evidence of 1,4-DCB carcinogenicity in animals based on the induction of liver tumors in 
mice exposed by both the oral and inhalation routes.  Unlike the kidney tumors in male rats, the 
mechanistic basis of the liver tumors in mice is not adequately defined, indicating that additional studies 
could help to better assess their relevance to humans.   
Data on the effects of chronic dermal exposure to 1,4-DCB might be useful if dermal absorption and 
systemic distribution of 1,4-DCB can be demonstrated from toxicokinetic studies, since chronic dermal 
exposure to 1,4-DCB occurs as a result of bathing and showering in drinking water that contains low 
levels of this chemical in many U.S. communities.   
Genotoxicity.    Genotoxic effects of 1,2- and 1,3-DCB have been investigated in various animal test 
systems with generally mixed results.  The genotoxicity of 1,4-DCB has been extensively studied in a 
wide variety of in vitro and in vivo animal assays with a preponderance of negative results.  Additional 























3. HEALTH EFFECTS 
There are considerable data supporting a sustained proliferative response following 1,4-DCB exposure as 
the mode of action for liver tumor formation; however, the existing evidence is incomplete. 
Reproductive Toxicity.    The reproductive toxicity of 1,2-DCB has been evaluated in a 2-generation 
inhalation study in rats (Bio/dynamics 1989), but not by the oral route.  The inhalation study found no 
effects on reproduction in either generation at exposure levels higher than those causing liver effects in 
the parental animals, indicating that it can be used to partially address the data gap for oral exposure. 
No information was located on possible reproductive effects of 1,3-DCB, indicating that reproductive 
toxicity is a data need for both inhalation and oral exposure to this isomer. 
The reproductive toxicity of 1,4-DCB has been evaluated in inhalation and oral 2-generation studies in 
rats with no exposure-related effects on reproductive function (Bornatowicz et al. 1994; Tyl and Neeper-
Bradley 1989).  An inhalation study of male mice exposed to 1,4-DCB for 5 days did not find an adverse 
impact on their ability to impregnate females (Anderson and Hodge 1976).  Incidences of morpho­
logically abnormal sperm were increased in rats that were intraperitoneally injected with 1,4-DCB 
(Murthy et al. 1987).  Histopathology evaluations of 1,4-DCB-exposed animals have not demonstrated 
changes in reproductive tissues in the preponderance of studies.  Based on the available data, there is no 
compelling need for additional reproductive toxicity studies of 1,4-DCB.  
Developmental Toxicity.    The developmental toxicity of inhaled 1,2-DCB was evaluated in an 
adequate study of gestationally-exposed rats and rabbits (Hayes et al. 1985).  Skeletal variations, but no
teratogenic effects, occurred in rats at a concentration that also caused maternal toxicity.  A poorly 
reported oral study in which rats were gestationally exposed to 1,2-DCB (Ruddick et al. 1983) found no 
effects on fetuses and indicates that developmental toxicity, if induced, would only occur at levels that 
were maternally toxic.  No information is available on possible neurodevelopmental effects of 1,2-DCB, 
indicating that this is a data need. 
No information was located on the developmental toxicity of 1,3-DCB, indicating that this is a data need 
for both inhalation and oral exposure to this isomer. 
The developmental toxicity of inhaled 1,4-DCB was evaluated in adequate studies of gestationally­
exposed rats and rabbits (Hayes et al. 1985; Hodge et al. 1977).  No maternal or prenatal developmental 





















3. HEALTH EFFECTS 
circulatory system) in the rabbits at a concentration that was maternally toxic and higher than LOAELs 
for systemic toxicity in other studies.  Information on developmental toxicity of ingested 1,4-DCB is 
available from an 2-generation oral study in rats (Bornatowicz et al. 1994).  Fetuses were not examined 
for prenatal changes, but various effects occurred in the offspring perinatally and during the later pre-
weaning period, including decreased neonatal survival and impaired neurobehavioral development in 
F1 and F2 pups. This finding suggests that postnatal neurobehavioral development is a sensitive end point 
for 1,4-DCB that could be better characterized by additional studies.    
Immunotoxicity.    No information is available on immunological function in humans or animals 
exposed to 1,2-DCB or 1,3-DCB by the inhalation or oral routes.  Lymphoid depletion in the thymus was 
observed histologically in rats that were exposed to a high oral dose of 1,2-DCB for 13 weeks (NTP 
1985), suggesting that the immune system is a possible target of concern and providing an additional 
indication of the need for adequate assessments of immunotoxicity.  
No studies were located that directly assess the potential immunotoxic effects of 1,4-DCB in humans 
exposed by inhalation, oral, or dermal routes.  However, case reports of skin reactions in a 69-year-old 
man who was exposed via inhalation (Nalbandian and Pearce 1965) and a 19-year-old woman who 
ingested moth pellets (Frank and Cohen 1961) suggest that the immune system may be a target for 
1,4-DCB. Oral exposure to high doses of 1,4-DCB for 13 weeks caused lymphoid necrosis in the thymus, 
lymphoid depletion in the spleen, and hematopoietic hypoplasia in the spleen and bone marrow of mice, 
and lymphoid depletion of the thymus and spleen in rats (NTP 1987).  Effects of oral 1,4-DCB exposure 
on function of the immune system have not been studied, although there were no functional decrements in 
a 12-week inhalation immunotoxicity study in guinea pigs that assessed a limited number of indices 
(Suzuki et al. 1991).  Comprehensive immunological testing would help to adequately assess the 
immunotoxic potential of 1,4-DCB.   
Neurotoxicity.    Comprehensive neurobehavioral assessments have not been performed for any of the 
DCB isomers.  Clinical signs neurotoxicity (e.g., ataxia and clonic contractions) were observed in rats that 
were orally exposed to a high dose of 1,2-DCB for 15 days (Rimington and Ziegler 1963), but similar 
effects were not found in rats or mice in other studies of this isomer.  No signs of neurotoxicity occurred 
in rats were orally exposed to 1,3-DCB for up to 90 days (McCauley et al. 1995).
Neurological effects including dizziness, weakness, headaches, nausea, vomiting, numbness, clumsiness, 

























3. HEALTH EFFECTS 
studies of persons exposed to 1,4-DCB via inhalation (Cotter 1953; Miyai et al. 1988), as well as with 
other halogenated hydrocarbons.  There are no data on neurological effects in humans exposed to 
1,4-DCB through the oral or dermal routes.  Neurotoxic effects of 1,4-DCB occurred in rats, rabbits, and 
guinea pigs following inhalation exposure to high concentrations; effects included tremors, weakness, and 
periods of unconsciousness. Similar neurological responses were observed following oral exposure to 
high doses of 1,4-DCB (NTP 1987; Rimington and Ziegler 1963).  No studies were located that reported 
neurological effects after a dermal route of exposure. Additional information, particularly on subtle 
behavioral changes at low levels of inhalation and oral exposure, is needed to adequately assess the 
neurotoxic potential of 1,4-DCB and for quantifying dose-response relationships.   
Epidemiological and Human Dosimetry Studies.    A limited amount of information is available 
on the inhalation toxicity of 1,2- and 1,4-DCB in humans from observations in exposed workers, mainly
from assessments of symptoms and standard blood and urine indices as determined by periodic 
occupational health examinations (Hollingsworth et al. 1956, 1958).  No information is available on the 
toxicity of ingested 1,2- or 1,3-DCB in humans.  Information on toxic effects of 1,4-DCB in orally
exposed humans is limited to two case reports describing hematological changes, particularly anemia, 
following known or presumed repeated ingestion of unknown doses of the compound in commercial 
products (Campbell and Davidson 1970; Hallowell 1959).  The limited available information suggests 
that inhalation or oral exposure to DCBs can cause effects in humans similar to those found in animals, 
particularly in the respiratory tract, liver, and hematological systems.  There are no case studies or 
epidemiological data that suggest that levels of DCBs found in the environment are associated with 
significant human exposure.  The available data suggest that levels of DCBs in outside air are relatively
insignificant, although the compounds are widespread (IARC 1982; Scuderi 1986; Wallace et al. 1986b). 
Levels in groundwater and surface water are also relatively low (Coniglio et al. 1980; Dressman et al. 
1977; IJC 1989; Oliver and Nicol 1982a; Page 1981; Staples et al. 1985).  These observations indicate 
that the most likely population to exhibit effects of DCB exposures would be occupationally exposed 
groups. Human epidemiological studies that provide a more definitive dose-response relationship 
between exposure, clinical manifestations, and target organ toxicity (i.e., hepatic, hematological, and 
neurological systems) would be useful. 
Biomarkers of Exposure and Effect.     
Exposure. Exposure to DCBs can be identified by measuring levels of the isomers in blood (Bristol et al. 






















3. HEALTH EFFECTS 
1985; Hill et al. 1995; Kumagai and Matsunaga 1995, 1997; Zenser et al. 1997), adipose tissue (Jan 
1983), and breast milk (Jan 1983; Mes et al. 1986), as well as metabolites in the urine.  Urinary 
2,5-dichlorophenol is a well-documented biomarker for monitoring worker exposure to 1,4-DCB 
(McKinney et al. 1970; Pagnotto and Walkley 1965), and urinary 2,3- and 3,4-dichlorophenols, as well as 
3,4- and 4,5-dichlorocatechols, have been shown to be useful indicators of exposure to 1,2-DCB 
(Kumagai and Matsunaga 1997).  Additional data with which to correlate these measurements to exposure 
levels, particularly by the inhalation route, and potential health effects, would be useful. 
Effect. There are no health effects that are uniquely associated with exposure to DCBs.  Therefore, 
studies to identify a specific biomarker of effect for DCBs would be useful. 
Absorption, Distribution, Metabolism, and Excretion.  There are no data on the toxicokinetics 
of any DCB isomer in humans.  Experiments with laboratory animals indicate that DCBs are absorbed via 
oral or inhalation exposure and distributed mainly to adipose tissue, with some distribution to the liver 
and kidney, and minor amounts to other organs (Hawkins et al. 1980; Kimura et al. 1979).  Absorbed 
DCBs are principally metabolized to dichlorophenol metabolites (e.g., 2,5-dichlorophenol from 1,4-DCB) 
by oxidation and is rapidly eliminated, primarily in urine (Azouz et al. 1955; Hawkins et al. 1980).  The 
available data indicate that the route of exposure is likely to have little effect on the subsequent 
metabolism and excretion of DCBs.  Scant data are available on absorption and systemic distribution 
resulting from exposure via the dermal route.  Dermal absorption data would be particularly useful 
considering that the inhalation MRLs are based on whole-body exposure.  1,4-DCB produces a burning 
sensation when applied to the skin for a prolonged period of time, indicating at least minimal penetration 
to nerve endings within the skin (Hollingsworth et al. 1956).  The little information that is available 
suggests that dermal exposure is associated with low systemic toxicity in both humans and laboratory
animals.  It would be useful to confirm this because it could provide a basis for assessing the likelihood of 
toxic effects resulting from dermal exposure and the need to conduct various toxicity studies via the 
dermal route.  Additional toxicokinetic data would be useful for quantitating route-specific absorption 
rates. 
Comparative Toxicokinetics.    There are no available studies that compare the toxicokinetics of any 
of the DCB isomers across species.  This has been an important area of concern in interpreting the results 
of animal studies with 1,4-DCB with respect to their relevance to humans, most notably in the
observations of renal toxicity and carcinogenicity in male rats.  Although this specific issue has been 























3. HEALTH EFFECTS 
species in order to understand better which animal model is likely to compare most directly with humans 
with regard to other toxic effects in response to 1,4-DCB exposure.  From the available data in humans 
and laboratory animals, the primary metabolite produced after exposure to 1,4-DCB is 2,5-dichloro­
phenol.  This metabolite appears mainly in the urine after undergoing phase II metabolism, principally to
the sulfate and glucuronide conjugates, with some exiting via the bile (Azouz et al. 1955; Fisher et al. 
1995; Hissink et al. 1997a; Hallowell 1959; Kimura et al. 1979; Klos and Dekant 1994). 
Methods for Reducing Toxic Effects.    Based on the chemical and physical properties of DCBs, 
absorption is most likely to occur by passive diffusion.  However, this has not been investigated.  Studies 
that investigate the mechanism by which DCBs are absorbed could be useful in developing methods for 
reducing its absorption.  Standard methods exist for reducing the absorption of DCBs across the skin, 
lungs, and gastrointestinal tract (HSDB 1996) and are described in more detail in Chapter 7 of this profile; 
however, none of these are specific for exposures to 1,2-, 1,3-, or 1,4-DCB.  DCBs can be retained in fatty 
tissues at low levels (EPA 1986f; Hawkins et al. 1980; Morita and Ohi 1975; Morita et al. 1975).  
Additional studies that characterize the metabolic pathways that enhance excretion may be useful in 
developing a method for reducing body burden.  However, since most of an absorbed dose is likely to be 
eliminated within several days (Hawkins et al. 1980), it seems unlikely that methods for reducing body
burden would be of much benefit.  There is limited evidence that DCBs are metabolically activated to 
hepatotoxic intermediates (Fisher et al. 1991a; Lattanzi et al. 1989).  Additional studies that further 
characterize the metabolic activation of DCBs could be useful for understanding how metabolites interact 
and to develop methods for interfering with the mechanism of action. 
Children’s Susceptibility.    Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above. 
Essentially all of the studies on effects of exposure of humans to DCBs have focused on adults.  It is 
unknown whether children differ from adults in their susceptibility to health effects from DCBs.  Only
two case reports of 1,4-DCB specifically referenced potential exposure to a child (Campbell and 
Davidson 1970; Hallowell 1959).  Data relating to health effects in general for children are lacking.  
There are no data describing the developmental effects in humans.  Such data, although potentially useful, 
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Although there is no reason to suspect that the pharmacokinetics of DCBs differs in children and adults, 
scant data are available to support or disprove this statement.  Studies of absorption, distribution, 
metabolism, and excretion in children would aid in determining if children are at an increased risk, 
particularly if conducted in an area where a high-dose acute or low-dose chronic exposure to an
environmental source were to occur.  With regard to exposure during development, additional research on 
maternal and fetal/neonatal toxicokinetics, placental biotransformation, the mechanism of action in 
children, and the risk associated with the transfer of DCBs to an infant via breast milk would be useful in 
obtaining a more complete picture of prenatal and neonatal development.  Direct evidence on whether 
DCBs crosses the placenta and on the kinetics associated with that transfer is also needed.  Data needs 
exist for determining if specific biomarkers of exposure or effect exist in children (and how those differ 
from adults) and how DCBs interact with other chemicals (i.e., other organochlorine pesticides, drugs, 
etc.) Data needs also exist for methods to reduce peak absorption after exposure, to reduce body burden, 
and to interfere with the mechanism of action for toxic effects targeted for adults as well as for children. 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:  
Exposures of Children. 
3.12.3 Ongoing Studies 



















4. CHEMICAL AND PHYSICAL INFORMATION 
4.1 CHEMICAL IDENTITY  
Dichlorobenzenes (DCBs) are chlorinated aromatic compounds.  1,2-DCB is used primarily as a 
precursor for 3,4-dichloroaniline herbicides (CMR 1996).  1,3-DCB is used in the production of various 
herbicides, insecticides, pharmaceuticals, and dyes (Krishnamurti 2001).  1,4-DCB is used as a deodorant 
for restrooms (Howard 1989), for moth control (O’Neil 2001), and as an insecticide (Farm Chemicals 
Handbook 1983).  Information regarding the chemical identity of 1,2-, 1,3-, and 1,4-DCB is located in 
Table 4-1. 
4.2 PHYSICAL AND CHEMICAL PROPERTIES  
The dichlorobenzene isomers, 1,2-DCB and 1,3-DCB, are colorless volatile liquids at room temperature 
(EPA 1985a). 1,2-DCB has a pleasant odor, while the odor of 1,3-DCB is unspecified (EPA 1985a; 
NIOSH 2005). 1, 4-DCB is a combustible crystalline solid that tends to sublime at ordinary room
temperatures.  It possesses a distinctive odor reportable to be noticeable at airborne concentrations 
between 30 and 60 ppm (by weight [ppm-w] or by volume [ppm-v] not specified; presumably "ppm" 
would refer to ppm by weight).  Information regarding the physical and chemical properties of 1,2-, 1,3-, 























4. CHEMICAL AND PHYSICAL INFORMATION 
Table 4-1. Chemical Identity of 1,2-, 1,3-, and 1,4-Dichlorobenzene 
Characteristic Value 	 Reference 
Chemical name  	 1,2-Dichlorobenzene Lide 2000 
Synonyms 	o-Dichlorobenzene; o-dichlorobenzol; RTECS 2005 
orthodichlorobenzene 
Trade names	 Chloroben; Cloroben; Dilatin DB; HSDB 2005; RTECS 2005
Dowtherm E; Dizene; Special termite 
fluid; Termitkil 
Chemical formula 	 C6H4Cl2 RTECS 2005 
Chemical structure 	 Cl 
Cl 
Identification numbers: 
CAS Registry 95-50-1 Lide 2000 
 NIOSH RTECS CZ4500000 RTECS 2005
EPA Hazardous Waste U070; F002 HSDB 2005 
 OHM/TADS No data 
DOT/UN/NA/IMCO Shipping UN 1591; IMO 6.1 HSDB 2005 
HSDB 521 HSDB 2005 



















   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
257 DICHLORORBENZENES
4. CHEMICAL AND PHYSICAL INFORMATION 
Table 4-1. Chemical Identity of 1,2-, 1,3-, and 1,4-Dichlorobenzene 
Characteristic Value Reference 
Chemical name  1,3-Dichlorobenzene Lide 2000; HSDB 2005 
Synonyms m-Dichlorobenzene; m-DCB; RTECS 2005 
m-dichlorobenzol; m-phenylene 
dichloride 
Trade names No data 
Chemical formula C6H4Cl2 RTECS 2005 
Chemical structure Cl 
Cl 
Identification numbers: 
CAS Registry 541-73-1 Lide 2000 
 NIOSH RTECS CZ4499000 RTECS 2005
EPA Hazardous Waste U071 HSDB 2005 
 OHM/TADS No data 
DOT/UN/NA/IMCO Shipping No data 
HSDB 522 HSDB 2005 


























4. CHEMICAL AND PHYSICAL INFORMATION 
Table 4-1. Chemical Identity of 1,2-, 1,3-, and 1,4-Dichlorobenzene 
Characteristic Value Reference 
Chemical name  1,4-Dichlorobenzene Lide 2000 
Synonyms para-Dichlorobenzene; p-dichloro- RTECS 2005 
benzene; p-chlorophenyl chloride; 
PDB; PDCB; p-dichlorobenzol 
Trade names Paracide; Paradow; Paradi; RTECS 2005 
Santochlor; Paramoth; Paranuggets; 
Parazene; Persia-perazol; Para 
crystals; Global; Evola; Di-chloricide 
Chemical formula C6H4Cl2 RTECS 2005 
Chemical structure Cl 
Cl 
Identification numbers: 
CAS Registry 106-46-7 Lide 2000 
 NIOSH RTECS CZ4550000 RTECS 2005
EPA Hazardous Waste U072; D027 HSDB 2005 
 OHM/TADS No data 
DOT/UN/NA/IMCO Shipping UN 1592; IMO 6.1 HSDB 2005 
HSDB 523 HSDB 2005 
NCI NCI-C54955 RTECS 2005
CAS = Chemical Abstracts Service; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/Intergovernmental Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 




























4. CHEMICAL AND PHYSICAL INFORMATION 
Table 4-2. Physical and Chemical Properties of 1,2-, 1,3-, and 
1,4-Dichlorobenzene 
Property Value Reference 
Chemical name 1,2-Dichlorobenzene Lide 2000 
Molecular weight 147.00 Lide 2000 
Color Colorless to pale yellow NIOSH 2005
Physical state Liquid Lewis 1997 
Melting point -16.7 °C Lide 2000 
Boiling point 180 °C Lide 2000 
Density at 20 °C 1.3059 g/mL Lide 2000 
Odor Pleasant, aromatic NIOSH 2005
Odor threshold: 
 Water 0.01 mg/L Verschueren 2001 
Air 50 ppm (301 mg/m3) Verschueren 2001 
Solubility: 
Water 156 mg/L at 25 °C Banerjee et al. 1980 
Organic solvents Miscible with alcohol, ether, benzene O’Neil 2001 
Partition coefficients: 
Log octanol/water 3.43 Hansch et al. 1995 
 Log Koc 2.51 Chiou et al. 1983 
Vapor pressure at 25 °C 1.36 mm Hg Daubert and Danner 1992
Henry's law constant at 25 °C 1.92x10-3 atm m3/mol Shiu and Mackay 1997 
Autoignition temperature 640 °C Krishnamurti 2001 
Flashpoint 28 °C (closed cup) Krishnamurti 2001 
Flammability limits No data 
Conversion factors 1 mg/m3=0.116 ppm at 25 °C and Verschueren 2001 
760 mm Hg; 
1 ppm=6.01 mg/m3 at 25 °C and 
760 mm Hg 




























4. CHEMICAL AND PHYSICAL INFORMATION 
Table 4-2. Physical and Chemical Properties of 1,2-, 1,3-, and 
1,4-Dichlorobenzene 
Property Value Reference 
Chemical name 1,3-Dichlorobenzene Lide 2000 
Molecular weight 147.00 Lide 2000 
Color Colorless Lewis 1997 
Physical state Liquid Lewis 1997 
Melting point -24.8 °C Lide 2000 
Boiling point 173 °C Lide 2000 
Density at 20 °C 1.2884 g/mL Lide 2000 
Odor No data 
Odor threshold: 
 Water 0.02 mg/L Verschueren 2001 
Air No data 
Solubility: 
Water 125 mg/L at 20 °C Miller et al. 1984 
Organic solvents Soluble in alcohol, ether O’Neil 2001 
Partition coefficients: 
Log octanol/water 3.53 Hansch et al. 1995 
 Log Koc 2.47 Chiou et al. 1983 
Vapor pressure at 25 °C 2.15 mm Hg Daubert and Danner 1992
Henry's law constant at 25 °C 2.8x10-3 atm m3/mol Staudinger and Roberts 1996 
Autoignition temperature >500 °C Krishnamurti 2001 
Flashpoint No data 
Flammability limits No data 
Conversion factors 1 mg/ m3=0.116 ppm at 25 °C and HSDB 2005 
760 mm Hg; 
1 ppm=6.01 mg/m3 at 25 °C and 
760 mm Hg 





























4. CHEMICAL AND PHYSICAL INFORMATION 
Table 4-2. Physical and Chemical Properties of 1,2-, 1,3-, and 
1,4-Dichlorobenzene 
Property Value Reference 
Chemical name 1,4-Dichlorobenzene Lide 2000 
Molecular weight 147.00 Lide 2000 
Color Colorless or white NIOSH 2005
Physical state Solid Lewis 1997 
Melting point 52.7 °C Lide 2000 
Boiling point 174 °C Lide 2000 
Density at 20 °C 1.46 g/mL O’Neil 2001 
Odor Mothball-like; penetrating Lewis 1997; NIOSH 2005
Odor threshold: 
Water 0.011 mg/L Amoore and Hautala 1983
Air 0.18 ppm (1.1 mg/m3) Amoore and Hautala 1983
Solubility: 
Water 80.0 mg/L Yalkowsky and He 2003 
Organic solvents Soluble in alcohol, ether, benzene, O’Neil 2001 
chloroform, carbon disulfide 
Partition coefficients: 
Log octanol/water 3.44 Hansch et al. 1995 
 Log Koc 2.44 Chiou et al. 1983 
Vapor pressure at 25 °C 1.77 mm Hg Daubert and Danner 1992
Henry's law constant at 25 °C 2.41x10-3 atm m3/mol Shiu and Mackay 1997 
Autoignition temperature >500 °C Krishnamurti 2001 
Flashpoint 67 °C (closed cup) Krishnamurti 2001 
Flammability limits 6.2–16% Leber and Bus 2001 
Conversion factors 1 ppm=6.01 mg/m3 at 25 °C and Verschueren 2001 
760 mm Hg; 
1 mg/m3=0.166 ppm at 25 °C and 
760 mm Hg 












4. CHEMICAL AND PHYSICAL INFORMATION 



























5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
5.1 PRODUCTION 
Chlorinated benzenes are produced typically by reacting liquid benzene with gaseous chlorine in the 
presence of a catalyst at moderate temperature (unspecified) and atmospheric pressure (IARC 1999; 
Rossberg et al. 2002).  This reaction yields a mixture of chlorobenzene isomers with varying degrees of 
chlorination. A maximum dichlorobenzene yield of 98% is obtainable in a batch process in which 
2 moles of chlorine is used per mole of benzene (mass ratio approximately 1.8:1) in the presence of ferric 
chloride and sulfur monochloride (IARC 1999).  1,2- and 1,4- DCB are the major DCB isomers formed in 
this process, with 1,2:1,4 ratios dependant on the type of catalyst used (Table 5-1).  1,3-DCB is also 
formed, but in much smaller quantities (Krishnamurti 2001).  The DCB isomers are typically separated by
crystallization and distillation. 
Production of 1,4-DCB in the United States has risen from approximately 15 million pounds 
(6,800 metric tons) in 1981 to approximately 72 million pounds (32,600 metric tons) in 1993 (IARC 
1999).  The production volume of 1,4-DCB reported by manufacturers in 1998 and 2002 was within the 
range of greater then 50 million pounds to 100 million pounds (>23,000–45,000 metric tons) (EPA 
2002e). The historical rate of growth of this chemical from 1989–1998 was 1.1 percent per year (CMR 
1999). 
Production of 1,2-DCB in the United States fell from approximately 54 million pounds (24,700 metric 
tons) in 1975 to approximately 35 million pounds (15,800 metric tons) in 1993 (IARC 1999).  The 
production volume of 1,2-DCB reported by manufacturers in 1998 was within the range of >50 million 
pounds to 100 million pounds (>23,000–45,000 metric tons) (EPA 2002e).  In 2002, companies reported 
production within the range of <10 million pounds to 50 million pounds (<5,000–23,000 metric tons) 
(EPA 2002e).  The historical rate of growth of this chemical from 1986–1995 was 0.7 percent per year 
(CMR 1996).
Production of 1,3-DCB in the United States was <1 million pounds (500 metric tons) in 1983 (IARC 
1999).  The production volume of this chemical reported by manufacturers was within 10 thousand 
pounds to 500 thousand pounds (5–200 metric tons) during reporting year 1986, >1 million pounds to
























5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
Table 5-1. Influence of Catalysts on the Ratio 1,4-:1,2-Dichlorobenzene 
Proportion of 1,4-dichlorobenzene Ratio 1,4- : 1,2-di-
Catalyst (in percent) in the dichlorobenzene fraction chlorobenzene 
MnCl2 + H2O ca. 50 1.03 
SbCl5 1.5 
FeCl3 or Fe ca. 59 1.49–1.55
Metallosilicon organic 61–74 1.56–2.8 
compounds 
AlCl3 – SnCl4 2.21 
AlCl3 – TiCl4 2.25 
Fe – S – PbO ca. 70 
FeCl3 – diethyl ether 2.38 
Aluminum silicate­ 2.7 
hexamethylene-diamine 
FeCl3 – S2Cl2 ca. 76 
FeCl3 – divalent organic sulfur ca. 77 3.3 
compounds 
L-type zeolite ca. 88 8.0 
TiCl4 (chlorinating agent is  20–30 
FeCl3) 





















5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
1 million pounds (>200–500 metric tons) in reporting years 1994 and 1998 (EPA 2002e).  Production 
volume data were not listed for reporting year 2002. 
1,4-DCB is the most important of the three DCB isomers commercially (Elovaara 1998). However, the 
high 1,2- to 1,4-DCB ratio has traditionally created an isomer imbalance in the DCB market (CMR 1999).  
Decreasing demand for 1,2-DCB in recent years has resulted in an increased economic disadvantage for 
the companies producing these chemicals.   
1,4-DCB and 1,2-DCB are currently produced by 2 U.S. companies at 2 different locations:  Solutia Inc., 
in Sauget, Illinois and PPG Industries, Inc., in Natrium, West Virginia (SRI 2005).  Current annual 
1,4-DCB production capacity for Solutia Inc. and PPG Industries, Inc. are 39 and 40 million pounds 
(17,700 and 18,100 metric tons), respectively (SRI 2005).  Total annual production capacity for this 
isomer has fluctuated during the last 2 decades.  The annual production capacity was 119 (54,000), 
132 (59,900), 371 (168,000), 144 (65,000), 145(66,000), 154(70,000), and 79 (35,800) million pounds 
(metric tons) in 1983, 1988, 1995, 1997, 1999, 2001, and 2003 respectively (SRI 1984, 1988, 1995, 1997, 
1999, 2001, 2003).  Current annual 1,2-DCB production capacity for Solutia and PPG are 13 and 
20 million pounds (5,900 and 9,000 metric tons), respectively (SRI 2005).  The annual production 
capacity for the 1,2- isomer was 78 (35,000), 81 (37,000), 81 (37,000), 76 (34,000), 80 (36,000), 
83 (38,000), and 33 (15,000) million pounds (metric tons) in 1983, 1988, 1995, 1997, 1999, 2001, and 
2003 respectively (SRI 1984, 1988, 1995, 1997, 1999, 2001, 2003).   
Tables 5-2, 5-3, and 5-4 list the facilities in each state that manufacture or process 1,2-, 1,3-, and 
1,4-DCB, respectively.  These tables give the intended use and the range of maximum amounts of each 
DCB isomer that are stored on site.  The data listed in Tables 5-2 through 5-4 are derived from the Toxics 
Release Inventory (TRI03 2005).  Only certain types of facilities were required to report (EPA 1997b).  
Therefore, this is not an exhaustive list. 
5.2 IMPORT/EXPORT 
In 1978, about 1.09x104 kg (24,030 pounds) of 1,4-DCB were imported into the United States (HSDB 
2005; NTP 1989).  Import volumes of 1,4-DCB were 867,441 kg (1.9 million pounds), 1,113,676 kg 
(2.5 million pounds), 996,649 kg (2.2 million pounds), 3,283,759 kg (7.2 million pounds), and 


















5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
Table 5-2. Facilities that Produce, Process, or Use 1,2-Dichlorobenzene 
Minimum amount Maximum 
Number of on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AL 3 1,000 999,999 6, 11, 12 
AR 12 100 49,999,999 2, 3, 6, 7, 10, 12 
AZ 1 1000 9,999 11 
CA 15 100 9,999,999 2, 3, 7, 8, 9, 11, 12 
CO 1 1,000 9,999 7 
CT 2 1,000 99,999 12 
DE 6 1,000 9,999,999 1, 3, 4, 6, 7, 9
FL 2 10,000 99,999 7, 11 
GA 3 1,000 99,999 7, 8 
IL 3 1,000 9,999,999 1, 4, 12 
IN 8 100 999,999 2, 3, 7, 10, 12 
KS 3 100 99,999 12 
KY 2 10,000 999,999 1, 3, 6 
LA 12 100 999,999 1, 5, 6, 10, 12 
MA 8 100 999,999 7, 10, 11, 12 
MI 4 0 9,999 7, 8, 9, 12 
MN 1 1,000 9,999 12 
MO 6 100 99,999,999  7, 9, 12 
MS 5 0 999,999 1, 3, 9, 11, 12 
NC 12 100 999,999 2, 3, 6, 7, 10, 11, 12 
NE 2 10,000 999,999 12 
NH 1 0 99 12 
NJ 22 1,000 9,999,999 2, 3, 6, 7, 8, 9, 10, 12, 14 
NY 8 1,000 999,999 10, 11, 12 
OH 8 1,000 9,999,999 3, 7, 9, 10, 11, 12 
OK 1 1,000 9,999 12 
OR 2 10,000 99,999 8, 12 
PA 9 0 999,999 3, 7, 10, 11, 12 
RI 4 1,000 99,999 7, 8, 10 
SC 6 100 999,999 6, 10, 11, 12 
TN 3 10,000 999,999 10, 11 
TX 31 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13 
VA 2 10,000 999,999 12 
WI 3 10,000 999,999 9, 10 
WV 6 100,000 49,999,999 1, 4, 10, 11 
Source: TRI03 2005 (Data are from 2003) 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses:
1. Produce 6. Impurity 11. Chemical Processing Aid
2. Import 7. Reactant 12. Manufacturing Aid  
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses 
4. Sale/Distribution 9. Article Component 14. Process Impurity 





















5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
Table 5-3. Facilities that Produce, Process, or Use 1,3-Dichlorobenzene 
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AR 1 1,000 9,999 12 
CA 1 100 999 12 
DE 7 100 9,999,999 1, 3, 4, 5, 6, 13
IL 5 1,000 9,999,999 1, 4, 5, 12, 13 
IN 1 100 999 12 
KY 1 10,000 99,999 1, 3, 6 
LA 4 1,000 999,999 1, 5 
MI 2 100,000 999,999 2, 3, 6 
MO 3 100 99,999 6, 12 
MS 1 100 999 12 
NJ 3 100 999,999 3, 6, 10, 12 
OH 2 1,000 99,999 12 
SC 1 10,000 99,999 6 
TX 7 0 99,999 1, 5, 11, 12, 13 
WV 3 100,000 9,999,999 1, 4, 5, 13 
Source: TRI03 2005 (Data are from 2003) 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses:
1. Produce 6. Impurity 11. Chemical Processing Aid
2. Import 7. Reactant 12. Manufacturing Aid  
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses 
4. Sale/Distribution 9. Article Component 14. Process Impurity 




















5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
Table 5-4. Facilities that Produce, Process, or Use 1,4-Dichlorobenzene 
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AR 6 1,000 99,999 1, 2, 6, 7, 12, 13 
CA 2 100 999 3, 4, 9, 12 
DE 2 1,000,000 49,999,999 1, 3, 4, 6 
FL 4 10,000 99,999 4, 7, 9 
GA 9 1,000 999,999 7, 8, 9, 12 
IL 8 0 9,999,999 1, 2, 3, 4, 7, 9, 11, 12, 14 
IN 6 100 99,999 7, 8, 11, 12 
KS 8 100 999,999 7, 9, 12 
KY 3 1,000 99,999 2, 4, 12 
LA 8 0 999,999 1, 5, 6, 13 
MA 5 1,000 999,999 2, 3, 7, 11 
MI 2 1,000 99,999 2, 5 
MO 4 100 999,999 1, 5, 8, 12 
NC 5 100 999,999 2, 3, 6, 11, 12 
NE 1 10,000 99,999 12 
NJ 12 1,000 999,999 2, 3, 4, 7, 8, 9, 12 
NY 1 100 999 2, 4 
OH 13 1,000 999,999 1, 2, 3, 4, 7, 8, 9, 10, 11, 12 
OK 4 1,000 99,999 2, 3, 6, 8 
PA 6 100 99,999 3, 7, 9, 10, 11, 12 
SC 2 10,000 99,999 6, 12 
TX 12 0 49,999,999 1, 2, 3, 5, 6, 7, 12, 13 
UT 1 1,000 9,999 12 
VA 1 1,000 9,999 12 
WV 1 1,000,000 9,999,999 1, 4 
Source: TRI03 2005 (Data are from 2003) 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses:
1. Produce 6. Impurity 11. Chemical Processing Aid
2. Import 7. Reactant 12. Manufacturing Aid  
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses 
4. Sale/Distribution 9. Article Component 14. Process Impurity 




















5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
imports of 1,2-DCB were 6,300 kg in 1972 and 1,230,000 kg in 1975 (HSDB 2005).  U.S. imports of 
1,3-DCB were 56,600 kg in 1983 (HSDB 2005).  More recent import data for the DCB isomers were not 
available. 
In 1972, U.S. exports of 1,4-DCB were reported to be 4.5x106 kg (9.9 million pounds) (HSDB 2005).  
Exports of 1,4-DCB have expanded through the 1980s at about 1–2% per year due to the growth in 
production of polyphenylene sulfide (PPS) resin overseas (HSDB 2005; NTP 1989).  In 1990, the United 
States exported about 25% (about 33 million pounds) of its 1,4-DCB production volume (CMR 1990).
Export volumes of 1,4-DCB were 11,925,179 kg (24.1 million pounds), 11,185,034 kg (24.7 million 
pounds), 10,651,337 kg (23.5 million pounds), 13,390,545 kg (29.5 million pounds), and 11,078,150 kg 
(24.4 million pounds) for 1990, 1991, 1992, 1993, and 1994, respectively.  1,4-DCB exports during 
1994–1997 averaged 25 million pounds (11,000 metric tons) (CMR 1999).  U.S. exports of 1,2-DCB 
averaged 14 million pounds (6,000 metric tons) per year during 1991–1995 (CMR 1996).  Export data for 
1,3-DCB were not available. 
Based on a 1993 production volume value of 72 million pounds (32,600 metric tons), an import value of 
7 million pounds (3,000 metric tons), and an export value of 30 million pounds (14,000 metric tons), the 
total amount of 1,4-DCB available for use in U.S. commerce in 1993 was 49 million pounds 
(22,000 metric tons).  Based on a 1993 production volume value of  35 million pounds (15,800 metric 
tons) and an export value of 14 million pounds (6,000 metric tons), the total amount of 1,2-DCB 
remaining in the United States in 1993 was 21 million pounds (10,000 metric tons) assuming that imports 
of this chemical during that year were negligible.  It should be noted, however, that not all of the 1,2-DCB 
that is produced is expected to be available for use since large quantities of this chemical are more likely
to be disposed of when it is produced as a byproduct in the production of 1,4-DCB.  Although reported 
export values for 1,2- and 1,4-DCB show that considerable amounts of these chemicals have been sent to 
other countries in previous years, the production volumes for these chemicals have been consistently
higher suggesting that more than half of the amounts produced each year have remained in the United 
States. 
5.3 USE 
For the past 20 years, 1,4-DCB has been used principally (25–55% of all uses) as a space deodorant for
toilets and refuse containers, and as a fumigant for control of moths, molds, and mildews.  In recent years, 




























5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
50% of its total use).  1,4-DCB is also used as an intermediate in the production of other chemicals such 
as 1,2,4-trichlorobenzene (approximately 10%).  Minor uses of 1,4-DCB include its use in the control of 
certain tree-boring insects and ants, and in the control of blue mold in tobacco seed beds (CMR 1999; 
HSDB 2005).
1,2-DCB is used primarily as a precursor to 3,4-dichloroaniline herbicides.  Other uses of 1,2-dichloro­
aniline include its use as a solvent, in the synthesis of dyes, and in odor control products (CMR 1996; 
HSDB 2005).
1,3-DCB has been used in the production of herbicides and insecticides as well as in the production of 
pharmaceuticals and dyes (IARC 1999). 
5.4 DISPOSAL 
Wastes containing DCBs are considered hazardous if they meet certain criteria specified by law.  
Hazardous wastes are subject to the handling, transport, treatment, storage, and disposal regulations as 
promulgated under the Resource Conservation and Recovery Act (HSDB 2005; IRPTC 1985).  
Regulations governing the treatment and disposal of wastes containing DCBs are detailed in Chapter 8.  
Incineration by appropriate means is the recommended method for the disposal of waste 1,4-DCB (HSDB 
2005).  1,4-DCB may be disposed of by making packages of the chemical in paper or other disposable 
material and burning in a suitable combustion chamber equipped with an appropriate effluent gas cleaning 
device or by dissolving the chemical in a flammable solvent (such as alcohol) and atomizing in a suitable 
combustion chamber equipped with an appropriate effluent gas cleaning device (IRPTC 1985).
Halogenated compounds may be disposed of by incineration provided they are blended with other 
compatible wastes or fuels so that the composite contains <30% halogens.  Liquid injection, rotary kiln, 
and fluidized bed incinerators are typically used to destroy liquid halogenated wastes.  Temperatures of at 
least 2,000–2,200 °F are necessary.  Residence times of seconds are required for liquids and gases, while 
hours are required for solids (HSDB 2005).  1,2-DCB is produced in large quantities as a byproduct 
during the production of 1,4-DCB.  Unused supplies may be disposed of or released directly into the 
environment. 
No data were located regarding historic disposal trends or the amounts of 1,2-, 1,3-, or 1,4-DCB disposed 

























6. POTENTIAL FOR HUMAN EXPOSURE 
6.1 OVERVIEW
1,2-, 1,3- and 1,4-Dichlorobenzene (DCB) have been identified in at least 281, 175, and 330, respectively, 
of the 1,662 hazardous waste sites that have been proposed for inclusion on the EPA National Priorities 
List (NPL), respectively (HazDat 2005).  However, the number of sites evaluated for these DCB isomers 
is not known. The frequency of these sites can be seen in Figures 6-1, 6-2, and 6-3.  Of these sites, all are 
located within the United States. 
1,4-DCB is a widely used chemical that enters the environment primarily as releases to air during its use 
as a space deodorant, toilet deodorizer, and moth repellant.  1,2- and 1,3-DCB are expected to be released 
to the environment during their use in herbicide production or during the use of other products containing 
these isomers.  However, 1,2- and 1,3-DCB are used much less than the 1,4-isomer.  Disposal of 
1,2-DCB, which is produced as a by-product in the manufacture of 1,4-DCB, may be a significant 
pathway by which 1,2-DCB is released into the environment.  DCBs are not known to occur naturally in 
the environment and are solely produced by commercial, industrial, and consumer activities. 
DCBs are degraded in the atmosphere by reaction with hydroxyl radicals, with a calculated atmospheric 
lifetime of 14-31 days (Atkinson 1989; Howard 1989).  DCBs will exist predominantly in the vapor-
phase in the atmosphere, and their detection in rainwater suggests that atmospheric removal via washout 
is possible (Ligocki et al. 1985).  Depending on soil type, DCBs are expected to be moderately mobile in 
soil. They are also expected to volatilize from surface water and soil surfaces to the atmosphere.  
Volatilization, sorption, biodegradation, and bioaccumulation are likely to be competing processes, with 
the dominant fate being determined by local environmental conditions. 
The principal route of exposure to DCBs for the general population (including children) is via inhalation, 
with average daily adult intakes from ambient air estimated at about 35 µg for 1,4-DCB, 1.8 µg for 
1,2-DCB, and 0.8 µg for 1,3-DCB (EPA 1985a; Singh et al. 1981a, 1981b).  Recent data suggest that 
exposure to 1,4-DCB from indoor air may be an order of magnitude higher than exposures from ambient 
outdoor air (Wallace et al. 1986b).  Indoor inhalation exposure to 1,2- or 1,3-DCB is not expected to be as 
high as 1,4-DCB since these substances are not used in household and consumer products to the extent 
that 1,4-DCB is. Consumer contact with 1,4-DCB associated with its use in moth repellant crystals and  
272 DICHLOROBENZENES  
 




























273 DICHLOROBENZENES  
 
6.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
























274 DICHLOROBENZENES  
 
6.  POTENTIAL FOR HUMAN EXPOSURE 
 
 














































   
275DICHLOROBENZENES
6. POTENTIAL FOR HUMAN EXPOSURE 
toilet deodorizers is the most frequent means of exposure to this compound in the home (Wallace et al. 
1986b, 1989).  DCBs have been detected in various types of foods and drinking water, although generally
in low concentrations (Heikes et al. 1995; IARC 1999; Page and Lacroix 1995; Young and Heesen 1978; 
Young et al. 1980).  DCB exposure through these pathways is not expected to be important.  Children 
may be accidentally exposed to 1,4-DCB if they eat moth balls or toilet deodorizers.  Occupational 
exposure is primarily through inhalation or dermal contact with DCBs, with the highest exposure 
resulting from production or processing of these chemicals (IARC 1999). 
6.2 RELEASES TO THE ENVIRONMENT 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing 
facilities are required to report information to the TRI only if they employ 10 or more full-time 
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005).
According to the TRI, in 2003, a total of 92,973 pounds (42 metric tons) of 1,2-DCB was released to the 
environment from 39 large processing facilities (TRI03 2005).  Table 6-1 lists amounts released from
these facilities. Of this total, an estimated 87,443 pounds (40 metric tons) were released to air, 
1,240 pounds (0.6 metric tons) were released to water, 1,784 pounds (0.8 metric tons) were released to 
land, and 2,500 pounds (1 metric ton) were released via underground injection. The total amount of 
1,2-DCB released on-site was estimated as 91,868 pounds (42 metric tons).  The total amount released 
off-site was estimated as 1,104 pounds (0.5 metric tons) (TRI03 2005). 
According to the TRI, in 2003, a total of 1,966 pounds (0.9 metric tons) of 1,3-DCB was released to the 
environment from eight large processing facilities (TRI03 2005).  Table 6-2 lists amounts released from
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Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek On- and off-site 
AR 4 78 No data 0 0 0 78 0 78 
CA 1 640 No data 0 0 0 640 0 640 
IL 2 8,961 No data 0 5 5 8,961 10 8,971 
IN 1 9,700 750 0 0 0 10,450 0 10,450 
KS 1 2 No data 0 0 0 2 0 2 
KY 1 3 0 0 0 0 3 0 3 
LA 2 7,800 8 2,500 110 0 10,308 110 10,418 
MA 1 360 No data 0 0 0 360 0 360 
MS 2 510 No data 0 0 0 510 0 510 
NC 2 1,250 No data 0 0 0 1,250 0 1,250 
NE 1 5 No data 0 0 0 5 0 5 
NJ 2 652 13 0 1,267 0 1,225 707 1,932 
NY 1 5 No data 0 0 0 5 0 5 
OH 1 5 5 0 255 0 10 255 265 
PA 2 10 No data 0 0 0 10 0 10 
RI 1 2,068 4 0 22 0 2,072 22 2,094 
SC 2 9,707 5 0 0 0 9,712 0 9,712 
TN 1 No data No data No data No data No data No data 0 0 
TX 9 5,137 3 0 110 0 5,251 0 5,251 
WV 2 40,550 452 0 15 0 41,017 0 41,017 
Total 39 87,443 1,240 2,500 1,784 5 91,868 1,104 92,973 
Source: TRI03 2005 (Data are from 2003) 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used. 

dNumber of reporting facilities.
 
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 

fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 

and metal compounds). 

gClass I wells, Class II-V wells, and underground injection. 

hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills. 





jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 

kTotal amount of chemical transferred off-site, including to POTWs. 

RF = reporting facilities; UI = underground injection 
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Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf Landh On-sitej Off-sitek On- and off-site 
AR 1 0 No data 0 0 0 0 
IL 1 451 No data 0 451 0 451 
KY 1 2 0 0 2 0 2 
OH 1 5 5 255 10 255 265 
SC 1 182 5 0 187 0 187 
TX 2 43 3 0 47 0 47 
WV 1 664 350 0 1,014 0 1,014 
Total 8 1,347 363 255 1,711 255 1,966 
Source: TRI03 2005 (Data are from 2003) 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used. 

dNumber of reporting facilities.
 
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 

fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 

and metal compounds). 

gClass I wells, Class II-V wells, and underground injection. 

hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills. 





jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 

kTotal amount of chemical transferred off-site, including to POTWs. 

RF = reporting facilities; UI = underground injection 





















6. POTENTIAL FOR HUMAN EXPOSURE 
these facilities. Of this total, an estimated 1,347 pounds (0.6 metric tons) were released to air, 363 pounds 
(0.2 metric tons) were released to water, 255 pounds (0.1 metric tons) were released to land, and 0 pounds 
were released via underground injection.  The total amount of 1,3-DCB released on-site was estimated as 
1,711 pounds (0.8 metric tons).  The total amount released off-site was estimated as 255 pounds 
(0.1 metric tons) (TRI03 2005). 
According to the TRI, in 2003, a total of 96,993 pounds (44 metric tons) of 1,4-DCB was released to the 
environment from 21 large processing facilities (TRI03 2005).  Table 6-3 lists amounts released from
these facilities. Of this total, an estimated 85,463 pounds (39 metric tons) were released to air, 
815 pounds (0.4 metric tons) were released to water, 270 pounds (0.1 metric tons) were released to land, 
and 10,408 pounds (5 metric tons) were released via underground injection.  The total amount of 
1,4-DCB released on-site was estimated as 96,696 pounds (44 metric tons).  The total amount released 
off-site was estimated as 297 pounds (0.1 metric tons) (TRI03 2005).  The TRI data should be used with 
caution because only certain types of facilities are required to report.  This is not an exhaustive list. 
1,2-, 1,3-, and 1,4-DCB have been identified in a variety of environmental media (air, surface water, 
groundwater, soil, and sediment) collected at 281, 175, and 330 of the 1,662 NPL hazardous waste sites, 
respectively (HazDat 2005).  The number of these sites located in each state can be seen in Figures 6-1, 
6-2, and 6-3.  
Quantitative information on releases of DCBs to specific environmental media is discussed below. 
6.2.1 Air 
According to the TRI, estimated releases of 1,2-DCB of 87,443 pounds (40 metric tons) to the air from
39 large processing facilities accounted for about 93% of the total TRI environmental releases in 
2003 (TRI03 2005).  Table 6-1 lists amounts of 1,2-DCB released from these facilities.  Estimated 
releases of 1,3-DCB of 1,347 pounds (0.6 metric tons) to the air from eight large processing facilities 
accounted for about 69% of the total TRI environmental releases in 2003 (TRI03 2005).  Table 6-2 lists 
amounts of 1,3-DCB released from these facilities.  Estimated releases of 1,4-DCB of 85,463 pounds 
(38 metric tons) to the air from 20 large processing facilities accounted for about 88% of the total TRI 
environmental releases in 2003 (TRI03 2005).  Table 6-3 lists amounts of 1,4-DCB released from these 
facilities. The TRI data should be used with caution because only certain types of facilities are required 
to report (EPA 1997b).  Therefore, this is not an exhaustive list. 
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Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek 
On- and off-
site
AR 2 3 No data 0 0 0 3 0 3 
GA 1 No data No data No data No data No data No data 0 0 
IL 2 25,111 5 0 0 0 25,116 0 25,116 
KS 2 2,105 No data 0 5 0 2,105 5 2,110 
KY 1 2 No data 0 0 0 2 0 2 
MO 1 766 No data 0 0 0 766 0 766 
NC 1 11,515 6 0 0 0 11,521 0 11,521 
OH 2 1,385 5 0 255 0 1,390 255 1,645 
OK 1 569 No data 0 0 0 569 0 569 
PA 1 10 No data 0 0 0 10 0 10 
SC 1 No data No data No data No data No data No data 0 0 
TX 3 14,725 3 10,408 10 0 25,146 0 25,146 
UT 2 2 No data 0 0 37 2 37 39 
WV 1 29,270 796 0 0 0 30,066 0 30,066 
Total 21 85,463 815 10,408 270 37 96,696 297 96,993 
Source: TRI03 2005 (Data are from 2003) 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used. 

dNumber of reporting facilities.
 
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 

fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 

and metal compounds). 

gClass I wells, Class II-V wells, and underground injection. 

hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills. 





jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 

kTotal amount of chemical transferred off-site, including to POTWs. 

RF = reporting facilities; UI = underground injection 





















6. POTENTIAL FOR HUMAN EXPOSURE 
Because 1,4-DCB is a volatile substance that sublimes at room temperature, most environmental releases 
are to the atmosphere. In 1972, 70–90% of the annual U.S. production of 1,4-DCB was estimated to have 
been released into the atmosphere primarily as a result of its use in toilet bowl and garbage deodorants, 
and its use in moth control as a fumigant (IARC 1982).  It has been estimated that about 40% of the 
domestic use of 1,4-DCB is for space deodorants moth repellents (CMR 1999).  Assuming that 90% of 
the space deodorants and all of the moth repellents are released to the atmosphere (EPA 1981a), and using 
current production data (50–100 million pounds or 23,000–45,000 metric tons) (EPA 2002e), about 20– 
40 million pounds (9,000–18,000 metric tons) of 1,4-DCB were released to the air in 1994 from these 
sources. 1,4-DCB may also be emitted to air from other sources, such as hazardous waste sites (EPA 
1981a), during its use as a fumigant (EPA 1981a), or from emissions from waste incinerator facilities (Jay 
and Stieglitz 1995).  These emissions are likely to be a minor contribution to the total atmospheric 
loading of 1,4-DCB, but may be locally important.  There are no known natural sources of 1,4-DCB 
(IARC 1999).
1,2- and 1,3-DCB, which are volatile liquids at room temperature, are also expected to be released 
primarily to air.  Unlike 1,4-DCB, however, the 1,2- and 1,3- isomers are not widely used in household or 
consumer products and thus are not released into the air of homes and buildings to the extent of the 1,4- 
isomer.  1,2- and 1,3-DCB are expected to be released to the air during their use in herbicide production, 
during the use of other products containing these isomers, or from air emissions at hazardous waste sites 
and incinerator facilities. Another significant source for the release of 1,2-DCB to air may be from the 
disposal of this substance when it is produced as a by-product in the production of 1,4-DCB.  There are 
no known natural sources of 1,2- or 1,3-DCB (IARC 1999).  
The concentrations of 1,2-, 1,3-, and 1,4-DCB in the emissions of a municipal waste incineration plant 
were 2.32x10-6, 2.44x10-6, and 5.92x10-5 ppm, respectively (Jay and Stieglitz 1995).  DCBs were detected 
in emissions from municipal solid waste composting facilities at concentrations of 1.16x10-4 ppm for 
1,2-DCB, 2.32x10-4 ppm for 1,3-DCB, and 1.04x10-2 ppm for 1,4-DCB (Eitzer 1995).  Garcia et al. 
(1992) measured 1,4-DCB concentrations ranging from 3.48x10-5 to 4.99x10-4 ppm in the emissions of 
coal-fired power stations. 1,2-DCB was detected in landfill gas at the Fresh Kills municipal solid waste 
landfill in New York City with a mean concentration of 2.17 ppm (Eklund et al. 1998).
1,2-DCB has been identified in air samples collected at 15 of the 281 NPL hazardous waste sites, 
respectively, where it has been detected in at least one environmental medium (HazDat 2005).  1,3-DCB 
has been identified in air samples collected at 9 of the 175 NPL hazardous waste sites where it has been 
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6. POTENTIAL FOR HUMAN EXPOSURE 
detected in some environmental media (HazDat 2005).  1,4-DCB has been identified in air samples 
collected at 23 of the 330 NPL hazardous waste sites where it has been detected in some environmental 
media (HazDat 2005). 
6.2.2 Water 
According to the TRI, the estimated releases of 1,2-DCB of 1,240 pounds (0.6 metric tons) to water from
39 large processing facilities accounted for 1% of the total TRI environmental releases in 
2003 (TRI03 2005).  An additional 1,104 pounds (0.5 metric tons) (1% of total TRI environmental 
releases) were released off-site, which includes release to publicly owned treatment works (POTWs).  
Table 6-1 lists amounts of 1,2-DCB released from these facilities.  Estimated releases of 1,3-DCB of 
363 pounds (0.2 metric tons) to water from eight large processing facilities accounted for 18% of the total 
TRI environmental releases in 2003 (TRI03 2005).  An additional 255 pounds (0.1 metric tons) (13% of 
total TRI environmental releases) were released off-site, which includes release to POTWs.  
Table 6-2 lists amounts of 1,3-DCB released from these facilities.  Estimated releases of 1,4-DCB of 
815 pounds (0.4 metric tons) to water from 21 large processing facilities accounted for 0.8% of the total 
TRI environmental releases in 2003 (TRI03 2005).  An additional 297 pounds (0.1 metric tons) (0.3% of 
total TRI environmental releases) were released off-site, which includes release to POTWs.  
Table 6-3 lists amounts of 1,4-DCB released from these facilities.  The TRI data should be used with 
caution because only certain types of facilities are required to report (EPA 1997b).  Therefore, this is not 
an exhaustive list. 
Less than 1% of environmental releases of 1,4-DCB are to surface water (EPA 1981a).  The main route 
for the release of this substance to surface water is expected to be through its extensive use in urinal 
deodorant blocks (IARC 1999).  1,2-DCB is released into industrial waste water during its production and 
use. 1,2-DCB might also be released into waste water during the disposal of this substance when it is 
produced as a by-product in the production of 1,4-DCB.  Data concerning the release of 1,3-DCB to water 
are lacking. Release of this substance to water may occur during its production, use, or disposal.  DCBs 
have been identified in industrial and municipal waste waters from several sources, at concentrations 
ranging from <3 to >900 ppb (Oliver and Nichol 1982a; Perry et al. 1979; Young and Heesen 1978; 
Young et al. 1980, 1981).  1,2- and 1,4-DCB were both detected in 1% of 84 possible detections in 
influent samples from the New York City municipal waste water treatment system at concentrations of 
22 and 4 ppb, respectively (Stubin et al. 1996). 1,2-DCB was detected in 2% while 1,4-DCB was 
detected in 1% of 84 possible detections in effluent samples at concentrations of 4–6 and 3 ppb, 
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respectively. The concentrations of 1,2-DCB were higher than those of 1,4-DCB, which is contrary to 
what is expected for these substances in residential and domestic waste water.  However, no explanation 
was offered for this. The concentration of 1,4-DCB in the effluent of the North Regional Wastewater 
Treatment Plant in Broward County, Florida was approximately 1.2 ppb (Tansel and Eyma 1999).  
1,4-DCB was detected above “standard levels” (unspecified) in sediment at the end of the Macaulay Point 
and Clover Point waste water outfalls off the coast of Vancouver, British Columbia (Taylor et al. 1998). 
DCB (unspecified isomers) has been reported in the leachate from industrial and municipal landfills at 
concentrations from 0.007 to 0.52 ppm (7–520 ppb) (Brown and Donnelly 1988).  Eganhouse et al. 
(2001) identified 1,4-DCB at a concentration of 0.1–5.6 ppb in a landfill leachate plume in groundwater 
from a municipal landfill located in Norman, Oklahoma.  DCBs have also been detected in wetland-
treated leachate water at a municipal solid waste landfill in central Florida (Chen and Zoltek 1995).  
Groundwater samples contained 1,2-DCB at concentrations of 0.09–1.56 ppb, 1,3-DCB at concentrations 
of 0.08–8.95 ppb, and 1,4-DCB at concentrations of 0.08–10.71 ppb.  Hallbourg et al. (1992) detected 
DCB (unspecified isomers) in groundwater at several landfill sites in Orange County, Florida.  These 
authors reported mean concentrations of DCBs of 0.37–21.2, 6–46.4, and <1–7.4 ppb at the Orange 
County Landfill, Alachua County Southwest Landfill, and the Alachua County Northeast Landfill, 
respectively. In their study, DCB was one of the 10 most frequently detected volatile organic compounds 
(VOCs). Plumb (1991) also reported 1,2-, 1,3-, and 1,4-DCB in groundwater samples collected at 36, 16, 
and 34 of 479 hazardous waste sites, respectively.
1,4-DCB was monitored for, but not detected, in 86 samples of urban storm water runoff in the National 
Urban Runoff Program (Cole et al. 1984).  DCBs were detected in four rivers (Aire, Calder, Don, and 
Trent) that drain an industrial catchment from the United Kingdom into the North Sea (Meharg et al. 
2000). Annual fluxes in these rivers ranged from 1.37 to 32.91 kg/year for 1,2-DCB, 0.12 to 9.33 kg/year 
for 1,3-DCB, and 6.80 to 28.96 kg/year for 1,4-DCB.  
1,2-DCB has been identified in surface water and groundwater samples collected at 29 and 186 of the 
281 NPL hazardous waste sites, respectively, where it was detected in at least one environmental medium
(HazDat 2005). 1,3-DCB has been identified in surface water and groundwater samples collected at 
13 and 107 of the 175 NPL hazardous waste sites, respectively, where it was detected in some
environmental media (HazDat 2005).  1,4-DCB has been identified in surface water and groundwater 
samples collected at 31 and 213 of the 330 NPL hazardous waste sites, respectively, where it was detected 
in some environmental media (HazDat 2005). 
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6.2.3 Soil 
According to the TRI, releases of 1,2-DCB to land of 1,784 pounds (0.8 metric tons) from 39 large 
processing facilities accounted for 2% of total TRI environmental releases in 2003 (TRI03 2005).  An 
estimated 2,500 pounds (1 metric ton) (3% of total TRI environmental releases) were released via 
underground injection.  Table 6-1 lists amounts of 1,2-DCB released from these facilities.  Releases of 
1,3-DCB of 255 pounds (0.1 metric tons) to the land from eight large processing facilities accounted for 
13% of total TRI environmental releases in 2003 (TRI03 2005).  Table 6-2 lists amounts of 1,3-DCB 
released from these facilities.  There were no releases of 1,3-DCB to the underground in 2003 as shown in 
Table 6-2. Releases of 1,4-DCB of 270 pounds (0.1 metric tons) to the land from 21 large processing 
facilities accounted for 0.2% of total TRI environmental releases in 2003 (TRI03 2005).  In addition, an 
estimated 10,408 pounds (0.5 metric tons) (11% of total environmental releases) were released via 
underground injection.  Table 6-3 lists amounts of 1,4-DCB released from these facilities.  The TRI data 
should be used with caution because only certain types of facilities are required to report (EPA 1997b).  
Therefore, this is not an exhaustive list. 
The principal sources of 1,4-DCB release to land are disposal of industrial waste in landfills, application 
of sewage sludge containing 1,4-DCB to agricultural land, and atmospheric deposition (Wang and Jones 
1994b; Wang et al. 1995).  Municipal wastes may include unused space deodorants and moth repellents 
containing 1,4-DCB, but these releases are not expected to be significant (EPA 1981a).  A survey of 
204 sewage sludges conducted in Michigan that analyzed for 73 organic compounds reported a 
concentration range of 0.04–633 mg/kg dry weight (ppm) for 1,4-DCB and mean and median 
concentrations of 12.0 and 2.02 ppm, respectively (Jacobs and Zabik 1983).  1,4-DCB from this source 
may be released to soils during land applications of sludge to agricultural soils.  A similar survey of 
sewage sludges in England found 1,4-DCB ranging from 561 to 2,320 µg/kg (0.561–2.32 ppm wet 
weight) in all 12 of the samples tested (Wang and Jones 1994b).  Wang et al. (1995) reported, however, 
that 1,4-DCB concentrations increased during the 1960s in both plots receiving sewage sludge 
applications and in control soil plots.  The authors concluded that atmospheric deposition during the 
1960s in particular, which corresponded to a period of increased production of many organochlorine 
compounds, was a likely source.  1,2-DCB was detected in all 12 sewage sludge samples at 
concentrations ranging from 71.3 to 4,110 µg/kg (ppb) dry weight (3.57–152 ppb wet weight).  The 
concentrations of 1,2-DCB in industrial sewage sludge was considerably higher than in urban sewage 
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sludge. 1,3-DCB was detected in 9 out of 12 sewage sludge samples at concentrations ranging from
below the detection limit to 467 µg/kg (ppb) dry weight (below the detection limit–13.5 ppb wet weight). 
1,2-DCB is produced in large quantities as a by-product in the production of 1,4-DCB.  The TRI data for 
this substance suggest that 1,2-DCB may be released into the ground during the disposal of unused 
supplies. Data concerning the release of 1,3-DCB to soil were lacking.  Based on TRI data, the 
production volume of these chemicals, and their uses, releases of this isomer to soil are expected to be 
minor compared to the other DCB isomers. 
1,2-DCB has been identified in soil and sediment samples collected at 111 and 37 of the 281 NPL 
hazardous waste sites, respectively, where it was detected in at least one environmental medium (HazDat 
2005).  1,3-DCB has been identified in soil and sediment samples collected at 64 and 25 of the 175 NPL 
hazardous waste sites, respectively, where it was detected in at least one environmental medium (HazDat 
2005).  1,4-DCB has been identified in soil and sediment samples collected at 112 and 52 of the 330 NPL 
hazardous waste sites, respectively, where it was detected in at least one environmental medium (HazDat 
2005). 
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
Whereas 1,2- and 1,3-DCB are liquids at room temperature, 1,4-DCB is a solid that sublimes readily.  
Sublimation rates of 1,4-DCB from consumer products were measured at 1.6x10-3 to 4.6x10-3 g/minute at 
temperatures ranging from 21 to 24 °C during a 19-day test period (Scuderi 1986).  DCBs tend to 
volatilize to the atmosphere from soil and water at a relatively rapid rate.  The estimated volatilization 
half-life for these chemicals was 4 hours in a model river and 120 hours from a model lake (HSDB 2005).  
The reported volatilization half-lives for 1,4-DCB measured in coastal seawater ranged from 10 to 
18 days (Wakeham et al. 1983).  1,2-DCB (100 ppm) and 1,4-DCB (300 ppm) both volatilized 
completely from nonaerated distilled water in <3 days and from aerated distilled water in <4 hours 
(Garrison and Hill 1972).  Volatilization from surface soil may be an important transport mechanism for 
DCBs (Wang and Jones 1994a), but adsorption to soil particulates may inhibit volatilization (Wilson et al. 
1981). 
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Since DCBs are slightly soluble in water (80.0–156 mg/L) (Banerjee et al. 1980; Miller et al. 1984; 
Yalkowsky and He 2003), partitioning to clouds, rain, or surface water may occur.  Henry's Law constant 
values ranging from 1.74x10-3 to 2.63x10-3 atm-m3/mol at 25 °C (Shiu and Mackay 1997; Staudinger and 
Roberts 1996) indicate that partitioning from air to water is likely to be minor relative to the reverse 
process of volatilization of the compound from water to air.  However, DCBs have been detected in 
rainwater and snow (Laniewski et al. 1998, 1999; Ligocki et al. 1985).  The concentration of 1,4-DCB 
detected in 6 of 7 rainwater samples collected in Portland, Oregon, ranged from 3 to 7 ppt (ng/L), while 
the concentration of 1,2-DCB detected in 5 out of 7 rainwater samples ranged from 0.13 to 0.62 ppt 
(Ligocki et al. 1985).  DCBs have been detected in surficial snow from Antarctica (Laniewski et al. 
1998), which suggests that these substances can be transported over long distances through the 
atmosphere. 
Based on measured soil organic carbon partition coefficient (Koc) values, which range from 275 to 
1,833 in different soils (Bahnick and Doucette 1988; Chiou et al. 1983; Newsom 1985; Schwartzenbach 
and Westall 1981; Wilson et al. 1981), DCBs are expected to sorb moderately to soils and sediments.  
Sorption is primarily to the soil organic phase (Chiou et al. 1983) and, therefore, depends on the organic 
content of the soil.  However, sorption is likely to be reversible; therefore, DCBs may leach from
hazardous waste sites and be transported to groundwater, or may migrate from surface water through the 
soil to groundwater (Newsom 1985; Schwartzenbach and Westall 1981).  In a sandy soil with low organic 
matter, 26–49% of 1,4-DCB percolated through the soil to a depth of 140 cm (Wilson et al. 1981). 
DCBs are expected to bioconcentrate in aquatic organisms.  High log octanol-water partition coefficient 
(log Kow) values of 3.43–3.53 (Hansch et al. 1995) also suggest that DCBs have a moderate to high 
potential for bioaccumulation.  A calculated bioconcentration factor (BCF) of 267 was reported for the 
fathead minnow (Pimephales promelas) (ASTER 1995). Measured mean BCF values of 370 and 
720 were experimentally determined at equilibrium for rainbow trout exposed to water concentrations of 
28 ng/L (ppb) and 670 ng/L (ppb), respectively, of 1,4-DCB for up to 119 days in laboratory aquaria 
(Oliver and Niimi 1983).  BCF values measured in this study for 1,2-DCB were 270 (47 ng/L in water) 
and 560 (940 ng/L in water), while BCF values measured for 1,3-DCB were 420 (28 ng/L in water) and 
740 (690 ng/L in water).  A study of chlorobenzenes in sediments, water, and selected fish from the Great 
Lakes indicated that many chlorobenzenes are bioconcentrated by fish, but that DCBs are concentrated to 
a smaller extent than some of the more highly chlorinated chlorobenzene compounds such as 
pentachlorobenzene and hexachlorobenzene (Oliver and Niimi 1982a).  For example, equilibrium/steady­
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state BCF values measured in fish maintained in flowing water systems typically increased with
increasing chlorination as shown in Table 6-4. 
DCBs can enter soil-plant systems through many routes including atmospheric deposition, sewage sludge 
application to agricultural land, and through industrial activities (Wang and Jones 1994a).  Wang and 
Jones (1994c) studied the uptake of several chlorobenzene compounds in carrots grown in spiked and 
sewage-amended soils.  The transfer of chlorobenzenes from soils to plants and subsequent 
bioaccumulation is of interest because chlorobenzenes are ubiquitous in sewage sludge.  Chlorobenzenes 
are also lipophilic and volatile compounds that can be taken up by plants by both root and foliage 
pathways.  Carrots were grown for 100 days in control soil, chemically-spiked soil, and in low and high 
rate sludge-amended soils. DCB concentration in the soils did not remain constant throughout the growth
period. BCF values are not traditional steady-state values since measurements were taken for only one 
time interval. The authors reported that concentrations of 1,4-DCB in soil before sowing and after the 
harvest were 5.9  and 2.6 ppb dry weight in the control, 16 and 11 ppb in the chemically-spiked soil, 
10 and 7.4 ppb in the low rate sewage-amended soil, and 38 and 30 ppb in the high rate sewage-amended 
soils, respectively. Concentrations of 1,4-DCB in carrot foliage and the corresponding bioconcentration 
factors (BCFs) were 13 ppb (BCF=3.1) for the control, 17 ppb (BCF=1.3) for the spiked soil, 22 ppb 
(BCF=2.5) for the low rate sewage-amended soil, and 49 ppb (BCF=1.5) for the high rate sewage-
amended soil.  The concentrations of 1,2-DCB in soil before sowing and after the harvest were both 
below the detection limit (unspecified) in the control, 29 and 17 ppb in the chemically-spiked soil, 13 and 
7.3 ppb in the low rate sewage-amended soil, and 60 and 45 ppb in the high rate sewage-amended soils, 
respectively. Concentrations of 1,2-DCB in carrot foliage and the corresponding BCFs were 6.7 ppb 
(BCF not given) for the control, 9.6 ppb (BCF=0.42) for the spiked soil, 12 ppb (BCF=1.2) for the low 
rate sewage-amended soil, and 26 ppb (BCF=0.49) for the high rate sewage-amended soil.  The 
concentrations of 1,3-DCB in soil before sowing and after the harvest were both below the detection limit 
(unspecified) in the control, 4.2 and 2.9 ppb in the chemically-spiked soil, 2.3 and 0.98 ppb in the low rate 
sewage-amended soil, and 8.2 and 5.8 ppb in the high rate sewage-amended soils, respectively.  
Concentrations of 1,3-DCB in carrot foliage and the corresponding BCFs were 0.72 ppb (BCF not given) 
for the control, 0.83 ppb (BCF=0.24) for the spiked soil, 1.3 ppb (BCF=0.80) for the low rate sewage-
amended soil, and 2.2 ppb (BCF=0.31) for the high rate sewage-amended soil.  The application of the 
low-rate sewage sludge stimulated both the carrot foliage and root production to the greatest extent.  The 
authors concluded that foliar uptake of all chlorobenzenes tested, including the DCBs, was an important 
bioaccumulation pathway.
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Table 6-4. Comparison of Bioconcentration Factors (BCFs) for Various 

Chlorinated Benzenes in Fish 














Source: EPA 1985a 


















6. POTENTIAL FOR HUMAN EXPOSURE 
The concentrations (dry weight) of the DCBs in the carrot peel were typically equal to or slightly lower 
than the concentrations in the carrot core (Wang and Jones 1994a). This indicated that DCBs, when 
present in carrots, penetrate into the core.  For carrot roots, the concentrations of 1,4-DCB in the core and 
peel were 9.4 µg/kg (ppb) (BCF=2.2) and 7.0 ppb (BCF=1.6) for the control, 5.9 ppb (BCF=0.44) and 
7.3 ppb (BCF=0.54) for the chemically-spiked soil, 5.9 ppb (BCF=0.68) and 5.8 ppb (BCF=0.67) for the 
low-rate sewage application, and 9.6 ppb (BCF=0.28) and 4.3 ppb (BCF=0.13) for the high-rate sewage 
treatment, respectively.  The concentrations of 1,2-DCB in the core and peel were 1.5 µg/kg (ppb) (BCF 
not given) and 1.4 ppb (BCF not given) for the control, 5.8 ppb (BCF=0.25) and 5.3 ppb (BCF=0.23) for 
the chemically-spiked soil, 0.0 ppb (BCF=0.0) and 0.84 ppb (BCF=0.085) for the low-rate sewage 
application, and 2.8 ppb (BCF=0.053) and 1.5 ppb (BCF=0.029) for the high-rate sewage treatment, 
respectively.  1,3-DCB was only detected in the core of the chemically-spiked soil at 1.0 ppb (BCF=0.29) 
and in the core of the high-rate sewage treatment at 1.8 ppb (BCF=0.26).  1,3-DCB concentrations in the 
root peels as well as the root core of the control were below the detection limit (unspecified).  Overall, 
<1% of the DCBs and other chlorobenzenes in the soil were accumulated by the carrots, which is minor 
compared with the other loss pathway from the soil, principally volatilization.  
Wang et al. (1996) found that a 1 ppm solution of 1,4-DCB was taken up by carrots (Daucus carota, 
49%), soybeans (Glycine max, 50%), and red goosefoot (Chenopodium rubrum, 62%), but not by
tomatoes (Lycopersicon esculentum). Only the soybean cell cultures provided evidence of the existence 
of metabolites of this compound, probably conjugates of chlorophenol.  The authors further observed that 
the uptake, metabolism, and toxicity of 1,4-DCB differed among the species tested.   
Zhang et al. (2005) studied DCB uptake in vegetables grown in urban areas of China.  DCB 
concentrations in spinach, Chinese cabbage, and celery were highest in roots, followed by leaves.  
Concentrations in radishes and carrots were highest in leaves, followed by stems.  The authors reported 
that the accumulation of chlorinated benzenes in these vegetables was affected by the lipid contents of the
vegetables, the volatilities of the chemicals, and the physiological characteristics of the vegetables. 
Data on biomagnification of DCBs through aquatic or terrestrial food chains were not located. 























6. POTENTIAL FOR HUMAN EXPOSURE 
6.3.2 Transformation and Degradation  
6.3.2.1 Air 
The main degradation pathway for DCBs in air is reaction with photochemically generated hydroxyl
radicals (Cuppitt 1980; EPA 1985a).  Reactions with ozone or other common atmospheric species are not 
expected to be significant (Cuppitt 1980; EPA 1985d). Therefore, the atmospheric lifetime of the DCBs 
may be predicted from an assumed hydroxyl radical concentration in air and the rate of reaction.  The 
reported rate for reaction of hydroxyl radicals with DCBs is 3.2–7.2x10-13 cm3/mol-sec (Atkinson 1989; 
Howard 1989), and the estimated atmospheric half-life for DCBs is about 14–31 days (Howard 1989).  
Since this degradation process is relatively slow, DCBs may become widely dispersed, but are not likely
to accumulate in the atmosphere.  The degradation pathways for 1,4-DCB in the atmosphere are shown in 
Figure 6-4. 
Reports of smog chamber studies of chlorobenzene degradation have indicated degradation after 5 hours 
of 21.5% of 1,2-DCB (EPA 1985a).  Chloronitrobenzenes and chloronitrophenols were identified as 
degradation products. Irradiation of chlorobenzenes with natural sunlight was reported to produce 
polychlorinated biphenyls (PCBs).  Whether this occurs under natural atmospheric conditions is 
unknown, but it would appear to be unlikely because of the normally low concentrations of 
chlorobenzenes in ambient air. 
6.3.2.2 Water 
Biodegradation may be an important transformation process for DCBs in water under aerobic, but not 
anaerobic, conditions (Bouwer and McCarty 1982, 1983, 1984; Schwartzenbach et al. 1983; Spain and 
Nishino 1987; Tabak et al. 1981). Although volatilization of 1,4-DCB may interfere with biodegradation 
studies, 14C studies indicate that significant biodegradation of 1,4-DCB does occur (Spain and Nishino 
1987). Longer acclimation periods are required when 1,4-DCB is the sole carbon source (Spain and 
Nishino 1987). 
Several aerobic screening tests have been performed on the DCB isomers.  1,2- and 1,3-DCB, both at 
initial concentrations of 30 mg/L, reached 0% of their theoretical BOD in 4 weeks using an activated 
sludge inoculum at 100 mg/L and the Japanese MITI test (CITI 1992).  During an OECD closed bottle 
test, removal of 1,4-DCB was 97.1%.  However, volatilization was considered to be the major mechanism 
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6. POTENTIAL FOR HUMAN EXPOSURE 
for removal.  During a modified porous pot test operated under normal conditions at a lower aeration rate, 
temperatures of 8, 15, and 20 °C, and sludge retention times of 3 and 6 days, removal of 1,4-DCB was 
>95%. The author reported that the major mechanism for 1,4-DCB removal in this test was 
biodegradation. Using acetate as the primary carbon source under aerobic conditions and after an 
acclimation period of 10 days, rapid bacterial degradation of 96% of a 1,2-DCB sample, 28% of a 
1,3-DCB sample, and 98% of a 1,4-DCB sample was reported (Bouwer and McCarty 1982).  1,4-DCB 
was completely mineralized to inorganic end products.  Possible explanations for the lower 1,3-DCB 
biodegradation rate were biodegradation with slow utilization kinetics or sorption removal.  The 
biodegradation rate of 1,2-DCB in a heterogeneous unconfined aquifer at Columbus Air Force Base in 
Columbus, Mississippi was measured to be 0.0059 day-1 (Stauffer et al. 1994).  This corresponds to a 
half-life of 117 days.  Biodegradation of 1,2-DCB in aquifer samples from Vejen and Grindsted, Denmark 
was slow, with >30% of the test compound remaining after 50 days.  1,4-DCB was not degraded in these 
samples after 50 days.  1,2-DCB (initial concentrations, 20 ppm) underwent 30–50% biodegradation in 
river water and 15–30% biodegradation in sea water after 3 days during an aerobic screening test (Kondo 
et al. 1988). 1,4-DCB (initial concentrations, 4 ppm) underwent 0% biodegradation in both the river 
water and sea water inocula after 3 days.  In-situ biodegradation rate constants were measured for 1,2- 
and 1,4-DCB in an aerobic aquifer (Nielsen et al. 1996).  Rate constants and lag phases were 0.02– 
0.06 day-1 (half-life, 12-35 days) and 0-20 days, respectively, for 1,2-DCB and 0.01–0.05 day-1 (half-life, 
14–69 days) and 0–22 days, respectively, for 1,4-DCB.  Half-lives reported for 1,4-DCB in seawater 
mesocosm experiments performed at various temperatures ranged from 10 to 18 days (Wakeham et al. 
1983). The authors noted that volatilization was the dominant removal process.  No degradation of DCBs 
was reported under denitrification or methanogenic conditions (Bouwer and McCarty 1983, 1984).  
Degradation pathways for 1,4-DCB in water are shown in Figure 6-5. 
6.3.2.3 Sediment and Soil 
Based on the Henry’s law constants of 1,2- and 1,3-DCB and the tendency of 1,4-DCB to sublime, 
volatilization rather than transformation is the most likely fate process for DCBs from surface soil.  
Transformation of DCBs by biodegradation, photolysis, chemical hydrolysis, and oxidation appear to be 
relatively minor processes.  Leaching of DCBs to groundwater from subsurface soils under certain 
conditions may occur (EPA 1985a).   
Wang and Jones (1994a) studied the fate of chlorobenzenes including DCBs in chemically-spiked and 
sewage-amended soils to determine the rate of volatilization, biodegradation, photolysis, and other  
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6. POTENTIAL FOR HUMAN EXPOSURE 
possible loss processes. These authors used sewage sludge collected from a sewage treatment facility 
serving a municipal (~60%) and industrial (~40%) catchment.  The sewage sludge or chemically-spiked
solutions containing chlorobenzenes were added to five experimental systems; (1) normal soil,
(2) sterilized soil (with 1% [weight] of sodium azide), (3) sterilized soil shaded with aluminum foil, 
(4) sterilized soil, shaded and sealed with a Teflon-coated septum, and (5) a control (untreated soil).  The 
mesocosms were incubated at 20–30 °C over a 259-day period.  Loss of all chlorobenzenes including 
DCBs was best represented by a two-step first-order kinetics model.  In the normal condition containing 
unsterilized soil exposed to sunlight and open to the air, during the first 35 days, 79.9% of the 1,2-DCB, 
85.1% of the 1,3-DCB, and 70.5% of the 1,4-DCB were lost with half-life values of 13.2, 12.4, and 
17.4 days, respectively.  From day 35 to day 259, only 4.29% of 1,2-DCB, 3.93% of 1,3-DCB, and 11.3%
of 1,4-DCB were lost with half-life values of 892, 579, and 294 days, respectively.  For the chemically-
spiked soil treatment, the first phase (days 0–17) loss was 75.6% for 1,2-DCB, 73.3% for 1,3-DCB, and 
73.2% for 1,4-DCB with half-life values of 8.63, 8.42, and 8.57 days.  The second phase (days 17–259) 
loss was 13.9% for 1,2-DCB, 25.4% for 1,3-DCB, and 11.2% for 1,4-DCB with half-lives of 191, 189, 
and 131 days, respectively.  Although the DCB loss rates in the sewage-amended soil were slower than 
those in the chemically-spiked soil, the total percentage losses of DCBs after 259 days were comparable.  
Based on the results of losses of DCBs observed in the other microcosm systems, the authors concluded 
that transformation processes including biodegradation, photolysis, and other abiotic losses (chemical 
hydrolysis and oxidation) were minor processes compared to volatilization.  The experimental results of 
Wang and Jones (1994a) showed that, during the first phase, volatilization rates were high and substantial 
portions of the DCBs were lost.  The second phase was much slower and portions of the DCBs remained 
in the soil for a much longer period.   
Neither 1,3- nor 1,4-DCB were biotransformed in an aerobic Rhine River sediment column (closed 
system) after 12 months (Bosma et al. 1990).  1,2-DCB was completely degraded after 4 months 
following a lag period of 60–100 days.  DCBs (unspecified isomers) were degraded slowly in alkaline 
para-brown soil (100 g soil per 2 mg compound) with 6.3% of theoretical CO2 evolution in a closed 
system after 10 weeks (Haider et al. 1974).  Half-lives corresponding to the biodegradation of 1,2-, 1,3-, 
and 1,4-DCB in anaerobic estuarine sediment from the Tsurumi River, Japan were 36.9, 433.2, and 
385.1 days, respectively (Masunaga et al. 1996).  Between 25 and 90% of 1,2- and 1,4-DCB were 
removed from an aerobic soil column (closed system) after 300 days of continuous operation, while 
<25% of 1,3-DCB was removed (Van der Meer et al. 1992).  These studies show that the rate of loss of 
DCBs in soils and sediments is much lower when volatilization is minimized.  This supports the
conclusion of Wang and Jones (1994a) that biodegradation is slow compared to volatilization.



















6. POTENTIAL FOR HUMAN EXPOSURE 
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
Reliable evaluation of the potential for human exposure to dichlorobenzenes depends in part on the 
reliability of supporting analytical data from environmental samples and biological specimens.  
Concentrations of dichlorobenzenes in unpolluted atmospheres and in pristine surface waters are often so 
low as to be near the limits of current analytical methods.  In reviewing data on dichlorobenzenes levels 
monitored or estimated in the environment, it should also be noted that the amount of chemical identified 
analytically is not necessarily equivalent to the amount that is bioavailable.  The analytical methods 
available for monitoring dichlorobenzenes in a variety of environmental media are detailed in Chapter 7. 
Due to their use and volatile nature, DCBs are detected much more frequently and at higher 
concentrations in air than in other environmental compartments such as soil, water, or sediment. 
6.4.1 Air 
1,4-DCB has been detected in indoor air, ambient outdoor air, and in occupational settings.  A summary
of levels of 1,4-DCB detected in indoor air is shown in Table 6-5.  An update of the 1980 national 
ambient VOCs database prepared for the EPA summarized concentrations of 1,4-DCB by site type (Shah 
and Heyerdahl 1988).  The median indoor air concentration of 1,4-DCB detected at 2,121 sites was 
0.283 ppb (mean 3.988 ppb), and the median concentration detected from personal air monitoring of 
1,650 individuals was 0.416 ppb (Shah and Heyerdahl 1988); for reference, the American Conference of 
Governmental Industrial Hygienists (ACGIH) Threshold Limit Value (TLV) (8-hour time-weighted 
average [TWA] for 1,4-DCB is 10 ppm (ACGIH 2005). The authors concluded that these values are a 
result of the use of 1,4-DCB in air fresheners and to control moths that could damage woolen clothing.  
Because of its indoor uses, reports of indoor air monitoring show higher concentrations of 1,4-DCB than 
those observed in ambient outdoor air.  This was also observed during the Total Exposure Assessment 
Methodology (TEAM) Study conducted by EPA between 1979 and 1985 in an effort to measure 
exposures to 20 VOCs in personal air, outdoor air, and drinking water.  Data from the TEAM study were 
presented for the sum of 1,3- and 1,4-DCB (Wallace et al. 1986a). Because 1,4-DCB is produced and 
used in much greater volume than 1,3-DCB, the authors assumed that the concentrations found were 
almost all 1,4-DCB.  The authors concluded that the major cause for the higher personal air  
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Table 6-5. Levels of 1,4-Dichlorobenzene in Indoor Air 
Concentration (ppm) 
Conditions Range Mean Median Maximum Reference 
Bathroom with one 7.80x10-2– Scuderi 1986
deodorizer block 1.26x10-1 
Bathroom with one 1.16x10-1– 
deodorizer block in one 2.20x10-1 
urinal and one toilet 
Inside closet with moth 2.19x10-1– 
flakes in closed garment bag 5.45x10-1 
Outside closet with moth 1.03x10-2– 
flakes in closed garment bag 7.10x10-2 
Inside wardrobe air 0.197 Morita and Ohi 1975 
Inside closet air 0.036 
Bedroom air 0.012 
2,121 Indoor sites 4x10-3 2.83x10-4 Shah and 
Heyerdahl 1988 
1,650 Personal air monitors 4.16x10-4 
1256 Dwellings 1.33x10-3 Brown et al. 1994 
Ventilated office air Field et al. 1992 
Prior to pollution event 4.43x10-3– 
7.75x10-3 
5.14x10-3 4.89x10-3 
During pollution event 3.54x10-3– 
7.29x10-3 
4.51x10-3 4.48x10-3 
32 Smoking homes 2.79x10-3 1.51x10-4 5.03x10-2 Heavner et al. 1996 
61 Nonsmoking homes 8.62x10-4 9.65x10-5 2.03x10-2 
757 Homes 2.61x10-3 Meek et al. 1994 
12 Homes 1.66x10-4– 2.50x10-3 Chan et al. 1990 
1.78x10-2 




2.66x10-1 IARC 1999 
Netherlands) in the 
United 
States) 
Inside four test houses 3.65x10-4– 1.2x10-3– Wallace et al. 1989 
4x10-2 1.22x10-1 
With solid deodorizer 5.64x10-2 
With spray deodorizer 6.14x10-3 
With liquid deodorizer 4.15x10-3 
With no deodorizer 4.32x10-3 
26 Normal houses 1.08x10-4 1.33x10-5 1.5x10-3 Kostiainen 1995 
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Table 6-5. Levels of 1,4-Dichlorobenzene in Indoor Air 
Concentration (ppm) 
Conditions Range Mean Median Maximum Reference 
Nationwide study of Fellin and Otson 





 0 °C 3.92x10-3
 0–15 °C 3.66x10-3
 15 °C 2.0x10-3 
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concentrations was the use of 1,4-DCB sources such as moth crystals and room deodorizers in the home 
(Wallace et al. 1986b).   
Wallace et al. (1989) studied the influence of personal activities on exposure to VOCs.  These authors 
reported that the median 1,4-DCB concentration in ambient outdoor air sampled 3 times/day over a 3-day
monitoring period at each of three test houses was <1 µg/m3 (0.17 ppb) and the maximum concentration 
was 17 µg/m3 (2.8 ppb). The median indoor 1,4-DCB air concentrations sampled individually at each of 
four study houses ranged from 2.2 to 240 µg/m3 (0.37–40 ppb), while the maximum concentrations ranged 
from 7.2 to 740 µg/m3 (1.2–123.3 ppb).  The mean personal air concentration for seven individuals living
in the study houses was 81 µg/m3 (13.5 ppb) (range 4.0–240 µg/m3 [0.7–40 ppb]), while the outdoor mean 
1,4-DCB personal air concentration was 1 µg/m3 (0.17 ppb).  The personal air to outdoor air ratio 
of 81 was 4 times higher than the ratios calculated for the other VOCs tested.  Two individuals living in
the same house both had mean personal air concentrations of 240 µg/m3 (40 ppb); the median levels of 
1,4-DCB in their breath were 40 and 47 µg/m3 (6.7 and 7.8 ppb), which was higher than the median breath 
level of 1.5 µg/m3 (0.3 ppb) in an individual receiving a personal exposure of 5.7 µg/m3 (1.5 ppb). 
Wallace et al. (1989) further studied the activities associated with increased personal exposure to, or 
increased indoor air concentrations of, 1,4-DCB.  The activities that increased both personal exposure and 
indoor air concentrations of 1,4-DCB were the use of solid toilet deodorizers, followed by spray
deodorizers and liquid deodorizers, compared to the use of no deodorizers at all. The median personal 
exposure concentrations to 1,4-DCB were 330 µg/m3 (55 ppb) (maximum, 500 µg/m3 [83.3 ppb]), 
33 µg/m3 (5.5 ppb) (maximum, 84 µg/m3 [14 ppb]), 12 µg/m3 (2 ppb) (maximum, 28 µg/m3 [4.7 ppb]), and 
2.4 µg/m3 (0.4 ppb) (maximum, 6.6 µg/m3 [1.1 ppb]) for solid, spray, liquid, and no deodorizer use, 

respectively. Median indoor air concentrations were 340 µg/m3 (56.7 ppb) (maximum, 

630 µg/m3 [105 ppb]), 37 µg/m3 (6.2 ppb) (maximum, 59 µg/m3 [9.8 ppb]), 25 µg/m3 (4.2 ppb) (maximum, 

30 µg/m3 [5 ppb]), and 2.6 µg/m3 (0.43 ppb) (maximum, 5.2 µg/m3 [0.87 ppb]) for solid, spray, liquid, and 

no deodorizer use, respectively. 

More recently, Kostianen (1995) identified >200 VOCs in the indoor air of 26 normal houses.  1,4-DCB 
was detected in 100% of the houses studied. 1,4-DCB was detected at a mean concentration of 
0.65 µg/m3 (0.1 ppb) (median 0.08 µg/m3 [0.013 ppb], minimum 0 µg/m3 [0 ppb], and maximum
8.94 µg/m3 [1.5 ppb]) in the houses studied.  Forty-eight compounds (including 1,4-DCB) were selected 
for further quantitative analysis in 50 normal houses and 38 “sick houses,” which had poor quality indoor 
air that was linked to odors and to a number of physiological follow-up study of normal and “sick 
houses,” the median concentration of 1,4-DCB (0.88 µg/m3 [0.15 ppb]) in the normal houses was 
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exceeded by 5–10% in 6% of the normal houses and by 10–50% in 18% of the normal houses, while in 
the “sick houses,” the median concentration was exceeded by 5–10% in 7.9% of the “sick houses”, by 10– 
50% in 2.6% of the sick houses, and by 50–200% in 5.3% of the “sick houses.”  The median 
concentrations of 1,4-DCB reported in the 38 “sick houses” ranged from 0.00 to 5.36 µg/m3 (0–0.89 ppb).
During a study of exposure of volatile organic compounds in the air of three photocopy centers, 1,4-DCB 
was detected in the breathing zone of photocopier operators at concentrations ranging from 0.1 to 3.7 ppb 
(Stefaniak et al. 2000).  1,4-DCB was not listed with the compounds detected in building background 
samples. 
A nationwide study of indoor air concentrations of 26 VOC compounds was conducted in Canada in 
1991 (Fellin and Otson 1994).  The authors reported that mean 1,4-DCB concentrations were 
35.75 µg/m3 (5.96 ppb) (winter), 15 µg/m3 (2.5 ppb) (spring), 10.54 µg/m3 (1.76 ppb) (summer), and 
15 µg/m3 (2.5 ppb) (fall), and that the concentrations declined with an increase in ambient air temperature.  
At ≤0, 0–15, and ≥15 °C, the 1,4-DCB mean concentrations were 23.64, 22.02, and 11.83 µg/m3 (3.94, 
3.67, and 1.97 ppb), respectively.  Analysis revealed that 1,4-DCB concentrations were associated with 
use of household products and moth repellant crystals.  These authors concluded that indoor sources of 
1,4-DCB (household products and moth repellant crystal) are likely to have a more significant influence 
on indoor air concentrations than climatic variables.  Summer conditions and outdoor temperatures 
>15.1 °C gave the lowest indoor air concentrations of 1,4-DCB.  Moth repellant crystals are also deployed 
in a manner that gives reasonably constant emissions over several weeks.  This compound produced a 
trend consistent with expected ventilation results.  The highest average concentrations were observed 
during the winter or when temperatures were <0 °C, when ventilation is expected to be lowest.  
Intermediate values were measured during the fall and spring, while the lowest values were measured 
during the summer, when ventilation of homes is expected to be highest.  Zhu et al. (2005) detected 1,2- 
and 1,4-DCB in the indoor air samples from 5 and 81% of 75 randomly selected dwellings in Ottawa, 
Canada, respectively.  Arithmetic mean concentrations in these air samples were 0.77 µg/m3 for 1,4-DCB 
and 0.01 µg/m3 for 1,2-DCB. 
Kinney et al. (2002) measured home outdoor, home indoor, and personal air concentrations of 1,4-DCB 
for selected students that attend school in the West Central Harlem section of New York City as part of 
the Toxic Exposure Assessment (TEACH) study.  Mean winter concentrations of 1,4-DCB were 
5.03 µg/m3 in 36 home outdoor samples, 54.9 µg/m3 in 36 home indoor samples, and 43.4 µg/m3 in 
36 personal air samples.  Mean summer concentrations of 1,4-DCB were 5.03 µg/m3 in 29 home outdoor 
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samples, 54.9 µg/m3 in 36 home indoor samples, and 43.4 µg/m3 in 40 personal air samples.  Similar 
results were obtained from TEACH study measurements in Los Angeles, California (Sax et al. 2004).  
Mean outdoor 1,4-DCB concentrations were 2.0 µg/m3 in 35 samples collected during the winter and 
3.5 µg/m3 in 32 samples collected during the fall.  Mean indoor 1,4-DCB concentrations were 40 µg/m3 in 
40 samples collected during the winter and 52 µg/m3 in 32 samples during the fall.  Personal air 
concentrations measured in Los Angeles were not reported in this study.  Shendell et al. (2004) measured 
1,4-DCB concentrations ranging from not detected to 3.36 µg/m3 in the air of 13 portable modular 
classroom structures and from not detected to 10 µg/m3 in the air of 7 main building classrooms (Shendell 
et al. 2004). Mean and median 1,4-DCB concentrations in air from 3 urban communities in Minnesota 
(Battle Creek, East St. Paul, and Phillips) were measured to be 0.1 and 0.1 µg/m3, respectively, in 
132 outdoor air samples, 1.2 and 0.2 µg/m3, respectively, in 292 indoor air samples, and 3.2 and 
0.4 µg/m3, respectively, in 288 personal air samples (Sexton et al. 2004). 
1,4-DCB has been detected in ambient air samples in several monitoring studies, as shown in Table 6-6.  
Kelly et al. (1994) reported that the median concentration of 1,4-DCB was below detection limits based 
on 1,447 samples collected from 57 different locations.  MacLeod and Mackay (1999) reported a 
1,4-DCB background concentration of 3.36x10-5 ppm for the Southern Ontario, Canada region.  The mean 
and median concentrations of 1,4-DCB in air from 25 sites across the state of Minnesota were 
3.36x10-5 and 2.55x10-5 ppm, respectively (Pratt et al. 2000).  Concentrations were not quantifiable in 
rural air (Shah and Heyerdahl 1988), but increasingly higher concentrations were detected in suburban 
and urban air.  Air samples from Mexicali, Mexico, a residential industrial area, contained 1,4-DCB with 
concentrations ranging from 6.0x10-5 to 2.22x10-2 ppm (mean=1.75x10-3 ppm), while air samples from
Rosarito, Mexico, a beach resort town, contained 1,4-DCB with concentrations ranging from 2.0x10-5 to 
1.8x10-4 ppm (mean=8.0x10-5 ppm).  Hartwell et al. (1992) reported that ambient outdoor concentrations 
of 1,4-DCB are considerably higher in the winter compared to the summer.  The authors concluded that 
this effect may be due to reduced levels of sunlight in the winter, which would hinder atmospheric 
removal by photooxidation.  Mean concentrations of 1,4-DCB in air, and in the vicinity of hazardous 
waste sites and sanitary landfill sites, generally average <4.2x10-3 ppm, but indoor air concentrations of 
1,4-DCB may be 1–3 orders of magnitude higher where 1,4-DCB is used as a space deodorizer or moth 
repellent (IARC 1982; Scuderi 1986; Wallace et al. 1986a, 1986b) (see Table 6-5).  
Concentrations of 1,4-DCB in workplace air were, not unexpectedly, the highest concentrations measured 
(IARC 1982), as shown in Table 6-7; concentrations ranged from 33–52 mg/m3 (5.4–8.7 ppm) detected in  











   
 
  
   
   
 
  
    
   
    
     




       
    
    





    
 










6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-6. Levels of 1,4-Dichlorobenzene in Outdoor Air 
Concentration (ppm) 
Location Mean Median Maximum Range Reference 
Rural 0.00a Shah and 
Heyerdahl 1988 
Semi-rural 2.0x10-5– 1.7x10-4–4.6x10-3c Bozzelli and 
(NJ) 2.1x10-4b Kebbekeus 1979 
Suburban 4.8x10-5 Shah and 
Heyerdahl 1988 
Suburban 1.5x10-4 5.0x10-5– Delfino et al. 2003 
5.0x10-4 
Suburban 2.8x10-3 <1.66x10-4–2.8x10-3 Wallace et al. 1989 
Suburban 4.06x10-4 Bevan et al. 1991 
Urban  5x10-5 Shah and 
Heyerdahl 1988 
Urban (NJ) Harkov et al. 1984 
Summer 4x10-5–7x10-5d
 Winter 2x10-5d 
Urban (NJ) 6x10-5d 
5x10-5–6.6x10-4b
 4.3x10-4–2x10-2c Bozzelli and 
Kebbekeus 1979 
Urban (DC) 1.5x10-4 1.57x10-3 Hendler and Crow
1992 
Urban 6.96x10-5 0.0–2.44x10-4 Fraser et al. 1998 
Urban 1.42x10-4 <2.0x10-4–1.3x10-3 Loscutoff and
Poore 1993 






 Grosjean 1991 
Urban 4.18x10-4 Bevan et al. 1991 











Waste dump 1.24x10-5–6.41x10-5 Nerin et al. 1996 
aLevel not quantifiable 
bRange in arithmetic mean concentrations 
cRange in maximum concentrations detected
dGeometric mean 
eRange in geometric mean concentrations
















6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-7. Levels of 1,4-Dichlorobenzene Detected in Workplace Air 
Concentration (ppm) 
Occupation Maximum Range 
Monochlorobenzene manufacturing plant 8.7 5.4–8.7 
Abrasive-wheel plant 11.5 8–11.5 
Mothball manufacturing plant 25 9–25 
Chlorobenzene manufacturing plant 34 24–34 
1,4-Dichlorobenzene manufacturing plant 548 12–548 
Monochlorobenzene and dichlorobenzene manufacturing plant 724 – 
Source: IARC 1982 



















6. POTENTIAL FOR HUMAN EXPOSURE 
air sampled at a monochlorobenzene manufacturing facility to 4,350 mg/m3 (724 ppm) detected in air 
sampled at a plant manufacturing monochlorobenzene and DCB. 
1,2- and 1,3-DCB have also been detected in air samples from various locations, though at much lower 
concentrations than 1,4-DCB.  Because these isomers are not used in household products to the extent that 
1,4-DCB is, they are not prevalent in indoor air.  For example, mean indoor air concentrations in a 
ventilated office in London were approximately 3.5x10-3 ppm for 1,4-DCB compared to 1.4x10-4 ppm for 
1,2-DCB (Field et al. 1992). Mean indoor air concentrations of 1,2-DCB from residences in some 
California communities were 1.39x10-5 ppm during the winter and 3.48x10-6 ppm during the summer 
(Pellizzari et al. 1986).  1,3-DCB was detected in the air from a university art building where there is 
heavy use of printmaking solvents.  Mean concentrations of 1,3-DCB were 0.4 µg/m3 (median=0.8 µg/m3) 
on the studio floor and 0.8 µg/m3 (median below 0.5–1.5 ppb) on a non-use floor (Ryan et al. 2002).
Some studies have reported 1,3-DCB air sample concentrations in combination with 1,4-DCB 
concentrations. However, based the production volumes of these isomers, it is expected that these 
concentrations represent 1,4-DCB almost entirely.  The concentrations of 1,2- and 1,3-DCB measured in 
ambient outdoor air are shown in Tables 6-8 and 6-9, respectively. Based on the data in these tables, 
ambient outdoor air concentrations generally range from 0.01 to 0.1 ppb for 1,2-DCB, and from 0.001 to 
0.1 ppb for 1,3-DCB. Concentrations of 1,2- and 1,3-DCB in workplace air were not located. 
6.4.2 Water 
DCBs have generally been detected at low concentrations in finished drinking water, surface water, and 
groundwater in the United States.  Finished drinking water samples from 20 of the 113 cities monitored in 
the National Organics Monitoring Survey (NOMS) had levels of 1,4-DCB ranging from 0.01 to 1.54 ppb, 
with a median value of 0.03 ppb (Dressman et al. 1977), and the compound was detected in about 13% of 
finished drinking water supplies using surface water sources (Coniglio et al. 1980).  1,2-, 1,3- and 
1,4-DCB were reported in drinking water samples from three cities on Lake Ontario at concentrations 
ranging from not detectable (ND) to 2 ppt, from ND to 7 ppt, and from 8 to 20 ppt, respectively (Oliver 
and Nicol 1982a).  DCB isomers were detected in 0–3% of drinking water samples from selected 
locations in New Jersey, North Carolina, and North Dakota locations (Wallace et al. 1986a). 
Concentrations of 1,3- and 1,4-DCB were generally <1 µg/L in treated and raw water samples taken from
30 Canadian potable water treatment facilities that serve about 5.5 million consumers (Otson et al. 1982). 












   
 
 
     
 
   
    
     






   
 
   
 











6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-8. Levels of 1,2-Dichlorobenzene in Outdoor Air 
Concentration (ppm) 
Location Mean Median Maximum Range Reference 
Semi-rural (New Jersey) 2x10-5–2.4x10-4a  2.1x10-4– 
3.9x10-3b
 Bozzelli and 
Kebbekeus 1979 
Beach resort town 3.0x10-5 1.0x10-5– Zielinska et al. 2001 
8.0x10-5 
Background (Southern 1.28x10-6 MacLeod and
Ontario) Mackay 1999
25 Sites across Minnesota 1.62x10-5 1.28x10-5 2.44x10-5 Pratt et al. 2000 
Urban (New Jersey) Harkov et al. 1984 
Summer 1x10-5–3x10-5c
 Winter 3x10-5–6x10-5c 




 Bozzelli and 
Kebbekeus 1979 




Singh et al. 1981a, 
1981b 
Urban 2.0x10-5 1.0x10-5– Zielinska et al. 2001 
6.0x10-5 
Urban 8.6x10-5 <1.0x10-4– Loscutoff and Poore 
6.0x10-4 1993 





 Grosjean 1991 
5.6x10-2 6.6x10-1
Hazardous waste sites and 





LaRegina et al. 1986 
Waste dump 1.58x10-5– 
9.13x10-5 
Nerin et al. 1996 
aRange in arithmetic mean concentrations 
bRange in maximum concentrations detected
cGeometric mean 
dLevel not quantifiable 
eRange in geometric mean concentrations











    
 





   
   
 
    
 







6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-9. Levels of 1,3-Dichlorobenzene in Outdoor Air 
Concentration (ppm) 
Location Mean Median Maximum Range Reference 
Beach resort town 0.00a Zielinska et al. 2001 
Background (Southern 1.39x10-6 MacLeod and
Ontario) Mackay 1999
25 Sites across 2.55x10-5 1.28x10-5 9.87x10-4 Pratt et al. 2000 
Minnesota 




Singh et al. 1981a, 
1981b 
Urban  0.00a Zielinska et al. 2001 
Urban 1.01x10-4 <2.0x10-4– Loscutoff and Poore 
3.0x10-4 1993 





 Grosjean 1991 
Waste dump 1.43x10-6– 
6.70x10-6 
Nerin et al. 1996 
aLevel not quantifiable 
bRange in maximum concentrations detected




















6. POTENTIAL FOR HUMAN EXPOSURE 
During a national groundwater supply survey, 1,4-DCB was detected in 2 out of 280 (0.7%) random
sample sites serving <10,000 persons and in 3 out of 186 (1.6%) random sample sites serving 
>10,000 persons above a quantitation limit of 0.5 µg/L (Westrick et al. 1984).  The mean positive 
concentration and maximum value were 0.60 and 0.68 µg/L, respectively, for the sites serving 
<10,000 persons and 0.66 and 1.3 µg/L, respectively, for the sites serving >10,000 persons.  1,2- and 
1,3-DCB were not detected above the quantitation limit (0.5 µg/L) in any of the random samples.  
1,4-DCB was detected above 0.5 µg/L in 4 out of 321 (1.2%) nonrandom sample sites serving 
<10,000 persons with a median positive concentration of 0.74 µg/L and a maximum value of 0.90 µg/L. 
This compound was not detected above 0.5 µg/L in 158 nonrandom sample sites serving >10,000 persons. 
1,2-DCB was detected above 0.5 µg/L in 1 out of 321 (0.3%) nonrandom sample sites serving 
<10,000 persons at a concentration of 2.2 µg/L and in 1 out of 158 (0.6%) nonrandom sample sites 
serving >10,000 persons at a concentration of 2.7 µg/L.  1,3-DCB was not detected above 0.5 µg/L in any 
of the nonrandom samples.  Stackelberg et al. (2001) detected 1,2-, 1,3-, and 1,4-DCB in approximately 8, 
4, and 8%, respectively, of samples collected from 30 public supply wells in southern New Jersey.  
Concentrations or limits of detection were not reported.  1,4-DCB had two detections at concentrations 
that were both below a laboratory reporting limit of 0.05 µg/L in samples from 178 active public supply
wells in the Los Angeles physiographic basin (Shelton et al. 2000).  1,2- and 1,3-DCB were analyzed for, 
but were not detected in any of the samples from these wells.  The laboratory reporting limits used for 
1,2-DCB were 0.031 and 0.048 µg/L.  The laboratory reporting limits used for 1,3-DCB were 0.03 and 
0.054 µg/L. 
1,2-DCB was detected in 0.6% of 1,077 surface water samples recorded in the STORET database at a 
median concentration of <10 ppb (Staples et al. 1985).  1,3-DCB was detected in 0.3% of 986 surface 
water samples recorded in the STORET database at a median concentration of <10 ppb.  1,4-DCB was 
detected in 3% of 8,576 surface water samples recorded in the STORET database at a median 
concentration of <0.1 ppb. 1,4-DCB was detected in 100% of 91 surface water samples from the Great 
Lakes at mean concentrations ranging from 0.28 ppt in Lake Huron to 1.5 ppt in Lake Ontario (IJC 1989).
Oliver and Nicol (1982a) also reported concentrations of DCBs in water samples collected from the Great 
Lakes region. Mean 1,2-DCB concentrations were 5 ppt (range, 2–7 ppt) in samples from Lake Ontario 
and 6 ppt (range, ND–31 ppt) in samples from the Grand River.  1,2-DCB was not detected in samples 
from Lake Huron.  Mean 1,3-DCB concentrations were 1 ppt (range, ND–4 ppt) in samples from the 
Grand River. 1,3-DCB was not detected in samples from Lake Ontario or Lake Huron.  Mean 1,4-DCB 
concentrations were 45 ppt (range, 33–64 ppt) in samples from Lake Ontario, 4 ppt (range, 3–6 ppt) in
samples from Lake Huron, and 10 ppt (range, ND–42 ppt) in samples from the Grand River.  During a 





















6. POTENTIAL FOR HUMAN EXPOSURE 
study of contaminants in 139 streams located in 30 states, 1,4-DCB was detected in 25.9% of samples in 
which it was searched for, with a median concentration of 0.09 µg/L and a maximum concentration of 
4.3 µg/L (Kolpin et al. 2002). 
Concentrations of 1,2-, 1,3- and 1,4-DCB from the Niagara River sampled in 1980 ranged from ND to 
56 ppt, from ND to 56 ppt, and from 1 to 94 ppt.  The highest concentration of 1,2- and 1,4-DCB 
occurred just below a chemical manufacturing plant’s effluent discharge, while the highest concentration 
of 1,3-DCB occurred just below a waste disposal dump (Oliver and Nicol 1982a).  1,2-, 1,3-, and 
1,4-DCB were also reported in waste water effluent samples collected from four plants on the Great 
Lakes at mean concentrations of 13 ppt (range, 6–22 ppt), 14 ppt (range, 7–13 ppt), and 660 ppt (range, 
484–920 ppt) (Oliver and Nicol 1982a).  In a New Jersey survey, 1,2-, 1,3- and 1,4-DCB were detected in 
3, 4, and 6%, respectively, of 463 surface water samples (Page 1981).  Maximum concentrations were 
8.2 ppb for 1,2-DCB, 242 ppb for 1,3-DCB, and 31 ppb for 1,4-DCB.  DCBs have been reported in 
surface waters in the vicinity of hazardous waste sites at unspecified concentrations (Elder et al. 1981)
and at a concentrations of 9 ppt (1,2-DCB), 18 ppt (1,3-DCB), and 52 ppt (1,4-DCB) (Oliver and Nicol 
1982a). 
DCBs were monitored in wetland-treated leachate water at a municipal solid waste landfill site in central 
Florida from 1989 to 1990 and from 1992 to 1993 (Chen and Zoltek 1995).  During the first sampling 
period, surface water samples contained 1,2-DCB at concentrations ranging from 0.02 to 0.10 ppb, 
1,3-DCB at concentrations ranging from 0.02 to 0.10 ppb, and 1,4-DCB at concentrations ranging from
0.04 to 0.13 ppb.  Groundwater samples contained 1,2-DCB at concentrations ranging from 0.09 to 
1.56 ppb, 1,3-DCB at concentrations ranging from 0.08–8.95 ppb, and 1,4-DCB at concentrations ranging
from 0.08 to 10.71 ppb.  During the second sampling period (1992–1993), the three DCB isomers were 
not detected in surface water samples.  1,2- and 1,4-DCB were each detected in two groundwater samples 
at concentrations ranging from 0.75 to 0.84 ppb and from 0.45 to 3.74 ppb, respectively.  1,3-DCB was 
not detected in groundwater samples collected during the second sampling period.  No detection limits 
were given. DCB (isomers unspecified) was detected in a study of three landfills in central Florida 
(Hallbourg et al. 1992). These authors reported DCB concentration ranges in groundwater of 0.37–21.2, 
6–46.4, and <1–7.4 µg/L (ppb) at three different landfill sites.  Plumb (1991) reported that 1,2-, 1,3-, and 
1,4-DCB were detected in groundwater collected at 36, 16, and 34 of 479 hazardous waste sites, 
respectively. This author reported that 1,2-DCB was detected in 240 samples collected from 36 sites in 
9 of the 10 EPA regions, 1,3-DCB was detected in 82 samples collected from 16 sites in 8 of the 10 EPA 
regions, and 1,4-DCB was detected in 191 samples collected from 34 sites in 9 of the 10 EPA regions.   
























6. POTENTIAL FOR HUMAN EXPOSURE 
Untreated, ambient groundwater samples from 406 urban wells and 2,542 rural wells from across the 
conterminous United States were collected between 1985 and 1995 as a part of the National Water-
Quality Assessment Program (NAWQA) of the U.S. Geological Survey (Squillace et al. 1999).  1,2-DCB 
was detected in 1.4% of the urban well samples with a median concentration of approximately 0.2 µg/L 
(range 0.2–100 µg/L).  This compound was detected in 0.2% of the rural well samples with a median 
concentration of approximately 1 µg/L (range 0.3-5 µg/L).  1,4-DCB was detected in 1.8% of the urban 
well samples with a median concentration of approximately 1 µg/L (range 0.3–50 µg/L).  It was detected 
in 0.2% of the rural well samples with a median concentration of approximately 1.5 µg/L (range 0.6– 
8 µg/L). 1,3-DCB was not included in this study.  Similar results were reported by Moran et al. (2004) in 
a summary of 1985-1999 NAWQA monitoring data involving chemical concentrations measured in 
1,926 rural private wells.  1,2- and 1,3-DCB were not detected at all, while 1,4-DCB was detected in only
1 out of 1,925 samples at a concentration of 1.2 µg/L.  1,2-, 1,3-, and 1,4-DCB were detected in 
approximately 25, 15, and 10%, respectively, of samples collected from 95 monitoring wells in southern 
New Jersey, respectively (Stackelberg et al. 2001).  Concentrations or limits of detection were not 
reported. In a separate New Jersey survey, 1,2-, 1,3-, and 1,4-DCB were detected in 3, 2, and 3 of 
685 groundwater samples (Page 1981). Maximum concentrations were 6,800 ppb for 1,2-DCB, 237 ppb 
for 1,3-DCB, and 995 ppb for 1,4-DCB.  1,4-DCB had a frequency of detection of approximately 10%
and a maximum concentration of 1.7 µg/L in groundwater samples from 29 alluvial wells beneath the 
Denver, Colorado area (Bruce and McMahon 1996). The authors also analyzed for 1,3-DCB, although it 
was not detected above the minimum detection level (0.2 µg/L) in any of the samples.  1,3-DCB was 
detected in two groundwater samples from five developing urban sites in the Upper Colorado River Basin 
with an estimated maximum concentration of 0.01 µg/L (Apodaca et al. 2002).  
6.4.3 Sediment and Soil 
Little information on soil concentrations of DCBs was located for the United States.  One study 
conducted in England, however, reported DCB concentrations in agricultural soils increased during the 
1960s, corresponding to a period of increased production of chlorobenzene compounds (Wang et al. 
1995).  The mean 1,4-DCB soil concentration reported for agricultural land was 2.17 ppb in 1942, 
0.75 ppb in 1951, 1.73 ppb in 1960, 9.82 ppb in 1967, 3.9 ppb in 1972, 3.06 ppb in 1980, 1.4 ppb in 1984, 
and 0.4 ppb in 1991.  The mean 1,3-DCB soil concentration was 0.20 ppb in 1960, 0.31 ppb in 1967, 
0.36 ppb in 1972, and 0.30 ppb in 1980.  1,3-DCB soil concentrations were below the detection limit 
(0.2 ppb) in 1942, 1951, 1984, and 1991.  1,2-DCB soil concentrations were below the detection limit 




















6. POTENTIAL FOR HUMAN EXPOSURE 
(0.2 ppb) during all 8 sampling years.  It should be noted that 1,4-DCB has been reported to occur in soils 
as a result of lindane degradation (EPA 1980a; IARC 1982), so the detection of 1,4-DCB may not be 
indicative of 1,4-DCB disposal per se. 
1,2-DCB was detected in 0.9% of 352 sediment samples, 1,3-DCB was detected in 0.3% of 357 sediment 
samples, and 1,4-DCB was detected in 2% of 357 sediment samples recorded on the STORET database 
(Staples et al. 1985).  DCBs have been detected in sediments near hazardous waste sites (Elder et al. 
1981; Hauser and Bromberg 1982).  During a study of semivolatile organic compounds in streambed 
sediment, 1,2-DCB was detected in 0.6% of samples collected at 516 sites from 20 major river basins in 
the United States during 1992–1995 with a maximum concentration of 86 µg/kg (95th percentile, 
<50 µg/kg) (Lopes and Furlong 2001).  1,4-DCB was detected in 1.2% of samples collected at 518 sites 
with a maximum concentration of 140 µg/kg (95th percentile, <50 µg/kg).  1,3-DCB was not detected in 
samples collected from 516 sites.  The concentrations of 1,2- and 1,4-DCB were both <100 µg/kg in 
streambed sediment samples from 9 out of 14 river sites in the New England Coastal Basin (USGS 2002). 
Both of these compounds were at concentrations below the minimum reporting level (50 µg/kg) in 
samples from the remaining five river sites.  Redmond et al. (1996) detected 1,2-, 1,3-, and 1,4-DCB at 
concentrations up to 4.4, 7.2, and 3.6 mg/kg, respectively, in the sediment of the Calcasieu River estuary, 
Louisiana. 
Oliver and Nicol (1982a) reported DCB concentrations in surficial sediments from 13 sites in Lake 
Superior, 42 sites in Lake Huron, 5 sites in Lake Erie, and 11 sites in Lake Ontario.  Mean 1,2-DCB 
concentrations detected were 1 ppb (range, ND–1 ppb), 8 ppb (range, ND–56 ppb), 2 ppb (range, 1– 
4 ppb), and 11 ppb (range, 4–27 ppb) for Lakes Superior, Huron, Erie, and Ontario, respectively.  Mean 
1,3-DCB concentrations detected were 2 ppb (range, ND–7 ppb), 2 ppb (range, ND–14 ppb), 4 ppb 
(range, 1–9 ppb), and 74 ppb (range, 15–250 ppb) for Lakes Superior, Huron, Erie, and Ontario, 
respectively. Mean 1,4-DCB concentrations detected were 5 ppb (range, ND–9 ppb), 16 ppb (range, 2– 
100 ppb), 9 ppb (range, 3–20 ppb), and 94 ppb (range, 22–210 ppb) for Lakes Superior, Huron, Erie, and 
Ontario, respectively.  These authors also reported detecting DCB concentrations in deep sediment layers 
in Lake Ontario from core samples from the Niagara Basin.  Concentrations of 1,2-DCB in various depths 
of the sediment cores were as follows:  14 ppb (0–1 cm), 15 ppb (1–2 cm), 19 ppb (2–3 cm), 16 ppb (3– 
4 cm), 26 ppb (4–5 cm), 13 ppb (5-6 cm), and 2 ppb (6–7 cm).  Concentrations of 1,3-DCB in various 
depths of the sediment cores were as follows:  240 ppb (0–1 cm), 330 ppb (1–2 cm), 190 ppb (2–3 cm), 
48 ppb (3–4 cm), 38 ppb (4–5 cm), 17 ppb (5–6 cm), and 4 ppb (6–7 cm).  Concentrations of 1,4-DCB in 
various depths of the sediment cores were as follows:  110 ppb (0–1 cm), 120 ppb (1–2 cm), 88 ppb (2– 























6. POTENTIAL FOR HUMAN EXPOSURE 
3 cm), 230 ppb (3–4 cm), 88 ppb (4–5 cm), 29 ppb (5-6 cm), and 17 ppb (6–7 cm).  None of the DCBs 
were detected in the 7–8 cm sediment core.  Chapman et al. (1996a, 1996b) also reported detecting 
1,4-DCB in sediments collected around the diffuser of a large marine municipal sewage discharge outfall 
at Macaulay Point in Victoria, Canada.  Sediment quality guidelines are set by the government to protect 
indigenous sediment-dwelling organisms.  1,4-DCB was detected at concentrations exceeding sediment 
quality guidelines (110 µg/kg [ppb] dry weight) and showed a distinctive concentration gradient, which 
peaked at the outfall at concentrations up to 1,710 ppb dry weight and decreased with increasing distance 
from the outfall.  The authors attributed the source of the 1,4-DCB in the relatively untreated municipal 
sewage effluent to the extensive use of toilet block deodorizers. 
In a recent study conducted in England, Wang and Jones (1994b) analyzed the chlorobenzene content of 
contemporary sewage sludge collected from 12 waste water treatment plants.  Most of the plants surveyed
received waste water from urban and industrial effluent and all of the sewage-treatment plants used 
primary treatment.  1,2- and 1,4-DCB were detected in 100% of the samples tested.  1,3-DCB was 
detected in 75% of the samples tested.  Concentrations of 1,2-DCB ranged from 71.3 to 4,110 µg/kg (ppb) 
dry weight (3.57–152 ppb wet weight).  For 1,2-DCB, the mean and median concentrations for the 
12 plants were 877 and 237 ppb (dry weight), respectively.  The authors reported that except for the 
monochlorobenzenes, 1,2-DCB had the highest concentration in the industrial sludges.  This was believed 
to be the result of industrial uses of 1,2-DCB as a solvent, cleaner, degreaser, polish, and deodorant.  
Concentrations of 1,3-DCB ranged from below the detection limit to 467 µg/kg (ppb) dry weight (from
below the detection limit to 13.5 ppb wet weight).  For 1,3-DCB, the mean and median concentrations for 
the 12 plants were 82.3 and 30 ppb (dry weight), respectively.  Concentrations of 1,4-DCB ranged from
561 to 2,320 µg/kg (ppb) dry weight (21.9–187 ppb wet weight).  For 1,4-DCB, the mean and median 
concentrations for the 12 plants were 1,310 and 1,250 ppb (dry weight), respectively.  The authors also 
reported that 1,4-DCB was the most abundant compound detected (exclusive of the monochlorobenzenes) 
and was detected at higher concentrations in the urban sludges compared to the sludges dominated by
industrial sources. The authors believe that this was a result of the extensive use of the compound in
moth repellent crystals, insecticides, germicides, and space deodorants.  Since 1,4-DCB also has industrial 
uses, the absolute content of this compound was not lower in the industrial sludges as compared to the 
urban sludges.  The authors also found that the 1,4-DCB content and that of other chlorobenzene 
compounds in sewage sludges from the same treatment plant were consistent over time.  Wang et al. 
(1995) further reported that at a site in Woburn, England, sewage sludge applied to agricultural land from
1942 to 1961 contained 1,2-DCB concentrations of ND to 126 ppb (mean, 17.4 ppb; median, 6.60 ppb), 
1,3-DCB concentrations of ND to 101 ppb (mean, 17.4 ppb; median, 6.60 ppb), and 1,4-DCB 




















6. POTENTIAL FOR HUMAN EXPOSURE 
concentrations of 7.76–71.8 ppb (mean, 29.8 ppb; median, 25.5 ppb).  These authors found that while 
concentrations of the other chlorobenzenes remained stable during the 1960s after the sludge applications 
were halted in 1961, the concentrations of 1,4-DCB in both the sludge-amended and control soils actually
increased. The authors concluded that the 1,4-DCB could have increased in both soil plots as a result of 
pesticide applications since 1,4-DCB was often found as an impurity in many organochlorine pesticides 
or by atmospheric deposition of airborne emissions from industrial facilities or municipal waste 
incinerators. 
6.4.4 Other Environmental Media 
DCBs have been detected in meat, poultry, fish, and other types of foodstuffs.  Pork meat has reportedly
been tainted with a disagreeable odor and taste as a result of the use of deodorant blocks in pig stalls 
(EPA 1980a; IARC 1982).  Eggs also have been similarly tainted after hens were exposed to 20– 
30 mg/m3 (3.3–5.0 ppm) of 1,4-DCB (IARC 1982).  1,4-DCB was detected in 69 out of 234 table-ready
food items from the FDA’s total diet study at concentrations ranging from 4.26 to 114 ppb 
(mean=10.7 ppb) (Heikes et al. 1995).  1,2-DCB was detected in 45 of the 234 food items at 
concentrations ranging from 7.80 to 24.4 ppb (mean=9.47 ppb).  1,3-DCB was detected in 6 of the food 
items at concentrations ranging from 5.31 to 9.76 ppb (mean=7.36).  The highest level food items were 
chocolate chip cookies (1,4-DCB), cake doughnuts (1,2-DCB), and sandwich cookies (1,3-DCB).  Page 
and Lacroix (1995) detected 1,4-DCB in both noncitrus based soft drinks and 10% butterfat cream at 
0.1 µg/kg during a study of contaminants in Canadian foods.  1,4-DCB concentrations in different brands 
of butter, margarine, and peanut butter were 1.3–2.7, 12.2–14.5, and 1.2–8.8 µg/kg, respectively. Flour 
contained 1,2-DCB at 1.1 µg/kg and 1,4-DCB at 7.3 µg/kg, while pastry mix contained these isomers at 
concentrations of 1.0 and 22.0 µg/kg, respectively.  Fresh food composites grown in Ontario, Canada 
were tested for the presence of DCBs (detection limits=0.0001 µg/g) as well as other contaminants 
(Davies 1988). Only 1,3-DCB was detected in fruit and root vegetables at concentrations of 0.0044 and 
0.0011 µg/kg, respectively, while 1,2-DCB was the only isomer detected in the eggs/meat food group at a 
concentration of 0.0018 µg/kg.  Both 1,3- and 1,4-DCB were detected in milk at concentrations of 
0.00014 and 0.00055 µg/kg, respectively.  None of the DCBs in this study were detected in leafy
vegetables. The concentrations of 1,4-DCB in retail vegetables from the United Kingdom were 
0.198 µg/kg (carrot cores), 0.416 µg/kg (carrot peels), 0.224 µg/kg (potato peels), 0.214 µg/kg 
(cauliflower stems), 0.529 µg/kg (cauliflower flowers), 0.237 µg/kg (inner lettuce leaves), and 
0.118 µg/kg (outer lettuce leaves) (Wang and Jones 1994d).  1,2- and 1,3-DCB were detected only in 
potato cores at 0.328 and 0.096 µg/kg, respectively. 



















6. POTENTIAL FOR HUMAN EXPOSURE 
All three DCB isomers were detected in lake and rainbow trout from the Great Lakes at concentrations 
ranging from 0.3 to 1 ppb for 1,2-DCB, from 0.3 to 3 ppb for 1,3-DCB, and from 1 to 4 ppb for 1,4-DCB, 
(Oliver and Nicol 1982a).  DCBs were detected in biota collected in the vicinity of an industrial outfall in 
the Calcasieu River estuary, Louisiana (Pereira et al. 1988).  The concentrations of 1,2-, 1,3-, and 
1,4-DCB in catfish ranged from not detected to 0.11 ppm, from 0.03 to 0.19 ppm, and from 0.17 to 
0.47 ppm, respectively.  The concentrations of DCBs in Atlantic croakers, blue crabs, spotted sea trout, 
and blue catfish collected from the Calcasien River estuary were 0.08, 0.26, 0.06, and 0.06 ppm, 
respectively for 1,2-DCB, 0.19, 0.356, 0.09, and 0.12 ppm, respectively, for 1,3-DCB, and 0.24, 0.60, 
0.90, and 2.5 ppm, respectively, for 1,4-DCB.  Chung (1999) detected 1,4-DCB in the leg meat, body 
meat, and carapace meat of Charybdis feriatus, a popularly consumed edible crab in Asia, at concen­
trations of 0.5, 0.6, and 5.1 ppm, respectively.  DCBs were detected in the edible tissue of various species 
of trout, nase, whiting, mullet, and pilichard fresh water fish from rivers in Slovenia and the Gulf of 
Triest, Yugoslavia (Jan and Movnersic 1980). 1,4-DCB concentrations in these fish ranged from trace to 
0.45 ppb, while 1,2-DCB concentrations ranged from trace to 1.14 ppb.  The mean upper limit of 
1,4,-DCB concentrations detected in livers of flatfish (Dover sole) collected off Los Angeles, California, 
was <77 ppb wet weight; the mean upper limit of concentrations found in muscle tissue was <7 ppb 
(Young and Heesen 1978).  1,2-DCB was also detected in these fish at mean liver concentrations at or 
below 4.0 ppb (Young et al. 1980). Concentrations of 1,4-DCB reported in mackerel from Japanese 
coastal water ranged up to 0.05 ppm wet weight (50 ppb) (EPA 1980a; IARC 1982).  Jori et al. (1982) 
reported that 1,4-DCB has been detected in carp at 0.1 ppm and in farmed fish at 0.04 ppm. 
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
Inhalation is the predominant route of exposure to DCBs for the general population.  According to data 
from the TEAM study, which includes exhaled breath measurements from about 800 individuals, 
1,4-DCB was found in 44–100% of air and breath samples from several U.S. locations, and indoor air 
levels were up to 25 times higher than ambient outdoor levels for DCB (1,3- and 1,4-DCB) (Wallace et al. 
1986b). Mean concentrations of 1,3- and 1,4-DCB measured together in breath samples collected in New 
Jersey and California ranged from 2.9 to 8.1 µg/m3 (Wallace 1986b). Median concentrations of these 
isomers in breath samples from New Jersey, California, North Dakota, and North Carolina ranged from
0.3 to 1.3 µg/m3 (Wallace et al. 1987, 1996).  1,2-DCB was detected above quantifiable limits (0.2– 
2 µg/m3) in only 2% of the breath samples collected in New Jersey (Wallace et al. 1986c).  Mean 
1,2-DCB concentrations ranged from 0.08 to 0.1 µg/m3 in breath samples collected in California (Wallace 
















6. POTENTIAL FOR HUMAN EXPOSURE 
et al. 1988). The EPA has estimated that adult exposure to 1,4-DCB is about 35 µg/day, based on a mean 
ambient air concentration of 1.6 µg/m3 (0.27 ppb) (EPA 1985a).  In a separate study, average intake 
values for persons exposed to 1,2- and 1,3-DCB were estimated to be 1.8 and 0.8 µg/day, respectively, 
based on the concentrations of these substances in ambient outdoor air samples from seven large cities in 
the United States and a total air intake of 23 m3/day (Singh et al. 1981a, 1981b).  Inhalation exposure to 
1,4-DCB may be considerably higher indoors where space deodorants or moth repellents that contain this 
chemical are used.  Indoor inhalation exposure of the general population to 1,2- or 1,3-DCB is not 
expected to be important since these substances are not used in household and consumer products to the 
extent that 1,4-DCB is.  However, one study reported that 1,3-DCB was detected in the air from a 
university art building where there is heavy use of printmaking solvents.  Mean concentrations of 
1,3-DCB were 0.4 µg/m3 (median=0.8 µg/m3) on the studio floor and 0.8 µg/m3 (median below 
0.5-1.5 ppb) on a non-use floor (Ryan et al. 2002).  During this study, mean and median personal 
exposure concentrations for this compound were 2.0 and 2.3 µg/m3, respectively.
Because water and food concentrations of DCBs are generally quite low, exposure from sources other 
than air is unlikely to be important.  For example, drinking water containing 0.1 ppb 1,4-DCB would 
provide an additional intake of only 0.2 µg per day for an adult drinking 2 L of water per day.  In the past, 
concentrations of all three DCB isomers have been detected in some freshwater fish from the Great Lakes 
region (Oliver and Nicol 1982a). In addition, concentrations of 1,2- and 1,4-DCB have been found in 
marine fishes, especially in areas near effluent discharges (Young and Heesen 1978; Young et al. 1980).  
However, more recent information on concentrations in edible fish and shellfish tissues is lacking.  
Results of the National Human Adipose Tissue Survey (NHATS) conducted in 1982, which estimated the 
general population exposure to toxic organic chemicals, found that 1,4-DCB was detected in 100% of 
46 composite human adipose tissue specimens analyzed at levels ranging from 12 to 500 ppb while 
1,2-DCB was detected in 63% of the 46 specimens at levels ranging from <0.1–2 ppb (EPA 1986f, 
1989d).  These measurements indicate widespread exposure of the general population to DCBs.  Using 
the same data, ranks for each of the 9 census regions were assigned according to the composite sample 
concentrations for 1,2- and 1,4-DCB or the means of multiple composite sample concentrations (Phillips 
and Birchard 1991). These authors reported that exposure to 1,4-DCB was highest for children (aged 0– 
14 years) living in the west south central (Arkansas, Louisiana, Oklahoma, and Texas), east south central 
(Kentucky, Tennessee, Alabama, and Mississippi), and south Atlantic regions (Delaware, Maryland, the 
District of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, and Florida); for 
15- to 44-year-olds, exposure was highest in the south Atlantic, middle Atlantic (New Jersey, New York, 



























6. POTENTIAL FOR HUMAN EXPOSURE 
and Pennsylvania), and east north central regions (Illinois, Indiana, Michigan, Ohio, and Wisconsin); and 
for adults 45 years and older, exposure was highest nationally in the east south central, west south central, 
and east north central regions. Exposure to 1,2-DCB was highest for children (0–14 years) living in the 
New England (Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, and Connecticut), east 
north central, and west north central regions (Minnesota, Iowa, Missouri, Nebraska, Kansas, North 
Dakota, and South Dakota); for 15- to 44-year-olds, exposure was highest in the New England, mid 
Atlantic, and Pacific regions (California, Hawaii, Washington, Oregon, and Alaska); and for adults 
45 years and older, exposure was highest nationally in the mid Atlantic, west north central, and west south 
central regions. 
Table 6-10 summarizes concentrations of 1,4-DCB in blood samples from various studies.  Morita and 
Ohi (1975) found that 1,4-DCB was present in all 34 adipose tissue and 6 blood samples taken from
residents of the Tokyo, Japan metropolitan area.  1,4-DCB concentrations in the adipose tissue samples 
ranged from 0.2 to 11.7 ppm in the adipose tissue samples with an average concentration of 2.3 ppm and 
from 4 to 16 ng/ml (ppb) in the blood samples with an average concentration of 9.5 ng/mL (ppb).  
1,2-DCB was detected in paired blood and biopsy fat samples obtained from 25 patients (7 male and 
18 female) from British Columbia, Canada (Mes 1992).  Median concentrations in whole blood, biopsy
fatty tissue, blood lipids, and adipose tissue were <3.12, 28.1, <3, and 38 ppb, respectively.  Maximum
concentrations of 1,2-DCB in these media were 14.29, 154.5, 20,005, and 194 ppb, respectively.   
Concentrations of 1,4-DCB in blood samples of 48 individuals in Alaska during February 1995 ranged
from below the limit of detection (0.040 ppb) to 7.10 ppb with median values ranging from 0.02 to 
0.04 ppb (Backer et al. 1997). During the Third National Health and Nutrition Evaluation Survey
(NHANES III), 1,4-DCB was detected in 94.6% of 1,100 blood samples at a median concentration of 
0.33 µg/L and a 95th percentile value of 9.2 µg/L (Buckley et al. 1997).  Blood samples collected from
July 1995 to May 1997 during the National Human Exposure Assessment Survey (NHEXAS) in EPA 
Region 5 (Minnesota, Wisconsin, Michigan, Illinois, Indiana, and Ohio) contained 1,4-DCB (Pellizzari et 
al. 2001).  It was detected in approximately 80 out of 145 samples with a median concentration of 
0.10 ppb, an arithmetic mean concentration of 0.38 ppb, and a maximum concentration of 45 ppb 
(Bonanno et al. 2001).  Ashley et al. (1994, 1996) reported a mean blood level of 1,4-DCB of 1.9 ppb 
(median 0.33 ppb) in 1,037 samples collected from a reference group of nonoccupationally exposed 
individuals.  Concentrations of VOCs in blood samples from a group of 126 nonsmokers and 42 smokers 
were also studied (Ashley et al. 1995).  These authors found that mean 1,4-DCB blood levels were 
3.2 ng/L (ppb) (median, 0.45 ppb; range ND–96 ppb) for nonsmokers and 2.2 ppb (median, 0.47 ppb;  




















   









6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-10. Concentrations of 1,4-Dichlorobenzene in Blood Samples 
Test subjects Range (ppb) Median (ppb) Mean (ppb) Reference 
British Columbia, Canada ≤14.29 <3.12 Mes 1992 
(n=25)
Alaska, United States <0.040a–7.10 0.02–0.04 Backer et al. 1997 
(n=48)
NHANES III (n=1,100) 0.33 Buckley et al. 1997 
EPA Region 5 (n=145) ≤45 0.10 0.38 Pellizzari et al. 2001 
Non-occupationally 0.33 1.9 Ashley et al. 1994, 1996 
exposed individuals 
(n=1,037) 
Nonsmokers (n=126) ND–96 0.45 3.2 Ashley et al. 1995 
Smokers (n=42) ND–17 0.47 2.2 Ashley et al. 1995 
Residents of the Love 0.15–68 EPA 1985a 
Canal area, Niagara Falls, 
New York
World Trade Center 0.274 Edelman et al. 2003 
firefighters present during 
the collapse (n=148) 
World Trade Center 0.289 Edelman et al. 2003 
firefighters arriving within 
2 days of the collapse 
(n=142) 




Other World Trade Center 0.231 Edelman et al. 2003 
firefighters 
SHIELD—children in 0.21 4.22 Sexton et al. 2005 
Minneapolis, Minnesota 
(n=134) 
Adults in the United States ≤49 0.33 2.1 Hill et al. 1995 
(n=1,000) 
aBelow the limit of detection 



















6. POTENTIAL FOR HUMAN EXPOSURE 
range, ND–17 ppb) for smokers.  Blood levels of 1,4-DCB were not dependent on whether the subject 
was from the smoking or control group.  All three DCB isomers have been detected in blood samples 
from residents of the Love Canal area in Niagara Falls, New York (IARC 1999).  DCB concentrations in 
blood samples from nine Love Canal residents ranged from 0.15 to 68 ppb (EPA 1985a).  1,4-DCB 
concentrations (geometric mean) in blood samples collected from firefighters responding to the World 
Trade Center fire and collapse were 0.274 µg/L for 148 firefighters who were present during the collapse 
and 0.289 µg/L for 142 firefighters who arrived after the collapse (within 2 days) (Edelman et al. 2003).  
The mean concentrations in the blood of 95 special operations command individuals were 0.343 µg/L 
compared to 0.231 µg/L in the blood of other firefighters. 
Hill et al. (1995) analyzed both blood and urine samples of 1,000 adults in the United States.  These 
authors reported that 96% of the individuals in the study had detectable concentrations of 1,4-DCB in 
their blood and 98% had detectable concentrations of 2,5-dichlorophenol (the metabolite of 1,4-DCB) in 
their urine. 1,4-DCB levels in the blood ranged up to 49 µg/L (ppb), with median and mean 
concentrations of 0.33 ppb and 2.1 ppb, respectively. Urinary 2,5-dichlorophenol concentrations ranged 
up to 8,700 µg/L (ppb), with median and mean concentrations of 30 ppb and 2,000 ppb, respectively.  
There was a highly significant correlation (p<0.0001) between 2,5-dichlorophenol in the urine and 
1,4-DCB in the blood.  The authors concluded that 1,4-DCB is a common, worldwide environmental 
contaminant.  Metabolites of 1,2-DCB (2,3- and 3,4-dichlorophenol and 3,4- and 4,5-dichlorocatechol) 
have been detected in the urine of chemical factory workers at unspecified concentrations (Kumagai and 
Matsunaga 1995, 1997).  These workers had been exposed to 1,2-DCB used as a solvent during the work 
shift prior to sample collection.  
DCB (all isomers) was identified in 100% of 42 samples of human breast milk collected in five urban 
areas of the United States at concentrations of 0.04–68 ppb (Erickson et al. 1980).  DCB (all isomers) was 
identified in human breast milk in 8 of 12 women who were residents of Bayonne, New Jersey 
(6 women), Jersey City, New Jersey (2 women), Bridgeville, Pennsylvania (2 women), and Baton Rouge, 
Louisiana (2 women); however, concentrations were not specified (Pellizzari et al. 1982).  DCB (all 
isomers) was identified in breast milk samples collected from five different regions across Canada in 
1982 (Mes et al. 1986).  1,2-DCB was identified in 97% of the 210 samples collected with mean and 
maximum milk concentrations of 3 and 29 ppb, respectively and mean and maximum concentrations in 
milkfat of 84 and 890 ppb, respectively.  1,3- and 1,4-DCB were identified together in 100% of the 
210 samples collected with mean and maximum milk concentrations of 6 and 75 ppb, respectively and 
mean and maximum concentrations in milkfat of 161 and 4,180 ppb, respectively.  Mean concentrations 






















6. POTENTIAL FOR HUMAN EXPOSURE 
of 1,2-, 1,3-, and 1,4-DCB in breast milk samples collected in Slovenia, Yugoslavia in 1981 were 9, <5, 
and 25 µg/kg, respectively (Jan 1983).  1,2- and 1,4-DCB concentrations in the milkfat of these samples 
were 230 and 640 µg/kg, respectively. 
Occupational exposure to DCBs may be important in several industries associated with the production of
various chlorobenzene compounds.  Workers may be exposed to DCBs during production, processing, 
and industrial use of these compounds, including the production and handling of products that contain 
these compounds (IARC 1999).  Workplace air levels of 1,4-DCB ranging up to 4,350 mg/m3 (724 ppm)
were measured at facilities producing or using the compound (IARC 1982).  A summary of the levels of 
1,4-DCB detected in various occupational settings is presented in Table 6-7.  Currently, workers in the 
industries identified in Table 6-7 are likely to have the highest potential for exposure to 1,4-DCB.  Levels 
of 1,2- and 1,3-DCB in workplace air were not found.  NIOSH estimated that about 34,000 workers were 
potentially exposed to 1,4-DCB, about 92,000 workers were potentially exposed to 1,2-DCB, and about 
400 workers were potentially exposed to 1,3-DCB in the early 1980s (NOES 1990). 
6.6 EXPOSURES OF CHILDREN  
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
There have been no measurements of the levels of DCBs in amniotic fluid, meconium, cord blood, or 
neonatal blood to investigate prenatal exposure.  However, DCBs have been detected in full-term
placentas collected from five regions of the Slovak Republic (Reichrtova et al. 1999, 2001).  Over 
40 placentas were sampled from each region.  DCB concentrations measured in these placentas are 
provided in Table 6-11.  DCBs were found most frequently in placentas from Bratislava, Slovakia  















6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-11. Dichlorobenzene Concentrations (µg/kg) in Human Placentas from 

Five Slovak Regions 

1,2-DCB 1,3- and 1,4-DCB 
Region % Detected Median Maximum % Detected Median Maximum 
1. Bratislava 82 0.8 46.9 81 1.4 218.0 
2. Nove Zamky 75 0.1 1.3 55 0.2 10.2 
3. Spisska Nova Ves 10 0.0 0.2 34 0.0 45.0 
4. Kosice 10 0.0 0.8 40 0.0 99.5 
5. Stara Lubovna 82 8.1 64.3 79 0.8 26.9 
Source: Reichrtova et al. 1999, 2001 
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(industrial region–petrol, pesticide, and rubber industries), Nove Zamky, Slovakia (agricultural region 
with high use of fertilizers), and Stara Lubovna, Slovakia (partially agricultural rural region with 
increasing cross-county traffic).  DCBs were found less frequently in samples from Spisska Nova Ves and 
Kosice (industrial regions with heavy metal pollution). 
Consumption of human milk can potentially expose nursing infants to DCB.  DCB (all isomers) was 
detected in 100% of 42 samples of human milk collected in five urban areas of the United States at 
concentrations ranging from 0.04–68 ppb; however, concentrations of the individual isomers were not 
specified (Erickson et al. 1980).  DCB (all isomers) was also identified in human breast milk in 8 of 
12 women who were residents of Bayonne, New Jersey (6 women); Jersey City, New Jersey (2 women); 
Bridgeville, Pennsylvania (2 women); and Baton Rouge, Louisiana (2 women); however, concentrations 
of the individual isomers were not specified (Pellizzari et al. 1982).  DCB (all isomers) were identified in 
breast milk samples collected from five different regions across Canada in 1982 (Mes et al. 1986).  
1,2-DCB was identified in 97% of the 210 samples collected with mean and maximum milk concentration 
of 3 and 29 ppb, respectively, and mean and maximum concentrations in milkfat of 84 and 890 ppb, 
respectively.  1,3-and 1,4-DCB were identified together in 100% of the 210 samples collected with mean 
and maximum milk concentrations of 6 and 75 ppb, respectively, and mean and maximum concentrations 
in milkfat of 161 and 4,180 ppb, respectively.  Mean concentrations of 1,2-, 1,3-, and 1,4-DCB in breast 
milk samples collected in Slovenia, Yugoslavia in 1981 were 9, <5, and 25 µg/kg, respectively (Jan 
1983). 1,2- and 1,4-DCB concentrations in the milkfat of these samples were 230 and 640 µg/kg, 
respectively.
Children are exposed to 1,4-DCB primarily by inhalation of vapors from toilet deodorants, moth proofing 
crystals, and moth balls used in the home or by consumption of moth balls.  Consumption of DCBs in 
foods (see Section 6.4.4) and drinking water (see Section 6.4.2) contaminated with DCBs is thought to be
a minor exposure pathway.  There have been no body burden measurements made on children. 
The National Human Adipose Tissue Survey (NHATS) conducted in 1982, estimated general population 
exposure to a variety of toxic organic chemicals.  1,4-DCB was detected in 100% of 46 composite human
adipose tissue specimens analyzed at levels ranging from 12 to 500 ppb, whereas 1,2-DCB was detected 
in 63% of the 46 specimens at levels ranging from <0.1 to 2 ppb (EPA 1986f, 1989d).  These measure­
ments indicate widespread exposure of the general population including children (aged 0–14 years) to 
DCBs. Using this same data, ranks for each of the nine census regions were assigned according to the 
composite adipose tissue concentration of 1,4-DCB or the mean of multiple adipose composite samples 
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(Phillips and Birchard 1991).  These authors reported that exposure to 1,4-DCB based on adipose tissue 
levels was highest nationally for children (aged 0–14 years) in the west south central (Arkansas, 
Louisiana, Oklahoma, and Texas), east south central (Kentucky, Tennessee, Alabama, and Mississippi), 
and south Atlantic regions (Delaware, Maryland, the District of Columbia, Virginia, West Virginia, North 
Carolina, South Carolina, Georgia and Florida) as compared to other areas of the United States.  Exposure 
to 1,2-DCB was highest for children (0–14 years) living in the New England (Maine, New Hampshire, 
Vermont, Massachusetts, Rhode Island, and Connecticut), east north central (Illinois, Indiana, Michigan, 
Ohio, and Wisconsin), and west north central regions (Minnesota, Iowa, Missouri, Nebraska, Kansas, 
North Dakota, and South Dakota).  2,5-Dichlorophenol, a metabolite of 1,4-DCB, and 3,4-dichloro­
phenol, a metabolite of 1,2-dichlorophenol, were detected in urine samples from 197 Arkansas children 
(Hill et al. 1989). 2,5-Dichlorophenol was detectable in 96% of the samples with median and maximum 
concentrations of 9 and 1,200 ppb, respectively.  3,4-Dichlorophenol was detectable in 6% of the samples 
with median and maximum concentrations of <1 ppb (detection limit) and 9 ppb. 
Childhood exposures can be reduced by appropriate use of 1,4-DCB-containing compounds in the home 
and appropriate supervision of young children.  Small children, because of their hand-to-mouth activity, 
may receive significant exposure from ingestion of 1,4-DCB.  Moth balls look like candy; a young child 
may be tempted to eat them.  Accidental poisoning by consumption of this household chemical is likely to
occur if the moth balls and/or crystals are placed in a location easily accessed by children and under 
conditions where children are not properly supervised.  It is also important that children not be allowed to 
play around toilet deodorants and air fresheners unsupervised.  Since some 1,4-DCB is applied as a 
crystalline form, children may be exposed dermally, orally (in hand-to-mouth activities), or by inhalation 
of dust particles or vapors while playing on floors or carpeting where 1,4-DCB-contaminated particles 
may have fallen after moth proofing activities in the home.  It is important that children not be allowed 
entry into 1,4-DCB-treated storage areas until the moth crystals have sublimated and the vapors have 
dissipated. 
Children living in homes of adults that are occupationally exposed to DCBs must not be exposed to the 
contaminated work clothes or shoes of adults (DHHS 1995).  While the vast majority of occupational 
exposures are likely to be by inhalation of DCB vapors by workers, a potential route of exposure to other 
members of the worker’s family including children may occur if DCB contaminated work clothes are 
brought home for laundering.  The chemical contamination on the clothing may then vaporize releasing 
DCBs into the indoor air of the workers’ home.  Occupational protection statements for the end use DCB 
products state that individuals occupationally exposed to these products should take off all wet or 
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contaminated work clothes and shoes and shower using soap and water, and then put on clean clothes 
(NIOSH 1997). Although no studies were found that investigated this pathway of exposure, it is 
conceivable that poor hygiene practices among occupationally exposed adults could potentially result in 
domestic exposures of other family members to DCBs carried home on work clothes and subsequently to
the vapors released. 
As discussed in Section 6.5 of this profile, inhalation of indoor air is the major exposure route for both 
adults and children in the general population; however, several other minor pathways may also result in 
exposure. Like adults, children living in proximity to hazardous waste sites may be exposed to DCBs in 
contaminated groundwater.  If residential wells are the primary source of drinking water, this may pose a 
risk to human health by consumption of contaminated water and by increased inhalation of, and dermal 
contact with DCBs during showering and bathing.   
Little information on the levels of DCB concentrations in infant and toddler foods and in baby formula 
was located.  Page and Lacroix (1995) analyzed a variety of beverage and food samples for 32 different 
volatile contaminants, including 1,4-DCB, and found residue levels to be quite low (range, 0.1–22 ppb). 
Soft drink samples contained 0.1 µg/kg (ppb), while cream with 10% butterfat, butter, margarine, peanut 
butter, flour, and pastry mix contained concentrations of 0.1, 1.3–2.7, 12.2–14.5, 1.2–8.8, 7.3, and 22 ppb,
respectively.  1,2-, 1,3-, and 1,4-DCB were detected in 45, 6, and 69 out of 234 table-ready food items
from the FDA’s total diet study, respectively.  Positive detections of all three isomers had concentrations 
within a range of 4.26 to 114 ppb (Heikes et al. 1995).  No information was located to determine whether 
children differed in their weight-adjusted intake of 1,4-DCB. 
There are some parental exposures to DCBs that might result in potential exposures of children to this 
chemical.  DCBs are not genotoxic and, thus, there should be no concern about exposure to parental germ
cells (see Table 3-3 and 3-4 for further information).  Additional information on the genotoxicity of these 
compounds can be found in Section 3.7, Children’s Susceptibility.  Because DCBs have been widely
detected in samples of human adipose tissue, the potential exists for these compounds to be stored in 
maternal tissues from preconception exposures and mobilized during gestation or lactation so that the 
developing fetus or embryo or nursing infant is exposed even after external exposure to the mother has 
ceased. Like all organochlorine compounds, DCBs are stored in fatty tissue.  1,4-DCB was detected in 
100% of adipose tissue samples of adults and children analyzed as part of the National Adipose Tissue 
study (EPA 1986f).  As previously mentioned, there have been measurements of all DCB isomers 
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(combined) in human breast milk (Erickson et al. 1980; Pellizzari et al. 1982).  For additional information 
on developmental effects of this compound, please see Section 3.7, Children’s Susceptibility.
During the Minnesota Children’s Pesticide Exposure Study, 1,4-DCB was detected above 0.2 µg/m3 in 
70 of 73 personal air samples, 83 of 101 indoor air samples, and 42 of 100 outdoor air samples collected 
from households with children (Adgate et al. 2004).  The mean concentration of 1,4-DCB was 
1.4 µg/m3 in the personal air samples, 0.9 µg/m3 in the indoor air samples, and 0.3 µg/m3 in the outdoor 
air samples.  During the School Health Initiative:  Environment, Learning, Disease (SHIELD) study, the 
median concentrations of 1,4-DCB measured in the outdoor home air, indoor school air, indoor home air, 
and personal air of 113 children from two inner-city schools in Minneapolis, Minnesota were 0.1, 0.5, 0.7, 
and 1.0 µg/m3, respectively, during the winter and 0.2, 0.5, 0.9, and 1.3 µg/m3, respectively, during the 
summer (Adgate et al. 2004).  The mean, median, and 95th percentile concentrations of 1,4-DCB 
measured in the blood of 134 children during the SHIELD study were 4.22, 0.21, and 24.5 µg/m3, 
respectively (Sexton et al. 2005). 
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
In addition to individuals who are occupationally exposed to DCBs (see Section 6.5), several groups 
within the general population have potentially higher exposures (higher than background levels) to DCBs 
than the general population.  These populations include individuals living near sites where DCB are 
produced or used in manufacturing and sites where DCBs are disposed.  
Those individuals living or working near industrial facilities or hazardous waste sites with higher than 
average levels of DCBs in the air would have the potential for above-average exposures.  In addition, 
individuals using space deodorants (air fresheners), toilet block deodorants, or moth repellents (moth balls 
or crystal) containing 1,4-DCB in their homes have the potential for high exposure to this compound 
(Scuderi 1986). Indoor air concentrations resulting from the use of these products in bathrooms and 
closets have been measured at levels up to 1.3 mg/m3 (0.22 ppm) (Scuderi 1986). 
Individuals living in proximity to hazardous waste sites may also be exposed to DCB by contaminated 
groundwater. If residential wells are the primary source of drinking water, this may pose a risk to human 
health by consumption of contaminated water and by increased inhalation of and dermal contact with 
DCBs during showering and bathing. 
















    
 
 







6. POTENTIAL FOR HUMAN EXPOSURE 
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of dichlorobenzenes is available.  Where adequate information 
is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of dichlorobenzenes. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical and chemical properties of the DCBs are 

sufficiently well characterized to allow estimation of its environmental fate (Amoore and Hautala 1983; 

Chiou et al. 1983; Howard 1989; Lide and Frederikse 1994; Newsom 1985; NFPA 1994; Sax and Lewis 

1987; Schwartzenbach and Westall 1981; Verschueren 1983; Wilson et al. 1981).  On this basis, it does 

not appear that further research in this area is required. 

Production, Import/Export, Use, Release, and Disposal. Data on the production and uses of 

DCBs in the United States are available (CMR 1990; HSDB 2005; IRPTC 1985; SRI 1996; TRI03 2005).  

Incineration is the recommended disposal method for DCBs (HSDB 2005; IRPTC 1985).  Disposal of this
 
compound is controlled by federal regulations (HSDB 2005; IRPTC 1985).  Available information 

appears to be sufficient for assessing the potential for release of, and exposure to, DCBs. 

According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C.
 
Section 11023, industries are required to submit substance release and off-site transfer information to the 

EPA. The TRI, which contains this information for 2003, became available in May of 2005.  This 

database is updated yearly and should provide a list of industrial production facilities and emissions. 




















6. POTENTIAL FOR HUMAN EXPOSURE 
Environmental Fate. The environmental fate of the DCBs has been well characterized.  Their 
volatilization into air from other media, reaction with hydroxyl radicals in the atmosphere, transport 
through soil, and biodegradation by water and soil microorganisms seem to be well understood (Bouwer 
and McCarty 1982, 1983, 1984; Chiou et al. 1983; Cuppitt 1980; EPA 1985d; Garrison and Hill 1972; 
Howard 1989; Ligocki et al. 1985; Newsom 1985; Schwartzenbach and Westall 1981; Singh et al. 1981a, 
1981b; Scuderi 1986; Spain and Nishino 1987; Tabak et al. 1981; Wakeham et al. 1983; Wang and Jones 
1994a, 1994b, 1994c; Wilson et al. 1981).  Volatilization, sorption, biodegradation, and bioaccumulation 
appear to be competing processes for the removal of DCBs from water (Spain and Nishino 1987).  
Additional data on the rates of these reactions under various environmental conditions would be useful, 
but do not appear to be essential to understand the behavior of DCBs in the environment. 
Bioavailability from Environmental Media.    DCBs have been shown to be well absorbed by
laboratory animals via inhalation and oral exposure (Hawkins et al. 1980; Kimura et al. 1979).  No 
information has been located regarding absorption by the dermal route.  Although no information has 
been located on the absorption of this substance from breathing contaminated air or ingesting DCBs that 
are contained in soil or plant material are expected to be well absorbed from these media.  It would be 
useful to have information on whether, and to what extent, absorption of DCBs can occur as a result of 
dermal contact with soil or from swimming in surface water or bathing or showering in groundwater that 
contains DCBs. 
Food Chain Bioaccumulation. Bioconcentration of DCBs has been documented for several aquatic 
species (ASTER 1995; Chiou 1985; Oliver and Nicol 1982a; Oliver and Niimi 1983).  Based on the 
relatively high Kow, it appears that bioaccumulation does occur (Leo et al. 1971).  Oliver and Nicol 
(1982a) measured concentrations of chlorobenzenes in sediments, water, and selected fish from the Great 
Lakes. Their limited fish analyses indicate that chlorobenzenes, including DCBs, are bioconcentrated by 
fish, but to a much smaller extent than compounds such as DDT or PCBs.  DCBs have also been shown to 
be accumulated by terrestrial plants (Wang et al. 1996).  No data were located on biomagnification of 
DCBs through terrestrial or aquatic food chains.  Additional information on bioconcentration of DCBs by
commercially important fish, shellfish, and plant species and biomagnification would be helpful in 
evaluating the potential importance of food chain bioaccumulation to human exposure. 
Exposure Levels in Environmental Media.    Several studies are available documenting levels of 
DCBs in indoor and ambient outdoor air, water, and soil and sediments in rural, suburban, and urban 
areas and in the environs of hazardous waste sites (Bozzelli and Kebbekus 1979; Coniglio et al. 1980;
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Dressman et al. 1977; Elder et al. 1981; Fellin and Otson 1994; Harkov et al. 1984, 1985; Hauser and 
Bromberg 1982; IARC 1982; IJC 1989; Kostianen 1995; LaRegina et al. 1986; Oliver and Nicol 1982a; 
Page 1981; Scuderi 1986; Shah and Heyerdahl 1988; Staples et al. 1985; Wallace et al. 1986a, 1986b, 
1989). It would be valuable to have more recent monitoring data to better estimate the potential for 
current human exposure levels from these media, especially in the vicinity of hazardous waste sites. 
Although there is little information on DCB levels in food (IARC 1982; Oliver and Niimi 1983; Page and 
Lacroix 1995), it does not appear that this is an important source of human exposure.  However, 
additional data on DCB levels in foodstuffs, especially commercially important fish, shellfish, and plants, 
would be useful to confirm this assumption. 
Reliable monitoring data for the levels of dichlorobenzenes in contaminated media at hazardous waste 
sites are needed so that the information obtained on levels of dichlorobenzenes in the environment can be 
used in combination with the known body burden of dichlorobenzenes to assess the potential risk of 
adverse health effects in populations living in the vicinity of hazardous waste sites. 
Exposure Levels in Humans.  Detection of DCBs in breath, adipose tissue, breast milk, and blood 
can be used as indicators of human exposure (Ashley et al. 1994, 1995; EPA 1986f, 1989d; Erickson et al. 
1980; Hill et al. 1995; Pellizzari et al. 1982; Wallace et al. 1986b). Levels of DCBs in breath appear to 
provide rough estimates of recent preceding exposure (Wallace et al. 1986b), while levels in adipose 
tissue may be useful to indicate less recent past exposure (EPA 1986f, 1989d).  The level of 2,5-dichloro­
phenol (a metabolite of 1,4-DCB) has also been reported in urine of 1,000 individuals (Hill et al. 1995), 
and is highly correlated to 1,4-DCB in blood.  Additional data correlating levels in environmental media 
with human tissue levels, particularly for populations living in the vicinity of hazardous waste sites that 
contain DCBs, would be helpful in establishing levels of the chemical to which humans have been 
exposed. Additional monitoring data on the occupational exposure of workers to DCBs would be helpful. 
Additional studies reporting inhalation exposure through the use of toilet air fresheners and mothballs that 
contain DCBs would be useful. 
This information is necessary for assessing the need to conduct health studies on these populations. 
Exposures of Children.    Children, like all members of the general population, are exposed to DCBs 
primarily by inhalation.  No exposure or body burden studies were specifically located related to children. 
Studies to quantify the amount of DCBs in amniotic fluid, meconium, cord blood, or neonatal blood
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would be useful in assessing prenatal exposure.  Maternal-fetal exposure should be evaluated since there 
is some genotoxic potential.  Studies on the amount of the DCBs specifically in breast milk would be 
useful in assessing exposures in nursing infants.  Although inhalation of 1,4-DCB is the most important 
exposure pathway in humans, consumption of moth crystals or moth balls by young children also may
result in additional exposure of concern.  It is not known whether children are different from adults in 
their weight-adjusted intake of 1,4-DCB.  Studies on this topic with respect to inhalation and dietary
intake are needed. Childhood exposure to this chemical can be decreased by the appropriate use of this 
compound particularly in the home and by appropriate supervision of young children.  Education 
programs for parents and young children may be appropriate to reduce poisoning incidents.  Studies on 
exposures of janitorial personnel and other occupationally exposed adults would also be helpful in 
determining the amount of 1,4-DCB that may accumulate on work clothes and whether crystalline 
particles of the toilet deodorants or moth crystal can be carried home on work clothing leading to
additional domestic exposures from crystals and subsequently to vapors.   
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for dichlorobenzenes were located.  This substance is 
not currently one of the compounds for which a sub-registry has been established in the National 
Exposure Registry. The substance will be considered in the future when chemical selection is made for 
sub-registries to be established. The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to 
exposure to this substance. 
6.8.2 Ongoing Studies 
A search of Federal Research in Progress (FEDRIP 2005) identified one ongoing study that is related to 
dichlorobenzenes.  James Heist of Ftc Acquisition Corporation is being funded by the Air Force to study 
material recycling and waste minimization using a freeze crystallization process.  Dichlorobenzenes are 
among the substances for which recycling via this method will be considered. 











6. POTENTIAL FOR HUMAN EXPOSURE 























7. ANALYTICAL METHODS 
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring dichlorobenzenes, its metabolites, and other biomarkers of exposure and 
effect to dichlorobenzenes. The intent is not to provide an exhaustive list of analytical methods.  Rather, 
the intention is to identify well-established methods that are used as the standard methods of analysis.  
Many of the analytical methods used for environmental samples are the methods approved by federal 
agencies and organizations such as EPA and the National Institute for Occupational Safety and Health 
(NIOSH). Other methods presented in this chapter are those that are approved by groups such as the 
Association of Official Analytical Chemists (AOAC) and the American Public Health Association 
(APHA). Additionally, analytical methods are included that modify previously used methods to obtain 
lower detection limits and/or to improve accuracy and precision. 
7.1 BIOLOGICAL MATERIALS  
Methods are available for measuring levels of DCBs in blood, urine, tissue, and breath.  Representative 
methods are summarized in Table 7-1. Methods include sample collection, preparation, cleanup, and 
determination.  Sample preparation techniques are usually required to separate the compound of interest 
from the complex biological sample medium.  Gas purge and solvent extraction are used most frequently
to separate DCBs from blood, urine, and tissues.  The breath matrix is relatively simple and does not 
require preparation steps; however, special techniques such as use of a spirometer are required to provide 
pure air for inhalation and a mechanism for collection of exhaled air.  Gas chromatography (GC) is used 
most frequently to detect DCBs in biological materials.  Detectors used to identify DCBs in biological 
materials include the electron capture detector (ECD) (Bristol et al. 1982; Jan 1983), the photoionization 
detector (PID) (Langhorst and Nestrick 1979), and mass spectrometry (MS) (Ashley et al. 1992; Michael 
et al. 1980). ECD and PID provide some selectivity, but confirmation using a different GC column or 
detector is often recommended.  MS provides identification as well as quantitation of analytes. 
Separation of DCBs from biological samples may be accomplished by extraction with hexane (Bristol 
et al. 1982; Jan 1983), or carbon tetrachloride (Langhorst and Nestrick 1979), or by purging with an inert 
gas and trapping on a sorbent material. Solvent extraction permits concentration, thereby increasing 
sensitivity, but the extraction solvents can interfere with the analysis, and evaporative losses can result in 
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matrix Analytical Sample Percent 
(analyte) Sample preparation method detection limit recovery Reference 
Blood Headspace purge; cap. GC/MS 3 ng/mL 86.3 IARC Method
(1,3-DCB) thermal desorption 25; Pellizzari et 
al. 1985 
Blood Headspace purge; cap. GC/MS Low-ppb 86– Michael et al. 
(model thermal desorption 120 (model 1980 
compounds) compounds) 
Blood Solvent extraction; GC/PID 3.6 ppb 85 Langhorst and 
(1,2-DCB) silica gel column Nestrick 1979
clean-up 
Blood Solvent extraction; GC/PID 2.8 ppb 82 Langhorst and 
(1,3-DCB) silica gel column Nestrick 1979
clean-up 
Blood Solvent extraction; GC/PID 3.0 ppb 89 Langhorst and 
(1,4-DCB) silica gel column Nestrick 1979
clean-up 
Blood Solvent extraction GC/ECD 1.4 ppb 76.6 Bristol et al. 
(1,2-DCB) 1982 
Blood Solvent extraction GC/ECD 1.3 ppb 74.5 Bristol et al. 
(1,3-DCB) 1982 
Blood Solvent extraction GC/ECD 2 ppb 81.6 Bristol et al. 
(1,4-DCB) 1982 
Blood Purge and trap cap. GC/MS 0.05 ppb 77–122 Ashley et al. 
(1,2-DCB) 1992 
Blood Purge and trap cap. GC/MS 0.04 ppb 130–162 Ashley et al. 
(1,3-DCB) 1992 
Blood Purge and trap cap. GC/MS 0.04 ppb 93–98 Ashley et al. 
(1,4-DCB) 1992 
Blood, urine Purge-and-trap, GC/MS No data No data Barkley et al. 
(unspecified thermal desorption 1980 
DCBs) cap 
Urine Solvent extraction; GC/PID 0.90 ppb 83 Langhorst and 
(1,2-DCB) silica gen column Nestrick 1979
clean-up 
Urine Solvent extraction; GC/PID 0.70 ppb 78 Langhorst and 
(1,3-DCB) silica gen column Nestrick 1979
clean-up 
Urine Solvent extraction; GC/PID 0.75 ppb 81 Langhorst and 
(1,4-DCB) silica gen column Nestrick 1979
clean-up 
Urine Headspace purge; cap. GC/MS Low-ppb 48– Michael et al. 
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matrix Analytical Sample Percent 
(analyte) Sample preparation method detection limit recovery Reference 
Adipose Maceration; cap. GC/MS Low-ppb 13– Michael et al. 
tissue headspace purge; 80 (model 1980 
(model thermal desorption compounds) 
compounds) 
Human milk Headspace purge; GC/MS 0.6 62.9 Erickson et al. 
(chloro­ thermal desorption 1980 
benzene) 
Human milk Solvent extraction; GC/ECD No data >80 Jan 1983 
(unspecified cleanup with sulfuric
DCBs) acid, Florisil 
Adipose Solvent extraction; GC/ECD No data >80 Jan 1983 
tissue cleanup with sulfuric
(unspecified acid, Florisil 
DCBs) 
Tissue Maceration; cap. GC/MS 6 ng/g 56.5 IARC Method
(1,3-DCB) headspace purge; 25; Pellizzari et 
thermal desorption al. 1985 
Breath Collection using a GC/MS No data No data Barkley et al. 
(unspecified spirometer; 1980 
DCBs) adsorption on Tenax 
traps; thermal 
desorption cap 
Breath Collection into cap. GC/MS-SIM low-µg/m3 49–80 Thomas et al. 




cap. = capillary; ECD = electron capture device; GC = gas chromatography; MS = mass spectrometry; PID = photo-
























7. ANALYTICAL METHODS 
headspace technique is relatively simple, but may be less sensitive than the purge-and-trap method. The 
purge-and-trap method, while providing increased sensitivity, requires more complex instrumentation and 
may result in artifact formation (Seto 1994).  
Although a variety of methods are available for determination of DCBs in blood, few are well 
characterized and validated.  A method has been developed which utilizes headspace purge followed by
thermal desorption of the trapped, purged analytes.  DCBs are then determined by capillary GC/MS 
(Michael et al. 1980; Pellizzari et al. 1985).  Recovery is very good (>85%) and detection limits are in the 
low-ppb range for model compounds (Michael et al. 1980; Pellizzari et al. 1985).  A sensitive and reliable 
method for identification and quantitation of DCBs in samples of whole blood has been developed by
Ashley and coworkers at the Centers for Disease Control and Prevention (CDC) (Ashley et al. 1992).  The 
method involves purge-and-trap of a 10 mL blood sample with analysis by capillary GC/high resolution 
MS. Anti-foam procedures are utilized as well as special efforts to remove background levels of volatile 
organic compounds (VOCs) from reagents and equipment.  The method is sensitive enough (ppt levels) to 
determine background levels of VOCs in the population.  Percent recoveries were 77–122% for 1,2-DCB, 
130–162% for 1,3-DCB, and 93–98% for 1,4-DCB. 
Methods are available for monitoring DCBs in urine and tissues, particularly adipose tissue and mother's
milk. Solvent extraction, silica gel column clean-up, and GC/ECD or GC/PID analysis has been used for 
urine (Langhorst and Nestrick 1979), mother's milk (Jan 1983), and adipose tissue (Jan 1983).  Recovery
is good (>80% recovery) and detection limits are in the low-ppb range (Jan 1983; Langhorst and Nestrick 
1979). Headspace purge followed by capillary GC/MS analysis has been utilized for urine (Michael et al.
1980), mother's milk (Erickson et al. 1980), and tissue (Pellizzari et al. 1985).  Recovery, where reported, 
is adequate (>60%) (Erickson et al. 1980), and detection limits are in the low-ppb range (Erickson et al. 
1980). 
Breath samples are usually collected through a spirometer onto a sorbent cartridge (Barkley et al. 1980) or
into passivated canisters (Thomas et al. 1991).  Analytes are concentrated cryogenically from a portion of 
the canister contents or after thermal desorption from the sorbent, then analyzed by GC/MS.  Recovery of 
1,4-DCB using Tenax cartridges was 86–101% and the detection limit was about 1 µg/m3. The method is 
sufficiently sensitive and reliable for monitoring exposure to DCBs.  Recovery for collection of 1,4-DCB 
in canisters was 49–80% and the detection limits were in the low-µg/m3 range (Thomas et al. 1991).  The 
spirometer system utilizing canisters is compact, and may be useful as a field screening method (Thomas 
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7.2 ENVIRONMENTAL SAMPLES 
Methods are available for determining DCBs in a variety of environmental matrices.  A summary of 
representative methods is shown in Table 7-2.  Validated methods, approved by agencies and 
organizations such as EPA, ASTM, APHA, and NIOSH, are available for air, water, and solid waste 
matrices. These methods for analysis of drinking water, waste water, and soil/sediment samples are 
included in Table 7-2.  Many of the methods published by APHA and ASTM for water are equivalent to 
the EPA methods.   
GC is the most widely used analytical technique for quantifying concentrations of DCBs in environmental 
matrices.  Various detection devices used for GC include the flame ionization detector (FID), ECD, Hall 
electroconductivity detector (HECD), and PID.  Confirmation using a second column is usually 
recommended.  MS provides identification as well quantitation for GC analysis.  Because of the 
complexity of the sample matrix and the usually low concentrations of VOCs in environmental media, 
sample concentration is generally required prior to GC analysis.  Methods suitable for determining trace 
amounts of DCBs in aqueous and other environmental media include three basic approaches to the 
pretreatment of the sample:  gas purge-and-trap technique, headspace-gas extraction, and extraction with 
solvent. Care must be taken during sample collection and processing to avoid evaporative losses.  
Contamination is another potential analytical problem and monitoring is required.  1,4-DCB is a relatively
common chemical compound and can contaminate reagents and glassware. 
Charcoal adsorbent is used for collection of DCBs in occupational air.  The compounds are desorbed with 
carbon disulfide and analyzed by GC/FID.  The method is sufficiently sensitive and reliable for 
determining occupational exposure to DCBs (NIOSH 1994).  
Ambient air samples are collected on adsorbents such as Tenax (Wallace 1987), or multisorbent (Heavner 
et al. 1992; Oliver et al. 1996), or in passivated canisters (EPA 1988a).  Tenax traps are thermally
desorbed, concentrated cryogenically, and analyzed by capillary GC/MS (Wallace et al. 1987).  Recovery
is good (81–110%), precision for side-by-side samples is acceptable (9–45% RSD), and the detection 
limit is ≈1 µg/m3 (Wallace 1987).  Multisorbent traps may be solvent desorbed and analyzed by capillary
GC/MS. Recovery and precision are good and detection limits as low as 0.019 ppb have been reported 
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matrix Analytical Sample Percent 
(analyte) Sample preparation method detection limit recovery Reference 
Occupational 
air 
Collection on charcoal 
tubes; desorption with 







Collection on charcoal 
tubes; desorption with 





Ambient air Collection in cap. GC with FID, No data No data Method TO-14 
(VOCs canisters; ECD or MS EPA 1988a 
including cryofocussing;
DCBs) thermal desorption 
Air-emission MM5 sampling train cap. GC/MS No data -13 to -16 Method 0010
sources (condensate, filter, EPA 1994f 
(selected adsorbent); 
compounds) condensate, impinger 
and rinses, solvent 
extraction, 
evaporation; XAD­




Air-emission VOST sampling train GC/MS No data No data Method 0030
sources (sorbent traps); EPA 1994h 
(volatile thermal desorption 
organics) 
Drinking Purge and trap GC/HECD; conf. <0.01 µg/L for 95 Method 502.1
water on second col. or most VOCs EPA 1991a 
(1,2- and GC/MS 
1,3-DCB) 
Drinking Purge and trap GC/HECD; conf. <0.01 µg/L for 90 Method 502.1
water on second col. or most VOCs EPA 1991a 
(1,4-DCB) GC/MS 
Drinking Purge and trap GC/PID-HECD; 0.03–0.05 µg/L 97–102 (PID); Method 502.2
water conf. by GC/MS (PID); 0.02– 98– EPA 1991b 
(1,2-DCB) 0.04 µg/L 100 (HECD) 
(HECD) 
Drinking Purge and trap GC/PID-HECD; 0.02 µg/L (PID); 97–104 (PID); Method 502.2
water conf. by GC/MS 0.02–0.07 µg/L 97– EPA 1991b 
(1,3-DCB) (HECD) 106 (HECD) 
Drinking Purge and trap GC/PID-HECD; 0.01–0.03 µg/L 97–103 (PID); Method 502.2
water conf. by GC/MS (PID); 0.01– 97– EPA 1991b 




Purge and trap GC/PID; conf. on 
second col. or
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matrix Analytical Sample Percent 
(analyte) Sample preparation method detection limit recovery Reference 
Drinking Purge and trap GC/PID; conf. on 0.006 µg/L 91 Method 503.1
water second col. or EPA 1991c 
(1,3-DCB) GC/MS 
Drinking Purge and trap GC/PID; conf. on 0.006 µg/L 91–107 Method 503.1
water second col. or EPA 1991c 
(1,4-DCB) GC/MS 
Drinking Purge and trap cap. GC/MS 0.03–0.05 µg/L 93–97 Method 524.2
water EPA 1992a 
Drinking Purge and trap cap. GC/MS 0.05–0.12 µg/L 87–100 Method 524.2
water EPA 1992a 
Drinking Purge and trap cap. GC/MS 0.03–0.04 µg/L 93–103 Method 524.2
water EPA 1992a 
Waste water Purge and trap GC/HECD; conf. 0.15 µg/L ND–208 Method 601 
on second col. or EPA 2002c 
GC/MS 
Waste water Purge and trap 	 GC/HECD; conf. 0.32 µg/L 7–187 Method 601 
on second col. or EPA 2002c 
GC/MS 
Waste water Purge and trap 	 GC/HECD; conf. 0.24 µg/L 42–143 Method 601 
on second col. or EPA 1984c; 
GC/MS EPA 2002c 
Waste water Purge and trap 	 GC/PID; conf. on 0.4 µg/L 37–154 Method 602 
second col. or EPA 2002d 
GC/MS 
Waste water Purge and trap 	 GC/PID; conf. on 0.3 µg/L 50–141 Method 602 
second col. or EPA 2002d 
GC/MS 
Waste water Purge and trap 	 GC/PID; conf. on 0.3 µg/L 42–143 Method 602 
second col. or EPA 1984f; 
GC/MS EPA 2002d 
Waste water 	 Solvent extraction; GC/ECD 1.14 µg/L 9–160 Method 612 
optional Florisil EPA 2002b 
column clean-up 
Waste water 	 Solvent extraction; GC/ECD 1.19 µg/L DL–150 Method 612 
optional Florisil EPA 2002b 
column clean-up 
Waste water 	 Solvent extraction; GC/ECD 1.34 µg/L 13–137 Method 612 
optional Florisil EPA 1984c; 
column clean-up EPA 2002b 
Waste water Purge and trap GC/MS No data 18–190 Method 624 
(1,2- and EPA 1984d; 
1,4-DCB) EPA 2002a 
Waste water Purge and trap GC/MS No data 59–156 Method 624 
(1,3-DCB) EPA 1984d; 
EPA 2002a 
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matrix Analytical Sample Percent 
(analyte) Sample preparation method detection limit recovery Reference 
Waste water Purge and trap cap. GC/MS 0.045 µg/L 108 Method 6200B 
APHA 1998 
Waste water Purge and trap cap. GC/MS 0.033 µg/L 106 Method 6200B 
APHA 1998 
Waste water/ Purge and trap cap GC/HECD, 0.023 µg/L 93 (HECD); Method 6200
Drinking PID (HECD); 67 (PID) APHA 1998 
water 0.031 µg/L (PID) 
(1,2-DCB) 
Waste water/ Purge and trap cap GC/HECD, 0.017 µg/L 95 (HECD); Method 6200
Drinking PID (HECD); 70 (PID) APHA 1998 
water 0.028 µg/L (PID) 
(1,3-DCB) 
Waste water/ Purge and trap cap GC/HECD, 0.059 µg/L 91 (HECD); Method 6200
Drinking PID (HECD); 70 (PID) APHA 1998 
water 0.061 µg/L (PID) 
(1,4-DCB) 
Drinking Purge and trap GC low µg/L 99 Method D 3871 
water ASTM 1994 
(VOCs)
Solid waste Closed system purge GC/ECD, FID, Not reported Not reported Method 5035
(VOCs) and trap and MS EPA 1996c 
extraction 
Solid waste Purge and trap, direct GC/HECD, PID 0.02 µg/L 100 (HECD); Method 8021B 
(1,2-DCB) injection, headspace, (HECD); 102 (PID) EPA 1996d 
or vacuum distillation 0.05 (PID) 
Solid waste Purge and trap, direct GC/HECD, PID 0.02 µg/L 106 (HECD); Method 8021B 
(1,3-DCB) injection, headspace, (HECD); 104 (PID) EPA 1996d 
or vacuum distillation 0.02 (PID) 
Solid waste Purge and trap, direct GC/HECD, PID 0.01 µg/L 98 (HECD); Method 8021B 
(1,4-DCB) injection, headspace, (HECD); 103 (PID) EPA 1996d 
or vacuum distillation 0.07 (PID) 
Solid waste Solvent extraction Single or dual 270 ng/L 102 Method 8121
(1,2-DCB) cap. GC/ECD EPA 1994l 
Solid waste Solvent extraction Single or dual 250 ng/L 103 Method 8121
(1,3-DCB) cap. GC/ECD EPA 1994l 
Solid waste Solvent extraction Single or dual 890 ng/L 104 Method 8121
(1,4-DCB) cap. GC/ECD EPA 1994l 
aEstimated limit of detection 
cap. = capillary; conf. = confirmation; col. = column; DL = detection limit; ECD = electron capture detector; 
FID = flame ionization detector; GC = gas chromatography; HECD = Hall electrolytic conductivity detector; 
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(EPA 1988a), but performance data are unavailable.  Passive sampling devices are also widely used, due 
in part to their ease of use and small size (Lewis et al. 1985). 
For water, soil, or sediment samples, DCBs are purged from the sample with an inert gas such as helium
or nitrogen, and then passed through the sorbent (EPA 1984a, 1984b, 1991a, 1991b, 1991c, 1992a, 1994a, 
1994f).  The analytes are thermally desorbed and analyzed by GC/HECD, GC/PID, GC/ECD, or GC/MS 
techniques. Detection limits for waste waters and solid wastes are in the low-ppb range, which is 
probably well below levels of health concern.  Detection limits for drinking water samples are generally
in the ppt range (0.006–0.05 µg/L) (EPA 1991a, 1991b, 1991c, 1992a). 
Several physical parameters may interfere with analytical accuracy.  High sampling flow rates and high 
temperature and humidity may cause decreased adsorption of DCB vapor on the solid sorbent (APHA 
1995a). Interference by other VOCs with similar retention times may be resolved by using different GC 
column materials and temperatures or be using MS techniques. 
The use of capillary columns rather than packed column GC has improved resolution and sensitivity and 
shortened the analysis time (Washall and Wampler 1988).  However, more stringent sample clean-up 
procedures are required for capillary column GC (Oliver and Nicol 1982b).  The development of methods 
using whole column cryotrapping (Pankow and Rosen 1988; Pankow et al. 1988) and cryogenic 
refocusing (Washall and Wampler 1988) provide even greater sensitivity and resolution for GC analysis. 
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of dichlorobenzenes is available.  Where adequate information 
is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of dichlorobenzenes. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 





















7. ANALYTICAL METHODS 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.     
Exposure. Exposure to DCBs may be evaluated by measuring the levels of these compounds in blood, 
breath, milk, and adipose tissue, and by measuring the level of 2,5-dichlorophenol, a metabolite of 
1,4-DCB, or the levels of 2,3-dichlorophenol, 3,4-dichlorophenol, 3,4-dichlorocatechol, and 
4,5-dichlorocatechol, metabolites of 1,2-DCB, in urine (Bristol et al. 1982; Erickson et al. 1980; Jan 
1983; Kumagai and Matsunaga 1995, 1997; Langhorst and Nestrick 1979; Mage et al. 2004; Pellizzari 
et al. 1985). Sensitive analytical methods are available for measurements in blood.  Development of 
methods with improved specificity and sensitivity for other tissues and breath would be valuable in 
identifying individuals with low-level exposure.  Development of standardized procedures would permit 
comparison of data and facilitate the study of correlations between exposure and measured levels 
biological samples.  Interlaboratory studies are also needed to provide better performance data for 
methods currently in use. 
Effect. There are no known health effects such as elevated liver enzymes that are uniquely associated 
with exposure to DCBs.  Therefore, the identification of specific health effects and the development of 
analytical methods to determine biomarkers of effect for DCBs would be useful. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media.  Air is the environmental medium of most concern for human exposure to DCBs.  Exposure 
from drinking water may also be of concern in some areas, such as near hazardous waste sites.  Existing 
analytical methods can measure DCBs in these and other environmental media at background levels (EPA 
1988a, 1984a, 1984b, 1991a, 1991b, 1991c, 1992a, 1994a, 1994f; NIOSH 1994). The accuracy and 
precision of the methods for water and wastes are well documented and MS provides adequate specificity. 
Performance data for measurements in ambient and indoor air would be helpful.  Development of 
techniques to improve the accuracy and ease of sample preparation and transfer for these methods would 












7. ANALYTICAL METHODS 
7.3.2 Ongoing Studies 
No ongoing studies involving analytical techniques for DCBs were found in a search of the Federal 
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8. REGULATIONS AND ADVISORIES 

The international, national, and state regulations and guidelines pertaining to dichlorobenzenes in air, 
water, and other media are summarized in Table 8-1.
ATSDR has derived an MRL of 2 ppm for acute-duration inhalation exposure to 1,4-DCB.  The acute 
inhalation MRL is based on a NOAEL of 15 ppm for irritant effects in humans exposed to 1,4-DCB in the 
workplace (Hollingsworth et al. 1956).  An uncertainty factor of 10 for human variability was applied. 
ATSDR has derived an MRL of 0.2 ppm for intermediate-duration inhalation exposure to 1,4-DCB.  The 
intermediate inhalation MRL is based on benchmark dose analysis of liver weight increases in male rats 
exposed to 1,4-DCB vapors for 6 hours/day for 15 weeks (Tyl and Neeper-Bradley 1989).  The resulting 
BMCL1sd of 92.45 ppm was duration-adjusted from intermittent to continuous exposure, converted to a 
human equivalent concentration (23 ppm), and divided by an uncertainty factor of 100 (10 for
extrapolating from animals to humans and 10 for human variability). 
ATSDR has derived an MRL of 0.01 ppm for chronic-duration inhalation exposure to 1,4-DCB.  The 
chronic inhalation MRL is based on benchmark dose analysis of incidences of nasal lesions in female rats
exposed to 1,4-DCB vapors for 6 hours/day, 5 days/week for 104 weeks (Aiso et al. 2005b).  The 
resulting BMCL10 of 9.51 ppm was duration-adjusted from intermittent to continuous exposure, converted 
to a human equivalent concentration (0.27 ppm), and divided by an uncertainty factor of 30 (3 for 
extrapolating from animals to humans and 10 for human variability).   
ATSDR has derived an MRL of 0.7 mg/kg/day for acute-duration oral exposure to 1,2-DCB.  The acute 
oral MRL is based on benchmark dose analysis of liver weight increases in female rats administered 
1,2-DCB by daily oral gavage for 10 days (Robinson et al. 1991). The resulting BMDL1sd of 
67.73 mg/kg/day was divided by an uncertainty factor of 100 (10 for extrapolating from animals to 
humans and 10 for human variability). 
ATSDR has derived an MRL of 0.6 mg/kg/day for intermediate-duration oral exposure to 1,2-DCB.  The 
intermediate oral MRL is based on benchmark dose analysis of liver weight increases in female rats 
administered 1,2-DCB by oral gavage on 5 days/week for 13 weeks (NTP 1985).  The resulting BMDL1sd 


















   
 






8. REGULATIONS AND ADVISORIES 
divided by an uncertainty factor of 100 (10 for extrapolating from animals to humans and 10 for human 
variability).  
ATSDR has derived an MRL of 0.3 mg/kg/day for chronic-duration oral exposure to 1,2-DCB.  The 
chronic oral MRL is based on benchmark dose analysis of incidences of kidney lesions in male mice 
administered 1,2-DCB by oral gavage on 5 days/week for 103 weeks (NTP 1985).  The resulting 
BMDL10 of 43.04 mg/kg/day was duration-adjusted from intermittent to daily exposure 
(30.74 mg/kg/day) and divided by an uncertainty factor of 100 (10 for extrapolating from animals to 
humans and 10 for human variability). 
ATSDR has derived an MRL of 0.4 mg/kg/day for acute-duration oral exposure to 1,3-DCB.  The acute 
oral MRL is based on benchmark dose analysis of liver weight increases in female rats administered 
1,3-DCB by oral gavage for 10 days (McCauley et al. 1995).  The resulting BMDL1sd of 36.32 mg/kg/day 
was divided by an uncertainty factor of 100 (10 for extrapolating from animals to humans and 10 for 
human variability). 
ATSDR has derived an MRL of 0.02 mg/kg/day for intermediate-duration oral exposure to 1,3-DCB.  
The intermediate oral MRL is based on benchmark dose analysis of incidences of pituitary lesions in male 
rats administered 1,3-DCB by daily oral gavage for 90 days (McCauley et al. 1995).  The resulting 
BMDL10 of 2.1 mg/kg/day was divided by an uncertainty factor of 100 (10 for extrapolating from animals 
to humans and 10 for human variability). 
ATSDR has derived an MRL of 0.07 mg/kg/day for intermediate-duration oral exposure to 1,4-DCB.  
The intermediate oral MRL is based on benchmark dose analysis of serum alkaline phosphatase levels in 
female dogs administered 1,4-DCB by capsule on a presumed 5 days/week for 6 months (Naylor and 
Stout 1996). The resulting BMDL1sd of 9.97 mg/kg/day was duration-adjusted from intermittent to daily 
exposure (7 mg/kg/day) and divided by an uncertainty factor of 100 (10 for extrapolating from animals to 
humans and 10 for human variability). 
ATSDR has derived an MRL of 0.07 mg/kg/day for chronic-duration oral exposure to 1,4-DCB.  The 
chronic oral MRL is based on benchmark dose analysis of serum alkaline phosphatase levels in female 
dogs administered 1,4-DCB by capsule on a presumed 5 days/week for 1 year (Naylor and Stout 1996).

















8. REGULATIONS AND ADVISORIES 
(7 mg/kg/day) and divided by an uncertainty factor of 100 (10 for extrapolating from animals to humans 
and 10 for human variability). 
EPA has verified an oral reference dose (RfD) of 0.09 mg/kg/day for 1,2-DCB based on a NOAEL of 
85.7 mg/kg/day for kidney effects in rats and an uncertainty factor of 1,000 (IRIS 2005).  EPA also 
verified an inhalation reference concentration (RfC) of 0.8 mg/m3 (0.1 ppm) for 1,4-DCB based on a 
NOAEL of 75 mg/m3 for liver effects in rats and an uncertainty factor of 100 (IRIS 2005). 
EPA has determined that 1,2-DCB and 1,3-DCB are not classifiable as to human carcinogenicity and 
assigned them cancer weight-of-evidence classification Group D (IRIS 2005).  IARC similarly 
determined that 1,2-DCB and 1,3-DCB are not classifiable as to carcinogenicity to humans (Group 3) 
(IARC 1999).  IARC additionally determined that 1,4-DCB is possibly carcinogenic to humans 
(Group 2B) (IARC 1999).  The Department of Health and Human Services (DHHS) concluded that 














   
   
   
 
   
   
   





    
  





   
  





   
  
   




8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Dichlorobenzenes 
Agency Description 	 Information Reference 
INTERNATIONAL
Guidelines: 
 IARC Carcinogenicity classification 

 1,2-Dichlorobenzene Group 3a

 1,3-Dichlorobenzene Group 3a

 1,4-Dichlorobenzene Group 2Bb
 
WHO Air quality guideline No data 
Drinking water guideline 
 1,2-Dichlorobenzene 1 mg/Lc
Toxicological data are 
insufficient to permit  1,3-Dichlorobenzene derivation of health-based
guideline value 
 1,4-Dichlorobenzene 0.3 mg/Lc 
NATIONAL
Regulations and Guidelines: 
a. 	Air 
ACGIH TLV (8-hour TWA) 
 1,2-Dichlorobenzene 25 ppm 
STEL 50 ppm 
  Carcinogenicity classification A4d
 1,4-Dichlorobenzene 10 ppm 

  Carcinogenicity classification A3e
 
EPA Hazardous air pollutant 

 1,4-Dichlorobenzene Yes 

NIOSH REL (10-hour TWA) 

1,2-Dichlorobenzene (ceiling limit) 50 ppm 

 1,4-Dichlorobenzene Carcinogen 

IDLH 
 1,2-Dichlorobenzene 200 ppm 
 1,4-Dichlorobenzene 150 ppm 
PEL (8-hour TWA) for general OSHA industry 
1,2-Dichlorobenzene (ceiling limit) 50 ppm 
 1,4-Dichlorobenzene 75 ppm 
PEL (8-hour TWA) for construction 
industry 
1,2-Dichlorobenzene (ceiling limit) 50 ppm 





























    
    







   
  
  
   
     
    
 
   
    
 
   
  
  






    
 
   
   
  
   
343 DICHLOROBENZENES
8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Dichlorobenzenes 
Agency Description 	 Information Reference 
NATIONAL (cont.)
PEL (8-hour TWA) for shipyard industry
1,2-Dichlorobenzene (ceiling limit) 
 1,4-Dichlorobenzene 
b. 	Water 
Designated as a hazardous substances 




Drinking water standard 
 1,2-Dichlorobenzene 
 1,4-Dichlorobenzene 




1-Day HA for a 10-kg child
10-Day HA for a 10-kg child 
DWEL 
Lifetime HA (70-kg adult) 
 1,4-Dichlorobenzene 
1-Day HA for a 10-kg child
10-Day HA for a 10-kg child  
DWEL 






































































    
  






    
   
   
   







   












    
    
 
   
   
 
   
344 DICHLOROBENZENES
8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Dichlorobenzenes 
Agency Description 	 Information Reference 
 1,2-Dichlorobenzene 	 No data 
NATIONAL (cont.)
 1,3-Dichlorobenzene No data 
 1,4-Dichlorobenzene 8x10-1 mg/m3






 1,4-Dichlorobenzene No data 
Community right-to-know; toxic chemical EPA 2004j 
release reporting; effective date 40CFR372.65 
 1,2-Dichlorobenzene 01/01/1987 
 1,3-Dichlorobenzene 01/01/1987 
 1,4-Dichlorobenzene 01/01/1987 










Chemical information rules; 
manufacturers reporting period for 
1,2-dichlorobenzene and 1,4-dichloro- EPA 2004k 
benzene 40CFR712.30 
Effective date 08/04/1995 
Sunset date 10/03/1995 
Superfund; reportable quantity 
 1,2-Dichlorobenzeneg 100 pounds EPA 2004b 
 1,3-Dichlorobenzeneh 100 pounds 40CFR302.4
 1,4-Dichlorobenzenei 100 pounds 
NTP Carcinogenicity classification 
 1,2-Dichlorobenzene No data 
 1,3-Dichlorobenzene No data NTP 2005 
Reasonably anticipated




 No data 
b. 	Water 
Drinking water standards and guidelines HSDB 2005 
 Arizona 	  1,2-Dichlorobenzene 620 µg/L 
 1,3-Dichlorobenzene 620 µg/L 
 1,4-Dichlorobenzene 75 µg/L 
California 	  1,3-Dichlorobenzene 130 µg/L 












    
 
   
 
 
   
 
   
 
    








8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Dichlorobenzenes 
Agency Description 	 Information Reference 
 Florida  1,3-Dichlorobenzene 10 µg/L 
STATE (cont.)
 Maine  1,2-Dichlorobenzene 63 µg/L 
 1,4-Dichlorobenzene 21 µg/L 
 Massachusetts  1,4-Dichlorobenzene 5 µg/L 
 Minnesota  1,2-Dichlorobenzene 600 µg/L 
 1,4-Dichlorobenzene 10 µg/L 
 New Jersey  1,2-Dichlorobenzene 600 µg/L 
 1,3-Dichlorobenzene 600 µg/L 
 Wisconsin  1,3-Dichlorobenzene 1,250 µg/L 
c. 	Food 
 No data 
d. 	Other 
 No data 
aGroup 3: Not classifiable as to its carcinogenicity to humans. 

bGroup 2B: Possibly carcinogenic to humans. 

cConcentrations of the substance at or below the health-based guideline value may affect the appearance, taste or 

odor of the water, leading to consumer complaints. 

dGroup A4: Not classifiable as a human carcinogen. 

eGroup A3: Confirmed animal carcinogen with unknown relevance to humans. 

fGroup D: Not classifiable as to human carcinogenicity. 

gDesignated as a hazardous substance pursuant to Section 311(b)(2) of the Clean Water Act, Section 307(a) of the 

Clean Water Act, and Section 3001 of RCRA. 





iDesignated as a hazardous substance pursuant to Section 311(b)(2) of the Clean Water Act, Section 307(a) of the 

Clean Water Act, Section 112 of the Clean Air Act, and Section 3001 of RCRA. 

ACGIH = American Conference of Governmental Industrial Hygienists; CFR = Code of Federal Regulations; 

DWEL = drinking water equivalent level; EPA = Environmental Protection Agency; FDA = Food and Drug
 
Administration; HA = health advisory; HSDB = Hazardous Substances Data Bank; IARC = International Agency for 

Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; 

MCL = maximum contaminant level; MCLG = maximum contaminant level goal; NIOSH = National Institute for 

Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health
 
Administration; PEL = permissible exposure limit; RCRA = Resource Conservation and Recovery Act; 

REL = recommended exposure limit; RfC = reference concentration; RfD = reference dose; STEL = short-term 

exposure limit; TLV = threshold limit values; TWA = time-weighted average; USC = United States Codes; 
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10.  GLOSSARY 

Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 




































Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies. 
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
































Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1. 
































Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group. 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 


































Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 































Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group. 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded. 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 

















Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest­
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1. 



































APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
















MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public.  They
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 















































MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,4-Dichlorobenzene (1,4-DCB) 
CAS Numbers: 106-46-7 
Date:   August 2006
Profile Status: Post-Public, Final 
Route: [X] Inhalation  [ ] Oral 
Duration: [X] Acute   [ ] Intermediate   [ ] Chronic 
Graph Key: 1 
Species: Human 
Minimal Risk Level: [ ] mg/kg/day  [2] ppm
Reference: Hollingsworth RL, Rowe VK, Oyen F, et al.  1956.  Toxicity of paradichlorobenzene:  
Determinations on experimental animals and human subjects.  AMA Arch Ind Health 14:138-147. 
Experimental design: Periodic occupational health examinations were conducted on 58 men who had 
worked in unspecified industrial operations involving the handling of 1,4-DCB, generally for 8 hours/day 
and 5 days/week, continually or intermittently for periods of 8 months to 25 years (average 4.75 years).  
Effects of different workplace exposure levels on eye and nose irritation were summarized.  The medical 
evaluations included careful examination of the eyes, blood cell counts (RBC, WBC, and differential), 
hemoglobin, hematocrit, mean corpuscular volume, blood urea nitrogen, sedimentation rate, and 
urinalysis. 
Effects noted in study and corresponding doses: Observations in the workers provide information 
relevant to acute exposures. The odor was found to be faint at 15–30 ppm and strong at 30–60 ppm.  
Painful irritation of the eyes and nose was usually experienced at 50–80 ppm, although the irritation 
threshold was higher (80–160 ppm) in workers acclimated to exposure.  Concentrations above 160 ppm
caused severe irritation and were considered intolerable to people not adapted to it.  The odor and 
irritation properties were considered to be fairly good acute warning properties and were expected to 
prevent excessive exposures, although the industrial experience indicated that it is possible for people to 
become sufficiently acclimated to tolerate high concentrations of the vapor.  No cataracts or any other 
lens changes in the eyes, or effects on the clinical indices were attributable to exposure. 
Dose and end point used for MRL derivation: 
[15] NOAEL [] LOAEL 
As discussed above, eye and nose irritation are critical effects of acute inhalation exposure to 1,4-DCB in 
humans.  Because odor detection is a warning property expected to prevent irritation caused by 1,4-DCB, 
the highest level at which an odor was detected that was simultaneously without irritant effects, 30 ppm,
was designated a minimal LOAEL for irritation for the purposes of derivation of the MRL; the 15 ppm
level was therefore designated a NOAEL for irritant effects. 
Uncertainty Factors used in MRL derivation: 
[X]  10 for human variability

























If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable. 
Was a conversion used from intermittent to continuous exposure? No. 
Other additional studies or pertinent information that lend support to this MRL: A limited amount of 
information is available on the toxicity of inhaled 1,4-DCB in humans.  Case reports of people who 
inhaled 1,4-DCB provide indications that the liver and nervous system are systemic targets of inhalation 
toxicity in humans, but are limited by lack of adequate quantitative exposure information and/or 
verification that 1,4-DCB was the only factor associated with the effects (Cotter 1953; Miyai et al. 1988; 
Reygagne et al. 1992). 
Information on effects of acute-duration inhalation exposure to 1,4-DCB in animals is available from
short-term systemic toxicity studies in rats and guinea pigs (Hollingsworth et al. 1956), a male 
reproduction study rats (Anderson and Hodge 1976), and developmental toxicity studies in rats and 
rabbits (Hayes et al. 1985; Hodge et al. 1977).  In the systemic toxicity study, five rats of each sex and 
five guinea pigs of each sex were exposed to 175 ppm of 1,4-DCB for 7 hours/day, 5 days/week for 
16 days (Hollingsworth et al. 1956).  Mild histological effects of interstitial edema, congestion, and 
alveolar hemorrhage were observed in the lungs of male rats and female guinea pigs.  The experimental 
design and report of this study have a number of deficiencies, such that reported observations provide 
only qualitative evidence of exposure-related respiratory effects.  In the reproduction study (a dominant 
lethal test), a NOAEL of 450 ppm was identified for reproductive performance in male mice that were 
exposed for 6 hours/day for 5 days prior to weekly mating with unexposed females for 8 weeks 
(Anderson and Hodge 1976).  No maternal or developmental toxicity occurred in rats that were exposed 
to 75–500 ppm for 6 hours/day on days 6–15 of gestation (Hodge et al. 1977), indicating that the highest 
NOAEL for reproductive effects in rats is 500 ppm.  A developmental study in which rabbits were 
exposed to 100–800 ppm for 6 hours/day on gestation days 6–18 found evidence of fetotoxicity (a minor 
variation of the circulatory system) only at 800 ppm, which was also maternally toxic as shown by body
weight loss early in gestation (Hayes et al. 1985), indicating that 800 ppm is a LOAEL for maternal and 
developmental effects in rabbits. 
The lung appears to be a target of concern for inhaled 1,4-DCB in rats and guinea pigs exposed to 
173 ppm (Hollingsworth et al. 1956), because the only effects observed in the reproductive and 
developmental studies were indications of maternal and fetotoxicity in rabbits at a much higher levels of 
800 ppm (Hayes et al. 1985).  Support for the respiratory tract as a sensitive target for 1,4-DCB inhalation 
in animals is provided by the induction of nasal lesions in rats intermittently exposed to levels as low as 
75 ppm for 104 weeks in the study used to derive the chronic inhalation MRL for 1,4-DCB (Japan 
Bioassay Research Center 1995).  Additionally, the animal data are consistent with the human experience, 
indicating that occupational exposure to 1,4-DCB causes painful nose and eye irritation in the range of 
50–160 ppm (Hollingsworth et al. 1956).   







































MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,4-Dichlorobenzene (1,4-DCB) 
CAS Numbers: 106-46-7 
Date:   August 2006
Profile Status: Post-Public, Final 
Route: [X] Inhalation  [ ] Oral 
Duration: [ ] Acute  [X] Intermediate   [ ] Chronic 
Graph Key: 14 
Species: Rat 
Minimal Risk Level: [ ] mg/kg/day  [0.2] ppm
References: Aiso A, Arito H, Nishizawa T, et al.  2005a. Thirteen-week inhalation toxicity of 
p-dichlorobenzene in mice and rats.  J Occup Health 47:249-260. 
Tyl RW, Neeper-Bradley TL.  1989.  Paradichlorobenzene:  Two generation reproductive study of 
inhaled paradichlorobenzene in Sprague-Dawley (CD) rats.  Laboratory Project 86-81-90605.
Washington, DC:  Chemical Manufacturers Association, Chlorobenzene Producers Association. 
Experimental design and effects noted (Aiso et al. 2005a): This is a systemic toxicity study in which 
groups of 10 male and 10 female F344 rats and 10 male and 10 female BDF1 mice were chamber-exposed 
to 1,4-DCB vapor (>99.9% pure) at target concentrations of 0, 25, 55, 120, 270, or 600 ppm for 
6 hours/day, 5 days/week for 13 weeks.  Deviations in mean observed concentrations from the target 
concentrations were <9.6%.  End points evaluated during the study included clinical signs (daily) and 
body weight and food consumption (weekly).  End points evaluated at the end of the 13-week exposure 
period included hematology (RBC, Hb, Hct, MCV, MCH), blood biochemistry (total protein, albumin, 
total cholesterol, triglyceride, phospholipid, AST, ALT, AP, BUN, creatine), organ weights, and 
histopathology. The histological examinations were comprehensive and included the nasal cavity, in 
accordance with OECD test guidelines for a 90-day inhalation study (Aiso 2005a; OECD 1981).  
There were no exposure-related effects on survival, clinical signs, or body weight gain in the rats.  
Hematological changes suggestive of microcytic anemia occurred in male rats, including significantly
decreased RBC count and hemoglobin concentration at ≥120 ppm, hematocrit at ≥270 ppm, and MCV 
and MCH at 600 ppm.  Serum biochemical changes included significant increases in total protein in both 
sexes at 600 ppm, albumin in females at ≥270 ppm and males at 600 ppm, and total cholesterol and 
phospholipid in males at ≥270 ppm and females at 600 ppm, and significant decreases in triglycerides in 
males at 600 ppm, AST in both sexes at 600 ppm, and ALT and AP in males at ≥270 ppm.  Organ weight 
changes included >10% increases in absolute and relative weights of liver in males at ≥270 ppm and 
females at 600 ppm, kidneys in males at ≥270 ppm, and spleen in males at 600 ppm.  Histological effects 
included significantly increased incidences of liver centrilobular hepatocellular hypertrophy in male rats
at 600 ppm (incidences in the control to high dose groups were 0/10, 0/10, 0/10, 0/10, 3/10, and 10/10), 
and kidney lesions indicative of α2µ-globulin nephropathy (hyaline droplets, granular casts, tubular cell 
necrosis, cytoplasmic basophila, and papillary mineralization) in male rats at ≥270 ppm.  There were no 
histopathological changes in hematopoietic tissues (e.g., increased extramedullary hematopoiesis or 
hemosiderosis in the spleen), leading the investigators to suggest the possibility that the anemia in the 
male rats was secondary to α2µ-globulin nephropathy-related effects on erythropoietin synthesis in the 
renal tubules. 
There were no exposure-related effects on survival, clinical signs, or body weight gain in the mice.  Organ 































600 ppm (absolute) and females at 600 ppm (absolute and relative); relative liver weights were 9.7, 9.7, 
10.1, 23.9, and 62.6% higher than controls in the low- to high-dose males.  There were no significant 
hematological changes in either sex.  Serum ALT levels were significantly increased in males at 
≥270 ppm (18.2, 9.1, 18.2, 54.5, and 164% higher than controls in the low- to high-dose groups).  Other 
serum biochemical changes included significant increases in ALT in females at 600 ppm, AST in males at 
600 ppm, and total cholesterol and total protein in both sexes at 600 ppm.  Histological examinations 
showed significantly (p≤0.01) increased incidences of centrilobular hepatocellular hypertrophy at in male
mice at ≥270 ppm and female mice at 600 ppm; incidences in the control to high dose groups were 0/10, 
0/10, 0/10, 0/10, 10/10, and 10/10 in the males and 0/10, 0/10, 0/10, 0/10, 0/10, and 10/10 in the females.  
Affected hepatocytes were characterized by cell enlargement, varying nuclear size and shape, and coarse 
chromatin and inclusion bodies in the nucleus; the severity of these lesions was rated as slight at 270 ppm
(males) and moderate at 600 ppm (both sexes).  The moderate hepatocellular hypertrophy in the 600 ppm
male mice was accompanied by single cell necrosis (1/10) and focal liver necrosis (2/10). 
The lowest effect level is 270 ppm based on the kidney and hematological effects in male rats and liver 
effects in rats and mice.  The kidney and hematological effects are consistent with α2µ-globulin
nephropathy, which is specific to male rats and not relevant to humans.  The mice were more sensitive to 
the liver effects of 1,4-DCB than the rats because the only hepatic change in the 270 ppm rats was 
increased liver weight, whereas hepatocellular hypertrophy and increased serum ALT occurred in 
addition to increased liver weight in the 270 ppm mice.  Additionally, at the next highest tested level of 
600 ppm, the mice had nuclear changes and evidence of necrosis in the hypertrophic hepatocytes, and 
increased serum AST as well as ALT, whereas none of these indicators of hepatocellular damage 
occurred in the rats. Based on increased relative liver weight (>10%) in both species and histological and 
serum ALT changes in the mice, this study identified a NOAEL of 120 ppm and a LOAEL of 270 ppm
for hepatic effects. The identification of the liver as a critical target of 1,4-DCB is supported by findings 
of increased liver weight and serum liver enzymes, as well as histopathologic liver lesions in dogs 
administered 1,4-DCB orally for up to 1 year (Naylor and Stout 1996). 
Experimental design and effects noted (Tyl and Neeper-Bradley 1989): This is a two-generation study in
which groups of 28 Sprague-Dawley rats of each sex were exposed to actual mean 1,4-DCB 
concentrations of 0, 66, 211, and 538 ppm for 6 hours/day, 7 days/week.  Additional groups of 10 females 
were similarly exposed for 10 weeks in a satellite study.  The animals in the main study were paired 
within groups for a 3-week mating period to produce the F1 generation.  Main study males that did not 
successfully mate in the first 10 days of the mating period were paired with the satellite females for 
10 days.  Main study females that did not successfully mate during the first 10 days of the mating period 
were paired with proven males for the remaining 11 days of the mating period. Exposures of the main 
study F0 females were continued throughout the mating period and the first 19 days of gestation, 
discontinued from gestation day 20 through postnatal day 4, and then resumed until sacrifice at weaning 
on postnatal day 28. Exposures of the satellite F0 females were continued through mating until sacrifice 
on gestation day 15.  Exposures of the F0 males continued until sacrificed at the end of the study and 
satellite mating periods (F0 males were exposed for a total of 15 weeks).  Groups of 28 F1 weanlings/sex 
and satellite groups of 10 F1 female weanlings were exposed for 11 weeks and mated as described above 
to produce the F2 generation.  Additionally, 20 F1 weanlings/sex from the control and high exposure 
groups served as recovery animals that were observed without exposure for 5 weeks prior to sacrifice.  
Complete necropsies were performed on all F0 and F1 adult (parental) animals, F1 recovery animals, 
F1 weanlings not used in the rest of the study, and F2 weanlings, and histology was evaluated in the F0 and 
F1 parental animals.  Histological examinations were conducted on the liver and kidneys in all groups and 
on selected other tissues (pituitary, vagina, uterus, ovaries, testes, epididymides, seminal vesicles, 
prostate, and tissues with gross lesions) in the control and high exposure groups.  The kidney evaluation 
included examination for the presence of α2µ droplets.  Additional end points evaluated in the parental 

































fertility indices were determined for F0 and F1 males and females, and gestational, live birth, postnatal 
survival (4-, 7-, 14-, 21-, and 28-day), and lactation indices were determined for the F1 and F2 litters. 
There were no effects on reproductive parameters in either generation, although systemic toxicity
occurred at all dose levels in F0 and F1 adult rats. Hyaline droplet nephropathy was found in F0 and 
F1 adult males at ≥66 ppm.  Manifestations of this male rat-specific renal syndrome included α2µ-globulin 
accumulation and increased kidney weights at ≥66 ppm, and other characteristic histological changes at 
538 ppm.  Body weights and weight gain were significantly reduced in F0 and F1 adult males and F1 adult 
females during the pre-breed exposure periods at 538 ppm.  Absolute liver weights were increased in 
F0 males by 6, 16, and 38% in the 66, 211, and 538 ppm groups, respectively; the differences were 
statistically significantly different from control in the 211 and 538 ppm groups.  In F0 females, absolute 
liver weights were increased by 9 and 31% at 211 and 538 ppm, respectively, but statistical significance 
was achieved only at 538 ppm.  Similar changes were seen in relative liver weights of the F0 generation, 
with respective increases of 5, 14, and 52% in the 66, 211, and 538 ppm males and 4, 9, and 31% in the 
66, 211, and 538 ppm females; all groups of treated males, and the 211 and 538 ppm female groups, were 
statistically significantly different from controls.  Relative liver weights were also significantly increased 
in F1 adult males at ≥211 ppm and F1 adult females at 538 ppm.  Hepatocellular hypertrophy was 
observed in the livers of F0 and F1 males and females at 538 ppm; no hepatic histological changes were 
induced at the lower exposure concentrations.  Other effects also occurred in the F0 and F1 males and 
females at 538 ppm, indicating that there was a consistent pattern of adult toxicity at the high exposure 
level, including reduced food consumption and increased incidences of clinical signs (e.g., tremors, 
unkempt appearance, urine stains, salivation, and nasal and ocular discharges); these effects only
sporadically occurred at 211 ppm.  Other effects at 538 ppm included reduced gestational and lactational 
body weight gain, and postnatal toxicity, as evidenced by increased number of stillborn pups, reduced pup 
body weights, and reduced postnatal survival in F1 and/or F2 litters. This study identified a (1) a NOAEL 
of 66 ppm and LOAEL of 211 ppm for increased (>10% above controls) relative liver weight in adult 
rats, and (2) a serious LOAEL of 538 ppm for systemic toxicity (central nervous system and other clinical 
signs) in adult rats and developmental toxicity (increased stillbirths and perinatal mortality) in their 
offspring. The identification of increased liver weight as a critical effect of 1,4-DCB toxicity is supported 
by findings of increased liver weight and serum liver enzyme levels and histopathologic liver lesions 
following repeated oral exposure (Naylor and Stout 1996). 
Dose and end point used for MRL derivation: 
[ ] NOAEL   [ ] LOAEL   [X] BMCL
As discussed below, a BMCL1sd of 92.45 ppm for increased liver weight in rats was used as the point of 
departure for the MRL. 
Benchmark dose (BMD) analysis was conducted using the Tyl and Neeper-Bradley (1989) data for 
relative liver weight in adult male rats (Table A-1) and the Aiso et al. (2005a) serum ALT data in male 
rats (Table A-2). A benchmark response (BMR) of 1 standard deviation change from the control mean 
was selected in the absence of a biological rationale for using an alternative BMR.  BMD analysis of the 
relative liver weight data from the Aiso et al. (2005a) study is precluded by insufficient information 
(standard deviations were not reported).  Incidences of hepatocellular hypertrophy in the male mice of the 
Aiso et al. (2005a) study were not subjected to BMD analysis because the response was observed in 0% 
of control, 25, 55, and 120 ppm animals and in 100% of the 270 and 600 ppm animals.  The F1 and 
F2 postnatal survival data (Tyl and Neeper-Bradley 1989) were not subjected to BMD analysis because 
the 211 ppm exposure level represents a NOAEL and the next higher exposure level (538 ppm) represents 
a frank effect level (FEL) for 4-day survival (12.6 and 28.1% reductions in 4-day survival of F1 and 

































Table A-1. Relative Liver Weight Data for F0 Male Rats Exposed to 
1,4-Dichlorobenzene Vapors 6 Hours/Day for 15 Weeks  
Mean measured exposure concentration (ppm) 
0 66 211 538 
Group size 27 









aMean ± standard deviation
bSignificantly different (p<0.05) from control group 
cSignificantly different (p<0.01) from control group 
Source: Tyl and Neeper-Bradley 1989 
Table A-2. Serum ALT Data for Male Rats Exposed to1,4-Dichlorobenzene 
Vapors 6 Hours/Day, 5 Days/Week for 13 Weeks  
Mean measured exposure concentration (ppm) 
0 25 55 120 270 600 
Group size 













aMean ± standard deviation
bSignificantly different (p<0.05) from control group 
cSignificantly different (p<0.01) from control group 
Source: Aiso et al. 2005a 
All appropriate continuous-variable (linear, polynomial, power) models in the EPA Benchmark Dose 
Software (Version 1.3.2) were fit to the serum ALT data from the male rats of the Aiso et al. (2005a) 
study (the Hill model was excluded due to an insufficient number of exposure groups).  An assumption of 
constant variance resulted in a p-value <0.0005 for the test of constant variance and a non-homogeneous 
variance assumption was suggested.  However, the assumption of non-homogeneous variance resulted in 
inadequately modeled variance (p-value <0.0005) and BMD analysis of the serum ALT data from the 
male rats of the Aiso et al. (2005a) study was considered an inadequate method for selecting a point of 
departure for deriving an intermediate-duration inhalation MRL for 1,4-DCB. 
Available continuous-variable models were also fit to the Tyl and Neeper-Bradley (1989) data for 
changes in liver weight.  A BMR of 1 standard deviation change from the control mean was selected in 
the absence of a biological rationale for using an alternative BMR.  The simplest model (linear) for 
continuous data was initially fit to the data; constant variance was selected (Table A-3).  The model 
output indicated that constant variance was appropriate, but inadequate model mean fit was obtained 
(p-value <0.01). The more complex (polynomial, power, Hill) models were also fit to the liver weight 
data. The Hill model provided inadequate mean fit due to an insufficient number of dose groups (4, 
including controls), which resulted in insufficient (0) degrees of freedom.  The 2-degree polynomial 
provided adequate mean fit and the power model provided marginally adequate mean fit as indicated by
the p-values for mean fit (Table A-3). The 2-degree polynomial model was the best fitting model (the 




















   






















(lower 95% confidence limit on the BMC1sd) of 119.91 and 92.45 ppm, respectively (Table A-3).  A plot
of observed and predicted relative liver weight from the 2-degree polynomial model is shown in 
Figure A-1. 
Table A-3. Model Predictions for Relative Liver Weight in F0 Male Rats Exposed 
to 1,4-Dichlorobenzene Vapors 6 Hours/Day for 15 Weeks 
Variance Mean fit BMC1sd BMCL1sd 
Model p-valuea p-valuea AIC (ppm) (ppm) 
Linearb, c 0.6877 0.00026 NA NA NA 
2-Degree polynomialb,c 0.6877 0.3926 -205.3345 119.907 92.4533 
Powerb 0.9241 0.09954 -202.3525 129.587 100.477 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bConstant variance assumed 
cRestriction = non-negative 
BMC1sd = benchmark dose based on a benchmark response of 1 standard deviation from the control mean; 
BMCL1sd = lower confidence limit (95%) on the BMC1sd; NA = not applicable because model failed a goodness-of-fit 
test
Figure A-1. Observed Liver Weights in Adult Male Rats Exposed  
to 1,4-Dichlorobenzene for 15 Weeks and Predicted Relative  
Liver Weights by the 2-Degree Polynomial Model* 
dose 
18:25 07/26 2006 


























   
     
 
 
   











The BMCL1sd of 92.45 ppm was duration-adjusted to 23 ppm, converted to a human equivalent 
concentration (HEC) of 23 ppm, and divided by an uncertainty factor of 100 to derive an MRL of 
0.2 ppm.
Uncertainty Factors used in MRL derivation: 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability
Although the rat BMCL was adjusted to a HEC (see below), an uncertainty factor of 10 for extrapolation 
from animals to humans was still applied, because the HEC calculation was based on an assumption of 
equivalent blood-gas partition coefficients, and not on actual data. 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: 
1,4-DCB exhibited the effects outside of the respiratory tract and consequently is treated as a 
category 3 gas for purposes of calculating the MRL. The HEC for extrarespiratory effects produced by a 
category 3 gas is calculated by multiplying the duration-adjusted BMCL1sd (BMCL1sd ADJ, see below) by
the ratio of blood:gas partition coefficients (Hb/g) in animals and humans (EPA 1994k).  Hb/g values were
not available for 1,4-DCB in rats and humans. Using a default value of 1 for the ratio of partition 
coefficients, the BMCL1sd HEC becomes 23 ppm: 
BMCL1sd HEC	 = (BMCL1sd ADJ) x [(Hb/g)RAT / (Hb/g)HUMAN],

= 23 ppm x [1] = 23 ppm
 
Was a conversion used from intermittent to continuous exposure? The BMCL1sd of 92 ppm was duration-
adjusted for intermittent exposure, as follows (EPA 1994k): 
BMCL1sd ADJ	 = (BMCL1sd) (hours/24 hours) (days/7 days) 
= (92.45 ppm) (6 hours/24 hours) (7 days/7 days) 
=  23  ppm  
Other additional studies or pertinent information that lend support to this MRL: Supporting information 
on hepatic effects of intermediate-duration inhalation exposure to 1,4-DCB are available from a 
multispecies subchronic toxicity study in which rats, mice, guinea pigs, rabbits, and monkeys were 
exposed to 96 or 158 ppm for 7 hours/day, 5 days/week for 5–7 months (Hollingsworth et al. 1956).
Some of these animals were also similarly exposed to 341 ppm for 6 months (rats and guinea pigs) or 
798 ppm for 23–69 exposures (rats, guinea pigs, and rabbits).  The experiments with rabbits and monkeys
exposed to levels of 96 or 158 ppm are limited by small numbers of animals (1–2/group).  Hepatic effects 
included increased relative liver weight and slight histological alterations in rats at 158 ppm (not observed 
at 96 ppm), and more severe histopathology (e.g., cloudy swelling and necrosis) in guinea pigs at 
341 ppm, and in rats, guinea pigs, and rabbits at 798 ppm.  Other findings in the animals exposed to 
798 ppm included eye irritation and frank signs of neurotoxicity (e.g., marked tremors).  The hepatic 
histological changes observed in rats at 158 ppm (cloudy swelling, congestion, or granular degeneration) 
were considered of questionable significance and were not reported at 358 ppm, indicating that neither 
158 nor 358 ppm is a reliable LOAEL for liver pathology in rats in this study.  The hepatic histological 
effects observed in the guinea pigs at 341 ppm appear have been more severe (fatty degeneration, focal 
necrosis, slight cirrhosis) than in rats, but only occurred in some of the animals (number not reported).  
Although this information suggests that 341 ppm is a LOAEL for liver histopathology in guinea pigs, 






























general limitation of the study).  The 798 ppm exposure concentration is a reliable LOAEL because this 
level clearly caused both liver histopathology (e.g., cloudy swelling and central necrosis) and overt signs 
of toxicity (e.g., marked tremors, eye irritation, and unconsciousness) in all three species. 
A chronic inhalation study was conducted in which rats and mice were exposed to 1,4-DCB in target 
concentrations of 0, 20, 75, or 300 ppm for 6 hours/day, 5 days/week for 104 weeks (Aiso et al. 2005b).  
Effects in the rats included nasal lesions at ≥75 ppm and increased liver weight at 300 ppm, and effects in 
the mice included increased liver weight and hepatocellular hypertrophy at 300 ppm.  The 75 ppm
NOAEL and 300 ppm LOAEL for liver effects in the chronic study are consistent with the 120 ppm
NOAEL and 211 ppm LOAEL for liver effects in the intermediate-duration studies (Aiso et al. 2005a; Tyl 
and Neeper-Bradley 1989).  The 75 ppm LOAEL for nasal lesions in rats indicates that these tissues are 
more sensitive than the liver following chronic exposure, and the nasal lesions were used as the basis for 
the chronic inhalation MRL for 1,4-DCB. Because nasal lesions were not found in the 13-week study, it 
appears that the lesions are late-developing effects of chronic exposure.  The lack of nasal lesions in the 
13-week study therefore indicates that these are not critical effects of intermediate-duration exposure. 
The NOAEL/LOAEL approach to MRL derivation results in the same MRL as the 0.2 ppm value derived 
using the BMD approach.  The 13-week study (Aiso et al. 2005a) and two-generation study (Tyl and 
Neeper-Bradley 1989) are consistent in identifying the liver as the most sensitive target of intermediate 
duration inhalation of 1,4-DCB and showing that hepatic effects increased in severity with increasing 
level of exposure. The 13-week study (Aiso et al. 2005a) identified a hepatic NOAEL of 120 ppm and a 
LOAEL of 270 ppm in rats (increased liver weight) and mice (increased liver weight, hepatocellular 
hypertrophy, and serum ALT).  The two-generation study identified a hepatic NOAEL of 66 ppm and a 
LOAEL of 211 ppm in rats (increased liver weight).  The 120 ppm NOAEL is the highest hepatic 
NOAEL below the lowest hepatic LOAEL of 211 ppm, indicating that it is an appropriate basis for MRL 
derivation using the NOAEL/LOAEL approach.  Using the NOAEL of 120 ppm for liver effects in male 
mice (the more sensitive species and sex), the NOAEL was duration-adjusted for the intermittent 
experimental exposure, as follows: 
NOAELADJ	 = (NOAEL) (hours/24 hours) (days/7 days) 
= (120 ppm) (6/24) (5/7) 
= 21.4 ppm
1,4-DCB exhibited the effects outside of the respiratory tract and consequently is treated as a 
category 3 gas for purposes of calculating the human equivalent concentration (HEC).  The HEC for extra 
respiratory effects produced by a category 3 gas is calculated by multiplying the NOAELADJ by the ratio 
of blood:gas partition coefficients (Hb/g) in animals and humans (EPA 1994k).  Hb/g values were not 
available for 1,4-DCB in rats, mice and humans.  Using a default value of 1 for the ratio of partition 
coefficients, the NOAELHEC is 21.4 ppm, calculated as follows: 
NOAELHEC 	 = (NOAELADJ) x [(Hb/g)MOUSE / (Hb/g)HUMAN],

= 21.4. ppm x [1] = 21.4 ppm 

The NOAELHEC was divided by the uncertainty factor of 100 to derive an MRL of 0.2 ppm.   


















   





















MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,4-Dichlorobenzene (1,4-DCB) 
CAS Numbers: 106-46-7 
Date:   August 2006
Profile Status: Post-Public, Final 
Route: [X] Inhalation  [ ] Oral 
Duration: [ ] Acute  [ ] Intermediate  [X] Chronic 
Graph Key: 32 
Species: Rat 
Minimal Risk Level: [ ] mg/kg/day  [0.01] ppm
References: Aiso S, Takeuchi T, Arito H, et al.  2005b.  Carcinogenicity and chronic toxicity in mice and
rats exposed by inhalation to para-dichlorobenzene for two years.  J Vet Med Sci 67(10):1019-1029. 
Japan Bioassay Research Center.  1995. Toxicology and carcinogenesis studies of p-dichlorobenzene in 
344/DuCrj rats and Crj:BDF1 mice.  Two-year inhalation studies.  Japan Industrial Safety and Health 
Association. Study carried under contract with the Ministry of Labour of Japan.
Experimental design: Groups of 50 male and female F344/DuCrj rats and 50 male and female 
Crj:BDF1 mice were exposed to 1,4-DCB in target concentrations of 0, 20, 75, or 300 ppm for 
6 hours/day, 5 days/week for 104 weeks.  Study end points included clinical signs and mortality, body
weight (weekly for the first 13 weeks, and subsequently every 4 weeks), and hematology, blood
biochemistry, and urinalysis indices (evaluated at end of study).  Selected organ weight measurements 
(liver, kidneys, heart, lungs, spleen, adrenal, brain, testis, ovary) and comprehensive gross pathology and 
histology evaluations were performed on all animals at the end of the study or at time of unscheduled 
death. No interim pathology examinations were performed. 
Effects noted in study and corresponding doses: For the rats, the actual mean chamber concentrations 
were 0, 19.8, 74.8, or 298.4 ppm over the duration of the study.  The number of rats surviving to 
scheduled termination was significantly (p<0.05) reduced at 300 ppm in males.  Survival in the male rats 
was noticeably lower than controls beginning at approximately study week 80, and overall survival at 0, 
20, 75, and 300 ppm was 66% (33/50), 68% (34/50), 58% (29/50), and 36% (18/50), respectively. There 
were no exposure-related decreases in survival in the female rats, or effects on growth or food 
consumption in either sex.  Changes in various hematological and blood biochemical indices (mean cell 
volume, total cholesterol, phospholipids, blood urea nitrogen, creatinine, and calcium in males; total 
protein, total bilirubin, blood urea nitrogen, and potassium in females) occurred at 300 ppm (Japan 
Bioassay Research Center 1995), but a lack of both numerical data and statistical analysis precludes 
interpretations of significance for these end points. Absolute and relative liver weights in both sexes and 
kidney weights in males were significantly increased at 300 ppm.  Additional findings included 
histopathological changes in the nasal epithelia and kidneys.  The nasal lesions mainly included increased 
incidences of eosinophilic changes (globules) in the olfactory epithelium (moderate or greater severity) in
males at 300 ppm and females at ≥75 ppm.  Incidences of this lesion at 0, 20, 75, and 300 ppm were 1/50, 
2/50, 2/50, and 7/50 in males, and 27/50, 29/50, 39/50, and 47/50 in females.  The increases were 
statistically significant (p≤0.05, Fisher's Exact Test performed by ATSDR) at ≥75 ppm in females and 
300 ppm in males, and there was a trend of increasing response with increasing dose in both sexes 
(Cochran-Armitage test, performed by ATSDR).  Other nasal lesions that were significantly increased at 
300 ppm were eosinophilic globules in the respiratory epithelium (11/50, 10/50, 14/50, 38/50) and 
respiratory metaplasia in the nasal gland (5/50, 4/50, 4/50, 33/50) in females at 300 ppm.  Kidney lesions 






























mineralization of the renal papilla (0/50, 1/50, 0/50, 41/50) and in hyperplasia of the urothelium (7/50, 
8/50, 13/50, 32/50).  
For the mice, the actual mean chamber concentrations were 0, 19.9, 74.8, or 298.3 ppm over the duration 
of the study. Survival was significantly reduced in male mice at 300 ppm (due to an increase in liver 
tumor deaths), but comparable to controls in the females.  Terminal body weight was significantly
reduced at 300 ppm in males (11.5% less than controls, beginning at study week 80).  Changes in various 
hematological and blood biochemical indices (total cholesterol, SGOT, SGPT, LDH, and AP in both 
sexes; platelet numbers, total protein, albumin, total cholesterol, blood urea nitrogen, and calcium in 
females) occurred at 300 ppm (Japan Bioassay Research Center 1995), but a lack of reported numerical 
data and results of statistical analysis precludes interpretation of these end points.  Absolute and relative 
liver and kidney weights in both sexes were significantly increased at 300 ppm.  Additional findings 
included histopathological changes in the nasal cavity, liver, and testes.  The nasal lesions included 
significantly increased incidences of respiratory metaplasia in the nasal gland (moderate severity) in 
males at 75 ppm (9/49, 12/49, 18/50, 11/49) and olfactory epithelium (slight severity) in males at 75 ppm
(23/49, 30/49, 37/50, 22/49) and females at 300 ppm (7/50, 6/50, 2/49, 20/50); the effects in the males 
were not dose-related (i.e., incidences were increased at 75 ppm but not at 300 ppm).  The incidence of 
centrilobular hepatocellular hypertrophy was significantly increased in male mice at 300 ppm (0/49, 0/49, 
0/50, 34/49).  Incidences of liver tumors were also increased at 300 ppm; these included hepatocellular 
carcinoma in males (12/49, 17/49, 16/50, 38/49) and females (2/50, 4/50, 2/49, 41/50), hepatocellular 
adenoma in females (2/50, 10/50, 6/49, 20/50), hepatoblastoma in males (0/49, 2/49, 0/50, 8/49) and 
females (0/50, 0/50, 0/49, 6/50), and histiocytic sarcoma in males (0/49, 3/49, 1/50, 6/49).  Testicular 
mineralization was significantly increased in males at ≥75 ppm (27/49, 35/49, 42/50, 41/49) (Japan 
Bioassay Research Center 1995).  The testicular mineralization was not considered to be a toxicologically 
significant effect (Aiso 2006) because (1) no signs of testicular toxicity were observed in mice exposed 
for 13 weeks (Aiso et al. 2005a), and (2) it was confined to the testicular capsules and testicular blood 
vessels and not observed in the testicular parenchyma, indicating that it is a finding commonly observed 
in aged mice independent of exposure to 1,4-DCB (Aiso 2006). 
The results of this study indicate that moderate or severe eosinophilic changes in the nasal olfactory
epithelium in female rats is the most sensitive toxic effect in the most sensitive species and sex.  The 
NOAEL and LOAEL for these nasal lesions are 19.8 and 74.8 ppm, respectively.
Dose and end point used for MRL derivation: 
[ ] NOAEL   [ ] LOAEL   [X] BMCL
As discussed below, a BMCL10 of 9.51 ppm for increased incidences of nasal lesions in female rats is 
used as the point of departure for the MRL. 
BMD analysis was conducted using the incidences for eosinophilic changes of moderate or greater 
severity in the nasal olfactory epithelium in female rats and the actual exposure concentrations.  The data 
that were modeled are shown in Table A-4.  Data for other end points were not modeled because the 
effects occurred at higher concentrations (nasal lesions and hepatocellular hypertrophy in mice, kidney 
lesions in rats) or were not toxicologically significant (testicular mineralization in mice).  All 
dichotomous models in the Benchmark Dose Software (version 1.3.2) were fit to the female rat nasal 
lesion incidence data.  A 10% extra risk above the control incidence was selected as the BMR in the 
absence of a biological rationale for using an alternative BMR.  As assessed by the chi-square goodness-
of-fit statistic, all models provided adequate fits to the data (the quantal quadratic model was marginally
adequate based on a chi-square p-value of 0.09 rather than the conventionally acceptable p-value of ≥0.1).



























best-fitting models based on the lowest AIC value (Table A-5). These models each provided a 
benchmark concentration (BMC10) of 14.08 ppm and lower 95% confidence limit (BMCL10) of 9.51 ppm.  
A representative plot of the observed and predicted incidences of nasal lesions from the quantal linear 
model output is shown in Figure A-2.  The BMCL10 of 9.51 ppm was duration-adjusted to 1.70 ppm, 
converted to a HEC of 0.27 ppm, and divided by an uncertainty factor of 30 to derive an MRL of 
0.01 ppm. 
Table A-4. Incidences of Nasal Lesions in Female Rats Exposed to 
1,4-Dichlorobenzene by Inhalation for 104 Weeks 
Exposure concentration (ppm) 0 19.8 74.8 298.4 

Nasal olfactory epithelial lesions (incidence)a 27/50b 29/50 39/50c 47/50c
 
aLesions of moderate or greater severity. 

bSignificant trend of increasing response with increasing dose (Cochran-Armitage Test, performed by ATSDR). 

cSignificantly (p≤0.05) different from control value (Fisher’s Exact Test performed by ATSDR). 

Source: Aiso et al. 2005b 
Table A-5. Modeling Results for Incidences of Nasal Lesions in Female Rats 























Probit 0.42 218.21 22.17 16.70 
Log-probitc 0.74 218.52 16.09 3.20 











aValues <0.1 fail to meet conventional goodness-of-fit criteria 
bRestrict power >=1 
cSlope restricted to >1
dRestrict betas ≥0; Degree of polynomial=2 
AIC = Akaike’s Information Criteria; BMC10 = benchmark dose associated with a 10% extra risk; BMCL10 = lower 






   
Figure A-2. Observed and Predicted Incidences of Nasal Lesions in Female Rats 
Exposed to 1,4-Dichlorobenzene for 104 Weeks* 






































13:24 07/24 2006 
*BMD = BMC; BMDL = BMCL; BMC and BMCL (in ppm) are associated with a 10% extra risk.  The quantal linear 
model plot in this figure is identical to the plots produced by the gamma, multistage, and Weibull models. 
Uncertainty Factors used in MRL derivation: 
[X]  3 for extrapolation from animals to humans 
[X]  10 for human variability
A 3-fold uncertainty factor was used instead of a default 10-fold factor to extrapolate from rats to humans 
because the dosimetry adjustment (i.e., calculation of the human equivalent exposure for time and 
concentration [HEC]) addresses one of the two areas of uncertainty encompassed in an interspecies 
extrapolation factor.  The dosimetric adjustment addresses the pharmacokinetic component of the 
extrapolation factor, but the pharmacodynamic area of uncertainty remains as a partial factor for 
interspecies uncertainty. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: For 
the nasal olfactory epithelium changes in female rats, 1,4-DCB was treated as a category 1 gas with 
effects in the extrathoracic region for purposes of calculating the HEC.  Using EPA (1988, 1994b) 










   
        
       
 
    




























RGDRET = [(VE/SAET)A/(VE/SAET)H] 
=  (0.24 m3/day/15cm2)/(20 m3/day/200cm2) 
= 0.16 
 where: RGDRET = regional gas deposition ratio in the extrathoracic region 
VE = minute volume in rats (VE)A or humans (VE)H 
  SAET = extrathoracic surface area in rats (SAET)A or humans (SAET)H 
The HEC was calculated by multiplying the rat BMCL10 ADJ by the RGDRET to yield a BMCL10 HEC of 
0.27 ppm, as follows: 
BMCL10 HEC = BMCL10 ADJ x RGDRET
 = 1.70 ppm x 0.16 
= 0.27 ppm
Was a conversion used from intermittent to continuous exposure? The animal BMCL10 value of 
15.34 ppm was duration-adjusted for intermittent experimental exposure, as follows: 
BMCL10 ADJ = (BMCL10) (hours/24 hours) (days/7 days) 
= (9.51 ppm) (6 hours/24 hours) (5 days/7 days) 
= 1.70 ppm
Other additional studies or pertinent information that lend support to this MRL: The only other 
information on the chronic inhalation toxicity of 1,4-DCB in animals is available from another study in 
rats and mice (Riley et al. 1980a, 1980b).  In this study, rats of both sexes and female mice were exposed 
to 75 or 500 ppm of 1,4-DCB for 5 hours/day, 5 days/week for up to 76 weeks (rats) or 57 weeks (mice), 
followed by 32 weeks (rats) or 18–19 weeks (mice) without exposure.  There were no exposure-related 
histopathological changes in the nasal cavity or other tissues in either species.  Liver and kidney weights 
were increased in rats of both sexes at 500 ppm, but the toxicological significance is questionable due to 
the negative histopathology findings and the lack of related clinical chemistry effects.  Evaluation of the 
mouse data is limited by reporting insufficiencies in the available summary of the study.
A limited amount of information is available on the long-term toxicity of inhaled 1,4-DCB in humans.  
Periodic occupational health examinations of workers who were exposed to 1,4-DCB for an average of 
4.75 years (range 8 months to 25 years) showed no changes in standard blood and urine indices 
(Hollingsworth et al. 1956).  The odor was found to be faint at 15–30 ppm and strong at 30–60 ppm.  
Painful irritation of the eyes and nose was usually experienced at 50–80 ppm, although the irritation 
threshold was higher (80–160 ppm) in workers acclimated to exposure.  Concentrations above 160 ppm
caused severe irritation and were considered intolerable to people not adapted to it.  Occasional 
examination of the eyes showed no cataracts or any other lens changes.  The odor and irritation properties 
were considered to be fairly good warning properties that should prevent excessive exposures, although 
the industrial experience indicated that it is possible for people to become sufficiently acclimated to 
tolerate high concentrations of the vapor.  The data from this study are inadequate for chronic MRL 
derivation due to poor characterization of long-term exposure levels, insufficient investigation of systemic 
health end points, reporting and other study deficiencies.  Although the available human information is 
insufficient for chronic MRL derivation, the human eye and nose irritation data are consistent with the 
nasal effects observed in the chronically exposed animals. 
The NOAEL/LOAEL approach to MRL derivation results in an MRL of 0.02 ppm, similar to the 


























in the nasal olfactory epithelium in rats (Aiso et al. 2005b), the NOAEL was duration-adjusted for 
intermittent experimental exposure, as follows: 
NOAELADJ = (NOAEL) (hours/24 hours) (days/7 days) 
= (19.8 ppm) (6 hours/24 hours) (5 days/7 days) 
= 3.54 ppm
A HEC was calculated using EPA (1994a) inhalation dosimetric adjustment methodology.  For the 
olfactory epithelium changes in rats, 1,4-DCB was treated as a category 1 gas with effects in the 
extrathoracic region.  Using EPA (1988, 1994b) reference values, the regional gas deposition ratio was 
calculated as follows: 
RGDRET = [(VE/SAET)A/(VE/SAET)H] 
=  (0.24  m3/day/15cm2)/(20 m3/day/200cm2) 
= 0.16 
 where: RGDRET = regional gas deposition ratio in the extrathoracic region 
VE = minute volume in rats (VE)A or humans (VE)H 
  SAET = extrathoracic surface area in rats (SAET)A or humans (SAET)H 
The rat NOAELADJ was multiplied by the RGDRET to yield a NOAELHEC of 0.57 ppm (3.54 ppm x 0.16),
and the NOAELHEC was divided by the uncertainty factor of 30 to derive an MRL of 0.02 ppm.  





































MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,2-Dichlorobenzene (1,2-DCB) 
CAS Numbers: 95-50-1 
Date:   August 2006
Profile Status: Post-Public, Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [X] Acute   [ ] Intermediate   [ ] Chronic 
Graph Key: 11 
Species: Rat 
Minimal Risk Level: [0.7] mg/kg/day   [ ] ppm
Reference: Robinson M, Bercz JP, Ringhand HP, et al.  1991.  Ten and ninety-day toxicity studies of 
1,2-dichlorobenzene administered by oral gavage to Sprague-Dawley rats.  Drug Chem Toxicol 
14(1&2):83-112. 
Experimental design: Groups of 10 male and 10 female Sprague-Dawley rats were administered 
1,2-DCB in corn oil by gavage in doses of 0, 37.5, 75, 150, or 300 mg/kg/day for 10 consecutive days.  
The doses were selected on the basis of a reported rat oral LD50 of 500 mg/kg.  End points evaluated 
during the study included clinical signs, body weight, and food and water consumption.  Evaluations at 
the end of the exposure period included hematology (five indices), serum chemistry (nine indices 
including AST, ALT, LDH, cholesterol, BUN, and creatinine), and selected organ weights (brain, liver, 
spleen, lungs, thymus, kidneys, adrenal glands, heart, and testes or ovaries).  Histological examinations 
were performed on various tissues including liver, kidneys, urinary bladder, heart, skin, muscle, bone, 
respiratory tract (nasal cavity with turbinates, lungs), nervous system (brain, sciatic nerve), 
immunological (spleen, thymus, lymph nodes), gastrointestinal (duodenum, ileum, jejunum, salivary
gland, colon, cecum, rectum), endocrine (adrenal glands, pancreas), and reproductive (testes, seminal 
vesicles, prostate, ovaries) in the high-dose and control groups.  Target organs identified in the high-dose 
groups were also histologically evaluated at the lower dose levels. 
Effects noted in study and corresponding doses: No clinical signs or effects on survival were observed.  
Body weight gain was significantly reduced in the male rats at 300 mg/kg/day (final body weights were 
10.9% lower than controls), but not in females, and there were no exposure-related changes in food 
consumption in either sex.  Statistically significant changes in organ weights predominantly occurred at 
300 mg/kg/day, including significantly decreased absolute spleen weight in both sexes, and decreased 
absolute heart, kidney, thymus, and testes weights in males.  Liver weight (relative and absolute) was 
significantly increased in females at ≥150 mg/kg/day and in males at 300 mg/kg/day; compared to 
controls in the low- to high-dose females, absolute liver weights were 1.8, 9.0, 20.5, and 29.0% increased 
and relative liver weights were 6.8, 7.6, 21.7, and 34.5% increased.  Clinical chemistry findings included 
significantly increased serum ALT in both sexes at 300 mg/kg/day and serum phosphorus in females at 
≥150 mg/kg/day.  Serum cholesterol was significantly increased in females at ≥37.5 mg/kg/day, but the 
toxicological significance is unclear because values were similar at all dose levels and showed no dose-
response. Histopathological findings were limited to the liver and included necrosis that was slight in 
severity and significantly (p=0.04) increased in males at 300 mg/kg/day (4/10 compared to 0/10 in 
controls; incidences in the other dose groups were not reported, although the study authors indicated that 
target organs in the high-dose groups were histologically evaluated at the lower dose levels.  Incidences 
of other hepatic lesions were not significantly increased, but included inflammation (characterized by 
lymphocyte and macrophage infiltrates) and degeneration of hepatocytes (characterized by varying 
degrees of fibrillar or vacuolated cytoplasm and swelling with intact cell membranes).  Because 
















































the control and high-dose females were 0/10 and that the lower female dose groups were not assessed for 
liver lesions. This study identified a NOAEL of 75 mg/kg/day and LOAEL of 150 mg/kg/day for 
increased liver weight in female rats, as well as a LOAEL of 300 mg/kg/day for liver necrosis in male 
rats. 
Dose and end point used for MRL derivation: 
[ ] NOAEL   [ ] LOAEL   [X] BMDL
As discussed below, a BMDL1sd of 67.73 mg/kg/day for increased liver weight in female rats is used as 
the point of departure for the MRL. 
BMD analysis was conducted using the rat absolute liver weight data (Robinson et al. 1991) shown in 
Table A-6. The liver lesion data were not subjected to BMD analysis because incidences of liver necrosis 
were only reported for control and high-dose rats.  Serum liver enzyme (ALT, AST, LDH) data were not 
subjected to BMD analysis because a statistically significant increase was noted only for serum ALT in 
the high-dose group of male rats and the magnitude of the increase (50% higher than the control serum
ALT level) is not considered to be adverse. 
Table A-6. Absolute Liver Weights in Rats Orally Exposed to 
1,2-Dichlorobenzene for 10 Days 
Dose (mg/kg/day) 
Effect Sex 0 37.5 75 150 300 













n=10 n=10 n=10 n=10 n=10
aMean ± standard deviation
bSignificantly (p≤0.05) different from control value 
Source: Robinson et al. 1991
All continuous variable models in the EPA Benchmark Dose Software (Version 1.3.2) were fit to the 
absolute liver weight data from male and female rats.  One standard deviation increase from the control 
mean value was selected as the BMR in the absence of a biological rationale for using an alternative 
BMR. The modeling results are shown in Table A-7. Constant variance was assumed; the assumption 
was considered appropriate based on p-values >0.1 for the test of homogeneous variance.  The linear, 
2-degree polynomial, power, and Hill models provided adequate mean fit to the male rat liver weight 
data, as determined by p-values >0.1 for the test of mean fit.  The linear model was determined to the 
best-fitting model (lowest AIC among all adequate model outputs) for the male rat liver weight data and 
provided a BMD1sd of 249.04 mg/kg/day and a BMDL1sd of 158.55 mg/kg/day.  For the female liver 
weight data, the linear and Hill models provided adequate mean fit (p-values >0.1).  The linear model was 
the best-fitting model (lowest AIC) for the female rat liver weight data and provided a BMD1sd of 
84.67 mg/kg/day and a BMDL1sd of 67.73 mg/kg/day.  Among the best-fitting model results for absolute 
liver weight in the male and female rats, the lowest (linear model-generated) BMDL1sd of 
67.73 mg/kg/day for increased absolute liver weight in female rats is selected as the point of departure for 
deriving the MRL.  The BMDL1sd of 67.73 mg/kg/day was divided by an uncertainty factor of 100 to




















   























Table A-7. Model Predictions for Increased Absolute Liver Weight in Rats Orally
 
Exposed to 1,2-Dichlorobenzene for 10 Days 

Variance Mean fit BMD1sd BMDL1sd 
Model p-valuea p-valuea AIC (mg/kg/day) (mg/kg/day) 
Males 
 Linearb 0.15 0.48 41.40 249.04 158.55 
Polynomialb,c,d 0.15 0.38 42.87 274.93 164.78 
Powerb,e 0.15 0.38 44.86 281.79 164.87 
Hillb,f 0.15 0.17 46.80 180.01 No value 
Females 
 Linearb 0.12 0.19 -11.85 84.67 67.73 
Polynomialb,c,d, 0.12 0.09 -11.85 84.67 67.73 
Powerb,e 0.12 0.09 -7.85 84.67 67.73 
Hillb,f 0.12 0.84 -10.55 71.51 43.18 
aValues <0.1 fail to meet conventional goodness-of-fit criteria 
bConstant variance assumed 
cRestriction = non-negative 
d2-degree polynomial 
eRestrict power >=1 
fRestrict n>1 
gNon-homogeneous variance assumed 
AIC = Akaike’s Information Criteria; BMD1sd = benchmark dose associated with one standard deviation increase 
above control mean; BMDL = lower confidence limit (95%) on the benchmark dose 
Figure A-3. Observed and Predicted Mean Absolute Liver Weight in Female Rats 
Orally Exposed to 1,2-Dichlorobenzene for 10 Days* 
dose 
14:10 08/01 2006 
*The BMD and BMDL (in mg/kg/day) represent a 1 standard deviation increase in mean absolute liver weight from 































Uncertainty Factors used in MRL derivation: 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable. 
(gavage study) 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable. 
Was a conversion used from intermittent to continuous exposure? Not applicable. 
Other additional studies or pertinent information that lend support to this MRL: Information on effects of 
acute oral exposure to sublethal doses of 1,2-DCB essentially consists of findings in three systemic 
toxicity studies in rats and mice and one developmental toxicity study in rats (NTP 1985; Rimington and
Ziegler 1963; Robinson et al. 1991; Ruddick et al. 1983).  These studies administered the compound by 
gavage and collectively identify the liver as the most sensitive target.  Severe liver damage, characterized 
by intense necrosis and fatty changes as well as porphyria, occurred in rats administered 455 mg/kg/day 
for 15 consecutive days (Rimington and Ziegler 1963).  Rats that were exposed to 300 mg/kg/day for 
10 consecutive days had hepatic effects that included necrosis and increased serum ALT (Robinson et al. 
1991).  Hepatocellular degeneration and necrosis occurred in mice that were exposed to 250 or
500 mg/kg/day for 14 consecutive days (NTP 1985). The 15-day rat and 14-day mouse studies are 
limited by small numbers of animals (3–5 per dose) and lack of a NOAEL due a single dose level 
(Rimington and Ziegler 1963) or lack of histopathology evaluations at doses lower than the LOAEL (NTP
1985). The 10-day study (Robinson et al. 1991) is the most appropriate basis for MRL derivation because 
it is well designed, included four dose levels, and provides dose-response data for several hepatic end 
points. 
The NOAEL/LOAEL approach to MRL derivation results in an MRL similar to the 0.7 mg/kg/day value 
based on BMD analysis.  Using the 75 mg/kg/day NOAEL for increased liver weight (Robinson et al. 
1991) and the uncertainty factor of 100, the NOAEL/LOAEL approach yields an MRL of 0.8 mg/kg/day.







































MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,2-Dichlorobenzenes (1,2-DCB) 
CAS Numbers: 95-50-1 
Date:   August 2006
Profile Status: Post-Public, Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [X] Intermediate   [ ] Chronic 
Graph Key: 17 
Species: Rat 
Minimal Risk Level: [0.6] mg/kg/day   [ ] ppm
Reference: NTP. 1985.  Toxicology and carcinogenesis studies of 1,2-dichlorobenzene 
(o-dichlorobenzene) (CAS No.  95-50-1) in F344/N rats and B6C3F1 mice (gavage studies).  Research 
Triangle Park, NC: National Toxicology Program.  NTP TR 255. NIH Publication No.  86-2511. 
Experimental design: Groups of 10 male and 10 female F344/N rats and 10 male and 10 female 
B6C3F1 mice were administered 1,2-DCB (>99% pure) in corn oil by gavage in doses of 0, 30, 60, 125, 
250, or 500 mg/kg on 5 days/week for 13 weeks.  Evaluations included clinical signs, body weight, food
consumption, hematology, clinical chemistry, urine volume, urine uroporphyrins and coproporphyrins, 
liver porphyrins, organ weights, and necropsies in all groups of animals.  Complete histological 
examinations were performed on all control and high-dose animals; histology exams in lower dose groups 
were limited to liver, kidneys and thymus at 125 and 250 mg/kg/day. 
Effects noted in study and corresponding doses: Effects in the rats included necrosis of individual 
hepatocytes at ≥250 mg/kg/day and centrilobular degeneration at 500 mg/kg/day; total incidences of these 
lesions at 0, 125, 250, and 500 mg/kg/day were 0/10, 1/10, 4/9, and 8/10 in males, and 0/10, 3/10, 5/10, 
and 7/8 in females.  Relative liver weights were significantly increased at 125, 250, and 500 mg/kg/day in 
the males (8, 17, and 45% higher than controls) and females (8, 15, and 30%); increased relative liver 
weights were not seen at lower doses in either sex.  There were no increases in serum levels of liver 
enzymes [ALT, AP, or GGPT] at any dose in either sex.  Serum cholesterol was significantly increased in 
males at ≥30 mg/kg/day (50.0, 17.6, 26.5, 70.6, and 109% higher than controls in the low- to high-dose 
groups, not significant at 60 mg/kg/day) and females at ≥125 mg/kg/day (12.2, 12.2, 32.6, 26.5, and 
51.0%). Although increases in serum cholesterol were observed at levels as low as 30 mg/kg/day, the 
toxicological significance is unclear because there was no clear dose-response unless the increase at 
30 mg/kg/day is considered to be outlying.  Urinary concentrations of uroporphyrin and coproporphyrin
were 3–5 times higher than controls in the 500 mg/kg/day males and females, but this increase was not 
considered indicative of porphyria because total porphyrin concentration in the liver was not altered at 
any dose level and no pigmentation indicative of porphyria was observed by ultraviolet light at necropsy.
The increases in relative liver weight and liver lesions seen in both sexes at 125 mg/kg/day are believed to 
represent the beginning of adverse hepatic effects, and are thus designated a minimal LOAEL for this 
study.  The NOAEL is therefore 60 mg/kg/day. 
In the mice, no compound-related histopathological changes were observed in either sex at 0 and 
125 mg/kg/day, or in females at 250 mg/kg/day.  Lesions that were significantly increased included 
necrosis of individual hepatocytes, hepatocellular degeneration and/or pigment deposition in 4/10 males 
at 250 mg/kg/day, and centrilobular necrosis, necrosis of individual hepatocytes, and/or hepatocellular 
degeneration in 9/10 males and 9/10 females at 500 mg/kg/day.  Relative liver weights were significantly
increased at 500 mg/kg/day in both sexes, but there were no exposure-related changes in serum levels of 






























mice). Based on the liver lesion data, the NOAEL and LOAEL in mice are 125 and 250 mg/kg/day, 
respectively.
Dose and end point used for MRL derivation: 
[ ] NOAEL   [ ] LOAEL   [X] BMDL
As discussed below, a BMDL1sd of 89.27 mg/kg/day for increased relative liver weight in female rats is 
used as the point of departure for the MRL. 
Benchmark dose analysis was conducted using the male and female rat and male mouse liver lesion 
incidence data summarized in Table A-8.  Dichotomous models available in the EPA Benchmark Dose 
Software were fit to data for incidences of liver lesions (single cell necrosis, centrilobular necrosis, and/or 
hepatocellular degeneration) in male and female rats (combined) and male mice.  Because there were no 
apparent differences in sensitivity to 1,2-DCB among the male and female rats, the liver lesion data were 
combined to increase the statistical power for BMD analysis.  For each data set (combined incidences in 
male and female rats and incidences in male mice), the Chi-square p-value and AIC were used to select 
the best fitting model from which BMDs and their lower 95% confidence limits (BMDLs) were 
calculated, using a BMR of 10% extra risk. 
Table A-8. Incidences of Liver Lesions in Rats and Mice Orally Exposed to 
1,2-Dichlorobenzene for 13 Weeks 
Lesions: Individual cell or focal necrosis; Dose (mg/kg/day) 
centrilobular degeneration in high-dose group  0 30 60 125 250 500 
Male rat 0/10 ND ND 1/10 4/9a 8/10a 
Female rat 0/10 ND ND 3/10 5/10a 7/8a 
Combined (male and female) 0/20 ND ND 4/20a 9/19b 15/18b 
Male mouse 0/10 ND ND 0/10 4/10a 9/10a 
aSignificantly (p<0.05) different from control; Fisher Exact Test performed by ATSDR 
bSignificantly (p<0.01) different from control; Fisher Exact Test performed by ATSDR 
ND = no histological examinations conducted in this group 
Source: NTP 1985 
All models provided adequate fit to liver lesion data for male and female rats combined (Table A-9).  The 
best-fitting model (lowest AIC) was the quantal quadratic model, which provided a BMD10 of 
108.71 mg/kg/day and a BMDL10 of 92.08 mg/kg/day.  The log-probit model was determined to be the 





























Table A-9. BMD Model Results of Incidence Data for Liver Lesions in Male and 

Female Rats (Combined) and Male Mice Exposed to 1,2-Dichlorobenzene 

for 13 Weeks 

Chi-square BMD10 BMDL10 
Model p-valuea AIC (mg/kg/day) (mg/kg/day) 
Male and female rats combined 
Gammab 0.99 66.53 81.08 31.38 
 Logistic 0.34 69.78 112.08 81.57 
 Log Logisticc 0.94 66.64 89.36 39.14 
Multi-staged 0.99 66.55 66.22 31.31 
Probit 0.38 69.33 106.79 78.36 
Log-probitc 0.94 66.64 92.42 54.15 
 Quantal-linear 0.67 66.20 38.18 27.93 
 Quantal-quadratic 0.64 66.02 108.71 92.08 
Weibull 0.99 66.52 75.28 31.39 
Male mice 
Gammab 0.75 24.78 172.36 102.08 
 Logistic 0.44 26.24 168.53 106.72 
 Log-logisticc 0.81 24.62 175.35 110.25 
Multi-staged 0.48 24.57 116.66 63.82 
Probit 0.48 25.93 167.39 102.39 
Log-probitc 0.86 24.42 176.05 114.58 
 Quantal-linear 0.14 30.41 44.73 28.59 
 Quantal-quadratic 0.69 24.57 116.66 91.67 
 Weibull 0.61 25.46 158.84 86.28 
aValues <0.1 fail to meet conventional goodness-of-fit criteria 
bRestrict power >=1 
cSlope restricted to >1
dRestrict betas >=0; lowest degree polynomial (2-degree) with an adequate fit 
AIC = Akaike’s Information Criteria; BMD10 = benchmark dose based on a benchmark response of 10%; BMDL10 = 
lower confidence limit (95%) on the BMD10 
BMD analysis was also conducted using the relative liver weight data for male and female rats shown in 
Table A-10). Continuous variable models in the EPA Benchmark Dose Software were fit to the liver 
weight data, and one standard deviation from the control mean was selected as the BMR in the absence of 
a biological rationale for using a different BMR.  For the male rat relative liver weight data, results of 
model runs using constant variance indicated that non-homogeneous variance was more appropriate.  
However, selection of non-homogeneous variance resulted in inadequate mean fits (p-value <0.04) from
the linear, polynomial, and power models, and the Hill model would not generate an output.  For the 
relative liver weight data of the female rats, constant variance was appropriate (p-value >0.1) and 
adequate mean fits were obtained from the linear, polynomial, and power models (Table A-11).  The Hill 
model would not generate an output for the female relative liver weight data.  Among the adequate mean 



























female rat relative liver weight data (Table A-11, Figure A-4), which resulted in a BMD1sd of 
108.15 mg/kg/day and a BMDL1sd of 89.27 mg/kg/day. 
Table A-10. Relative Liver Weight Data for Male and Female Rats Orally Exposed 
to 1,2-Dichlorobenzene for 13 Weeks 
Mean measured exposure concentration (ppm) 
0 30 60 125 250 500 
Males 
 Group size 9 9 10 9 9 10 
 Relative liver weighta 3.18 3.28 3.10 3.43b 3.72b 4.61b
 Standard deviation 0.20 0.22 0.15 0.22 0.29 0.47 
Females 
 Group size 10 10 10 10 10 8 
 Relative liver weighta 2.90 2.98 2.92 3.13b 3.33b 3.78b
 Standard deviation 0.20 0.15 0.16 0.20 0.18 0.30 
aMean value 
bSignificantly different (p<0.05) from control group 
Source: NTP 1985 
Table A-11. Model Predictions for Relative Liver Weight in Female Rats Orally
Exposed to 1,2-Dichlorobenzene for 13 Weeks 
Variance Mean fit 
Model p-valuea p-valuea AIC BMD1sd (ppm) BMDL1sd (ppm) 
Linearb 0.338 0.719 -129.0910 108.15 89.27 
2-Degree polynomialb,c 0.338 0.559 -127.1169 112.34 89.34 
Powerb,d 0.338 0.5679 -125.1600 116.96 89.47 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bConstant variance assumed 
cRestriction = non-negative 
dPower restricted to >=1 
AIC = Akaike’s Information Criteria; BMD1sd = benchmark dose based on a benchmark response of 1 standard 






   
Figure A-4. Observed and Predicted Mean Relative Liver Weights in Female Rats 
Orally Exposed to 1,2-Dichlorobenzene for 13 Weeks* 







































18:07 08/01 2006 
*BMD and BMDL (in mg/kg/day) are associated with a benchmark response of 1 standard deviation increase above 
the control mean 
The BMDL1sd of 89.27 mg/kg/day from the best-fitting modeling results of the female rat relative liver 
weight data is lower than the BMDL10 of 92.08 mg/kg/day from the best-fitting modeling results of liver 
lesion incidences in the male and female rats combined and the BMDL10 of 114.58 mg/kg/day from the 
best-fitting model results of liver lesion incidences in the male mice.  Therefore, the BMDL1sd of 
89.27 mg/kg/day for increased relative liver weight in the female rats is selected as the point of departure 
for the MRL. The BMDL1sd of 89.27 mg/kg/day was duration-adjusted to 63.76 mg/kg/day and divided 
by an uncertainty factor of 100 to yield an MRL of 0.6 mg/kg/day. 
Uncertainty Factors used in MRL derivation: 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable 
(gavage study). 

























Was a conversion used from intermittent to continuous exposure? The BMDL1sd of 89.27 mg/kg/day was 
duration-adjusted for intermittent exposure, as follows (EPA 1994k): 
BMDL1sd ADJ = (BMDL1sd) (days/7 days) 
= (89.27 mg/kg/day) (5 days/7 days) 
= 63.76 mg/kg/day
Other additional studies or pertinent information that lend support to this MRL: Information on effects of 
intermediate-duration oral exposure to 1,2-DCB are available from three intermediate studies in rats and 
mice identifying the liver as the most sensitive target of toxicity (Hollingsworth et al. 1958; NTP 1985; 
Robinson et al. 1991).  Incidences of degenerative liver lesions were significantly increased in rats and 
mice exposed to ≥250 mg/kg/day, 5 days/week for 13 weeks (NTP 1985), 376 mg/kg/day, 5 days/week 
for 192 days (Hollingsworth et al. 1958; NTP 1985), and 400 mg/kg/day for 90 consecutive days 
(Robinson et al. 1991).  Necrotic lesions also occurred in several rats at 125 mg/kg/day (1/10 males, 
3/10 females) in the NTP (1985) study, but the increase was not statistically significant.  Other hepatic 
findings in rats exposed to lower doses (125–188 mg/kg/day for >13 weeks) in these studies included 
small increases in relative liver weight and serum levels of ALT, cholesterol, and serum protein, and 
decreases in serum triglycerides.  Increased serum ALT is an inconsistent finding because it was induced 
in rats exposed to >100 mg/kg/day for 90 days (Robinson et al. 1991), but not in rats exposed to 
≥125 mg/kg/day for 13 weeks (NTP 1985).  Additionally, the increase in serum ALT was not dose-
related, and serum levels of other liver-associated enzymes were not increased in either the Robinson et 
al. (1991) study (AST, LDH, and AP) or the NTP (1985) study (AP and gamma-glutamyltranspeptidase 
[GGTP]).  The lowest LOAEL is 125 mg/kg/day, which is a minimal LOAEL for increased liver weight 
in rats in the NTP (1985) study; the corresponding NOAEL is 60 mg/kg/day.   
The NOAEL/LOAEL approach to MRL derivation results in a lower MRL than the 0.6 mg/kg/day value 
based on benchmark dose analysis.  Using the 60 mg/kg/day NOAEL for increased liver weight in rats 
(NTP 1985), the NOAEL is duration-adjusted to 42.9 mg/kg/day (60 mg/kg/day x 5 days/7 days) and 
divided by the uncertainty factor of 100 to yield an MRL of 0.4 mg/kg/day. 

















   























MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,2-Dichlorobenzene (1,2-DCB) 
CAS Numbers: 95-50-1 
Date:   August 2006
Profile Status: Post-Public, Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [ ] Intermediate  [X] Chronic 
Graph Key: 31 
Species: Mouse 
Minimal Risk Level: [0.3] mg/kg/day   [ ] ppm
Reference: NTP. 1985.  Toxicology and carcinogenesis studies of 1,2-dichlorobenzene 
(o-dichlorobenzene) (CAS No.  95-50-1) in F344/N rats and B6C3F1 mice (gavage studies).  Research 
Triangle Park, NC: National Toxicology Program.  NTP TR 255. NIH Publication No.  86-2511. 
Experimental design: Groups of 50 male and 50 female F344/N rats and 50 male and 50 female 
B6C3F1 mice were administered 1,2-DCB (>99% pure) in corn oil by gavage in doses of 0, 60, or 
120 mg/kg on 5 days/week for 103 weeks.  Evaluations included clinical signs, body weight, and gross 
observations in all groups of animals.  Complete histological examinations were performed on all 
animals, and included evaluations of at least 30 tissues. 
Effects noted in study and corresponding doses: Survival was significantly reduced in high-dose male 
rats, relative to control male rats, but not in the low-dose group or in any group of female rats.  Mean 
body weights of high-dose male rats were slightly, but not statistically significantly, lower than those of 
controls throughout the study; the mean body weights of low-dose males were comparable to those of 
controls, and exposed female rats had higher body weights than controls.  No changes in clinical signs 
were reported for either sex of rats.  No increases in gross observations were reported on necropsy, and no 
changes in nonneoplastic lesions were seen in the liver, kidney, bone marrow, spleen, thymus, or other 
organs or tissues in exposed rats. 
In the mice, no statistically significant differences in survival were seen in either sex at any dose level.  
Mean body weights were similar to controls for all treated groups of male and female mice.  In male 
mice, there was a dose-related increase in the incidence of renal tubular regeneration (controls:  8/48; low 
dose: 12/50; high dose:  17/49); the increase was statistically significant (Fisher’s Exact Test, performed 
by ATSDR) in the high-dose group.  No other increases were observed in nonneoplastic lesions of the 
liver, bone marrow, spleen, or any other evaluated organ or tissue. 
Dose and end point used for MRL derivation: 
[ ] NOAEL   [ ] LOAEL   [X] BMDL
As discussed below, a BMDL10 of 43.04 mg/kg/day for increased incidences of renal tubular regeneration 
in male mice is used as the point of departure for the MRL. 
BMD analysis was conducted using the kidney lesion incidence data summarized in Table A-12.  All 
dichotomous models in the Benchmark Dose Software (version 1.3.2) were fit to the male mouse 
incidence data for renal tubule regeneration. A 10% extra risk above the control incidence was selected 
as the BMR in the absence of a biological rationale for using an alternative BMR.  The modeling results 



































square p-values for goodness of fit statistic (Chi-square = 0; degrees of freedom = 0) and were therefore 
not considered for selection of a point of departure.  The other models (logistic, multistage, probit, log­
probit, quantal-linear, and quantal-quadratic) provided adequate fits to the data (Chi-square p-values 
≥0.1). The logistic model was the best-fitting model for the renal tubule regeneration incidence data, 
based on the lowest AIC, and provided a BMD10 of 62.96 mg/kg/day and a BMDL10 of 43.04 mg/kg/day
(Table A-13, Figure A-5). The BMDL10 of 43.04 mg/kg/day was duration-adjusted to 30.74 mg/kg/day 
and divided by an uncertainty factor of 100 to yield an MRL of 0.3 mg/kg/day. 
Table A-12. Incidences of Kidney Lesions in Male Mice Orally Exposed to  
1,2-Dichlorobenzene for 103 Weeks 
Dose (mg/kg/day) 
Lesion: Regeneration of kidney tubule cells  0 60 120 
Incidence/group size 8/48 12/50 17/49a 
aSignificantly (p<0.05) different from control; Fisher Exact Test performed by ATSDR 
Source: NTP 1985 
Table A-13. BMD Modeling of Incidence Data for Kidney Lesions in Male Mice 
Exposed to 1,2-Dichlorobenzene for 103 Weeks 
Chi-square BMD10 BMDL10 
Model p-value AIC (mg/kg/day) (mg/kg/day) 











Multi-stagec 0.77 165.71 53.90 29.58 
Probit 0.91 165.64 61.60 41.20 
Log-probitb 0.84 165.67 72.33 46.85 
Quantal-linear 0.77 165.71 53.90 29.58 
Quantal-quadratic 0.74 165.73 79.20 57.20 
Weibull NA 167.62 66.03 29.80 
aRestrict power >=1 
bSlope restricted to >1
cRestrict betas >=0; lowest degree polynomial (1-degree) providing adequate fit 
AIC = Akaike’s Information Criteria; BMD10 = benchmark dose associated with 10% extra risk; BMDL10 = lower 












   
Figure A-5. Observed and Predicted Incidences of Kidney Lesions in Male Mice 
Exposed to 1,2-Dichlorobenzene for 103 Weeks* 





































14:08 07/21 2006 
*BMD and BMDL (in mg/kg/day) are associated with a 10% extra risk. 
Source: NTP 1985 
Uncertainty Factors used in MRL derivation: 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable 
(gavage study). 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable. 
Was a conversion used from intermittent to continuous exposure? The BMDL10 of 43.04 mg/kg/day was 
duration-adjusted for intermittent exposure, as follows (EPA 1994k): 
BMDL10 ADJ = (BMDL10) (days/7 days) 
= (43.04 mg/kg/day) (5 days/7 days) 
= 30.74 mg/kg/day
Other additional studies or pertinent information that lend support to this MRL: No other studies were 


















The NOAEL/LOAEL approach to MRL derivation results in a similar chronic-duration oral MRL value 
as the benchmark dose approach. Using the NOAEL of 60 mg/kg/day for increased incidence of renal 
tubular regeneration, the NOAEL is duration-adjusted to 43 mg/kg/day (60 mg/kg/day x 5 days/7 days) 
and divided by the uncertainty factor of 100 to yield an MRL of 0.4 mg/kg/day. 



































MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,3-Dichlorobenzene (1,3-DCB) 
CAS Numbers: 541-73-1 
Date:   August 2006
Profile Status: Post-Public, Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [X] Acute   [ ] Intermediate   [ ] Chronic 
Graph Key: 2 
Species: Rat 
Minimal Risk Level: [0.4] mg/kg/day   [ ] ppm
Reference: McCauley PT, Robinson M, Daniel FB, et al.  1995.  Toxicity studies of 1,3-dichlorobenzene 
in Sprague-Dawley rats.  Drug Chem Toxicol 18(2 & 3):201-221. 
Experimental design: Groups of 10 male and 10 female Sprague-Dawley rats were administered 
1,3-DCB in gavage doses of 0, 37, 147, 368, or 735 mg/kg/day in corn oil for 10 consecutive days. End 
points evaluated during the study included clinical signs, survival, body weight, and food and water 
consumption.  At the end of the study, blood was collected for hematology and serum chemistry analyses 
(erythrocytes, leukocytes, hemoglobin, hematocrit, mean corpuscular volume, glucose, BUN, creatinine, 
AP, AST, ALT, cholesterol, LDH, and calcium levels), and selected organs were weighed (brain, liver, 
spleen, lungs with lower half of trachea, thymus, kidneys, adrenal glands, heart, and gonads).  Gross 
pathology was evaluated in all animals, and comprehensive histological examinations were performed in 
the high dose and control groups; histology in the lower dose groups was limited to the liver.  
Inflammatory and degenerative lesions were graded on a relative scale from one to four depending on the 
severity (minimal, mild, moderate, or marked). 
Effects noted in study and corresponding doses: No compound-related deaths or overt clinical signs were 
observed. Body weight was significantly reduced in both sexes at 735 mg/kg/day (20 and 13% lower 
than controls in males and females, respectively).  Food consumption was significantly decreased at 
735 mg/kg/day in males (12%, normalized by body weight), and water consumption was significantly
increased (8–13%) in females at ≥735 mg/kg/day.  The hematological evaluation showed 8% decreased 
MCV in females at 735 mg/kg/day.  The clinical chemistry analyses showed statistically significant 
changes in several indices, but serum cholesterol was the only end point that had values that exceeded the 
reference range.  Serum cholesterol was significantly increased in females at 368 and 735 mg/kg/day
(94 and 63% higher than controls, respectively), as well as in males at 368 and 735 mg/kg/day (79 and 
84% higher than controls, respectively).  Relative liver weight was significantly increased in males at 
≥147 mg/kg/day and females at ≥368 mg/kg/day; increases in the males were 9.1, 31.3, 50.63, and 32.5% 
higher than controls in the low- to high-dose groups. Other significant changes in relative organ weight 
included decreased spleen weight in females at ≥368 mg/kg/day and in males at 735 mg/kg/day, 
decreased thymus weight in both sexes at 735 mg/kg/day, and decreased testes weight in males at 
735 mg/kg/day.  Absolute organ weights were not reported.  Histological changes primarily occurred in 
the liver, particularly centrilobular hepatocellular degeneration at ≥368 mg/kg/day.  This lesion was 
characterized by varying degrees of cytoplasmic vacuolization and swelling with intact membranes, and 
occurred in the 368 and 735 mg/kg/day groups in 2/10 and 9/10 males, respectively, and in 6/10 and 
10/10 females, respectively; incidences in the other groups were not reported, but are presumed to be 
0/10.  Other hepatic alterations included hepatocellular necrosis that was sporadically noted in the 147, 
368, and 735 mg/kg/day groups.  This change was usually minimal to mild, and tended to increase in 
incidence and severity in the males in a dose-related manner; however, incidences were not reported.  The 




















































differentiation between medulla and cortex.  The thymic atrophy was observed in 2/10 males (both 
marked in severity) and 2/9 females (both mild in severity) at 735 mg/kg/day; this change was not 
observed in controls, and the other dosed groups were not examined.  The 147 mg/kg/day dose is a 
LOAEL based on the >30% increase in relative liver weight in male rats.  The NOAEL for increased liver 
weight is 37 mg/kg/day. 
Dose and end point used for MRL derivation: 
[ ] NOAEL   [ ] LOAEL   [X]   BMDL
As discussed below, a BMDL1sd of 36.32 mg/kg/day for increased liver weight in female rats is used as 
the point of departure for the MRL. 
BMD analysis was conducted on hepatic effects data in the male and female rats of the McCauley et al. 
(1995) study.  The liver effects data modeled included the incidences of hepatocellular degeneration, 
absolute liver weights, and mean serum cholesterol levels shown in Table A-14. 
Table A-14. Liver Effects Observed in Rats Orally Exposed to 
1,3-Dichlorobenzene for 10 Days 
Dose (mg/kg/day) 
Effects Sex 0 37 147 368 735 
Centrilobular M 0/10a 0/10a 0/10a 2/10 9/10b 
hepatocellular 
degeneration
F 0/10a 0/10a 0/10a 6/10b 10/10b 
Absolute liver M 11.04±1.00 12.06±1.56 14.5±2.30b 16.63±1.62b 14.63±2.26b 
weight (g) n=10 n=10 n=9 n=10 n=9 
F 7.68±0.75 8.12±0.77 9.18±0.99 11.90±1.19b 12.66±2.55b 
n=10 n=10 n=9 n=10 n=9 
Mean serum M 63.0±10.2 63.6±3.7 92.4±20.9 112.5±16.3b 116.0±49.6b 
cholesterol n=10 n=10 n=10 n=9 n=10
(mg/dL) F 64.8±12.2 73.3±10.8 87.9±13.8 125.4±27.0b 105.7±16.6b 
n=8 n=10 n=9 n=10 n=9 
aIncidences of centrilobular hepatocellular degeneration were not reported for the 0, 37, and 147 mg/kg/day dose 





bSignificantly (p≤0.05) different from control value. 

Source: McCauley et al. 1995
All dichotomous variable models available in the EPA Benchmark Dose Software (Version 1.3.2) were fit 
to the incidence data for hepatocellular degeneration in male and female rats.  A BMR of 10% extra risk 
was selected in the absence of a biological rationale for selecting an alternative BMR.  The modeling 
results are shown in Table A-15.  All dichotomous models provided adequate fit to the male and female 
hepatocellular degeneration incidence data, as determined by Chi-square p-values >0.1 (Table A-15).  
The log-probit model was determined to be the best-fitting (lowest AIC) model for the male data and 
provided a BMD10 of 319.18 mg/kg/day and a BMDL10 of 207.86 mg/kg/day.  The log-logistic model was 
determined to be the best-fitting (lowest AIC) model for the female data and provided a BMD10 of 























Table A-15. Modeling Results for Incidences of Centrilobular  
Degeneration in Male and Female Rats Orally Exposed to  
1,3-Dichlorobenzene for 10 Days 
Chi-square 

Model p-valuea AIC BMD10 (mg/kg/day) BMDL10 (mg/kg/day) 

Males 
Gammab 0.9997 20.53 314.37 196.42 
 Logistic 0.9386 21.15 322.99 215.61 
 Log-logisticc 0.9992 20.55 317.16 206.86 
Multi-staged 0.9895 20.72 305.72 156.48 
Probit 0.9787 20.81 316.14 205.06 
Log-probitc 1.0000 20.51 319.18 207.86 
 Quantal linear 0.1153 28.95 82.93 51.49 
 Quantal quadratic 0.7150 21.46 190.83 148.00 
 Weibullb 0.9918 20.69 306.04 182.80 
Females 
Gammab 1.00 15.48 251.73 145.75 
 Logistic 1.00 17.46 338.16 167.41 
 Log-logisticc 1.00 15.46 318.46 159.37 
Multi-staged 0.97 15.92 216.50 124.71 
Probit 1.00 17.46 310.54 153.36 
Log-probitc 1.00 17.46 303.18 153.81 
 Quantal linear 0.13 28.04 45.74 29.88 
 Quantal quadratic 0.75 19.06 128.58 99.32 
 Weibullb 1.00 17.46 313.61 138.53 
aValues <0.1 fail to meet conventional goodness-of-fit criteria 
bRestrict power >=1 
cSlope restricted to >1
dRestrict betas ≥0; Degree of polynomial=2 
AIC = Akaike’s Information Criteria; BMD10 = benchmark dose associated with a 10% extra risk; BMDL10 = lower 
confidence limit (95%) on the benchmark dose
All continuous variable models in the EPA Benchmark Dose Software (Version 1.3.2) were fit to the 
mean absolute liver weight data and mean serum cholesterol level data from the male and female rats.  A 
BMR of 1 standard deviation increase above the control mean was selected in the absence of a biological 
rationale for using an alternative BMR. None of the available models provided adequate mean fit to the 
male rat absolute liver weight data or the female rat serum cholesterol data, based on p-values <0.01 for 
mean fit. Modeling of the male rat serum cholesterol data resulted in failed tests for both constant and 
non-homogeneous variance. 
For the female rat absolute liver weight data, results of testing for constant and non-homogeneous 
variance indicated that a non-homogeneous variance assumption was appropriate.  The modeling results 
are shown in Table A-16. Based on this assumption, the linear, 2-degree polynomial, and Hill models 
provided adequate mean fit to the female rat absolute liver weight data.  The power model provided a 
























of-fit standard. Although the Hill model provided adequate mean fit, it failed to determine a BMDL and 
was rejected from further consideration for selection of a point of departure for deriving an acute-duration 
oral MRL. The best-fitting model for the female rat absolute liver weight data was the 2-degree 
polynomial model (lowest AIC), which provided a BMD1sd of 51.83 mg/kg/day and a BMDL1sd of
36.32 mg/kg/day. 
In summary, BMD analysis of liver effects in the male and female rats of the principal study (McCauley
et al. 1995) resulted in a BMDL10 of 207.86 mg/kg/day for hepatocellular degeneration in male rats (best­
fitting [log-probit] model), a BMDL10 of 159.37 mg/kg/day for hepatocellular degeneration in female rats 
(best-fitting [log-probit] model), and a BMDL1sd of 36.32 mg/kg/day for absolute liver weight changes in 
female rats (best-fitting [2-degree polynomial] model).  Using a conservative approach, the BMDL1sd of 
36.32 mg/kg/day for absolute liver weight changes in female rats (Table A-16, Figure A-6) is selected as 
the point of departure for deriving an MRL.  The BMDL1sd of 36.32 mg/kg/day was divided by an 
uncertainty factor of 100 to derive an MRL of 0.4 mg/kg/day. 
Table A-16. Modeling Results for Absolute Liver Weight Data in Female Rats 































Hilld,g 0.36 0.37 67.87 78.40 No value 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bConstant variance assumed 
cRestriction = non-negative 
dNon-homogeneous variance assumed 
eLowest degree polynomial (2-degree) providing adequate fit 
fRestrict power >=1 
gRestrict n>1 
AIC = Akaike’s Information Criteria; BMD1sd = benchmark dose associated with one standard deviation increase 
above control mean; BMDL1sd = lower confidence limit (95%) on the BMD1sd; F= BMDL computation failed due to 












   









1,3-Dichlorobenzene for 10 Days* 






























15:04 07/28 2006 
*BMD and BMDL (in mg/kg/day) are for a 1 standard deviation increase above the control mean. 
Uncertainty Factors used in MRL derivation: 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable 
(gavage study). 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable. 

Was a conversion used from intermittent to continuous exposure? Not applicable. 

Other additional studies or pertinent information that lend support to this MRL: No additional acute-

duration studies of 1,3-DCB were located. 

The NOAEL/LOAEL approach to MRL derivation results in same MRL as the 0.4 mg/kg/day value 

derived using the benchmark dose approach.  Using the 37 mg/kg/day NOAEL for increased liver weight 
and the uncertainty factor of 100, the NOAEL/LOAEL approach yields an MRL of 0.4 mg/kg/day.   

































    
A-37 DICHLOROBENZENES
APPENDIX A 
MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,3-Dichlorobenzene (1,3-DCB) 
CAS Numbers: 541-73-1 
Date:   August 2006
Profile Status: Post-Public, Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [X] Intermediate   [ ] Chronic 
Graph Key: 7 
Species: Rat 
Minimal Risk Level: [0.02] mg/kg/day  [ ] ppm
Reference: McCauley PT, Robinson M, Daniel FB, et al.  1995.  Toxicity studies of 1,3-dichlorobenzene 
in Sprague-Dawley rats.  Drug Chem Toxicol 18(2 & 3):201-221.
Experimental design: Groups of 10 male and 10 female Sprague-Dawley rats were administered 
1,3-DCB in gavage doses of 0, 9, 37, 147, or 588 mg/kg/day in corn oil for 90 consecutive days
(McCauley et al. 1995).  End points evaluated during the study included clinical signs and mortality, body
weight, and food and water consumption.  At end of the exposure period, blood was collected for 
hematology and serum chemistry analyses (erythrocytes, leukocytes, hemoglobin, hematocrit, mean 
corpuscular volume, glucose, BUN, creatinine, AP, AST, ALT, cholesterol, LDH, and calcium levels), 
selected organs were weighed (brain, liver, spleen, lungs with lower half of trachea, thymus, kidneys, 
adrenal glands, heart, and gonads), and gross pathology was assessed.  Histological examinations were 
performed on all tissues that were examined grossly in all high-dose rats and in one-half of control rats, as 
well as in the liver, thyroid, and pituitary glands from all animals in the 9, 37, and 147 mg/kg/day dose 
groups. Inflammatory and degenerative lesions were graded on a relative scale from one to four 
depending on the severity (minimal, mild, moderate, or marked).   
Effects noted in study and corresponding doses: No compound-related deaths or overt clinical signs were 
observed. Body weight was reduced in both sexes at 588 mg/kg/day (24 and 10% lower than controls in 
males and females, respectively).  The decreased weight gain was progressive throughout the exposure 
period and occurred despite increased food and water consumption in the same groups.  Other effects 
included increased relative kidney weight in males at ≥147 mg/kg/day and in females at 588 mg/kg/day, 
but there were no renal histopathological changes in any of the exposed animals.  Hematological 
alterations consisted of significant increases in leukocyte levels in males at 147 mg/kg/day and in females 
at 588 mg/kg/day, and erythrocyte levels in males at 588 mg/kg/day.  Histopathology and serum
chemistry findings indicated that the thyroid, pituitary, and liver were the most sensitive targets of 
toxicity, as discussed below.  The lowest LOAEL is 9 mg/kg/day, which is the lowest tested dose and a 
minimal LOAEL for thyroid and liver effects. 
Thyroid effects included significantly (p≤0.05) increased incidences of reduced colloidal density in 
follicles that exceeded normal variability in male rats at ≥9 mg/kg/day and in female rats at 
≥37 mg/kg/day (control to high dose group incidences of 2/10, 8/10, 10/10, 8/9, and 8/8 in males, and 
1/10, 5/10, 8/10, 8/10, and 8/9 in females).  Depletion of colloid density in the thyroid was characterized 
by decreased follicular size with scant colloid and follicles lined by cells that were cuboidal to columnar.  
The severity of the colloid density depletion generally ranged from mild to moderate, increased with dose 
level, and was greater in males than females.  Incidences of male rats with thyroid colloidal density 
depletion of moderate or marked severity were significantly increased at ≥147 mg/kg/day (0/10, 0/10, 



































because the morphological alterations (reduced colloidal density in follicles) are unlikely to be associated 
with functional changes in the thyroid. 
Pituitary effects included significantly (p≤0.05) increased incidences of cytoplasmic vacuolization in the 
pars distalis in male rats at ≥147 mg/kg/day (2/10, 6/10, 6/10, 10/10, 7/7).  The vacuoles were variably 
sized, irregularly shaped, and often poorly defined, and the severity of the lesions (i.e., number of cells 
containing vacuoles) ranged from minimal to mild and generally increased with increasing dose level.  
Incidences of male rats with pituitary cytoplasmic vacuolization of moderate or marked severity were 
significantly increased at 588 mg/kg/day (1/10, 0/10, 2/10, 3/9, and 7/7).  The pituitary lesion was 
reported to be similar to "castration cells" found in gonadectomized rats and considered to be an indicator 
of gonadal deficiency.  No compound-related pituitary lesions were observed in female rats.  Serum
cholesterol was significantly increased in males at ≥9 mg/kg/day and in females at ≥37 mg/kg/day in a 
dose-related manner, and serum calcium was significantly increased in both sexes at ≥37 mg/kg/day.  The 
investigators suggested that these serum chemistry changes might reflect a disruption of hormonal 
feedback mechanisms, or target organ effects on the pituitary, hypothalamus, and/or other endocrine 
organs. Based on the increased incidences of cytoplasmic vacuolation, the LOAEL for pituitary effects is 
147 mg/kg/day. 
Hepatic effects occurred in both sexes at 147 and 588 mg/kg/day, including significantly increased 
relative liver weight and incidences of liver lesions. Absolute organ weights were not reported. Liver 
lesions were characterized by inflammation, hepatocellular alterations (eosinophilic homogeneous 
inclusions), and hepatocellular necrosis.  Liver lesions that were significantly (p≤0.05) increased included 
hepatocellular cytoplasmic alterations of minimal to mild severity in males at ≥147 mg/kg/day (1/10, 
2/10, 1/10, 6/10, 7/9) and in females at 588 mg/kg/day (0/10, 2/10, 0/10, 1/10, 7/9), and necrotic 
hepatocyte foci of minimal severity at 588 mg/kg/day in both males (1/10, 2/10, 1/10, 2/10, 5/9) and 
females (0/10, 0/10, 0/10, 3/10, 5/9).  Other statistically significant liver-associated effects included 
significantly increased serum AST levels (90–100% higher than controls) in males at ≥9 mg/kg/day and 
in females at ≥37 mg/kg/day.  Serum cholesterol levels were significantly increased in males at 
≥9 mg/kg/day and in females at ≥37 mg/kg/day, but might be pituitary-related, as indicated above.  Serum
LDH levels were reduced in males at ≥9 mg/kg/day and BUN levels were reduced in both sexes at 
588 mg/kg/day, but the biological significance of decreases in these indices is unclear.  The 9 mg/kg/day
dose is considered to be a minimal LOAEL for liver effects because the main effect, increased serum
AST, showed no clear dose-response and was only accompanied by necrotic liver lesions at a much 
higher dose (588 mg/kg/day). 
Dose and end point used for MRL derivation: 
[ ] NOAEL   [ ] LOAEL   [X] BMDL
As discussed below, a BMDL10 of 2.1 mg/kg/day for increased incidences of pituitary lesions is used as 
the basis for the MRL. 
Benchmark dose analysis was conducted using the thyroid and pituitary lesion incidence data and serum











     
 
    
    
 
    
 















Table A-17. Thyroid, Pituitary and Liver Effects in Rats Orally Exposed to 
1,3-Dichlorobenzene for 90 Days 
Dose (mg/kg/day) 
Effect Sex 0 9 37 147 588 
Thyroid, reduced follicular M 2/10 8/10a 10/10a 8/9a 8/8a 
colloidal density 
Pituitary, cytoplasmic M 2/10 6/10 6/10 10/10a 7/7a 
vacuolation in pars distalis
Serum AST (U/L) M 43.7 ± 37.7 87.6 ± 24.7a 109.8 ± 9.5 88.0 ± 23.3a 82.8 ± 13.8a 
(mean ± SD) (n=10) (n=10) (n=10) (n=10) (n=8) 
Serum cholesterol (mg/dL) M 73.5 ± 1.4 96.6 ± 1.7a 111.1 ± 1.6a 157.9 ± 2.5a 89.5 ± 1.5a 
(mean ± SD) (n=10) (n=10) (n=10) (n=10) (n=8) 
Serum cholesterol (mg/dL) F 68.2 ± 1.7 85.0 ± 3.0 108.4 ± 2.2a 158.9 ± 1.8a 152.6 ± 2.6a 
(mean ± SD) (n=10) (n=10) (n=10) (n=10) (n=9) 
aSignificantly (p≤0.05) different from control
Source: McCauley et al. 1995
Continuous variable models (linear, polynomial, power, and Hill) in the EPA Benchmark Dose Software 
(Version 1.3.2) were fit to the serum AST levels in the male rats and the serum cholesterol levels in the 
male and female rats. One standard deviation change from the control mean was selected as the BMR for 
each data set in the absence of a biological rationale for an alternative BMR.  Initial modeling results 
using constant variance indicated that modeling should be performed using non-homogeneous variance.  
However, modeling results using non-homogeneous variance for each of the continuous variable models 
resulted in inadequate mean fit to the serum AST and cholesterol data, as indicated by p-values 
<0.0001 for mean fit. 
Dichotomous variable models available in the EPA Benchmark Dose Software were fit to the male rat 
incidence data for: (1) reduced follicular colloidal density in the thyroid, and (2) cytoplasmic vacuolation 
in the pars distalis of the pituitary.  For each variable, AIC was used to select the best-fitting model from
which BMDs and BMDLs were calculated, using a BMR of 10% extra risk.  For the thyroid incidence 
data, none of the available dichotomous variable models provided adequate fit as indicated by chi-square 
goodness of fit p-values ≤0.002.  For the pituitary cytoplasmic vacuolation incidence data, all of the 
models provided adequate fit as indicated by chi-square goodness of fit p-values >0.1 (Table A-18).  The 
probit model provided the lowest AIC (43.442).  However, a nearly identical AIC value (43.467) was 
provided by each of three other models (gamma, quantal-linear, and Weibull).  Because the BMD10 of
4.08 mg/kg/day and associated BMDL10 of 2.10 mg/kg/day from the gamma, quantal-linear, and Weibull 
models are lower than those from the probit model (BMD10 = 7.79 mg/kg/day; BMDL10 = 
4.46 mg/kg/day), a conservative health protective approach was taken and the lower BMDL10 of 
2.10 mg/kg/day was selected as the point of departure for deriving the MRL (Table A-18, Figure A-7).  
The BMDL10 of 2.1 mg/kg/day was divided by an uncertainty factor of 100 (10 for extrapolation from
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Table A-18. BMD Modeling Results of Incidence Data for Pituitary Lesions in 

Male Rats Exposed to 1,3-Dichlorobenzene for 90 Days 

Chi-square BMD10 BMDL10 
Model p-valuea AIC (mg/kg/day) (mg/kg/day) 
Probit 0.4823 43.442 7.79 4.46 
































aValues <0.1 fail to meet conventional goodness-of-fit criteria 
bRestrict power >=1 
cSlope restricted to >1
dRestrict betas ≥0; Degree of polynomial=2
Figure A-7. Observed Incidences for Pituitary Lesions in Male Rats and 

Incidences Predicted by the Gamma Model*
 
*BMD and BMDL (in mg/kg/day) are associated with a benchmark response of 10% extra risk.  The gamma model 
plot in this figure is identical to plots produced by the quantal-linear and Weibull models. 
Uncertainty Factors used in MRL derivation: 
[X]  10 for extrapolation from animals to humans 





















Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable. 
(gavage study) 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable. 
Was a conversion used from intermittent to continuous exposure? Not applicable. 
Other additional studies or pertinent information that lend support to this MRL: No additional
intermediate-duration studies of 1,3-DCB were located. 
The NOAEL/LOAEL approach to MRL derivation provides support to the MRL of 0.02 mg/kg/day based 
on the BMD analysis of pituitary lesions.  The lowest tested dose of 9 mg/kg/day is considered a minimal 
LOAEL for thyroid lesions and increases in serum AST.  Using the minimal LOAEL of 9 mg/kg/day and 
an uncertainty factor of 300 (3 for use of a minimal LOAEL, 10 for extrapolation from animals to 
humans, and 10 for human variability), the NOAEL/LOAEL approach yields an MRL of 0.03 mg/kg/day.











































MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,4-Dichlorobenzene (1,4-DCB) 
CAS Numbers: 106-46-7 
Date:   August 2006
Profile Status: Post-Public, Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [X] Intermediate   [ ] Chronic 
Graph Key: 44 
Species: Dog 
Minimal Risk Level: [0.07] mg/kg/day  [ ] ppm
References: Naylor MW, Stout LD.  1996.  One year study of p-dichlorobenzene administered orally via 
capsule to beagle dogs. Environmental Health Laboratory, Monsanto Company, St. Louis, MO.  Study
No. ML-94-210, March 25, 1996.  MRID# 43988802.  Unpublished. 
EPA. 1996b.  Data Evaluation Record (DER) for p-dichlorobenzene – chronic oral toxicity in dogs 
(MRID# 439888-01 and -02) for Section 6 (a) (2) and reregistration need.  U.S. Environmental Protection 
Agency, Office of Prevention, Pesticides and Toxic Substances. 
Experimental design: Groups of five male and five female beagle dogs were orally administered 
1,4-DCB by capsule in dose levels of 0, 10, 50, or 75 mg/kg/day for 1 year.  Based on the summarized 
design of a 4-week dose range-finding study, it is presumed that dosing was 5 days/week.  The
75 mg/kg/day dose is a time-weighted average level reflecting dose decreases at the beginning of the 
study in response to unexpected severe toxicity.  An initial high dose of 150 mg/kg/day was adjusted to 
100 mg/kg/day for males during week 3, and a further decrease to 75 mg/kg/day was made for both sexes 
at the beginning of week 6.  Both high dose males and females were untreated during weeks 4 and 5 to 
allow for recovery.  End points evaluated throughout the study included clinical observations (daily),
body weight (weekly), and food consumption (weekly).  Ophthalmoscopic examinations were performed 
prior to study start and just prior to study completion.  Hematology (11 indices, including activated partial 
thromboplastin time), clinical chemistry (18 indices, including ALT, AST, GGTP, AP, and creatinine 
phosphokinase), and urinalysis (10 indices) were performed at month 6 and study completion.  Organ 
weights, gross pathology, and histology were evaluated at study completion. 
Effects noted in study and corresponding doses: Mortality occurred the first 25 days of the study before 
dose reduction; exposure to 150 mg/kg/day caused one male dog to be sacrificed in extremis on day 12, 
one male death on day 25, and one female death on day 24.  A control male died on day 83, but all other 
dogs survived to the end of the study.  Treatment-related clinical signs were primarily limited to severely
affected high-dose dogs and the control male that died; these included hypoactivity, dehydration, 
decreased defecation, blood-like fecal color, emesis, emaciation, and/or pale oral mucosa.  There were no 
significant group differences in mean body weight at the end of the study.  Body weight gain was 
significantly reduced during the first month of the study, but recovered following dose reduction and 
adjustment of food availability.  A mild anemia was observed at month 6 (significantly reduced red blood 
cells in females and HCT in males) at 75 mg/kg/day, but resolved by the end of the study.  The mild 
anemia correlated with histologic findings of bone marrow erythroid hyperplasia in females, and splenic 
excessive hematopoiesis and megakaryocyte proliferation in both sexes, indicating a compensatory
response to the earlier anemia.  Hepatic effects occurred after 6 and 12 months at ≥50 mg/kg/day in both 
sexes as shown by changes in liver enzymes, increased liver weight, and/or histopathology. Effects on 
serum enzyme levels included significantly increased AP in males at 50 mg/kg/day at months 6 and 


































12 (525 and 330% higher), and females at 75 mg/kg/day at months 6 and 12 months (761 and 680%
higher). Serum AP levels were not statistically significantly increased in the 75 mg/kg/day males at 
months 6 or 12, but only 3 animals were evaluated in this dose group.  Other clinical chemistry findings 
included significantly increased ALT in females at 75 mg/kg/day at month 12 (253% higher than 
controls), increased GGTP in females at 75 mg/kg/day at months 6 and 12 (131 and 161% higher), and 
decreased albumin in males at 50 and 75 mg/kg/day at month 6 (16 and 18% lower than controls) and 
females at 75 mg/kg/day at month 6 (19% lower).  Absolute and relative liver weights were significantly
increased (40–70% higher than controls) in both sexes at 50 and 75 mg/kg/day (except absolute liver 
weight in 50 mg/kg/day males).  Hepatic lesions included hepatocellular hypertrophy (diffuse or 
multifocal in all males and females at 50 and 75 mg/kg/day and one female at 10 mg/kg/day), 
hepatocellular pigment deposition (two males and one female each at 50 and 75 mg/kg/day), bile 
duct/ductule hyperplasia (one male and one female at 75 mg/kg/day), and hepatic portal inflammation 
(periportal accumulation of neutrophils in one male at 50 mg/kg/day and two males at 75 mg/kg/day). 
Kidney effects included collecting duct epithelial vacuolation in one male at 75 mg/kg/day and at all dose 
levels in females (one each at 10 and 50 mg/kg/day and two at 75 mg/kg/day). The renal lesion was 
considered to be a possible effect of treatment at ≥50 mg/kg/day, because it was accompanied by
increased relative kidney weight in females at ≥50 mg/kg/day and grossly observed renal discoloration in 
two females at 75 mg/kg/day.    
The highest NOAEL and lowest LOAEL are 10 and 50 mg/kg/day, respectively, based on the increases in 
serum AP at 6 months.  This serum enzyme change is a sufficient indication of intermediate-duration 
hepatotoxicity because the increases were similar in magnitude to those that were observed after 1 year 
and associated with increased liver weight and liver lesions; the latter effects likely developed earlier in 
the study but could not be detected due to the lack of organ weight and histology examinations at 
6 months. 
Dose and end point used for MRL derivation:
[ ] NOAEL  [ ] LOAEL [X] BMDL
As discussed below, a BMDL1sd of 10 mg/kg/day for increased serum AP is used as the basis for the 
MRL. 
BMD analysis was conducted using the Naylor and Stout (1996) data for changes in serum AP in female 
dogs administered 1,4-DCB orally for 6 months, as shown in Table A-19.  A BMR of 1 standard 
deviation change from the control mean was selected in the absence of a biological rationale for using an 
alternative BMR. Mean serum AP levels in the female dogs exhibited a dose-response relationship and 
were significantly higher in the 50 and 75 mg/kg/day groups, relative to controls.  Although significantly
increased mean serum AP levels were noted in the 50 mg/kg/day male dogs, the increase was not 
significant in the 75 mg/kg/day males; only three males in this dose group were available for the 
assessment of serum AP levels.  Therefore, the male serum AP data were not modeled.  The simplest 
model (linear) for continuous data from the EPA Benchmark Dose Software (Version 1.3.2) was initially
fit to the female serum AP data; constant variance was selected.  As shown in Table A-20, the linear 
model output indicated inadequate fit for constant variance (as indicated by a p-value <0.01 for the test of 
constant variance) and a model run using nonhomogeneous variance was suggested.  However, using 
nonhomogeneous variance, inadequate model mean fit was obtained (p-value <0.01 for model mean fit) 
(see Table A-20).  The more complex (polynomial, power, Hill) models were also fit to the serum AP 
data. The Hill model provided inadequate mean fit due to an insufficient number of dose groups (4, 
including controls), which resulted in insufficient (0) degrees of freedom.  Both the polynomial and 
power models provided adequate mean fit (Table A-20).  Following conventional protocol for selection of 
































BMDL1sd of 9.97 mg/kg/day (lower 95% confidence limit on the BMD1sd of 12.48 mg/kg/day) was 
selected as the point of departure for deriving an intermediate-duration oral MRL for 1,4-DCB (see 
Table A-20, Figure A-8). The BMDL1sd of 9.97 mg/kg/day was duration-adjusted to 7 mg/kg/day and 
divided by an uncertainty factor of 100 to derive an MRL of 0.07 mg/kg/day. 
Table A-19. Serum Alkaline Phosphatase Levels in Female Dogs Orally Exposed 
to 1,4-Dichlorobenzene for 6 Months 
Mean serum AP level in IU/L 
Dose (mg/kg/day) Group size (percent of control mean) 
0 5 175.80 ± 50.05a 
--
10 5 176.00 ± 64.50 
(100) 
50 5 1098.20b ± 425.85 
(625) 
75 4 1513.50c ± 855.31 
(861) 
aStandard deviation 
bSignificantly different (p<0.01) from control group 
cSignificantly different (p<0.05) from control group 
Source: Naylor and Stout 1996
Table A-20. Model Predictions for Changes in Serum Alkaline  

Phosphatase Levels in Female Dogs Orally Exposed

to 1,4-Dichlorobenzene for 6 Months 


























aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bConstant variance assumed 
cRestriction = non-negative 
dNonhomogeneous variance assumed 
BMD1sd = benchmark dose based on a benchmark response of 1 standard deviation above the control mean; 













   










































Figure A-8. Changes in Serum Alkaline Phosphatase Levels in Female Dogs 

Orally Exposed to 1,4-Dichlorobenzene for 6 Months* 

dose 
17:43 06/29 2006 
*BMD and BMDL (in mg/kg/day) are associated with a benchmark response of 1 standard deviation above the control 
mean. 
Uncertainty Factors used in MRL derivation:
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable 
(capsule study). 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable. 
Was a conversion used from intermittent to continuous exposure? The BMDL1sd of 10 mg/kg/day was 
adjusted to a continuous exposure scenario as follows: 
  BMDL1sd ADJ = (BMDL1sd) (5days/7 days) 
= (10 mg/kg/day) (5 days/7 days) 
= 7 mg/kg/day
Other additional studies or pertinent information that lend support to this MRL: The NOAEL/LOAEL 
approach to MRL derivation results in the same intermediate-duration oral MRL value as the benchmark 
dose approach. Using the NOAEL of 10 mg/kg/day for increased serum AP in dogs (Naylor and Stout 
1996), the NOAEL is duration-adjusted to 7 mg/kg/day (10 mg/kg/day x 5 days/7 days) and divided by
the uncertainty factor of 100 to yield an MRL of 0.07 mg/kg/day. 
Information on the systemic toxicity of intermediate-duration oral exposure to 1,4-DCB is available from































and kidney effects are the most consistently observed, best characterized, and most sensitive findings in
these studies. The lowest observed adverse effect level is for liver toxicity in dogs, although reproductive 
and developmental studies in rats indicate that offspring are particularly sensitive to 1,4-DCB toxicity
during the postnatal pre-weaning period. 
Hepatic effects induced by intermediate-duration oral exposures to 1,4-DCB ranged from increased liver 
weight and hepatocyte enlargement to hepatocellular degeneration, lesions, necrosis, and tumors in rats, 
mice, rabbits, and dogs.  Increases in serum levels of enzymes and alterations in other end points (e.g., 
serum cholesterol and triglycerides) indicative of hepatocellular damage or liver dysfunction have also 
been induced. Increased liver weight is the most sensitive hepatic end point in subchronic studies in rats, 
observed at doses as low as 150 mg/kg/day for 4–13 weeks and 188 mg/kg/day for 192 days
(Hollingsworth et al. 1956; Lake et al. 1997; Umemura et al. 1998).  There was no indication of early
liver damage in rats exposed to 150 mg/kg/day for 4 weeks using an immunohistochemical marker of 
centrilobular hepatocyte injury (Umemura et al. 1998), and increases in liver porphyrins in rats exposed to 
50–200 mg/kg/day for 120 days were not considered to be toxicologically significant (Carlson 1977).  
Hepatocellular hypertrophy and decreased serum triglycerides occurred in rats exposed to 
≥300 mg/kg/day for 13 weeks (NTP 1987; Lake et al. 1997).  Higher dose levels of 1,4-DCB induced 
degenerative liver lesions in rats exposed to 376 mg/kg/day for 192 days (slight cirrhosis and focal 
necrosis) (Hollingsworth et al. 1956) or 1,200 mg/kg/day for 13 weeks (hepatocyte degeneration and 
necrosis) (NTP 1987).  In mice, hepatocellular degeneration was induced at doses ≥600 mg/kg/day for 
13 weeks (NTP 1987), and rabbits had cloudy swelling and minimal focal necrosis in the liver after 
exposure to 500 mg/kg/day for 367 days (Hollingsworth et al. 1956).  Dogs are more sensitive to hepatic 
effects of 1,4-DCB than the other species based on increases in serum enzymes following exposure to 
doses as low as 50 mg/kg/day for 6 months in the MRL study (Naylor and Stout 1996). 
Kidney effects, including collecting duct epithelial vacuolation, are additional effects of 1,4-DCB in the 
dogs exposed to ≥50 mg/kg/day for 1 year in the MRL study (Naylor and Stout 1996).  Renal changes, 
including hyaline droplet accumulation, increased kidney weights, and tubular lesions, are 
characteristically observed effects of subchronic and chronic oral exposure to 1,4-DCB in male rats at 
doses >75 mg/kg/day (Bomhard et al. 1988; Lake et al. 1997; NTP 1987).  These findings were not 
considered for MRL derivation because there is a scientific consensus that they are related to the 
α2µ-globulin nephropathy syndrome, which is specific to male rats and not relevant to humans.  
Subchronic studies in female rats found increased kidney weight, but no indications of nephrotoxic action 
(i.e., no histopathology or effects on urinary indices of renal function), following exposure to 
>188 mg/kg/day for 192 days or 600 mg/kg/day for 13 weeks (Bomhard et al. 1988; Hollingsworth et al. 
1956). 
Developmental toxicity studies provide no indications that 1,4-DCB is teratogenic in rats at oral doses as 
high as 1,000 mg/kg/day during gestation, although fetotoxicity occurred at maternally toxic levels 
>500 mg/kg/day (Giavini et al. 1986; Ruddick et al. 1983).  Decreased maternal weight gain and 
increased incidences of extra ribs, a skeletal variation attributable to the maternal toxicity, occurred in rats 
at gestational dose levels >500 mg/kg/day, but not at 250 mg/kg/day (Giavini et al. 1986).  In a 
2-generation study, reproductive and developmental toxicity were evaluated in male and female rats that 
were orally exposed to 30, 90, or 270 mg/kg/day of 1,4-DCB (Bornatowicz et al. 1994).  No effects on 
mating and fertility indices were observed at any level, although toxicity occurred in the offspring at 
doses >90 mg/kg/day. Effects at >90 mg/kg/day included reduced birth weight in F1 pups and increased 
total number of deaths from birth to postnatal day 4 in F1 and F2 pups, clinical manifestations of dry and
scaly skin (until approximately postnatal day 7) and tail constriction with occasional partial tail loss 
(during postnatal days 4–21) in F1 and F2 pups, reduced neurobehavioral performance (draw-up reflex 


















related changes were found at 30 mg/kg/day, indicating that this is the NOAEL for reproductive and 
developmental toxicity in rats. 
As indicated above, liver, kidney, and perinatal developmental toxicity are main effects of concern for 
intermediate-duration oral exposure to 1,4-DCB in animals.  The dog is the most sensitive tested species, 
as liver effects were induced by exposure to doses as low as 50 mg/kg/day for 6 months (Naylor and Stout 
1996), which are below subchronic LOAELs of approximately 150–200 mg/kg/day for liver and kidney
effects in rats and mice.  The two-generation study in rats demonstrates that oral exposure to 1,4-DCB can 
cause perinatal developmental toxicity, including reduced birth weight and neonatal survival in F1 and 
F2 pups, at doses >90 mg/kg/day (Bornatowicz et al. 1994).  Although this finding indicates that perinatal 
developmental toxicity is an additional sensitive end point for 1,4-DCB exposure, the hepatotoxicity
induced in dogs at the 50 mg/kg/day dose level (Naylor and Stout 1996) is a more appropriate basis for 
MRL derivation. 

















   


























MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 1,4-Dichlorobenzene (1,4-DCB) 
CAS Numbers: 106-46-7 
Date:   August 2006
Profile Status: Post-Public, Final 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute  [ ] Intermediate  [X] Chronic 
Graph Key: 61 
Species: Dog 
Minimal Risk Level: [0.07] mg/kg/day  [ ] ppm
References: Naylor MW, Stout LD.  1996.  One year study of p-dichlorobenzene administered orally via 
capsule to beagle dogs. Environmental Health Laboratory, Monsanto Company, St. Louis, MO.  Study
No. ML-94-210, March 25, 1996.  MRID# 43988802.  Unpublished. 
EPA. 1996b.  Data Evaluation Record (DER) for p-dichlorobenzene – chronic oral toxicity in dogs 
(MRID# 439888-01 and -02) for Section 6 (a) (2) and reregistration need.  U.S. Environmental Protection 
Agency, Office of Prevention, Pesticides and Toxic Substances. 
Experimental design: Groups of five male and five female beagle dogs were orally administered 
1,4-DCB by capsule in dose levels of 0, 10, 50, or 75 mg/kg/day for 1 year.  Based on the summarized 
design of a 4-week dose range-finding study, it is presumed that dosing was 5 days/week.  The
75 mg/kg/day dose is a time-weighted average level reflecting dose decreases at the beginning of the 
study in response to unexpected severe toxicity.  An initial high dose of 150 mg/kg/day was adjusted to 
100 mg/kg/day for males during week 3, and a further decrease to 75 mg/kg/day was made for both sexes 
at the beginning of week 6.  Both high-dose males and females were untreated during weeks 4 and 5 to 
allow for recovery.  End points evaluated throughout the study included clinical observations (daily),
body weight (weekly), and food consumption (weekly).  Ophthalmoscopic examinations were performed 
prior to study start and just prior to study completion.  Hematology (11 indices, including activated partial 
thromboplastin time), clinical chemistry (18 indices, including ALT, AST, GGTP, AP, and creatinine 
phosphokinase), and urinalysis (10 indices) were performed at month 6 and study completion (month 12).
Organ weights, gross pathology, and histology were evaluated at month 12. 
Effects noted in study and corresponding doses: Mortality occurred the first 25 days of the study before 
dose reduction; exposure to 150 mg/kg/day caused one male dog to be sacrificed in extremis on day 12, 
one male death on day 25, and one female death on day 24.  A control male died on day 83, but all other 
dogs survived to the end of the study.  Treatment-related clinical signs were primarily limited to severely
affected high-dose dogs and the control male that died; these included hypoactivity, dehydration, 
decreased defecation, blood-like fecal color, emesis, emaciation, and/or pale oral mucosa.  There were no 
significant group differences in mean body weight at the end of the study.  Body weight gain was 
significantly reduced during the first month of the study, but recovered following dose reduction and 
adjustment of food availability.  A mild anemia was observed at month 6 (significantly reduced red blood 
cells in females and HCT in males) at 75 mg/kg/day, but resolved by the end of the study.  The mild 
anemia correlated with histologic findings of bone marrow erythroid hyperplasia in females, and splenic 
excessive hematopoiesis and megakaryocyte proliferation in both sexes, indicating a compensatory
response to the earlier anemia.  Hepatic effects occurred at ≥50 mg/kg/day in both sexes as shown by
changes in liver enzymes, increased liver weight, and histopathology.  Effects on serum enzyme levels 
included significantly increased AP in males at 50 mg/kg/day at months 6 and 12 (731 and 620% higher 



























females at 75 mg/kg/day at months 6 and 12 months (761 and 680% higher).  Serum AP was also 
increased in males at 75 mg/kg/day after 6 and 12 months, but the changes were not statistically 
significant, possibly due to a reduced group size of 3 males at 75 mg/kg/day.  Other clinical chemistry
findings included significantly increased ALT in females at 75 mg/kg/day at month 12 (253% higher than 
controls), increased GGTP in females at 75 mg/kg/day at months 6 and 12 (131 and 161% higher), and 
decreased albumin in males at 50 and 75 mg/kg/day at month 6 (16 and 18% lower than controls) and 
females at 75 mg/kg/day at month 6 (19% lower).  Absolute and relative liver weights were significantly
increased (40-70% higher than controls) in both sexes at 50 and 75 mg/kg/day (except absolute liver 
weight in 50 mg/kg/day males).  Hepatocellular hypertrophy (diffuse or multifocal) occurred in all males 
and females at 50 and 75 mg/kg/day and in one female at 10 mg/kg/day.  The study authors (Naylor and 
Stout 1996) considered the hepatocellular hypertrophy (multifocal) in the single 10 mg/kg/day female dog 
to be an adaptive response to a xenobiotic agent rather than a direct treatment-related effect.  Other liver 
lesions considered to be treatment-related included hepatocellular pigment deposition (two males and one 
female each at 50 and 75 mg/kg/day), bile duct/ductule hyperplasia (one male and one female at 
75 mg/kg/day), and hepatic portal inflammation (periportal accumulation of neutrophils in one male at 
50 mg/kg/day and two males at 75 mg/kg/day).  Kidney effects included collecting duct epithelial 
vacuolation in one male at 75 mg/kg/day and at all dose levels in females (one each at 10 and 
50 mg/kg/day and two at 75 mg/kg/day).  The renal lesion was considered to be a possible effect of 
treatment at ≥50 mg/kg/day, because it was accompanied by increased relative kidney weight in females 
at ≥50 mg/kg/day and grossly observed renal discoloration in two females at 75 mg/kg/day.  The highest 
NOAEL and lowest LOAEL are 10 and 50 mg/kg/day, respectively, based on the hepatic effects 
(increased liver weight, changes in liver enzymes, and histopathology). 
Dose and end point used for MRL derivation: 
[ ] NOAEL  [ ] LOAEL [X] BMDL
As discussed below, a BMDL1sd of 10 mg/kg/day for increased serum AP is used as the basis for the 
MRL. 
BMD analysis was performed on serum AP level and relative liver weight data for the female dogs 
exposed to 1,4-DCB for 1 year.  The incidences of hepatocellular hypertrophy in the females (0/5, 1/5, 
5/5, and 5/5 at 0, 10, 50, and 75 mg/kg/day) and males (0/5, 0/5, 5/5, and 5/5) are inappropriate for BMD 
modeling due to actual or effective responses of 0% in the control and low dose groups and 100% in the 
higher dose groups. The response in the low-dose female dog is effectively 0% because the authors 
implied that the hypertrophy in this single animal was not a hepatotoxic response.  The incidences of the 
other liver lesions were not subjected to BMD analysis due to the low numbers of responders and group 


























Table A-21. Selected Liver Effects in Female Dogs Orally Exposed to 





Mean serum AP in IU/L 
(percent of control mean) 
Mean relative liver weight in percent 
(percent of control mean) 
0 5 173.40±55.09a 2.71±0.17a 
-- --
10 5 181.80±69.22 3.05±0.83
(105) (113) 








bSignificantly different (p<0.05) from control group 
cSignificantly different (p<0.01) from control group 
Source: Naylor and Stout 1996 
Table A-22. Model Predictions for Changes in Serum Alkaline 
Phosphatase Levels in Female Dogs Orally Exposed to 































aValues <0.1 fail to meet conventional goodness-of-fit criteria 
bConstant variance assumed 
cRestriction = non-negative 
dNonhomogeneous variance assumed 
AIC = Akaike’s Information Criteria; BMD1sd = benchmark dose based on a benchmark response of 1 standard 
deviation above the control mean; BMDL1sd = lower confidence limit (95%) on the BMD1sd; NA = not applicable 
because model failed a goodness-of-fit test 
For the relative liver weight data, the simplest continuous variable model (linear) from the EPA 
Benchmark Dose Software (Version 1.3.2) was initially fit; constant variance was assumed.  A BMR of 
1 standard deviation above the control mean was selected in the absence of a biological rationale for using 
an alternative BMR. The model output indicated that a non-homogeneous variance was more appropriate 
for the data set (as indicated by a p-value <0.01 for the test for constant variance).  However, using non­
homogeneous variance, inadequately modeled variance resulted (p-value <0.01).  Similar inadequate 
results were obtained using the more complex polynomial and power models.  The Hill model provided 
inadequate mean fit due to insufficient (0) degrees of freedom.  Therefore, the relative liver weight data 


































For the serum AP data, the simplest continuous variable model (linear) was initially fit; constant variance 
was assumed.  A BMR of 1 standard deviation above the control mean was selected in the absence of a 
biological rationale for an alternative BMR. The model output indicated that a non-homogeneous 
variance was more appropriate for the data set (as indicated by a p-value <0.01 for the test for constant 
variance). However, using non-homogeneous variance, inadequate model mean fit was obtained (p-value 
<0.01). The more complex (polynomial, power, and Hill) models for continuous data were also fit to the 
serum AP data.  The Hill model provided inadequate mean fit due to insufficient degrees (0) of freedom.  
Adequate mean fit was obtained with both the 2-degree polynomial and power models.  Following 
conventional protocol for selection of the point of departure (the adequate model with the lowest AIC, the 
BMDL1sd of 12.32 mg/kg/day (lower 95% confidence limit on the BMD1sd of 15.40 mg/kg/day) was 
selected as the point of departure for deriving the chronic-duration oral MRL (see Table A-22, 
Figure A-9). The BMDL1sd of 12.32 mg/kg/day was rounded to one significant figure (10 mg/kg/day), 
duration adjusted to 7 mg/kg/day, and divided by an uncertainty factor of 100 to derive an MRL of 
0.07 mg/kg/day.
Figure A-9. Changes in Serum Alkaline Phosphatase Levels in Female Dogs 

Orally Exposed to 1,4-Dichlorobenzene for 12 Months*
 

















0 10 20 30 40 50 60 70 80 
dose 
11:54 06/30 2006 
*BMD and BMDL (in mg/kg/day) are associated with 1 standard deviation above the control mean. 
Uncertainty Factors used in MRL derivation: 
[X]  10 for extrapolation from animals to humans 
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Not applicable 
(capsule study). 


























Was a conversion used from intermittent to continuous exposure? The BMDL1sd of 10 mg/kg/day was 
adjusted to a continuous exposure scenario as follows: 
  BMDL1sd ADJ = (BMDL1sd) (5days/7 days) 
= (10 mg/kg/day) (5/7) 
= 7 mg/kg/day
Other additional studies or pertinent information that lend support to this MRL: The NOAEL/LOAEL 
approach to MRL derivation results in the same chronic-duration oral MRL value as the benchmark dose 
approach. Using the NOAEL of 10 mg/kg/day for increased serum AP and other liver effects in dogs 
(Naylor and Stout 1996), the NOAEL is duration-adjusted to 7 mg/kg/day (10 mg/kg/day x 5 days/7 days) 
and divided by the uncertainty factor of 100 to yield an MRL of 0.07 mg/kg/day.
Additional information on the chronic oral effects of 1,4-DCB is available from one study each in rats, 
mice, and rabbits.  Observed effects included nephropathy in rats (including tubular degeneration and 
atrophy in females) exposed to ≥150 mg/kg/day on 5 days/week for 103 weeks (NTP 1987), 
hepatocellular degeneration and nephropathy in mice exposed to ≥300 mg/kg/day on 5 days/week for 
103 weeks (NTP 1987), and cloudy swelling and minimal focal necrosis in rabbits exposed to 
500 mg/kg/day in 263 doses in 367 days (Hollingsworth et al. 1956).  The lowest chronic LOAEL in 
these studies was 150 mg/kg/day for kidney effects in female rats (NTP 1987). Liver and kidney effects 
were induced in dogs in the principal study (Naylor and Stout 1996) at doses below the LOAELs in the 
other species.





































APPENDIX B.  USER'S GUIDE 
Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions: 
1.	 What effects are known to occur in humans? 
2. 	 What effects observed in animals are likely to be of concern to humans?
3. 	 What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 


























meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE) 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 

































See Sample LSE Table 3-1 (page B-6)
(1) 	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
(2) 	Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
(3) 	Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
(4) 	 Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
(5) 	Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6) 	Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
(7) 	System. This column further defines the systemic effects.  These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 


































which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
(9) 	LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs. 
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
(12)	 Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
LEGEND 
See Sample Figure 3-1 (page B-7) 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
(14) 	Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table. 
(15)	 Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
(16) 	NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 
18 corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 




















(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 













   
 
  







      
 
        
 
 
















     
 















































































































































































































































































































































































































































































































































APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy
DOL Department of Labor 






































DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO     North America/Intergovernmental Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System
Kd adsorption ratio 
kg kilogram
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 




























MCLG maximum contaminant level goal 
MF modifying factor 




mmHg millimeters of mercury
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
































OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit 
pg picogram
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States
USDA United States Department of Agriculture 
USGS United States Geological Survey
VOC volatile organic compound 
WBC white blood cell 

















> greater than 
≥ greater than or equal to 
= equal to 
< less than 








q1* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 




































APPENDIX D.  INDEX 

absorbed dose............................................................................................................................ 232, 237, 253 

adenocarcinomas........................................................................................................................... 18, 20, 192 

adipose tissue ...............12, 203, 204, 205, 207, 209, 222, 231, 233, 252, 312, 313, 318, 320, 324, 330, 336 

adrenal gland..................................................................................................... 17, 35, 40, 42, 176, 190, 192
 
adrenals ..................................................................................................................................................... 175 

adsorption.................................................................................................................................. 284, 329, 335 

aerobic....................................................................................................................................... 289, 291, 293 

alanine aminotransferase (see ALT) ................................................................................................... 14, 163 

ALT (see alanine aminotransferase) ............................ 14, 26, 27, 28, 29, 35, 36, 37, 38, 40, 42, 48, 50, 87, 

 160, 161, 162, 163, 164, 165, 169, 223 

ambient air .......................................................................................................... 12, 271, 289, 298, 299, 312
 
anaerobic ........................................................................................................................................... 289, 293 

anemia ........................................................................... 6, 26, 50, 84, 85, 156, 158, 225, 230, 235, 245, 251 

aspartate aminotransferase (see AST)......................................................................................................... 16 

AST (see aspartate amino transferase)............................... 16, 26, 27, 28, 35, 36, 37, 40, 42, 44, 48, 50, 87, 

 161, 162, 163, 164, 169 

bioaccumulation.......................................................................................................... 11, 271, 285, 286, 323 

bioconcentration factor ..................................................................................................................... 285, 286 

biodegradation..................................................................................................... 11, 271, 289, 291, 293, 323
 
biomarker .......................................................................................................................... 232, 233, 234, 252 

biomarkers ........................................................................................................ 232, 233, 234, 254, 327, 336
 
blood cell count..................................................................................................................... 24, 84, 157, 158 

body weight effects ............................................................................................................. 93, 179, 180, 245 

breast milk....................15, 202, 203, 204, 205, 207, 222, 231, 233, 252, 254, 315, 316, 318, 321, 324, 325 

cancer ............................................................................ 5, 6, 13, 15, 100, 101, 193, 224, 229, 246, 247, 341 

carcinogen ....................................................................................................................... 6, 18, 341, 344, 345 

carcinogenic .............................................. 6, 13, 18, 20, 21, 53, 54, 190, 191, 192, 201, 243, 247, 341, 345 

carcinogenicity.................................................................... 6, 13, 15, 18, 101, 246, 247, 248, 252, 341, 345 

carcinoma.............................................................................................................. 20, 33, 101, 191, 192, 193 

cardiovascular ............................................................................................................................. 82, 153, 154 

cardiovascular effects.................................................................................................................. 82, 153, 154 

chromosomal aberrations .................................................................................................................. 195, 202 

clearance ................................................................................................................................................... 216 

death.......................................................................... 32, 50, 53, 77, 102, 151, 152, 178, 193, 194, 239, 243 

deoxyribonucleic acid (see DNA)............................................................................................. 196, 199, 200 

dermal effects.......................................................................................................... 91, 92, 95, 177, 178, 230 

DNA (see deoxyribonucleic acid)...................................... 45, 164, 165, 167, 169, 172, 195, 196, 197, 198,  

199, 200, 201, 207, 231, 232 

endocrine..................................................... 15, 16, 36, 43, 91, 174, 175, 176, 226, 227, 228, 230, 244, 246 

endocrine effects ................................................................................................... 15, 91, 163, 174, 175, 176 

estrogen receptor....................................................................................................................................... 227 

estrogenic .................................................................................................................................................. 227 

fetal tissue ................................................................................................................................................. 188 

fetus........................................................................................................................................... 228, 231, 320 

follicle stimulating hormone (see FSH) .................................................................................................... 186 


















gastrointestinal effects ................................................................................................................ 83, 155, 156 

general population......................................................... 11, 80, 232, 236, 271, 311, 312, 318, 320, 321, 324 

genotoxic............................................................................................. 53, 195, 200, 202, 231, 243, 320, 325 

genotoxicity....................................................................................................... 193, 195, 200, 201, 248, 320
 
groundwater .................................................. 2, 251, 278, 282, 285, 291, 302, 305, 306, 307, 320, 321, 323 

half-life...................................................................................................................... 232, 284, 289, 291, 293 

hematological effects .............................................................................................. 27, 84, 85, 156, 157, 224 

hematopoietic.................................................................................................................. 17, 27, 85, 183, 250
 
hepatic effects ............................ 14, 15, 16, 18, 26, 28, 35, 38, 47, 51, 86, 87, 88, 159, 160, 161, 162, 163, 

 165, 167, 168, 169, 170, 175, 233, 234, 238 

hydrolysis.............................................................................................................. 12, 16, 202, 203, 291, 293 

hydroxyl radical .................................................................................................................. 11, 271, 289, 323 

immune system ......................................................................................................................................... 250 

immunological .......................................................................... 36, 53, 95, 96, 182, 183, 184, 244, 246, 250 

immunological effects................................................................................................................. 95, 182, 184 

Kow .................................................................................................................................................... 285, 323 





lymphoreticular ................................................................................................................................. 182, 183 

micronuclei ............................................................................................................................................... 201 

milk ..................................................................................................... 12, 231, 310, 315, 318, 329, 330, 336 

musculoskeletal effects ......................................................................................................... 85, 86, 158, 159 

neonatal ....................................................................................................... 48, 230, 231, 250, 254, 316, 324 

neoplastic .......................................................................................................................................... 101, 248 

neurobehavioral............................................................................................... 17, 20, 47, 189, 227, 230, 250 

neurodevelopmental .......................................................................................................................... 236, 249 

nuclear............................................................................................................................. 27, 28, 87, 157, 225 

octanol-water partition coefficient ............................................................................................................ 285 

ocular effects............................................................................................................................... 92, 178, 179 

partition coefficients ................................................................................................................... 30, 219, 220 

pharmacodynamic ..................................................................................................................................... 216 

pharmacokinetic.......................................................................................... 34, 216, 217, 218, 225, 228, 254 

photolysis .......................................................................................................................................... 291, 293 

placenta ................................................................................................................................... 7, 12, 231, 254 

rate constant ...................................................................................................................... 219, 220, 221, 291 

renal effects............................................................................................... 45, 89, 90, 91, 170, 171, 174, 248 

retention ............................................................................................................................................ 291, 335 

salivation ............................................................................................................................................... 17, 29 

sarcoma ............................................................................................................................................... 33, 101 

serum glutamic oxaloacetic transaminase (see SGOT)............................................................................... 33 

serum glutamic pyruvic transaminase (see SGPT) ..................................................................................... 33 

SGOT (see serum glutamic oxaloacetic transaminase)............................................................................... 33 

SGPT (see serum glutamic pyruvic transaminase) ..................................................................................... 33 

solubility ................................................................................................................................................... 223 

thyroid....................................... 6, 15, 17, 42, 43, 44, 91, 174, 175, 176, 187, 188, 192, 227, 236, 244, 245 

toxicokinetic........................................................................................ 53, 194, 231, 244, 246, 248, 252, 254 

tremors ............................................................................................................................ 17, 29, 97, 184, 251 

tumors ....................................................................... 18, 20, 33, 46, 101, 152, 190, 191, 192, 193, 246, 248 

volatilization ............................................................................................. 284, 285, 288, 289, 291, 293, 323 

weanlings .................................................................................................................................... 28, 186, 189 

 
 
 
 
 
 
 
 
 
 
 
 
